[
    {
        "page_number": 1,
        "text": "1"
    },
    {
        "page_number": 2,
        "text": "2PUBLISHEDBY:\nMalaysianSocietyofNeurosciences\n(PersatuanNeurosainsMalaysia)\nNeurologyLaboratory,6thFloor,SouthTower\nUniversityofMalayaMedicalCentre\n50603KualaLumpur\nMalaysia\neISBN978-967-11469-2-7\nAvailableatthefollowingwebsites:\nhttp://www.acadmed.org.my\nhttp://neuro.org.my\nhttp://www.moh.gov.my\nAlsoavailableasanappforAndroidandIOSplatform:MyMaHTAS\nCOPYRIGHT\nTheownersofthispublicationaretheMalaysianSocietyofNeurosciences(MSN)andtheAcademy\nofMedicineMalaysia.Thecontentinthisdocumentmaybeproducedinanynumberofcopiesandin\nanyformatormediumprovidedthatacopyrightacknowledgementtotheownersisincludedandthe\ncontentisnotchangedinanyformormethod,notsoldandnotusedtopromoteorendorseany\nproductorservice.Inaddition,thecontentisnottobeusedinanyinappropriateormisleading\ncontext.\n©2021MalaysianSocietyofNeurosciences.Allrightreserved."
    },
    {
        "page_number": 3,
        "text": "3STATEMENTOFINTENT\nThisguidelinewasdevelopedtobeaguideforbestclinicalpractice,basedonthebestavailable\nevidenceatthetimeofdevelopment.Specificattemptsweremadetouselocaldataandpublications\ntoensurelocalrelevance.Adherencetothisguidelinedoesnotnecessarilyleadtothebestclinical\noutcomeinindividualpatientcare.Everyhealthcareproviderisresponsibleforthemanagementof\nhis/heruniquepatientbasedontheclinicalpresentationandmanagementoptionsavailablelocally.\nREVIEWANDUPDATEOFTHEGUIDELINE\nThisguidelinewasissuedin2020andwillbereviewedin2025orearlierifimportantnewevidence\nbecomesavailable.Whentheyaredueforupdating,theChairmanoftheCPGorNationalAdvisorof\ntherelatedspecialtywillbeinformedaboutit.Adiscussionwillbeheldontheneedforarevision,\nincludingonthescopeoftherevisedCPG.Amultidisciplinaryteamwillbeformed,andthelatest\nsystematicreviewmethodologyusedbyMaHTASwillbeemployed.\nCPGSecretariat\nHealthTechnologyAssessmentUnit\nMedicalDevelopmentDivision\nLevel4,BlockEI,ParcelE\nGovernmentOfficesComplex\n62590Putrajaya,Malaysia"
    },
    {
        "page_number": 4,
        "text": "4MEMBEROFTHEEXPERTPANELS\nChairman:\nProfessorDrHjHamidonBasri\nConsultantPhysicianandNeurologist\nHospitalPengajarUniversitiPutraMalaysia\nMembers:\nDrSanthiDatukPuvanarajah\nConsultantPhysicianandNeurologist\nHospitalKualaLumpur\nAssociateProfessorDrHooFanKee\nConsultantPhysicianandNeurologist\nHospitalPengajarUniversitiPutraMalaysia\nDrKhairulAzmiIbrahim\nConsultantPhysicianandNeurologist\nHospitalSultanahNurZahirah\nDrLawWanChung\nConsultantPhysicianandNeurologist\nHospitalUmumSarawak\nDrLooiIrene\nConsultantPhysicianandNeurologist\nHospitalSeberangJaya\nDrMakChoonSoon\nConsultantPhysicianandNeurologist\nGleneaglesHospital,KualaLumpur\nAssociateProfessorDrTaiMei-LingSharon\nConsultantPhysicianandNeurologist\nUniversityofMalayaMedicalCentre\nDrTanWeeYong\nConsultantPhysicianandNeurologist\nThomsonHospitalKotaDamansara\nProfessorDatinDr.NorlinahMohamed\nIbrahim\nConsultantPhysicianandNeurologist\nHospitalCanselorTuankuMuhriz,\nUniversitiKebangsaanMalaysia\nAssociateProfessorDrWanAliaaWan\nSulaiman\nConsultantPhysicianandNeurologist\nHospitalPengajarUniversitiPutraMalaysiaAssociateProfessorDrWanNurNafisah\nbintiWanYahya\nConsultantPhysicianandNeurologist\nHospitalCanselorTuankuMuhriz,\nUniversitiKebangsaanMalaysia\nDrZariahAbdulAziz\nConsultantPhysicianandNeurologist\nHospitalSultanahNurZahirah\nDrWanAsyrafWanZaidi\nStrokeNeurologistandInternalMedicine\nPhysician\nHospitalCanselorTuankuMuhriz,\nUniversitiKebangsaanMalaysia\nDrAbdulHanifKhanYusofKhan\nInternalMedicinePhysician\nHospitalPengajarUniversitiPutraMalaysia\nDrIskasymarItamIsmail\nEmergencyPhysician/MedicalLecturer\nUnitKecemasanStrokRESQ\nHospitalPengajarUniversitiPutraMalaysia\nAssociateProfessorDrMohdIdzwan\nZakaria\nSeniorConsultantEmergencyPhysician\nUniversityofMalayaMedicalCentre\nDrSarahShaikhAbdulKarim\nConsultantEmergencyPhysician\nHospitalSungaiBuloh\nDrSitiSuhailaHamzah\nConsultantEmergencyPhysician\nHospitalSungaiBuloh\nDrLowMookYuang\nEmergencyPhysician\nHospitalUmumSarawak"
    },
    {
        "page_number": 5,
        "text": "5DrLeongYuenChin\nEmergencyPhysician\nHospitalSultanahBahiyah\nDrNurAbdulKarim\nConsultantEmergencyPhysician\nKPJDamansaraSpecialistHospital\nDrJahlelawatiZul\nEmergencyPhysician\nHospitalRajaPermaisuriBainun\nDrCh’ngSweeHock,Alan\nConsultantGeriatrician\nHospitalSeberangJaya\nDrCheahWeeKooi\nConsultantGeriatrician\nHospitalTaiping\nAssociateProfessorDrTanKitMun\nConsultantGeriatrician\nUniversityofMalayaMedicalCentreProfessorDrTanMawPin\nConsultantGeriatrician\nUniversityofMalayaMedicalCentre\nDrTiongIngKhieng\nConsultantGeriatrician\nHospitalUmumSarawak\nDrUngkuAhmadAmeenbinUngkuMohd\nZam\nConsultantGeriatrician\nHospitalTengkuAmpuanRahimah\nDrKurubaranA/LGanasegeran\nMedicalOfficerofClinicalResearchCentre\nHospitalSeberangJaya\nDrStephenieAnnA/PAlbart\nMedicalOfficerofClinicalResearchCentre\nHospitalSeberangJaya"
    },
    {
        "page_number": 6,
        "text": "6EXTERNALREVIEWERS\nProfessorDato'DrRaymondAzmanAli\nSeniorConsultantNeurologist\nUniversityTechnologyMaraMalaysia(UiTM)SgBuloh\nDato'DrMohdHanipRafia\nConsultantPhysicianandNeurologist\nHospitalSelayang\nDatukDrMuhammadRadziAbuHassan\nConsultantPhysicianandGastroenterologist\nHospitalSultanahBahiyah\nDatukDrMahatharAbdWahab\nConsultantEmergencyPhysician\nHospitalKualaLumpur\nDrRizahMazzuinRazali\nConsultantGeriatrician\nHospitalKualaLumpurdanHospitalRehabilitasiCheras\nProfessorDrAhmadSobriMuda\nConsultantRadiology\nHospitalPengajarUniversitiPutraMalaysia\nProfessorDrLeePingYein\nFamilyMedicineSpecialist\nHospitalPengajarUniversitiPutraMalaysia\nDrSa’aribin.MohamadYatim\nRehabilitationPhysician\nHospitalSerdang\nMsNorsimaNazifahSidek\nPharmacist\nHospitalSultanahNurZahirah\nSnZurainahKaman\nStrokeNurse\nHospitalUmumSarawak\nMsTracyChan\nHeadofRehabilitation&Physiotherapist\nNationalStrokeAssociationMalaysia(NASAM)"
    },
    {
        "page_number": 7,
        "text": "7TABLEOFCONTENTS\nChapter Title Page\n-STATEMENTOFINTENT\nREVIEWANDUPDATEOFTHEGUIDELINE3\n-MEMBEROFTHEEXPERTPANELS 4-5\n-EXTERNALREVIEWERS 6\n-TABLEOFCONTENTS 7\n-RATIONALE,OBJECTIVESANDPROCESSOFGUIDELINE\nDEVELOPMENT8-11\n-KEYTOEVIDENCESTATEMENTSANDGRADESOF\nRECOMMENDATIONS12\n-GLOSSARY 13-16\n-UPDATESINMANAGEMENTOFISCHAEMICSTROKECPG2020 17\n-KEYRECOMMENDATIONSOFSTROKECPG2020 18-21\n-RECOMMENDATIONSSUMMARYOFSTROKECPG2020 22-36\n1EPIDEMIOLOGY,DEFINITIONANDCLASSIFICATIONOFSTROKE 37-39\n2CAUSESANDPATHOPHYSIOLOGY 40-41\n3DIAGNOSISANDINITIALASSESSMENT 42-44\n4PROGNOSIS 45-46\n5PREVENTIONOFSTROKE 47-65\n6INVESTIGATIONS 66-67\n7EMERGENCYMEDICINESERVICES 68-73\n8ACUTEGENERALMANAGEMENT 74-80\n9REPERFUSIONOFISCHAEMICBRAIN 81-89\n10ENDOVASCULARTHROMBECTOMY 90-93\n11STROKEUNIT 94-96\n12STROKEINTHEOLDERPERSON 97-105\n13STROKEANDCARDIOEMBOLISM 106-109\n14STROKEINSPECIALCIRCUMSTANCES 110-117\n15MANAGEMENTOFSTROKEINPREGNANCY 118-120\n16STROKETHERAPIESWITHLIMITEDEVIDENCE 121-122\n17QUALITYASSURANCE 123\n-APPENDICES 124-129\n-REFERENCES 130-154\n-ACKNOWLEDGEMENT\nDISCLOSURESTATEMENT\nSOURCEOFFUNDING155"
    },
    {
        "page_number": 8,
        "text": "8Rationale\nAcuteischaemicstrokecontinuestobeamajorcauseofmorbidityandiscurrentlythethirdleading\ncauseofmortalityinMalaysia.Withcurrentadvancement,timelyintervention,andearlyreperfusion\neitherviamedicalthrombolysisorendovasculartreatment,theoutcomeofstrokehasimproved\nsignificantly.ThebiggestchallengeinMalaysiaisthelimitedavailability,notonlyintermsofa\ndedicatedstrokeunitinamajorhospitalbutalsotheavailabilityofreperfusiontherapy,particularly\nmechanicalthrombectomy.Furthermore,thelackofcommunityawarenessontheimportanceof\ntimelyhyperacuteinterventionforstrokeinMalaysiaisstillprominent.\nThe1stClinicalPracticeGuideline(CPG)onthemanagementofischaemicstrokewaspublishedin\n2006andthesecondeditionwaspublishedin2012.Sincethen,therewasarapiddevelopmentin\nthemanagementofacutestroke,mainlywiththeimprovementandadvancementofreperfusion\ntherapy,encompassingbothmedicalthrombolysisandmechanicalthrombectomy.Furthermore,the\nimportanceoftimelyintervention,especiallyintheemergencydepartment,hadsignificantly\nimprovedtheoutcomeinstrokepatients.Therefore,thiscurrentCPGemphasizesthehyperacute\nmanagementandhasintroducednewchapters,forexample,emergencymedicalservices.Withthe\ngrowingnumbersofelderlypopulationinMalaysia,wehavealsoincludedanewchapteronstrokein\ntheolderperson.This3rdeditionwasdevelopedtoprovideaclearandconciseapproachbasedon\ncurrentevidencewiththefocusbeingontheeffortstoreducetimeandimprovepre-hospitalcare.\nWehavesummarisedandadaptedrelevantclinicaltrialsdataandpublishedliteraturestoourlocal\npractice.\nThisCPGhasbeenpreparedbyapanelofcommitteemembersfromtheMalaysiaStrokeCouncil\n(MSC),theMinistryofHealth(MOH)andtheMinistryofHigherEducation(MOHE).Thecommittee\nmembersweremultidisciplinaryandcomprisedofneurologists,internalmedicinephysicians,\ngeriatricians,andemergencyphysiciansfromthegovernmentsector,privatesector,anduniversities.\nTheexternalreviewersincludedwerealsoconsultantsfrommultidisciplinarybranchesofmedicine.\nPatientandstrokecarergroupswere,however,notincludedasexternalreviewers.\nObjectives\nTheseguidelinesareintendedtoprovideawarenessandeducationtoreducethemorbidityand\nmortalityassociatedwithischaemicstrokeby:\nIdentifyingsymptomsandsignsofstroke\nIdentifyingthevarioustypesandcausesofischaemicstroke\nTheseguidelinesareintendedtoprovideevidencein:\nReducingthetotalischaemictime\nUpdatingthemanagementofischaemicstrokewithrespectto:\nDiagnosis\nHyperacutemanagement\nPosthyperacutecare\nPrimaryprevention\nSecondaryprevention\nTheseguidelineshoweverdonotcover:\nManagementofcerebralhaemorrhage\nStrokerehabilitation\nStrokeinthepaediatricaged-grouppopulationRATIONALE,OBJECTIVESANDPROCESSOFGUIDELINEDEVELOPMENT"
    },
    {
        "page_number": 9,
        "text": "9Process\nThecurrentCPGistheinitiativeoftheMalaysiaStrokeCounciloftheMalaysiaSocietyof\nNeurosciences.Apanelofcommitteememberswasappointedcomprisingofneurologists,internal\nmedicinephysicians,geriatricians,andemergencyphysiciansfromtheMinistryofHealth,\nuniversities,andprivatesector.AuthorsfromthesecondCPGwereinvitedtocontributeonnew\nupdatesthatwerediscussedbythepanelmembers.Thediscussionstartedfromearly2018till2020\nbeforebeingfinalisedandsenttotheappointedreviewers.Thepanelmembersmetseveraltimes\nthroughoutthedevelopmentoftheguidelines.\nAreviewofthecurrentmedicalliteratureonischaemicstrokesincethepublicationofthelastCPG\non31stJan2012wasperformed.Literaturesearchwascarriedoutusingthefollowingelectronic\ndatabases–PubMedandCochraneDatabaseofSystematicReviews.Thesearchwasconducted\nfromtheperiodofpreviousCPGpublicationuntil31stJuly2020.TherelevantMeSHtermsorfree\ntexttermswereusedeithersinglyorincombinationasthesearchstrategy(referAppendixA).\nThesearchwasfilteredtoclinicaltrialsandreviews,involvinghumans,andpublishedintheEnglish\nlanguage.Therelevantarticleswerecarefullyselectedfromtheretrievedlist.Inaddition,the\nreferencelistsofallrelevantarticlesretrievedweresearchedtoidentifyfurtherstudies.LocalCPGs\nwerealsostudied.Expertsintherelevantfieldwerealsocontactedtoobtainfurtherinformation.\nInternationalguidelinesmainlyfromtheAmericanHeartAssociation/AmericanStrokeAssociation\n(AHA/ASA)andtheEuropeanAcademyofNeurology/EuropeanStrokeOrganisation(EAN/ESO)\nwereusedasthemainreferences.\nAllliteratureretrievedwereappraisedandsubsequentlypresentedfordiscussionduringthegroup\nmeetings.Allstatementsandrecommendationsformulatedwereagreedcollectivelybymembersof\nexpertpanels.Wherebytheevidencewasinsufficient,therecommendationswereagreeduponby\nconsensusofthepanelmembers.Thedraftwasthensenttolocalexternalreviewersforcomments.\nThelevelofrecommendationsandthegradingofevidenceusedinthisguidelinewasadaptedfrom\ntheU.S/CanadianPreventativeServicesTaskForceandtheGuidelinesforClinicalPractice\nGuideline,MinistryofHealthMalaysia2003.\nTheprinciplesandlayoutfollowthemethodologystatedintheGuidelinesforClinicalPractice\nGuidelinesbookletpublishedbytheMedicalDevelopmentDivisionoftheMinistryofHealthMalaysia.\nTheseguidelineshavebeenpresentedtotheChairmanoftheHealthTechnologyAssessment(HTA)\nandClinicalPracticeGuidelinesCounciloftheMinistryofHealthMalaysiaforreviewandapproval.\nFormulationOfRecommendation\nInformulatingrecommendationsfortheCPG,evidencefromtheliteraturei.e.systematicreview,\nmeta-analysis,randomizedcontrolledtrialorcohortstudywerecriticallyappraisedusingCASP\n(criticalappraisalskillsprogram)checklist.Subsequently,thequalityofeachretrievedevidenceand\nitseffectsizewerecarefullyassessed/reviewedbytheCPGDevelopmentGroup.\nInformulatingtherecommendations,theoverallbalancesofthefollowingaspectswereconsidered\nindeterminingthestrengthoftherecommendations:\n1.Overallqualityofevidence\n2.Balanceofbenefitsversusharms\n3.Valuesandpreferences\n4.Resourceimplications\n5.Equity,feasibility,andacceptability"
    },
    {
        "page_number": 10,
        "text": "10ClinicalQuestionsAddressed:\nTherewereseveraltopicsandsubtopicsthatwereformulatedaddressingthediagnosisand\nmanagementofischaemicstroke.\n1.Whatisthecurrentbestpracticeformanagementofacuteischaemicstroke?\n2.Whatarethestrategiesinstrokeprevention?\n3.Whataretheeffectivenon-pharmacologicalmodificationinmanagingpatientswithstroke?\nFortherapy,thetopicsandsubtopicswereformulatedusingthePICOmethodasfollows:\nP:Population-Personswithischaemicstrokeand:\nDurationofstroke:\n<4.5hours\n<6hours\n6to24hours(extendedhours)\nMorethan24hours\nWakeupstroke\nAtrialFibrillation\nOlderpersons\nYoungstrokeandspecialcircumstances\nPregnancy\nI:Intervention:\nReperfusionstrategy:\nMedicalthrombolysis\nMechanicalthrombectomy\nCombinedmedicalthrombolysisandmechanicalthrombectomy\nConcomitantdrugtherapy\nAnti-platelettherapy–singleordual\nDirectoralanti-coagulants(DOACs)\nStatins\nAnti-hypertensiveagents\nAnti-diabeticagents\nC:Comparison:\nReperfusionvsnoreperfusion\nMedicalthrombolysisvsmechanicalthrombectomy/combinationtherapy\nSingleanti-platelettherapyvsdualanti-platelettherapy\nClopidogrelvscilostazolvsticagrelorasasingle/combinationanti-plateletagent\nO:Outcome:\nFunctionaloutcomeat3months\nReductionofrecurrentstroke\nReductioninmajorcardiovasculardiseaseeventrate(MI,heartfailure,cardiovascular(CV)\ndeath)\nReductioninall-causemortality\nTypeofQuestion-Involves:\nTherapy-Reperfusionstrategy,concomitantdrugtherapy\nHarm\nIncreaseofbleedingriskandstrokerate\nAdverseeffectsduetopharmacotherapy\nPrognosis–Improvementoffunctionalstatus,reductionofstrokerecurrenceor\nhaemorrhagictransformationandimprovementinall-causemortality"
    },
    {
        "page_number": 11,
        "text": "11TypeofStudy\nSystematicreviewandmeta-analysis\nRandomisedcontrolledstudies\nCohortstudies\nTargetGroup:\nTheseguidelinesaredevelopedforallhealthcareprovidersinvolvedinthemanagementof\nischaemicstrokeinadults.\nTargetPopulation:\nTheseguidelinesaredevelopedtotreatalladultswithischaemicstroke.\nPeriodofValidityoftheGuidelines:\nTheseguidelinesneedtoberevisedatleastevery5yearstokeepabreastwithrecentdevelopments\nandknowledgethatisavailable.\nApplicabilityoftheGuidelinesandResourceImplications:\nThisguidelinewasdevelopedtakingintoaccountourlocalhealthcareresources.Atpresentmedical\nthrombolysisisavailableatsomegovernmenthospitalsandprivatehealthcarecentreswhile\nmechanicalthrombectomyisavailablelikewiseinlimitedcentres.Strokenetworksarebeing\nestablishedinitsearlystagesinsomeregionsinMalaysia.Wehopetohaveanationwidestroke\nnetworkinnearfuture.\nThisguidelineaimstoeducatehealthcareprofessionalsonstrategiestooptimisetheavailable\nexistingresourcesforthetimelymanagementofpatientswithischaemicstroke.\nFacilitatorsandBarriers:\nThemajorbarriersforthesuccessfulimplementationofthisCPGisthefinancialand\nresourceimplicationsof:\ntransportingthesepatientstostrokereadyhospitalsassoonaspossibleusing\nwell-equippedambulancesandaccompaniedbytrainedpre-hospitalcarepersonnelor\nmedicalofficers\navailabilityofmedicalthrombolysis/mechanicalthrombectomycentresproviding24/7\nservice\nMedicalthrombolysis/mechanicalthrombectomy-costsofmedicationsandthrombectomy\ninstruments\nImplementationoftheGuidelines:\nTheimplementationoftherecommendationsofaCPGispartofgoodclinicalgovernance.\nToensuresuccessfulimplementationofthisCPG,wesuggest:\nIncreasingpublicawarenessofischaemicstrokeingeneralandeducatingthemonthe\nimportanceofseekingearlymedicalattentionwhentheydevelopedsymptomssuggestive\nofstroke.\nContinuousmedicaleducationandtrainingofhealthcareprovidersontheimportanceof\ntimelyreperfusionandappropriatemanagementofpatientswithischaemicstroke.Thiscan\nbedonebyroadshows,throughtheelectronicmediaandin-housetrainingsessions.\nProfessorDrHjHamidonBinBasri\nChairman"
    },
    {
        "page_number": 12,
        "text": "12LEVELSOFEVIDENCESCALE\nIEvidenceobtainedfromatleastoneproperlyrandomizedcontrolledtrial\nII–1Evidenceobtainedfromwell-designedcontrolledtrialswithoutrandomization\nII–2Evidenceobtainedfromwell-designedcohortorcase-controlanalyticstudies,\npreferablyfrommorethanonecentreorresearchgroup\nII–3Evidenceobtainedfrommultipletimeserieswithorwithouttheintervention.\nDramaticresultsinuncontrolledexperiments(suchastheresultsofthe\nintroductionofpenicillintreatmentinthe1940s)couldalsoberegardedasthis\ntypeofevidence\nIIIOpinionsofrespectedauthorities,basedonclinicalexperience,descriptive\nstudiesandcasereports;orreportsofexpertcommittees\nSource:U.S./CANADIANPREVENTIVESERVICESTASKFORCE\nSource:GuidelinesforCLINICALPRACTICEGUIDELINES,MinistryofHealthMalaysia2003KEYTOEVIDENCESTATEMENTSANDGRADESOFRECOMMENDATIONS\nGRADESOFRECOMMENDATIONS\nAAtleastonemeta-analysis,systematicreview,orrandomizedcontrolledtrial\n(RCT),orevidenceratedasgoodanddirectlyapplicabletothetargetpopulation\nBEvidencefromwell-conductedclinicaltrials,directlyapplicabletothetarget\npopulation,anddemonstratingoverallconsistencyofresults;orevidence\nextrapolatedfrommeta-analysis,systematicrevieworRCT\nCEvidencefromexpertcommitteereports,oropinionsand/orclinicalexperiencesof\nrespectedauthorities;indicatestheabsenceofdirectlyapplicableclinicalstudiesof\ngoodquality"
    },
    {
        "page_number": 13,
        "text": "13GLOSSARY\nAbbreviations Descriptions\nACA AnteriorCerebralArtery\nACAS AsymptomaticCarotidAtherosclerosis\nACCORD ActiontoControlCardiovascularRiskinDiabetes\nACE Angiotensin-ConvertingEnzyme\nACST AsymptomaticCarotidSurgeryTrial\nADC AmbulanceDispatchCentre\nADL ActivitiesofDailyLiving\nAED Anti-epilepticDrug\nAF AtrialFibrillation\nAIS AcuteIschaemicStroke\nANCA AntineutrophilCytoplasmicAntibodies\naPTT activatedPartialThromboplastinTime\nARB AngiotensinReceptorBlocker\nARR AbsoluteRiskReduction\nARRIVE AspirintoReduceRiskofInitialVascularEvents\nASCEND AStudyofCardiovascularEventsinDiabetes\nASCO Atherosclerosis,Small-vesseldisease,Cardiacsource,andOthercauses\nASCVD AtheroscleroticCardiovascularDisease\nASD AtrialSeptalDefect\nASTER ContactAspirationvsStentRetrieverforSuccessfulRevascularization\nAVERT AVeryEarlyRehabilitationTrialafterstroke\nBP BloodPressure\nCADASILCerebralAutosomalDominantArteriopathywithSubcorticalInfarctsand\nLeukoencephalopathy\nCAS CarotidAngioplastyandStenting\nCCS CausativeClassificationSystems\nCEA CarotidEndarterectomy\nCHA2DS2-VAScCongestiveheartfailure,Hypertension,Age≥75years,Diabetesmellitus,\nStroke,ortransientischemicattack(TIA),Vasculardisease,Age65to74\nyears,Gendercategory\nCISS ChineseIschaemicStrokeClassification\nCLOT ClotsinLegsOrStockingsafterStroke\nCNS CentralNervousSystem\nCPAP ContinuousPositiveAirwayPressure\nCPG ClinicalPracticeGuideline\nCPSS CincinnatiPrehospitalStrokeScale\nCRP C-ReactiveProtein\nCSP CryosupernatantPlasma\nCT ComputerizedTomography\nCTA ComputerizedTomographyAngiography\nCTB CTscansoftheBrain\nCTP/MRP CTorMRPerfusion\nCV Cardiovascular\nCVD CardiovascularDisease"
    },
    {
        "page_number": 14,
        "text": "14CVT CerebralVenousThrombosis\nDALYs DisabilityAdjustedLifeYears\nDASH DietaryActiontoStopHypertension\nDAWNClinicalMismatchintheTriageofWakeUpandLatePresentingStrokes\nUndergoingNeurointerventionWithTrevo\nDEFUSE EndovascularTherapyFollowingImagingEvaluationforIschemicStroke\nDNA DeoxyribonucleicAcid\nDOAC DirectOralAnticoagulant\nDSA DigitalSubtractionAngiography\nDVT DeepVeinThrombosis\nDWI-FLAIR MRIDiffusionWeightedImaging–FluidAttenuatedInversionRecovery\nDWI-MRI Diffusion-weightedimaging-MRI\nECG Electrocardiogram\nECHO Echocardiography\nEC-IC Extracranial–Intracranial\nED EmergencyDepartment\nEF EjectionFraction\neGFR estimatedGlomerularFiltrationRate\nEMD EmergencyMedicalDispatchers\nEMS EmergencyMedicalServices\nEMTS EmergencyMedicineandTraumaService\nENT Ear,Nose,andThroat\nESCT EuropeanSurgicalCarotidTrial\nESR ErythrocyteSedimentationRate\nESUS EmbolicStrokeofUndeterminedSource\nEVT EndovascularTreatment\nFAST Face,Arm,SpeechandTime\nFBC FullBloodCount\nFDA FoodandDrugAdministration\nFFP FreshFrozenPlasma\nFOOD FeedorOrdinaryDiet\nFORTA-A FitForTheAged-HighlyBeneficial\nFORTA-B FitForTheAged-Beneficial\nFRS FraminghamRiskScore\nFRS-CVD FraminghamCVDRiskScore\nFSRS FraminghamStrokeRiskScore\nGCS GlasgowComaScale\nGTN GlycerylTrinitrate\nGXM GroupandCrossmatch\nHAS-BLEDHypertension,Abnormalrenal/liverfunction,Stroke,Bleedinghistoryor\npredisposition,LabileINR,Elderly(ageover65),andDrugs/alcohol\nHCTZ Hydrochlorothiazide\nHELLP Haemolysis,ElevatedLiverEnzymelevels,andLowPlateletlevels.\nHHT HereditaryHaemorrhagicTelangiectasia\nHIV/AIDSHumanImmunodeficiencyVirusinfection/AcquiredImmuneDeficiency\nSyndrome\nHOPE-3 HeartOutcomesPreventionEvaluation-3\nIAS IntracranialArteryStenting\nICA InternalCarotidArtery\nICP IntracranialPressure\nICU IntensiveCareUnit"
    },
    {
        "page_number": 15,
        "text": "15IHD IschaemicHeartDisease\nINR InternationalNormalisedRatio\nIPC IntermittentPneumaticCompression\nIV Intravenous\nIVT IntravenousThrombolysis\nKPI KeyPerformanceIndicator\nLAPSS LosAngelesPrehospitalStrokeScreen\nLDL Low-DensityLipoprotein\nLDL-C Low-DensityLipoproteinCholesterol\nLFT LiverFunctionTest\nLMIC LowandMiddle-IncomeCountries\nLMWH LowMolecularWeightHeparin\nLSD D-lysergicaciddiethylamide\nLV LeftVentricular\nLVO LargeVesselOcclusion\nMBS ModifiedBariumSwallowExamination\nMCA MiddleCerebralArtery\nMD MedicalDoctor\nMECC MedicalEmergencyCoordinationCentre\nMELAS MitochondrialEncephalopathy,LacticAcidosis,andStroke-likeepisodes\nMPDS MedicalPriorityDispatchSystem\nMR MagneticResonance\nMRA MagneticResonanceAngiography\nMRC/BHF MedicalResearchCouncil/BritishHeartFoundation\nMRI MagneticResonanceImaging\nmRS ModifiedRankinScale\nmtDNA MitochondrialDNA\nMTHFR MethylenetetrahydrofolateReductase\nNASCET NorthAmericanSymptomaticCarotidEndarterectomyTrial\nNBM NilbyMouth\nNCCT Non-ContrastCT\nNES Neuroendovascularsurgeon\nNG Nasogastric\nNHMS NationalHealthMorbiditySurvey\nNIHSS NationalInstitutesofHealthStrokeScale\nNSAID Non-SteroidalAnti-InflammatoryDrug\nNSR NormalSinusRhythm\nNVAF Non-ValvularAtrialFibrillation\nOAC OralAnticoagulant\nOAC-FORTAOralAnticoagulant–FitfortheAged\nOCSP OxfordCommunityStrokeProject\nPACNS PrimaryAngiitisoftheCentralNervousSystem\nPAN PolyarteritisNodosa\nPAR Population-AdjustableRisk\nPCA PosteriorCerebralArtery\nPCC ProthrombinComplexConcentrate\nPCO2 PartialPressureofCarbonDioxide\nPEG PercutaneousEndoscopicGastrostomy\nPET PositronEmissionTomography\nPFO PatentForamenOvale\nPHC Pre-HospitalCare"
    },
    {
        "page_number": 16,
        "text": "16PREDIMED PrevenciónconDietaMediterránea(PreventionwithMediterraneanDiet)\nPT ProthrombinTime\nRCT RandomizedClinicalTrials\nRNA RibonucleicAcid\nRP RenalProfile\nrtPA recombinanttissuePlasminogenActivator\nRVCL RetinalVasculopathywithCerebralLeukodystrophy\nRVCL RetinalVasculopathywithCerebralLeukodystrophy\nSAMMPRISStentingandAggressiveMedicalmanagementforpreventionofRecurrent\nStrokeinIntracranialStenosis\nsICH SymptomaticIntracranialHaemorrhage\nSLE SystemicLupusErythematosus\nSOCRATESAcuteStrokeorTransientIschaemicAttackTreatedWithAspirinorTicagrelor\nandPatientOutcomes\nSPRINT SystolicBloodPressureInterventionTrial\nSSS-TOASTStop-StrokeStudyTOAST\nTB Tuberculosis\nTIA TransientIschaemicAttack\nTLSW TimeLastSeenWell\nTMS TranscranialMagneticStimulation\nTOAST TrialofOrg10172inAcuteStrokeTreatment\nTOE Trans-OesophagealEchocardiogram\nTT ThrombinTime\nTTE TransthoracicEchocardiogram\nUFH UnfractionatedHeparin\nUS UnitedStates\nVDRL VenerealDiseaseResearchLaboratory\nVFSE VideoFluoroscopicSwallowingExamination\nVISSIT VitesseIntracranialStentStudyforIschemicTherapy\nVKA VitaminKAntagonists\nVTE VenousThromboembolism\nWEAVE WingspanStentSystemPostMarketSurveillance"
    },
    {
        "page_number": 17,
        "text": "17UPDATESINMANAGEMENTOFISCHAEMICSTROKECPG2020\n1.Newrecommendationsinthisclinicalpracticeguideline(CPG)refertorecommendationsthat\narenewfromthepreviousManagementofIschaemicStrokeCPG2012.\n2.InthiscurrentCPG,newchaptershavebeenaddedtoupdatethepreviousCPG.Amongthe\nnewchaptersthathavebeenaddedinclude:\na.Chapter7:EmergencyMedicineServices.\nb.Chapter12:StrokeintheOlderPerson\nc.Chapter16:StrokeTherapieswithlimitedevidence.\nd.Chapter17:QualityAssurance\n3.ManagementofIschaemicStrokeCPG2020,alsoemphasisestheimportanceofhyperacute\ncareofstroke,withthepreviouschapteronacutetreatment,beingfurthersubdividedinto\nthreenewchaptersasfollowing:\na.Chapter8:AcuteGeneralManagement\nb.Chapter9:ReperfusionofIschaemicBrain–emphasizingonmedicalthrombolysis\ntreatment.\nc.Chapter10:EndovascularThrombectomy\n4.Thefollowingchaptershavealsobeenupdated:\na.Chapter14:StrokeinSpecialCircumstances–withanewsubsectiononthe\nmanagementofpatentforamenovale(PFO)instrokepatients.\nb.Chapter15:ManagementofStrokeinPregnancy."
    },
    {
        "page_number": 18,
        "text": "18KEYRECOMMENDATIONSOFSTROKECPG2020\nChapter1:Epidemiology,DefinitionandClassificationOfStroke\n1.Strokeisamajorcauseofmortalityandmorbidity,andinMalaysia,strokeisthethirdleadingcause\nofmortality.\n2.Ischaemicstrokeisthemostcommonstroke,andhypertensionwasthemostcommonriskfactor\nfollowedbydiabetesmellitus.\n3.Thenewdefinitionofstrokeandtransientischaemicattack(TIA)involvedeitherpathologicalimaging\norclinicalevidenceofischaemiaandcanbetimedbasedonthepresentationofsymptoms.\n4.Ischaemicstrokecanbeclassifiedaccordingtoclinical,phenotypicoraetiologicclassification.\nChapter2:CausesandPathophysiology\n1.Threemaincausesofischaemicstrokeincludeatherothrombosisoflargevessels,intracranialsmall\nvesseldisease,andembolism,whichmaycontributetoupto80%ofthecases.\n2.Cryptogenicinfarctionorstrokeofundeterminedaetiologymayberesponsibleforaround20to40%\nofthecasesdespiteextensiveworkoutandusuallywouldbeadiagnosisofexclusion.\nChapter3:DiagnosisandInitialAssessment\n1.Thediagnosisofstrokeismadebyevaluatingandanalysinginformationderivedfromagoodhistory,\nphysicalexaminationandselecteddiagnostictests.\n2.Thesymptomsandsignsofstrokedependonthetype,location,andtheextentoftheaffectedbrain\ntissues.\n3.Afullneurologicalexamination,includingthepatient’sconsciouslevelandtestsofhighermental\nfunctionismandatory.\n4.Strokemimicscommonlyconfoundtheclinicaldiagnosisofstroke.\nChapter4:Prognosis\n1.Haemorrhagicstrokehasahighermortalitythanischaemicstroke.\n2.Thereisadeclineinstrokemortalityinbothmenandwomensufferingfromischaemicor\nhaemorrhagicstrokeduetotheintroductionofdedicatedstrokeunitsandimprovedcontrolofstroke\nriskfactors.\n3.Therecurrenceratesare3-4%inthefirstmonthand12%inthefirstyear.\n4.Progressoftimeisanindependentcovariatewhichreflectsthespontaneousrecoveryofbodily\nfunctions."
    },
    {
        "page_number": 19,
        "text": "19Chapter5:PreventionofStroke\n1.Strokeisapreventablediseaseandmaybeattributedtomodifiableandnon-modifiableriskfactors.\n2.Modifiableriskfactorsarethefocusofprimarypreventionandcanbeclusteredintothreemain\ngroupsi.e.\na)Lifestyleriskfactors,i.e.,smoking,physicalinactivity,andunhealthyeating\nb)Metabolicriskfactors,i.e.,highsystolicBP,highcholesterol,highfastingbloodglucose,low\neGFRandhighBMI.\nc)Environmentalfactors,i.e.,airpollutionandleadexposure.\n3.Secondarypreventionofstrokeinvolvesthepreventionofrecurrentstroke,andthismayinvolve\nmedicalinterventionsincludesantiplatelettherapy,anti-hypertensivetreatment,lipid-lowering\nagents,glycaemiccontrol,preventionofcardio-embolismandre-vascularisationproceduresin\nselectedcases.\nChapter6:Investigations\n1.Investigationscarriedoutforstrokeareaimedtoconfirmthediagnosis,determinethemechanismof\nstroke,stratifyriskandtoidentifypotentialtreatablevascularlesions.\n2.Computedtomography(CT)brainismandatoryandpreferredimagingintheemergencysettingto\ndifferentiatehaemorrhagefromischaemia,determinethesite(s),cause,andextentofthelesion.\n3.Advanceimagingmayberequiredinselectedcasesintheemergencysettings,e.g.,rulingoutstroke\nmimics,reperfusiontherapyinextendedhoursanddeterminingpotentialre-vascularisation\nprocedure.\n4.Selectedbloodinvestigationsandimagingwillberequiredincertainpatientstodeterminethe\naetiologyofstroke.\nChapter7:EmergencyMedicineServices\n1.Thepublicshouldbeencouragedtocall999iftheysuspectapersonishavingastroke.\n2.Emergencymedicaldispatcherandprehospitalcareprovidersshouldbetrainedtorecognizeand\nidentifystrokeandareabletoproviderapidtransportationofsuspectedacutestrokepatientto\nneareststrokereadyhospital.\n3.Assessmentofpatientswithsuspectedacutestrokeinemergencydepartmentshouldbeprioritized\ninordertoexpediatethediagnosisofstrokeandtodeterminetheappropriateacutestroke\ninterventions.\n4.Auditofacutestrokecareandtrainingofemergencydepartmentpersonnelshouldbeconductedto\nimprovequalityofcareinacutestrokecases.\nChapter8:AcuteGeneralManagement\n1.Acutegeneralmanagementinstrokeincludessupportivecareandtreatmentofacutecomplications\ninordertoimprovethemortalityrateandfunctionaldisability.\n2.Generalmanagementincludesmanagementofbloodpressure,glucosecontrol,nutritionalsupport,\npreventionofinfectionandDVT,andalsototreatpotentialsequelae,e.g.raisedintracranialpressure\nandseizure."
    },
    {
        "page_number": 20,
        "text": "20Chapter9:ReperfusionofIschaemicBrain\n1.Intravenousalteplase(0.9mg/kg;maximumdoseof90mg)isrecommendedforthedefiniteonset\nstrokeforupto4.5hoursfromtheonset.ThetreatmentwindowcanalsobeextendedviaCT\nperfusionwithclinicalevidenceofpenumbra-coremismatchupto9hoursfromthetimeofthelast\nknowntobewell/midpointofsleeporviaMRI(DWI-FLAIRmismatch)donetoidentifypossiblestroke\nonsetwithinthelast4.5hours.\n2.Intravenoustenecteplase(0.25mg/kg;maximumdoseof25mg)isapossibletreatmentagentin\nacutestrokethatpresentedwithin4.5hourswithevidenceoflargevesselocclusiononimaging.\nChapter10:EndovascularThrombectomy\n1.Hyperacuteendovascularthrombectomyisrecommendedforthedefiniteonsetofstrokewith\nevidenceoflargevesselocclusionwhichiswithin6hoursfromtheonset.Thetreatmentwindowcan\nbeextendedviaCT/MRperfusion(penumbra-coremismatch)orMRI(clinical-imagingmismatch)\nwithcurrentevidenceshowedsignificantbenefitupto24hoursfromtheonset/timeoflastknownto\nbewell.However,treatmentpathwayshouldnotbedelayed,asthetreatmentoutcomecanbe\ninfluencebytheimaging-to-recanalizationtime.\n2.Drip&Ship(IVTpriortoEVT)asperChapter9isrecommendedforeligiblepatients.\nChapter11:StrokeUnit\n1.Theuseofcomprehensivespecializedstrokecarecentres(strokeunits)thatincorporates\nrehabilitationservicesareabletoreducemortalityanddisabilitiesamongstrokepatients.\nChapter12:StrokeinTheOlderPerson\n1.Allolderpersonswithacutestrokeshouldbeassessedforfitness/frailtylevelusingavalidated\ninstrumenttofacilitateatailoredandindividualisedtreatmentplan.\n2.Anolderpersoncanbenefitfromacutetreatmentforstrokeincludingstrokethrombolysisand\nendovascularthrombectomy,providingtheinclusionandexclusioncriteriaofthetreatmentaremet.\n3.Anolderpersoncanbenefitfromandshouldreceivetreatmentforstrokepreventionwith\nmanagementofpolypharmacyissues,individualisedmedicationdosagesandtreatmenttargetsasis\ntolerated,forstrokeriskfactors.\n4.Allolderpersonswithstrokeshouldbe:\n-screenedfordeliriumusingavalidatedtool,andreceiveatailoredmulticomponentintervention\nandmanagementplanfordelirium,whenadmittedwithanacutestroke\n-offeredfallsandfragilityfractureriskassessmentandmanagementduringthe\nrehabilitationperiod\n-assessedbyamultidisciplinaryteamwithanappropriatedischargeplan\n-abletoreceiveend-of-lifecareandrecommendationswhentheprognosisispoor\neitherfromthestrokeitself,complications,orotherseriouscomorbidconditions"
    },
    {
        "page_number": 21,
        "text": "21Chapter13:StrokeandCardioembolism\n1.Cardioemboliisacommoncauseofstroke.Strokepatientmusthavecardiacassessmenttolookfor\nthepresenceofcardioemboli.\n2.Itcausesmoreseverestrokeandcarryahighermorbidityandmortalityrates.\n3.Effectivetreatmenttopreventcardioembolismisavailableandshouldbeofferedtopatientsatrisk.\n4.NOACispreferredoverVKAforNVAF.\n5.PatientonVKAshouldhaveregularINRmonitoringandaimedfortimeintherapeuticrange(TTR)>\n70%.\n6.AntiplateletisnotrecommendedinNVAFforthepreventionofstroke.\nChapter14:StrokeinSpecialCircumstances\n1.Youngonsetstrokerequiresmorecomprehensiveinvestigationtodeterminethestroke\naetiology.\n2.Diagnosisofcryptogenicstrokeandembolicstrokeofunderterminedsource(ESUS)ismade\nafterstandardevaluationtoruleoutpossiblecauseofstroke.\n3.FurtherspecializedinvestigationsneededinthecryptogenicorESUSstrokeforexample\nprolongedHoltermonitoringtolookforatrialfibrillationortolookforevidenceofpatentforamen\novale(PFO).\n4.Cerebralvenousthrombosisisoneofthemajorcauseofvenousinfarctandwouldrequire\ninvestigationstodeterminethecauseofthrombosis.Treatmentmainlydirectedat\nanticoagulationwithadjunctivetherapytopreventassociatedcomplications.\nChapter15:ManagementofStrokeinPregnancy\n1.MRIofthebrain(withoutgadoliniumcontrast)istheradiologicalmodalityofchoiceforinvestigating\nstrokesinpregnancy.\n2.Aspirinistheonlychoiceofantiplateletforpregnantpatientswithawell-definedlowriskprofile.\nChapter16:StrokeTherapieswithLimitedEvidence\n1.Thereareavarietyofstrokemedicationsandtreatmentmodalities,buttheevidenceisverylimited."
    },
    {
        "page_number": 22,
        "text": "22RECOMMENDATIONSSUMMARYOFSTROKECPG2020\nChapter5:PrimaryPreventionofStroke\nTable5.2:PrimaryPreventionandManagementofRiskFactors\nFactors RecommendationsLevelof\nEvidenceGrade\nHypertension Self-BPmonitoringisrecommendedforallhypertensive\npatients.\nNewrecommendation\nI A RiskstratificationforhypertensionbasedonCVDrisk,target\norgandamageandcomplicationsarerecommendedfor\noptimizingtherapy.\nNewrecommendation\nLifestylechangesifsystolicBPisbetween130-139mmHg\nand/ordiastolicBPisbetween80-89mmHg,withthreeto\nsix-monthlyreview.\nNewrecommendationI A\nTreatmedicallyifsystolicBPis>140mmHgand/ordiastolic\nBPis>90mmHg.I A\nHypertensionshouldbetreatedintheveryelderly\n(age>80years)toreducetheriskofstroke.\nNewrecommendationI B\nDiabetesMellitusStrictbloodpressurecontrolisimportantinpatientswith\ndiabetes.I A\nMoreintensiveHbA1cglycaemiccontroltargets(<6.5%)may\nberequiredforoptimalischemicstrokeprevention.I A\nTargetBPfordiabeticsissystolicBP<130mmHganddiastolic\nBP<80mmHg,preferably<120mmHgiftolerated.\nNewrecommendationI A\nHyperlipidaemiaTreatmentofdyslipidaemia/LDL-Cisstratifiedbasedonrisk.\nI BHigh-riskgroup:loweringLDLto<1.8mmol/lisrecommended.\nNewrecommendation\nIntermediateandlowrisk:keepLDL<3.4mmol/l.\nLow-riskgroupmaybenefitfromcholesterol-loweringtherapy\nwithastatin.\nNewrecommendation\nNorisk–keepLDL<4.2mmol/L.\nSmoking Cessationofsmoking. III C\nAspirintherapyAspirintherapyisnotrecommendedforprimarypreventionof\nstrokeintheelderly,diabetics,orotherhigh-riskgroups.\nNewrecommendationI A\nPost-menopausal\nHormone\nReplacement\nTherapyOestrogen-basedHRTisnotrecommendedforprimarystroke\nprevention.II B\nAlcohol Avoidheavyalcoholconsumptionorlimitto<1drinkperday.\nNewrecommendationII-2 B\nPhysicalActivityPhysicalactivity(occupationalandleisuretime)is\nrecommendedforallgroupsofpatients.\nNewrecommendationI A\nPhysicalactivity>30mins/dayor>150mins/weekaspartofa\nhealthylifestyleisrecommended\nNewrecommendationI A"
    },
    {
        "page_number": 23,
        "text": "23Diet DASHdietisrecommendedtoreduceBP.\nNewrecommendationI A\nMediterraneandiet(lowglycaemiccontentwithhighintakeof\nvegetables)supplementedwithnutsandoliveoilisbeneficial.\nNewrecommendationII B\nDiethighinfruitsandleafygreenvegetablesisbeneficial.\nNewrecommendationII B\nTable5.3:SecondaryPreventionofStroke\nFactors/Treatment RecommendationsLevelof\nEvidenceGrade\nAntiplatelet(Singleagent)\nAspirinTherecommendeddoseofaspirinis75mgto325mgdaily.I A\nAlternatives:\nClopidogrelTherecommendeddoseis75mgdaily. I A\nTiclopidineTherecommendeddoseis250mgtwiceaday. I A\nTriflusalTherecommendeddoseis600mgdaily I A\nCilostazolTherecommendeddoseis100mgtwiceaday. I A\nDoubletherapy CombinationtherapyofClopidogrelandAspirinis\nrecommendedinpatientwithminorischaemicstrokeand\nhigh-riskTIAfor21days.\nNewrecommendationI A\nAntihypertensive\ntreatmentACE-inhibitorbasedtherapyshouldbeusedtoreduce\nrecurrentstrokeinnormotensiveandhypertensive\npatients.I A\nARB-basedtherapymaybenefitselectedhighrisk\npopulations.II-1 B\nLipidlowering Lipidreductionshouldbeconsideredinallpatientswith\npreviousischaemicstrokes.I A\nLDLtarget<1.8isrecommendedinallpatientswith\npreviousischaemicstroke.\nNewrecommendationI A\nDiabeticcontrol Alldiabeticpatientswithapreviousstrokeshouldhave\ngoodglycaemiccontrol.III C\nCigarettesmokingAllsmokersshouldstopsmoking. III C\nTable5.4:CardiacConditionsPredisposingtoIschaemicstroke\nMajorRisk\nConditionsAdditionalRiskFactors RecommendationsLevelof\nEvidenceGrade\nAtrial\nFibrillationRiskfactorstobe\nassessedby\nCHA2DS2-VASc\nScore.OACtopreventcardioembolicstrokeis\nrecommendedforallNVAFmalepatients\nwithCHA2DS2-VAScscoreof2ormore\nandfemalepatientswitha\nCHA2DS2-VAScscoreof3ormore.\nNewrecommendationI A\nAspirin75-325mgdailyissufficientfor\npatients<65yearsoldwith‘lone’AFand\nnoadditionalriskfactors.I A\nDirectOralAnticoagulant(DOAC)vs.Warfarin\nDabigatranissuperior(150mgbid)toand\naseffective(110mgbid)ascomparedto\nWarfarin,inpreventingstrokeand\nsystemicembolism.Bleedingratesare\nsimilarwithWarfarinat150mgbidbutwith\nalowerbleedingratesat110mgbid.I A"
    },
    {
        "page_number": 24,
        "text": "24Rivaroxabanwascomparedwith\nadjusted-dosewarfarinandwasfoundto\nbenon-inferiorwithregardtotheprimary\ncompositeendpointofstrokeor\nnon-centralnervoussystemicembolism.\nNewrecommendationI A\nApixabanwascomparedwith\nadjusted-dosewarfarinandwasfoundto\nbesuperiortowarfarininpreventing\nstrokeorsystemicembolism.Apixaban\nalsocausedlessmajorbleedingeventsas\ncomparedwithwarfarinandresultedin\nloweroverallmortality.\nNewrecommendationI A\nEdoxaban*ascomparedtowarfarinwas\nfoundtobenoninferiorwithregardtothe\nprimaryefficacyendpointandcaused\nlessbleeding.\nNewrecommendation\n*CurrentlynotavailableinMalaysia.I A\nProsthetic\nHeartValves\n(Mechanical)Moderaterisk:\nBi-leafletortiltingdisk\naorticvalvesinNSRLifelongWarfarin\nII-2 B\nHighrisk:\nBileafletortiltingdisk\naorticvalvesinAF;\nBileafletortiltingdisk\nmitralvalveinAFor\nNSR.LifelongWarfarin(targetINR3.0;range\n2.5-3.5)\nII-3 B\nCaged-balland\ncaged-diskdesigns;\nDocumentedstroke/TIA\ndespiteadequate\ntherapywithWarfarin.LifelongWarfarin\n(targetINR3.0;range2.5-3.5)plus\nAspirin75-150mgdaily II-1 B\nBioprosthetic\nheartvalvesHighrisk:\nAF;leftatrialthrombusat\nsurgery;previous\nstroke/TIAorsystemic\nembolism.Ifmajorriskfactorsarepresent,consider\nWarfarinfor3-12monthsorlonger.III C\nForallotherpatients,give\nWarfarinfor3monthspost-op,then\nAspirin75-150mgdaily.III C\nMitralStenosisHighrisk:\nAF;previousstroke/TIA;\nleftatrialthrombus;left\natrialdiameter>55mm\nonEcho.Ifmajorriskfactorsarepresent,consider\nlifelongWarfarin. II-3 B\nForallotherpatientsstartAspirin\n75-150mgdaily.II-2 B\nMIandLV\ndysfunctionHighrisk:\nAcute/recentMI(<6\nmonths);extensive\ninfarctwithanteriorwall\ninvolvement;previous\nstroke/TIA.\nVeryhighrisk:\nSevereLVdysfunction\n(EF<28%);LV\naneurysm;spontaneous\nechocontrast;LV\nthrombus;dilated\nnon-ischaemic\ncardiomyopathies.IfriskfactorsarepresentwithoutLV\nthrombus:considerWarfarinfor3-6\nmonthsfollowedbyAspirin75-150mg\ndaily.III C\nIfLVthrombusispresent,consider\nWarfarinfor6-12months III C\nFordilatedcardiomyopathiesincluding\nperipartum,considerlifelongWarfarin\nIII C\nRecommendedWarfarindoseINRtarget2.5[range2.0to3.0]unlessstatedotherwise"
    },
    {
        "page_number": 25,
        "text": "25Table5.5:AnticoagulationforthePatientwithAcuteCardioembolicStroke\nTreatment RecommendationsLevelof\nEvidenceGrade\nWarfarin Adjusted-dosewarfarinmaybecommencedwithin2-4days\nafterthepatientisbothneurologicallyandmedicallystable.II-2 C\nHeparin\n(unfractionated)Adjusted-doseunfractionatedheparinmaybestarted\nconcurrentlyforpatientsataveryhighriskofembolism.III C\nAnticoagulantAnticoagulantmaybedelayedfor1-2weeksiftherehasbeen\nsubstantialhaemorrhage.III C\nUrgentroutineanticoagulationwiththegoalofimproving\nneurologicaloutcomesorpreventingearlyrecurrentstrokeisnot\nrecommended.I A\nUrgentanticoagulationisnotrecommendedfortreatmentof\npatientswithmoderate-to-largecerebralinfarctsbecauseofthe\nhighriskofintracranialbleeding.I A\nTable5.6:RevascularisationProcedures\nTreatment RecommendationsLevelof\nEvidenceGrade\nCarotid\nEndarterectomy\n(CEA)PrimaryPrevention\nMaybeconsideredinpatientswithahighgrade\nasymptomaticcarotidstenosis(70-99%)whenperformedby\nsurgeonswithlessthan3%morbidity/mortalityrate.I A\nSecondaryPrevention\nIndicatedformostpatientswithastenosisof70-99%aftera\nrecentischaemiceventincentreswithcomplicationratesof\nlessthan6%.I A\nEarlierintervention(within2weeks)ismorebeneficial. II-1 B\nMaybeindicatedforpatientswithastenosisof50-69%after\narecentischaemiceventincentreswithcomplicationrates\noflessthan6%.III C\nNotrecommendedforpatientswithastenosisoflessthan\n50%.I A\nPatientsshouldremainonantiplatelettherapybeforeand\naftersurgery.II-2 B\nCarotidangioplasty\nandstenting(CAS)CASrepresentsafeasiblealternativetocarotid\nendarterectomyforsecondarystrokepreventionwhen\nsurgeryisundesirable,technicallydifficult,orinaccessible.II-2 B\nDistalprotectivedevicesshouldbeusedduringthe\nprocedure.I A\nUseofdualantiplateletforatleast4weeksafterCAS. I A\nThelong-termsafety(for4years)forCASisasgoodas\nCEA.I A\nComplexconfigurationoftheaorticarchandinternalcarotid\narterytortuosityincreasetheriskofcerebralischemiain\nCAS.II-2 B\nIntracranial\nangioplasty&stenting\n(IAS)RoleofIASinintra-cranialstenoses,asymptomatic\nstenosesandacutestrokeisunclearandmaynotbe\nrecommended.II-2 C"
    },
    {
        "page_number": 26,
        "text": "26Chapter7:EmergencyMedicineServices\nTable7.1:EmergencyMedicineServices\nManagement RecommendationsLevelof\nEvidenceGrade\nPre-HospitalManagement\nPubliceducationEducationalprogrammes\n-shouldbedesignedtocreateawarenessandknowledgeof\nstrokewarningsigns.\n-shouldincludethetimelyrecognitionandneedtoseek\nemergencycarebycalling999promptly.\nNewrecommendationII-1\nII-1A\nA\nEmergency\ndispatchsystemADC\n-shouldbefamiliarwithcommondescriptorsusedbythe\npublicforstroke.Wheneverthedescriptorsareused,EMD\naretrainedtousethestrokeprotocolstoidentifysuspected\nstrokepatients\n-shouldhaveaprotocolortoolsthatallowEmergency\nMedicalDispatchers(EMD)toidentifysuspectedstroke\npatients.e.g.MDPSStrokeDiagnosticTool,FASTstroke\nassessment.\n-shouldhaveasystemtoprioritiessuspectedstrokecallsto\nfacilitateearlyarrivalofpatientstotheED.\nNewrecommendationII-1\nII-1\nII-1A\nA\nA\nInitialon-scene\nmanagementPHCresponders\n-shouldrapidlyevaluateairway,breathingandcirculationto\nidentifylifethreateningsituation,andmanagethem\naccordingly.\n-shoulduseavalidatedandstandardizedstroke\nidentificationassessmenttoolsuchasFASTorBE-FAST\nstrokeassessment\n-shouldbetrainedtoidentifyhypoglycaemiaasa\nstroke-mimicandapplyappropriatemanagementprotocols\n-shouldascertainthetimeofonsetofstrokesymptomsfrom\nthepatientorwitness(es).\nPHCServiceProvidersshouldensureitsrespondersaremade\nawareofthenearesthospitalcapableofprovidingthrombolysisand\nhospitalcapableofperformingendovascularstroketreatment,\nwithintheirservicearea.Awrittenprotocolthatensuresthe\nambulancediversionofthepatienttosuchhospitalsshouldbe\nmadeavailableforuse.\nAllstrokepatientsfromPHCwithpositivesignsofstrokewithinthe\n4.5-hourtimewindowformedicalthrombolytictherapyshouldbe\ntransportedimmediatelytoanacutestrokereadyhospital.\nTitrateddoseofoxygenshouldbedeliveredtostrokepatientswith\nanoxygensaturationlevelofbelow95%.\nNewrecommendationII-1\nII-1\nI\nI\nI\nII-1\nII-3A\nA\nA\nA\nA\nA\nB\nPre-arrival\ncommunicationPHCRespondersshouldbetrainedtoprovidepre-arrival\nnotificationofstrokepatientstoreceivinghospitals.\nMECCandassociatedstrokereadyhospital(s)arerecommended\ntohavelocalregionalstrokereferralsystem/networkand\nagreementwiththeEDtofacilitatethetransportdecisionfromPHC\ntoensurethetreatmentwindowof4.5hoursisachieved.\nNewrecommendationII-1\nIA\nA"
    },
    {
        "page_number": 27,
        "text": "27EmergencyDepartmentManagement\nEDEvaluationAllpatientspresentingtoanEDwithsuspectedacutestrokemust\nhaveimmediateclinicalevaluationandinvestigationstoestablish\nthediagnosisandtodeterminetheeligibilityforintravenous\nthrombolytictherapyand/orEVT\nTheuseofclinicalscreeningtoolssuchasFASTorBE-FASTto\nidentifystrokebyEDstaffcanbebeneficial\nNewrecommendationI\nII-2A\nB\nInitial\nAssessmentin\nEDEDstaffshouldrapidlyevaluateairway,breathingandcirculationin\npatientswithsuspectedacutestrokeandmanageaccordingly\nAllpatientswithsuspectedacutestrokeshouldhavetheirblood\nglucoselevelcheckeduponarrivalattheED\nAstandardizedstrokeseverityscaleshouldbeusedsuchasthe\nNationalInstitutesofHealthStrokeScale(NIHSS)toassessstroke\nseverityintheED\nNewrecommendationI\nII-1\nII-1A\nA\nA\nImaging Allpatientswithsuspectedstrokewhoarecandidatesfor\nintravenousthrombolysisand/orEVTshouldundergoatleastCT\nscanimmediately.Allothersuspectedstrokepatientsshouldhave\nanurgentCTbrain.\nInterpretationofacutestrokeimagingforthrombolysisdecisions\nshouldonlybemadebyhealthcareprofessionalswhohave\nreceivedappropriatetraining.\nNewrecommendationII-1\nIIIA\nC\nOther\nConsiderationsPatientswithacutestrokeshouldonlyreceivesupplemental\noxygenonlyiftheiroxygensaturationisbelow95%.\nHypotensionandhypertensioninpatientswithacutestrokeshould\nbeidentifiedandmanagedaccordingly.\nPatientswithacutestrokeshouldhavetheirswallowingability\nscreenedasearlyaspossibleafterarrivalatthehospitaland\nbeforebeinggivenanyoralfood,fluid,ormedication\nNewrecommendationII-3\nIII\nII-2B\nC\nB\nQuality\nImprovementJointmultidisciplinaryaudittoreviewandmonitorstrokecare\nqualitybenchmarks,indicators,evidence-basedpractices,and\noutcomesshouldbeperformedperiodically.\nEDpersonnelshouldundergoastandardizedtraininginacute\nstrokemanagement.\nNewrecommendationII-1\nIIIA\nC"
    },
    {
        "page_number": 28,
        "text": "28Chapter8:AcuteGeneralManagement\nTable8.1:AcuteGeneralManagement\nFactors RecommendationsLevelof\nEvidenceGrade\nOxygenand\nAirwaysupportPatientswithacutestrokeshouldonlyreceivesupplementaloxygen\niftheiroxygensaturationisbelow95%andbetitratedtoachieve\nabove95%.\nNewrecommendationII-3 B\nObservationRegularobservationismandatorytorecogniseimpairedpulmonary\nfunction(pulseoxymeter),circulatoryfunction(pulserate,blood\npressure),NIHSSscore,headchart,GCS,andcomplicationsfrom\nmasseffect.III C\nMobilisationMobiliseearlytopreventcomplications. II-3 C\nHigh-dose,veryearlymobilisationwithin24hoursofstrokeonset\nshouldnotbeperformedbecauseitcanreducetheoddsofa\nfavourableoutcomeat3months.\nNewrecommendationI -\nBloodPressureLoweringBPinitiallyby15%isprobablysafe.Bloodpressure\nreductionshouldnotbedrastic.\nNewrecommendationIII C\nDonottreathypertensionifsystolicBPis<220mmHgordiastolicBP\nis<120mmHg.Mildhypertensionisdesirableat160-180/90-100\nmmHg.III C\nRecommendedtherapy:Labetalol10-20mgbolusesat10-minute\nintervalsupto150-300mgor1mg/mlinfusion,rateofinfusionfor\nLabetalolas1-3mg/minorCaptopril6.25-12.5mgorally.III C\nBloodGlucoseAfteranacutestroke,treathyperglycaemiatokeeptheblood\nglucoselevelsbetween6.0-10.0mmol/Landensurethat\nhypoglycaemiaisavoided.\nNewrecommendationIII C\nAvoidverytighttargetofglucosecontrol(4.0-7.5mmol/L)inthefirst\nhoursofacuteischaemicstroke.\nNewrecommendationI A\nNutrition Performawaterswallowingtest. III C\nInsertanasogastrictubeifthepatientfailstheswallowingtest. III C\nPEGissuperiortonasogastricfeedingonlyifprolongedenteral\nfeedingisrequiredII-1 B\nEnteralfeedingshouldbestartedwithin7daysofadmission(oralor\ntubefeeding).\nNewrecommendationI A\nInfection Searchforthepresenceofinfectioniffeverappearsandtreatitearly\nwithappropriateantibiotics.III C\nFever Useanti-pyreticstocontrolelevatedtemperatures. II-1 B\nContinenceTheapplicationofindwellingcathetershouldbeusedcautiouslyand\nshouldberemovedassoonaspossible.\nNewrecommendationI A\nAllstrokepatientsshouldbeassessedforurinaryretentionor\nincontinence,faecalincontinence,andconstipation.\nNewrecommendationIII C\nRaised\nIntracranial\nPressureHyperventilatetolowertheintracranialpressure. II-2 B\nMannitol(0.25to0.5g/kg)intravenouslyadministeredover20\nminuteslowerstheintracranialpressureandcanbegivenevery6\nhours.II-2 B\nIfhydrocephalusispresent,drainageofcerebrospinalfluidviaan\nintraventricularcathetercanrapidlylowerintracranialpressure.III C\nHemicraniectomyandsurgicaldecompressivetherapywithin48 I A"
    },
    {
        "page_number": 29,
        "text": "29hoursaftersymptomonsetisrecommendedtocontrolintracranial\npressureandpreventherniationamongthosepatientswithvery\nlargeinfarctsofthecerebralhemisphere.\nPatients>60yearsofagemaybeconsideredfordecompressive\ncraniectomyinselectedcases.\nNewrecommendationI A\nVentriculostomyandsub-occipitalcraniectomyareeffectivein\nrelievinghydrocephalusandbrainstemcompressioncausedby\nlargecerebellarinfarctions.II-2 B\nDeepVein\nThrombosis\nProphylaxisForimmobilestrokepatientswithoutcontraindications,intermittent\npneumaticcompression(IPC)inadditiontoroutinecare(aspirinand\nhydration)isrecommendedoverroutinecarealonetoreducethe\nriskofdeepveinthrombosis(DVT).\nNewrecommendationI A\nThebenefitofprophylactic-dosesubcutaneousheparin\n(unfractionatedheparin[UFH]orLMWH)inimmobilepatientswith\nAISisnotwellestablished.\nNewrecommendationIII C\nInischaemicstroke,elasticcompressionstockingsshouldnotbe\nused.\nNewrecommendationI A\nSeizureNew-onsetseizuresinadmittedpatientswithacutestrokeshouldbe\ntreatedusingappropriateshort-actingmedicationsiftheyarenot\nself-limiting.\nNewrecommendationIII C\nAsingle,self-limitingseizureoccurringattheonset,orwithin24\nhoursafteranischemicstroke(consideredan‘‘immediate’’\npost-strokeseizure)shouldnotbetreatedwithlong-term\nanticonvulsantmedications.Theuseofprophylacticanti-seizure\nmedicationsisnotrecommended.\nNewrecommendationIII C\nPatientsthathaveanimmediatepost-strokeseizureshouldbe\nmonitoredforrecurrentseizureactivityandshouldbetreatedasper\ntreatmentrecommendationsforseizuresinasinotherneurological\nconditionsandtreatmentshouldbeindividualised.\nNewrecommendationIII C\nChapter9:ReperfusionofIschaemicBrain\nTable9.1:TreatmentofAcuteIschaemicStrokewithIntravenousThrombolysis\nTreatment RecommendationsLevelof\nEvidenceGrade\nAlteplaseOnsetwithin4.5hours\nDose:0.9mg/kg,max90mg,10%bolusandremainingdosegiven\nasinfusionover1hour.I A\nOnset>4.5upto9hoursifknownonsetorwake-upstrokeguidedby\nCTperfusion,withthepresenceofasignificantpenumbracore\nmismatch.\nNewrecommendationII B\nUncertainonsetandwakeupstrokeguidedbyMRI(DWI-FLAIR\nmismatch)\nNewrecommendationII B\nTenecteplaseOnsetwithin4.5hoursandeligibleforthrombolytictreatmentcanbe\nconsideredforintravenousTenecteplasepriortoEVT.\nDose:0.25mg/kg;maximumdoseof25mg\nNewrecommendationII B"
    },
    {
        "page_number": 30,
        "text": "30Chapter10:EndovascularThrombectomy\nChapter11:StrokeUnit\nChapter12:StrokeintheOlderPerson\nTable12.1:StrokeintheOlderPerson\nManagement RecommendationsLevelof\nEvidenceGrade\nScreeningforFrailtyAllolderadultsshouldbescreenedforfrailtyusinga\nvalidatedinstrumentsuitableforthespecificsettingor\ncontextwithatailoredmanagementplanthereafter.\nNewrecommendationIII C\nStrokeThrombolysisAnolderpersonshouldreceiveandcanbenefitfrom\nintravenousthrombolysis.\nNewrecommendationI A\nEndovascular\nthrombectomyAnolderpersoncanbenefitfromendovascular\nthrombectomyforanteriorcirculatorylargevesselocclusion.\nNewrecommendationI ATable10.1:AcuteEndovascularThrombectomyTreatment\nTreatment RecommendationsLevelof\nEvidenceGrade\nAcuteEndovascular\nThrombectomy\n(EVT)EVTisindicatedforAISwithlargevesselocclusion;proximal\nmiddlecerebralarterysegment1(M1)/proximalM2\nocclusion/internalcarotidartery(ICA),andpresentingwithin6\nhoursfromonset.\nNewrecommendationI A\nEVTisindicatedinselectedpatientswhoarriveafter6hours\nandupto24hoursofstrokeonsetwithevidenceoflargevessel\nocclusion.\nNewrecommendationI A\nEVTbridgingwith\nAlteplase\n(Drip&Ship)AISpatientswhoarrivewithin4.5hoursofstrokeonsetandare\neligibleforrtPAtreatmentshouldbeconsideredfor\nthrombolytictreatmentpriortoEVT.\nNewrecommendationI A\nForpatientsundergoing“Drip&Ship”(EVTfollowing\nadministrationofIVT),thereshouldbenodelayinproceeding\ntoEVTtodeterminetheclinicaleffectivenessofAlteplase.\nNewrecommendationI A\nEVTbridgingwith\nTenecteplaseAISpatientswhoarrivewithin4.5hoursofstrokeonsetandare\neligibleforthrombolytictreatmentcanbeconsideredfor\nintravenousTenecteplasepriortoEVT.\nNewrecommendationII B\nTable11.1:StrokeUnit\nFactor RecommendationsLevelof\nEvidenceGrade\nStroke\nUnitEveryhospitalshouldsetupastrokeunitasitcansignificantlyreduce\ndeaths,dependency,institutionalisation,andlengthofhospitalstay.I A\nTheuseofcomprehensivespecializedstrokecare(strokeunits)that\nincorporatesrehabilitationisrecommended.I A\nAstrokeunitshouldbemanagedbyamultidisciplinarystroketeam. I A"
    },
    {
        "page_number": 31,
        "text": "31Managementof\nglucoselevelinthe\nacutephaseofstrokeAfteranacutestroke,treathyperglycaemiatokeepthe\nbloodglucoselevelsbetween6.0-10.0mmol/L(110-180\nmg/dL)andensurethathypoglycaemiaisavoided.\nNewrecommendationIII C\nAvoidverytighttargetsofglucosecontrol(4.0-7.5mmol/L)\ninthefirsthoursofacuteischaemicstroke.\nNewrecommendationI A\nHypertension Olderpersonswhohaveoneormoreofthefollowing:frailty,\nmultiplecomorbiditiesand/orcognitiveimpairment,require\nanindividualisedapproachforbloodpressuremanagement.\nNewrecommendationI A\nDiabetesMellitus Targetsofbloodglucosecontrolinolderpersonswith\ndiabetesshouldbeindividualisedtakingintoaccounttheir\nfunctionalstatus,medicalcomorbidities,andlikelihoodof\ndevelopingadverseevents.\nNewrecommendationIII C\nDyslipidaemia Statinsarerecommendedforstrokepreventioninolder\npersonswithalessdirectevidenceofbenefitforstroke\npreventionandprimarypreventionofvasculareventsin\nthoseagedover75years.\nNewrecommendationI A\nAtrialFibrillation Olderpersonswithatrialfibrillationcanbenefitfromoral\nanticoagulantforstrokepreventionwithanindividualised\ntreatmentplantakingintoaccountmedicalco-morbidities,\nfunctionalstatus,andsocialfactors.\nNewrecommendationI A\nMedication\nmanagementinthe\nolderpersonwith\nstrokeAcomprehensivecareplanforafrailolderpersonshould\nincludemanagementofpolypharmacy.\nNewrecommendationIII C\nDeliriumpost-acute\nstrokeAllpost-strokepatientsshouldbescreenedfordelirium\nthroughouthospitalization.\nNewrecommendationII-2 B\nScreeningforpost-strokedeliriumusingthe4ATtoolis\nrecommended.\nNewrecommendationII-2 B\nAmulti-componentinterventionforpost-strokedelirium\npreventionandmanagementshouldbeimplementedto\ndecreasetheincidenceandseverityofdeliriumaswellasto\nreducethelengthofstay.\nNewrecommendationII-2 B\nFallsprevention\npost-strokeAllpeoplewithstrokeshouldbeofferedfallsandfragility\nfractureriskassessmentandmanagementduringtheir\nrehabilitationperiod.\nNewrecommendationIII C\nDischargeplanning\nandearlysupported\ndischargepoststrokeDischargeplanningforolderpersonswithstrokeshould\noccurattheappropriatetimefollowingamultidisciplinary\nrecommendationinwhereanydecisionsaboutcareismade\nintheperson’sbestinterests.\nNewrecommendationII-3 B\nHospitalin-patientswithstrokewhohavemildtomoderate\ndisabilityshouldbeofferedearlysupporteddischarge,with\ntreatmentathomebeginningwithin24hoursofdischarge.\nNewrecommendationII-3 B\nAnearlystrokesupporteddischargeteamshouldbe\norganisedasasinglemulti-disciplinaryteamcomprisingof:\n●Doctors\n●Nurses\n●PhysiotherapistsII-1 A"
    },
    {
        "page_number": 32,
        "text": "32●Occupationaltherapists\n●Speechandlanguagetherapists\n●Clinicalpsychologists\n●Socialworkers\nNewrecommendation\nOlderpersonswithstrokeandtheirfamilymembers/carers\nshouldbeinvolvedindecisionsaboutthedischargeandare\npreparedtobeinvolvedintheircare.\nNewrecommendationIII C\nDischargeplanningshouldincludeprovidingnecessary\nequipmentandsupportservicesincludingidentificationof\nfollow-uptreatment.\nNewrecommendationIII C\nEvaluationofhomeenvironmentbyanoccupational\ntherapistshouldbecarriedout,bydoingahomevisitor\nconductinganinterviewaboutthehomeenvironment,\nincludingtakingphotographsorvideoswiththeconsentof\nthefamilymembers/carers.\nNewrecommendationIII C\nEnd-of-lifecare Themultidisciplinarystroketeamshouldbetrainedin\nprinciplesandpracticeofend-of-lifecare.\nNewrecommendationII-3 C\nBurdensometreatmentshouldbeavoidedattheend-of-life\ncareandthisshouldincludedecisionstocontinueoral\nfeedingandhydrationdespitepotentialriskofaspiration.\nNewrecommendationII-3 C\nAdvancedcareplanningshouldbeprovidedforindividuals\nwhoareexpectedtohavelimitedlifeexpectancy.\nNewrecommendationII-2 B\nDecisionstowithholdandwithdrawtreatmentshouldtake\nintoaccountpriorexpressedwishesoftheindividualwith\nstrokewhichoftenneedstobeestablishedfromthe\nnext-of-kinandcloserelatives.\nNewrecommendationIII C\nStroketeamsshouldbepreparedtofacilitatethetransferof\ncareoftheindividualdyingofstroketotheirownhomes\nsupportedbylocalhospicesandpalliativecareservicesif\navailable.\nNewrecommendationIII C\nChapter13:StrokeandCardioembolism\nTable13.1:PreventionofStrokeinAtrialFibrillationPatients\nTreatment RecommendationsLevelof\nEvidenceGrade\nStrokePrevention\nAntiplateletmonotherapyAntiplateletmonotherapyisnotindicatedforstroke\npreventioninpatientswithnon-valvularatrialfibrillation\n(NVAF).I A\nOralanticoagulant(OAC)OAChasbeenproventobesuperiortonotreatmentor\nAspirininpatientswithNVAF.I A\nOACisrecommendedtopreventcardioembolicstrokefor\nallNVAFmalepatientswithCHA2DS2-VAScscoreof2or\nmoreandfemalepatientswithaCHA2DS2-VAScscoreof3\normore.\nNewrecommendationI A"
    },
    {
        "page_number": 33,
        "text": "33TheOACofchoiceforvalvularAF(moderate-to-severe\nmitralstenosis)andmechanicalheartvalvespatientsis\nVitaminKAntagonist(Warfarin).I A\nSecondaryStrokePrevention\nParenteralanticoagulant\n(heparinorlowmolecular\nweightheparin)Afteracardioembolicstroke,parenteralanticoagulant\ntherapy(heparinorlowmolecularweightheparin)isnot\nrecommendedtopreventsecondarystroke.I A\nDOACs ForsecondarystrokepreventioninanAFpatient,the\ninitiationofDOACsisrecommendedafterexcluding\nhaemorrhagictransformation\nNewrecommendationII B\nDOACsarepreferredoverVKAandAspirininAFpatients\nwithapreviousstroke.\nNewrecommendationI A\nAspirinAspirincouldbeconsideredbeforetheinitiationofOAC\nafteranAFpatientdevelopsanischaemicstroke.III C\nCombinationtherapyof\nOACandantiplateletTheriskofbleedingishighafterinitiationofthe\ncombinationtherapyofOACandantiplateletforsecondary\nstrokeprevention.\nNewrecommendationIII C\nOAC Afteranintracranialhaemorrhage,OACcouldbe\nre-initiatedafter4-8weeksinaNVAFpatientwithhigh\nCHA2DS2-VAScscoreiftheunderlyingcauseandrisk\nfactorsofbleedinghavebeentreated.\nNewrecommendationII B\nChapter14:StrokeinSpecialCircumstances\nTable14.3:TreatmentofStrokeinCertainCircumstances\nTreatment RecommendationsLevelof\nEvidenceGrade\nAspirin Ifthecauseisnotidentified,Aspirinisusuallygivenwhileadditional\ntestsareobtainedtoguidethechoicebetweenlong-termantiplatelet\noranticoagulanttherapy.III C\nAntiplatelettherapyisrecommendedinpatientswhoarefoundto\nhaveabnormalfindingsoncoagulationtestingafteraninitial\nischaemicstrokeorTIAifanticoagulanttherapyisnotused.I A\nForpatientswithischaemicstrokeorTIAwhohavean\nanti-phospholipidantibodybutwhodonotfulfilthecriteriafor\nanti-phospholipidantibodysyndrome,antiplatelettherapyisI BTable14.2:InvestigationofYoungStroke\nInvestigation RecommendationsLevelof\nEvidenceGrade\nHomocysteinaemiaRoutinescreeningforhyperhomocysteinaemiaamongpatients\nwitharecentischaemicstrokeorTIAisnotindicated.III C\nAnti-phospholipid\nantibodiesRoutinetestingforanti-phospholipidantibodiesisnot\nrecommendedforpatientswithischaemicstrokeorTIAwhohave\nnoothermanifestationsoftheanti-phospholipidantibody\nsyndromeandwhohaveanalternativeexplanationfortheir\nischaemicevent,suchasatherosclerosis,carotidstenosis,orAF.III C\nSleepstudy Asleepstudymightbeconsideredforpatientswithanischaemic\nstrokeorTIA.II-2 B\nCoagulation\nscreeningTheusefulnessofscreeningforthrombophilicstatesinpatients\nwithischaemicstrokeorTIAisunknown.II-2 C"
    },
    {
        "page_number": 34,
        "text": "34recommended\nForpatientswithischaemicstrokeorTIAwhomeetthecriteriaforthe\nanti-phospholipidantibodysyndromebutinwhomanticoagulationis\nnotyetstarted,antiplatelettherapyisindicatedI A\nDOAC ESUS:\nThereisnoroleofanticoagulantinESUS.\nNewrecommendationI A\nForpatientswithanischaemicstrokeorTIAandbothaPFOanda\nvenoussourceofembolism,anticoagulationisindicated,depending\nonthecharacteristicsofthestroke.\nNewrecommendationI A\nAnticoagulationmightbeconsideredinpatientswhoarefoundtohave\nabnormalfindingsoncoagulationtestingafteraninitialischaemic\nstrokeorTIA,dependingontheabnormalityandtheclinical\ncircumstances.\nNewrecommendationII-2 C\nForpatientswithischaemicstrokeorTIAwhomeetthecriteriafor\nAPS,anticoagulanttherapymightbeconsidereddependingonthe\nperceptionofriskforrecurrentthromboticeventsandbleeding.\nNewrecommendationII-2 C\nDevice PFOclosuredevicetherapy\nPFOclosuredeviceshavemoderatebenefitinyoungand\nmiddle-agedpatientswithcryptogenicischaemicstroke.PFOclosure\ndevicescombinedwithantiplatelettherapyisalsorecommended.\nNewrecommendationI A\nContinuouspositiveairwaypressure(CPAP)machine\nCPAPtherapymightbeconsideredforpatientswithischaemicstroke\norTIAandsleepapnoeagiventheemergingevidenceinsupportof\nimprovedoutcomes.\nNewrecommendationII-2 B\nBlood\ntransfusionForpatientswithsicklecelldiseaseandpriorischaemicstrokeorTIA,\nlong-termbloodtransfusionstoreducethelevelofhaemoglobinSto\n<30%ofthetotalhaemoglobincompositionarerecommended.\nNewrecommendationI B\nSupplementsSupplementationwithfolate,vitaminB6andvitaminB1\nInadultswitharecentischaemicstrokeorTIAwhoareknowntohave\nmildtomoderatehyperhomocysteinaemia,supplementationwith\nfolate,vitaminB6andvitaminB12safelyreducesthehomocysteine\nlevelsbuthasnotbeenshowntopreventstroke.\nNewrecommendationIII B\nTable14.4:InvestigationofCerebralVenousThrombosis\nInvestigation RecommendationsLevelof\nEvidenceGrade\nCTV/MRV EitherCTorMRvenographycanbeusedasareliablealternative\ntoDSAforthediagnosisofCVTinpatientswithsuspectedCVTII-3B\nDigitalSubtraction\nAngiography(DSA)DSAasadiagnosticmodalityisindicatedincasesofsuspected\nCVTwhenthediagnosisofCVTisdoubtfulwithnon-invasive\nimagingalone.II-1C\nD-Dimer MeasurementoftheD-dimerlevelbeforeneuroimagingis\nrecommendedinpatientswithsuspectedCVT,exceptinthose\nwithisolatedheadacheorprolongeddurationofsymptoms(high\nfalsenegativerates).II-2B\nThrombophilia\nscreeningThrombophiliascreeningmaybeperformedinpatientswithhigh\npre-testprobabilityofhavingseverethrombophilia(i.e.apersonal\nand/orfamilyhistoryofvenousthrombosis,ayoungageatCVT\nand/orCVTwithoutatransientorapermanentriskfactor)toII-3B"
    },
    {
        "page_number": 35,
        "text": "35preventrecurrentvenousthromboticevents.However,routine\nthrombophiliascreeningisnotrecommendedtoreducedeaths,\nimprovefunctionaloutcome,orpreventrecurrentvenous\nthrombosisinpatientswithCVT.\nOccultmalignancy\nscreeningRoutinescreeningforoccultmalignancyinpatientswithCVTisnot\nrecommendedtoimproveoutcomesII-3B\nTable14.5:TreatmentofCentralVenousThrombosis\nTreatment RecommendationsLevelof\nEvidenceGrade\nAcuteanticoagulant\ntreatmentTreatmentofacuteCVTadultpatientswithheparinin\ntherapeuticdosageisrecommended,includinginthosewith\nintracerebralhaemorrhageatbaseline.I B\nTypeofheparinTreatmentofacuteCVTpatientswithLMWHinsteadofUFHis\nrecommended(unlessfastreversaloftheanticoagulanteffect\nisrequired,orthepatienthascontraindicationstoLMWH).I B\nThrombolysisin\nacuteCVTThrombolysisinacuteCVTpatientswithapre-treatmentlow\nriskofpooroutcomeisnotrecommended.III C\nEndovascular\ntherapyor\nThrombectomyEndovasculartherapyorThrombectomymaybeconsideredin\npatientswithclinicaldeteriorationdespiteanticoagulation,with\nsevereneurologicaldeficitsorincoma.II-2 C\nWarfarin Usingoralanticoagulants(vitaminKantagonists)foravariable\nperiod(3-12months)afterCVTisrecommendedtoprevent\nrecurrentCVTandothervenousthromboembolicevents.\nPatientswithrecurrentvenousthrombosisorwithan\nassociatedprothromboticconditionwithahighthromboticrisk\nmayneedpermanentanticoagulation.Wesuggestfollowing\nspecificrecommendationsforthepreventionofrecurrent\nvenousthromboemboliceventsinsuchconditions.III C\nDOACs TreatmentofCVTwithDOACsisnotrecommendedespecially\nduringtheacutephase.III C\nTherapeuticLPTherapeuticLPisnotrecommended.However,itmaybe\nconsideredinpatientswithcerebralvenousthrombosisand\nsignsofintracranialhypertension,becauseofapotential\nbeneficialeffectonvisuallossand/orheadache,wheneverits\nsafetyprofileisacceptable.III C\nAcetazolamideAcetazolamideisnotrecommendedinpatientswithacuteCVT\ntopreventdeathortoimprovethefunctionaloutcome.\nHowever,inisolatedintracranialhypertensionsecondaryto\nCVT,causingsevereheadachesoristhreateningthevision,\nAcetazolamidemaybeconsideredifitssafetyprofileis\nacceptableIII C\nSteroids SteroidsinpatientswithacuteCVTwithoutanyco-existing\ninflammatorydiseasearenotrecommendedtopreventdeath\nortoimprovethefunctionaloutcomeIII C\nShunt Routineshunting(withoutothersurgicaltreatment)inpatients\nwithacuteCVTandimpendingbrainherniationdueto\nparenchymallesionsisnotrecommendedtopreventdeathII-3 C\nDecompressive\nsurgeryDecompressivesurgeryforpatientswithacuteCVTand\nparenchymallesion(s)withimpendingherniationis\nrecommendedtopreventdeath.II-1 B\nAntiepilepticdrugs\n(AEDs)AntiepilepticdrugsusageinpatientswithacuteCVTwith\nsupratentoriallesionsandseizuresarerecommendedto\npreventearlyrecurrentseizures.II-3 C"
    },
    {
        "page_number": 36,
        "text": "36Chapter15:ManagementofStrokeinPregnancy\nTable15.1:ManagementofStrokeinPregnancy\nManagement RecommendationsLevelof\nEvidenceGrade\nDuring\npregnancyInAIS,Aspirinupto150 mgdailyiswelltoleratedduring\npregnancy.\nPregnantpatientswithwell-definedlowriskconditionsmaybe\ngivenUFHorLMWHinthefirsttrimester,followedbyalowdose\naspirininthesecondandthirdtrimesters.III C\nInpregnantpatientswithwell-definedlowriskconditions,no\nantiplateletotherthanAspirincanbeprescribed.III C\nInpregnantwomenwithwell-definedhigh-riskconditions,Vitamin\nKantagonistsneedtobeavoidedbetweenthe6thand12thweeks\nofpregnancyandalsoneartoterm.\nDuringthisperiod,UFHorLMWHcanbeused.II B\nInaddition,pregnantpatientswithwell-definedhigh-riskconditions\ncurrentlyondirectoralanticoagulants(DOACs)shouldbegiven\nUFHorLMWHbetweenthe6thand12thweeksofpregnancy.\nNewrecommendationIII C\nAtotherweeksofgestation,Warfarincanbegiven. III C\nLabour\ninductionWhenthelabourprocessispharmacologicallyinduced,Aspirin\ncanbecontinued.III C\nUFHandLMWHneedtobestopped24hoursbeforetheinduction\noflabour.III C\nUFHandLMWHshouldberestartedwithin24hoursofdeliveryif\ntherearenocontraindications.III C\nVitaminKantagonists(withoutloadingdose)mayberestarted\nafter24hoursofdeliveryiftherearenocontraindications.III C"
    },
    {
        "page_number": 37,
        "text": "37EPIDEMIOLOGY,DEFINITIONANDCLASSIFICATIONOFSTROKE\n1.1EpidemiologyofStroke\nStrokeisamajorcauseofmortalityanddisabilityinmanycountries,includingMalaysia.Global\nstrokeestimatesstudyreportedthat,in2013,therewereapproximately25.7millionstrokesurvivors,\n6.5milliondeaths,113milliondisability-adjustedlife-years(DALYs)lost,and10.3millionnewcases\nofstroke.1Thehighburdenofstrokewasmainlyobservedindevelopingcountries,andaccounted\nfor75.2%ofallstroke-relateddeathsand81%ofassociatedDALYslost.\nStatisticsfromtheDepartmentofStatistics,Malaysiashowedthatstrokeemergedasoneofthetop\nfiveleadingcausesofmortalitysince2000.Datain2017showedthatcerebrovasculardiseases\ncontributedto7.1%ofallmortalitiesrecordedintheMalaysianpopulation(Table1.1).\nTable1.1:LeadingCausesofMortalitiesinMalaysia\n1.IschaemicHeartDisease 13.9%\n2.Pneumonia 12.7%\n3.Stroke 7.1%\n4.TransportAccidents 4.6%\n5.MalignantCancer 2.3%\n(Source:DepartmentofStatisticsMalaysia,2017)\nIschaemicstrokeaccountedfor79.4%ofallstrokecases,followedbyhaemorrhagicstroke(18.2%),\ntransientischaemicattack(2%)andunclassifiedstroke(0.4%).2\nHypertensionwasthemostcommonriskfactor(72%),followedbydiabetesmellitus(47%),\ndyslipidaemia(32%)andsmoking(31%).3Hypertensionremainsthemostcommonmedicalrisk\nfactorforstroke,whereascurrentsmokingandphysicalinactivityarethemostpredominant\nlifestyle-relatedriskfactors.Ingeneral,hypertension,diabetesmellitusandtobaccosmokingtendto\nbemoreprevalentamongmen,whereashypercholesterolaemia,physicalinactivityandobesitywere\nmoreprevalentamongwomen.4\nThemeanageforischaemicstrokeinMalaysiawas62.8yearsforthefirststrokeand64.3yearsfor\nrecurrentcases.2Malaysianwomenwithafirst-everischaemicstrokehadagreaterseverity,higher\nnumberofriskfactorsandpoorerfunctionaloutcomes,ascomparedtomen.Afterpostgender–age\nadjustment,theMalaysianpopulationobservedanincreasedincidenceofstrokeinwomenas\ncomparedtomen.However,therewasnodifferencebetweengendersintermsofaccessto\nthrombolysistreatment.5\n1.2ConceptualDefinitions\n1.2.1Stroke\nStrokeisdefinedasaclinicalsyndromecharacterizedbyrapidlydevelopingclinicalsymptoms\nand/orsignsoffocal,andattimesglobal,lossofcerebralfunction,withsymptomslastingmorethan\n24hoursorleadingtodeath,withnoapparentcauseotherthanthatofavascularorigin.1"
    },
    {
        "page_number": 38,
        "text": "38Thenewdefinitionofcentralnervoussystem(CNS)infarctionwhichincorporatesscientificand\ntechnologicaladvancesis“brain,spinalcord,orretinalcelldeathattributabletoischaemia,basedon\neitherpathologicalimagingorotherobjectiveevidenceofcerebrospinalcordorretinalischaemic\ninjuryinadefinedvasculardistribution,orclinicalevidenceofischaemicinjury,basedonsymptoms\npersistingforgreaterthan24hours.”6\nStrokesmaybeclassifiedandtimedas:7\nI.Earlyhyperacute(astrokethatis0–6hoursold)\nII.Latehyperacute(6–24hours)\nIII.Acute(24hoursto7days)\nIV.Subacute(1–3weeks)\nV.Chronic(morethan3weeks)\n1.2.2TransientIschaemicAttack(TIA)\nTIAoriginallyhadatime-baseddefinitioncharacterizedbyanacutelossoffocalcerebralor\nmonocularfunctionswithsymptomslastinglessthan24hoursandwhichisthoughttobedueto\ninadequatecerebralandocularbloodsupplyasaresultofarterialthrombosisorembolism.However,\natime-baseddefinitionisinadequatebecausethereisriskofpermanenttissueinjury(i.e.infarction)\nevenwhenfocaltransientneurologicsymptomslastlessthanonehour.\nTIAcurrentlyusesatissue-baseddefinitioni.e.atransientepisodeofneurologicdysfunctioncaused\nbyfocalbrain,spinalcord,orretinalischaemia,withoutacuteinfarction.8\n1.3ClassificationofStroke\n1.3.1WhyClassifyStroke?\nStrokeclassificationhasnumerousimplicationsduringtheimmediatesupportivecareand\nrehabilitation,forprognosticpurposes,guidingcost-effectiveinvestigationsforunderlyingcausesas\nwellastoaiddecisionsfortherapyandsecondarystrokepreventionstrategies.Apartfrombeing\nusefulinsettingupstrokeregistriesanddatabanksforepidemiologicalstudies,properclassification\nofthecausativemechanismofstrokeisimportantforoptimizingstroketreatmentandprognosis.\n1.3.2WhatareStrokeClassificationSystemsthatareWidelyUsedNowadays?\nIschaemicstrokeclassificationcanbecategorizedinto:\nI.Clinical/SyndromicClassification\nII.PhenotypicClassification\nIII.Aetiologic/CausativeClassification\n1.3.3WhatOtherCommonClassificationSystemsareBeingUsed?\nThereareafewotherclassificationsystemscurrentlybeingusedworldwidewhichhaveitsown\nadvantagesanddisadvantages:\nI.TheOxfordCommunityStrokeProject(OCSP)whichwasdevelopedbasedonclinical\nfindingsespeciallyneurologicalsymptoms.9\nII.TheTrialofOrg10172inAcuteStrokeTreatment(TOAST)whichisavalidstraightforward\nandiscurrentlythemostwidelyusedclassificationsystembasedonstrokemechanism.This"
    },
    {
        "page_number": 39,
        "text": "39classificationsystemisfurthersubclassifiedtoStop-StrokeStudyTOAST(SSS-TOAST)which\nismorespecificusingalgorithms.10\nIII.TheCausativeClassificationSystems(CCS)isaweb-basedsystemwhichusesmultiple\nsourcesofclinicaldataandishighlydependentontheavailabilityofmoderndiagnostic\ntechnology.11\nIV.ASCOisthefirstpurelyphenotypicclassificationinwhicheverypatientischaracterizedby\nA-S-C-Oacronym:Atherosclerosis,Small-vesseldisease,Cardiacsource,andOther\ncauses.ASCODPhenotypingofIschaemicStrokeisthemodifiedversionoftheASCO\nclassification.12\nV.ChineseIschaemicStrokeClassification(CISS)isanewtwo-stepsystemthatlooksatthe\naetiologyandunderlyingmechanismofstroke.Ittakesintoaccounttheimportanceof\nintracranialatheromatousbranchdiseaseaffectingpenetratingarteriesandtheunderlying\nmechanismsofischaemicstrokescausedbylargearteryatherosclerosis,thatcommonlyfound\nintheAsianpopulation.13\nKeyRecommendations:\n1.Strokeisamajorcauseofmortalityandmorbidity,andinMalaysia,strokeisthethirdleading\ncauseofmortality.\n2.Ischaemicstrokeisthemostcommonstroke,andhypertensionisthemostcommonrisk\nfactorfollowedbydiabetesmellitus.\n3.Thenewdefinitionofstrokeandtransientischaemicattack(TIA)involvedeitherpathological\nimagingorclinicalevidenceofischaemiaandcanbetimedbasedonthepresentationof\nsymptoms.\n4.Ischaemicstrokecanbeclassifiedaccordingtoclinical,phenotypic,oraetiologic\nclassification."
    },
    {
        "page_number": 40,
        "text": "40CAUSESANDPATHOPHYSIOLOGY\n2.1PrincipalCausesofIschaemicStroke\nThethreemaincausesofischaemicstrokeare:1\nI.Atherothrombosisoflargevessels(20-50%)\nII.Intracranialsmallvesseldisease(25%)\nIII.Embolism(20%)\n2.1.1Atherothrombosis\nAtherothrombosisisdefinedasatherosclerosiswithsuperimposedthrombosis.2Atherosclerosis\naffectslargeandmedium-sizedarteries.Theprocessbeginsinchildhoodasfattystreaksand\nprogressesoveryearswithgradualbuild-upoffibrolipidplaqueandinfiltrationofinflammatorycells.\nThrombosisoccurswhenthisatheroscleroticplaqueisdisruptedresultinginplateletaggregation.\nAtherothrombosisleadstolocalarterialocclusionwithintraluminalpropagationofthethrombus\nproximallyordistallyoritcanresultindistalembolism.Intracraniallargearterydiseaseisthemain\ncauseofischaemicstrokeamongSouthAsianpatients.3\n2.1.2IntracranialSmallVesselDisease\nIntracranialsmallvesseldiseaseisthoughttobeduetolipohyalinosis,microatheromaandfibrinoid\nnecrosis.4Theclinicalsyndromecausedbythisphenomenonislacunarinfarctionduetoocclusionof\nsmallperforatingarteries.Table(2.1)exhibitsthevascularriskfactorsassociatedwithincreasedrisk\nofstroke.5-7\nTable2.1:CommonVascularRiskFactorsofStroke\nNon-Modifiable\nAge\nMalesex\nEthnicity/Race\nFamilyhistoryofstrokeModifiable\nHypertension\nSmoking\nDiabetesmellitus\nAtrialfibrillation\nCoronaryarterydisease\nObesity&physicalinactivity\nRaisedhomocysteinelevels\nHeavyalcoholconsumption\nPreviousstroke\n2.1.3Embolism\nCardioembolismcausesapproximately20%ofallischaemicstrokes.8Embolicmaterialformedwithin\ntheheartorlargearteriestravelsthroughthearterialsystem,lodginginavesselandpartiallyor\ncompletelyoccludingit.Themostcommoncausesareatrialfibrillationandvalvularheartdisease.\nRarecausesofembolismincludeair,fat,cholesterol,bacteria,andtumourtissues.9\n2.2OtherCauses\nOthercausesincludenon-atheroscleroticabnormalitiesofthecerebralvasculaturesuchasarterial\ndissection,fibromusculardysplasia,vasculitis,Moyamoyadisease,hypercoagulablestates,2"
    },
    {
        "page_number": 41,
        "text": "41metabolicdisorders,andinheritedconditionssuchasCerebralAutosomalDominantArteriopathy\nwithSubcorticalInfarctsandLeukoencephalopathy(CADASIL).\n2.3CryptogenicInfarctions\nCryptogenicinfarctionsorstrokeofundeterminedaetiologyareinfarctionswithoutadefinedcause\ndespiteacompleteworkupandaccountfor20-40%ofallischaemicstroke.Possiblemechanismsof\ncryptogenicstrokeareembolismsecondarytooccultparoxysmalatrialfibrillation,10paradoxical\nembolismoriginatingfromthesystemicvenouscirculationthatentersthearterialcirculationthrough\napatentforamenovale(PFO),atrialseptaldefect,ventricularseptaldefectorpulmonary\narteriovenousmalformationandsub-stenotic(<50%stenosis)atheroscleroticdisease.Anew\nterminologyfornon-lacunarcryptogenicstrokewithoutproximalarterialstenosisorcardioembolic\nsourcesisEmbolicStrokeofUndeterminedSource(ESUS).11Cryptogenicstrokeisadiagnosisof\nexclusion.\nThealgorithmasshownbelowoutlinesthepathophysiologyofischaemicstrokeandthevarious\ncauses.\nKeyRecommendations:\n1.Threemaincausesofischaemicstrokeincludeatherothrombosisoflargevessels,intracranial\nsmallvesseldisease,andembolismwhichmaycontributeupto80%ofthecases.\n2.Cryptogenicinfarctionorstrokeofundeterminedaetiologymayberesponsibleforaround20to\n40%ofthecasesdespiteanextensiveworkoutandisusuallyadiagnosisofexclusion."
    },
    {
        "page_number": 42,
        "text": "42DIAGNOSISANDINITIALASSESSMENT\n3.1GeneralAim\nIngeneral,thediagnosisofstrokeismadebyevaluatingandanalysinginformationderivedfroma\ngoodhistoryandphysicalexaminationandissupplementedwithselecteddiagnostictests.Dueto\nthenatureoftheillnessandthedramaticmannerinwhichtheneurologicaldeficitoccurs,historyisof\nutmostimportance.Everyeffortmustbemadetoobtaininformationfromthepatient,familymembers,\nfriends,andwitnesses.\nThediagnosisshouldprovideanswerstothefollowingquestions:\nI.Whatistheneurologicaldeficit?\nII.Whereisthelesion(s)?\nIII.Whatisthelesion?\nIV.Whyhasthelesionoccurred?\nV.Whatarethepotentialcomplicationsandprognosis?\n3.2SymptomsandSigns\nThesymptomsandsignsofstrokedependonthetype,location,andtheextentoftheaffectedbrain\ntissue.Strokepatientsusuallyhaveasuddenorrapidonsetoffocalneurologicalsymptoms,within\nminutestoanhour.Somepatientsmay,however,haveastepwiseorgradualworseningorwaxing\nandwaningofsymptoms.Athirdofallstrokesoccurduringsleepatnight,therefore,theweaknessis\nfirstrecognizedonwakingupinthemorning.Diagnosingstrokeintheinitialhoursisverydifficult,\nparticularlywhentheonsetisuncertain,thefeaturesareatypicalorevolving,thepatientisunwellor\nagitated,orwhenaccesstoimagingisdelayed,orwhenbrainimagingisnormal.1\nAfullneurologicalexamination,includingdocumentingthepatient’sconsciouslevelandtestsof\nhighermentalfunction(suchasthemini-mentalstateexamination)ismandatory.Everypositiveand\nnegativefindingshouldpointtothesiteoflesion.Thesecanbedividedinto2broadgroups:a)\nclinicalfeaturesthatarecausedbyanteriorcirculationstroke(carotidartery);andb)thosecausedby\nposteriorcirculationstroke(vertebrobasilarsystem)(seeTable3.1).\nTable3.1:ClinicalFeaturesofStroke\nAnterior(carotid)arterycirculation\nMiddlecerebralartery\nAphasia(dominanthemisphere)\nHemiparesis/hemiplegia\nHemisensoryloss/disturbance\nHomonymoushemianopia\nParietallobedysfunction,e.g.astereognosis,agraphaesthesia,impairedtwo-point\ndiscrimination,sensoryandvisualinattention,left-rightdissociationandacalculia\nAnteriorcerebralartery\nWeaknessoflowerlimbsmorethantheupperlimbs3"
    },
    {
        "page_number": 43,
        "text": "43Posterior(vertebrobasilar)arterycirculation\nHomonymoushemianopia\nCorticalblindness\nAtaxia\nDizzinessorvertigo\nDysarthria\nDiplopia\nDysphagia\nHorner’ssyndrome\nHemiparesisorhemisensorylosscontralateraltothecranialnervespalsy\nCerebellarsigns\nLesscommonly,somepatientspresentwithatypicalstrokesymptoms(stroke“chameleons”)that\ncanimitateotherneurologicaldiseases.2Thisisbecausethesymptoms:\nI.arenotanatomicallylocalising(suchasneuropsychiatricsymptoms,confusionand/oraltered\nconsciousness),\nII.arepositive(suchasabnormalinvoluntarymovements,ratherthanparalysis,duetoanepileptic\nseizure,alienhandsyndrome,isolatedhemifacialspasmsorhemiballismus),\nIII.seemstobeperipheralnerveinorigin[vestibularsyndrome,othercranialnervepalsy(especially\nthirdandseventhcranialnervepalsy),corticalhandsyndrome,acutemonoparesis],and\nIV.areisolated(isolatedvertigo,binocularblindness,amnesia,headache,anosognosia,dysarthria,\ndysphagia,stridor,orforeignaccentsyndrome).2-4Theseatypicalpresentationsaremorelikely\ntobeduetoastrokeifthepatienthasaknowncardiovasculardiseaseorriskfactors.2\n3.3DifferentialDiagnoses\nStrokemimicscommonlyconfoundtheclinicaldiagnosisofstroke(Table3.2).Inonestudy,19%of\npatientsdiagnosedwithacuteischaemicstrokebyneurologistsbeforecranialCTscanningactually\nhadnon-cerebrovascularcausesfortheirclinicalpresentations.5\nTable3.2:DifferentialDiagnosisofStroke1,2,6,7\nMetabolic/toxicencephalopathy(hypoglycaemia,non-ketotic,hyperglycaemia,hyponatraemia,\nWernicke-Korsakoffsyndromeordrugintoxication)\nEpilepticseizures(postictalTodd’sparesis)\nHemiplegicmigraine\nStructuralintracraniallesions(e.g.subduralhaematoma,braintumourorarteriovenous\nmalformation)\nBraininfectionse.g.encephalitis(e.g.herpessimplexvirus),brainabscessortuberculoma\nHeadinjury\nHypertensiveencephalopathy\nRelapsingMultipleSclerosis\nConversiondisorders\nHyperviscositysyndrome\nPeripheralnervelesions(e.g.Guillain-BarreSyndrome)\nSystemicinfection(sepsis)\nMemorydisturbancesduetodelirium,dementia,ortransientglobalamnesia"
    },
    {
        "page_number": 44,
        "text": "44Myelopathies(e.g.spinalstenosis,cervicalmyelopathy,etc.)\nSyncope\nPeripheralvestibulopathy(e.g.positionalvertigo,labyrinthinedisorder,etc.)\nKeyRecommendations:\n1.Thediagnosisofstrokeismadebyevaluatingandanalysinginformationderivedfromagood\nhistory,physicalexaminationandselecteddiagnostictests.\n2.Thesymptomsandsignsofstrokedependonthetype,location,andtheextentoftheaffected\nbraintissues.\n3.Afullneurologicalexamination,includingassessingthepatient’sconsciouslevelandtestsof\nhighermentalfunctionismandatory.\n4.Strokemimicscommonlyconfoundtheclinicaldiagnosisofstroke."
    },
    {
        "page_number": 45,
        "text": "45PROGNOSIS\nPrognosisofstrokedependsonthetypeofstroke,size,andlocationofthelesion.Haemorrhagic\nstrokehasahighermortalitythanischaemicstroke.1-4However,patientswithhaemorrhagicstroke\nshowabetterneurologicalandfunctionalrecovery.5Brainsteminfarction,largehemispheric\ninfarctionandcardioembolicstrokealsocarryapoorprognosis.6Lacunarinfarcthasthelowest\nmortalityrate.7\n4.1SurvivalafterStroke\nThereisadeclineinstrokemortalityinbothmenandwomensufferingfromischaemicor\nhaemorrhagicstrokeacrossallagesinmanycountriesoverthelastfewdecades.8,9Thiscanbe\nattributedtotheintroductionofstrokeunitswhichprovideorganizedstrokecareandbettercontrolof\nstrokeriskfactors,resultinginmilderstrokes.10-15\nApatientwhosurvivesthefirst30daysafterafirst-everstrokehasanannualdeathriskof\n9-10%.16,17Studiesinrecentyearsshowedthatcasefatalityratesafterafirst-everstroke(alltypes\ncombined)were10%atoneweek,14-20%atonemonth,27-30%atoneyear,47-60%at5years16,17\nand76%at10years.18,19Inapopulationstudy,morethan70%ofpatientseitherdiedorwere\ndisabledat5yearsaftertheindexstroke.19Age(<75years),verbalcomponentoftheGlasgow\nComaScale(orientated),armpower,abilitytowalkandpre-strokedependency(BarthelIndex≥12\noutof20)arethe5variablesthathavebeenshowntopredictindependentsurvivalat3monthsand\n12monthsafterstroke.20\nInalocalstudypublishedin2003,thein-hospitalmortalityinischaemicstrokewas11%whilefor\nhaemorrhagicstroke,itwasmuchhigher,at27.3%.21\nDeathoccurringwithinthefirst30daysafterstrokeiscommonlyduetothedirecteffectofbrain\ndamage.4There-after,mortalityisusuallycausedbycomplicationsofimmobilisation(e.g.\nbronchopneumonia,deepveinthrombosis,etc.),recurrentstrokeandcoronaryheartdisease.16\n4.2RiskFactorsforStrokeMortality\nPrevioususeofantiplateletdrugsnearlyhalvestheriskofearlydeathsinpatientswithischaemic\nstroke,whileoldage,atrialfibrillation,ischaemicheartdiseaseanddiabetesmellitusincreasesthe\nriskofearlydeaths.6Diabetesmellitus,bothdiastolicandsystolichypertension,smoking,increased\ncardiothoracicratioandpre-existingcoronaryheartdiseaseareriskfactorsforlong-termstroke\nmortality.22\n4.3RecurrentStroke\nTherecurrentratesare3-4%inthefirstmonthand12%inthefirstyear.Thereaftertheriskfallsto\nabout4-5%peryearandby5years,around26.4-30%ofpatientswillsufferarecurrentstroke.23-26\nUpto40%ofpatientswillhavearecurrenteventat10years.25\nTheriskishigheramongindividualswithcardiovascularriskfactors,symptomaticatherosclerotic\ndisease,anactivesourceofthrombosis,orwhohavediscontinuedtheirantiplateletand\nantihypertensivetherapies.274"
    },
    {
        "page_number": 46,
        "text": "464.4Disability\nProgressoftimeisanindependentcovariatewhichreflectsspontaneousrecoveryofbodilyfunctions.\nAbout16-42%ofimprovementscanbeseenduringthefirst6to10weeksofstrokeonset.28\nFollowingafirst-everstroke,around60%ofpatientsmaysurviveupto5years.18One-thirdofstroke\nsurvivorsmayexhibitsomeformofpersistentdisabilityaftertheinitialepisodeofstroke.Upto58%\nofpatientswhosurvivethefirststrokewillregainindependenceinactivitiesofdailyliving(ADL),with\nmostfunctionalrecoveryoccurringwithinthefirst2monthsofstroke.Lessfunctionalrecoveryis\nobservedatthesubsequent4to5monthsafterstroke.Improvementinfunctionalrecoveryisless\nthancertainafter6months,howevertheknownpredictorsofdisabilitywereolderage,verylow\npremorbidlevelofactivitiesbeforestrokeandsubsequentrecurrentstroke.29Overaperiodof10\nyearsoffollow-up,almostonehalfofsurvivorsremaineddisabled,andoneseventhrequired\ninstitutionalcare.26\nKeyRecommendations:\n1.Haemorrhagicstrokehasahighermortalitythanischaemicstroke.\n2.Thereisadeclineinstrokemortalityinbothmenandwomensufferingfromischaemicor\nhaemorrhagicstrokeduetotheintroductionofstrokeunitsandbettercontrolofstrokerisk\nfactors.\n3.Therecurrentratesare3-4%inthefirstmonthand12%inthefirstyear.\n4.Progressoftimeisanindependentcovariatewhichreflectsspontaneousrecoveryofbodily\nfunctions."
    },
    {
        "page_number": 47,
        "text": "47PREVENTIONOFSTROKE\n5.1PrimaryPrevention\n5.1.1EpidemiologyandRiskFactorsofStrokeinMalaysia\nStrokeincidenceandprevalenceinMalaysiahasincreasedsteadilyoverthelast2decades.Stroke\nisthethirdcauseofmortalityandthesecondleadingcauseofDisabilityAdjustedLifeYears(DALY)\ninMalaysia.1Theincidenceandprevalencerateforbothischaemicandhaemorrhagicstrokein\nMalaysiahadincreasedsteadilyfrom2010to2014.2Withouteffectiveinterventions,strokeincidence\nwillcontinuetorise,thusincreasingthehealthcareburden.2\nDatafromtheNationalStrokeRegistryshowedthatfirsteverstrokescontributedtoabout79.2%of\nallstrokecasesinMalaysia,while20.8%wereduetorecurrentstrokes.2Therefore,primary\npreventionisthekeytoanynationalstrategytoreducetheburdenofstroke.Topmodifiablerisk\nfactorsassociatedwithfirsteverstrokesamongMalaysianswerehypertension(69.9%),diabetes\nmellitus(41.4%),smoking(26.3%),hyperlipidaemia(24.4%),familyhistoryofstroke(5.8%),\nischaemicheartdisease(IHD)andatrialfibrillation(3.4%).However,geographicalandgender\ndifferencesareobserved.2Hypertensionanddiabetesweresignificantlyhigherinwomencompared\ntomen,whilesmokingandIHDwerehigherinmen.WithinPeninsularMalaysia,theEastCoasthad\nthehighestnumberofhypertensivepatients,whiletheSouthernregionshadthehighestnumberof\npatientswithdiabetes.EastMalaysiareportedthehighestnumberofsmokers.3\nTheINTERSTROKEstudy,whichinvolved32countriesincludingMalaysia,identifiedtenmodifiable\nriskfactors(hypertension,diabetes,hyperlipidaemia,waist-hip-ratio,poordiet,smoking,alcohol,\ncardiaccause,apo-lipoproteinlevelsandpsychosocialfactors)whichaccountedfor90%of\npopulation-adjustablerisk(PAR)ofstroke.4TheGlobalBurdenofDiseases2013studyidentified\nthreeclustersofmodifiableriskfactorsassociatedwithhigheststrokeburdeninLMIC5:\nI.Lifestyleriskfactors–smoking,physicalinactivity,andunhealthyeating(74.1%)\nII.Metabolicriskfactors–highsystolicBP,highcholesterol,highfastingbloodglucose,loweGFR\nandhighBMI(72%)\nIII.Environmental-airpollutionandleadexposure(33.9%)\nTheNationalHealthMorbiditySurvey(NHMS)2011and2015highlightedanalarmingtrendinthe\nprevalenceofcardiovascularriskfactorsamongMalaysians,with63%ofMalaysianadults(>18\nyears)havingatleastoneCVriskfactor(overweight/obesity,highbloodpressure,highblood\nglucoseandhighbloodcholesterol).6,7BasedonNHMS2015,theprevalenceforthethreemajorCV\nriskfactorsamongMalaysianadultswere7:\nHypertension(knownandundiagnosed)–30.3%\nDiabetesmellitus(knownandundiagnosed)-17.5%\nHypercholesterolaemia(knownandundiagnosed)–47.7%5"
    },
    {
        "page_number": 48,
        "text": "485.2ModifiableandNon-modifiableRiskFactors\n5.2.1Non-modifiableRiskFactors\nUnderstandingtheepidemiologyofriskfactorsforstrokeamongMalaysiansallowsprioritizationof\nprimarypreventionstrategiesspecifictotheneedsofthepopulation.Strokeriskfactorscanbe\ncategorizedintomodifiableandnon-modifiableriskfactors.Non-modifiableriskfactorsincludeage,\nsex,andfamilyhistory.\nAge:Thecumulativeeffectofagingonthecardiovascularsystemandtheprogressivenatureof\nstrokeriskfactorsoveraprolongedperiodoftimesubstantiallyincreasestrokerisk.Theriskof\nstrokedoublesineachsuccessivedecadeafter55yearsofage.8,9\nSex:Strokeismoreprevalentinmenthanwomen.8Overall,menhavehigherage-specificstroke\nincidenceratescomparedtowomen.10Exceptionsareinthe35to44year-oldsandinthoseover85\nyearsofage,ofwhomwomenhaveslightlygreaterage-specificincidencethanmen.10\nCircumstancessuchasoralcontraceptiveuseandpregnancyuniquelycontributestotheriskof\nstrokeinwomen.11-13\nFamilyHistory:Bothpaternalandmaternalhistoryofstrokemaybeassociatedwithanincreased\nrisk.Thismaybemediatedthroughgeneticandsharedenvironmentalfactors.14,15Patientswitha\nstrongfamilyhistoryofrecurrentsubcorticalinfarctsandleucoencephalopathyshouldbe\ninvestigatedforCADASIL,Fabry’sdiseaseormitochondrialdiseases.\n(Newrecommendation)\n5.2.2ModifiableRiskFactors\nTheNationalStrokeRegistryhasidentifiedthefollowingasthetopmodifiableriskfactorsforthe\nfirst-everstrokeamongMalaysians2:\nHypertension\nDiabetesmellitus\nHypercholesterolaemia\nSmoking\nIHD\nAtrialfibrillation\n5.3RiskStratificationandMonitoring\n5.3.1CardiovascularRiskEstimates\nForprimarypreventionstrategiestobeeffective,understandingriskestimatesiscrucialforboththe\npopulationatlargeandhealthcareproviders.Individualizedriskestimationscoresthattakesinto\naccountbothmodifiableandnon-modifiableriskfactors,validatedacrossmultipopulationssuchas\ntheFraminghamStrokeRiskScoreCalculator,ASCVDandQRISK2ishelpfultocreateawareness\nandstratifyingindividualsaccordingtocardiovascularriskcategories.16,17TheRevisedFSRSis\nshowntobebetterthantheconventionalFRSasitadjustsfortemporaltrendsinstrokeriskfactors\nandhasbetterdiscriminatoryindexfordetectingstrokeinvariouspopulations.18Theserisk\nestimationsallowstratifyingofindividualsintoriskcategoriesforbetterpreventivestrategies.\nThe2017MalaysianPrimaryandSecondaryPreventionofCardiovascularDiseaseClinicalPractice\nGuideline(CPG)hasadvocatedtheuseofFRStostratifyindividualsintolowrisk,intermediate,high\nandveryhighriskbasedontheir10-yearrisksofdevelopingcardiovascularevents.19"
    },
    {
        "page_number": 49,
        "text": "49Lowrisk-FRS-CVDrisk<10%\nIntermediaterisk–FRS-CVD10-20%\nHighrisk-FRS-CVD>20%\nVeryhighrisk-FRS-CVD>30%\nPatientswithlowriskshouldbecounselledtomaintaintheirstatusofhealthandtohaveregular\nreviews,whilethosewithintermediatetohighrisksshouldbefollowed-up,andmaintainedon\nlifestyleinterventionsandpharmacotherapyfortheirspecificriskfactors,e.g.treatmentof\nhypertension,LDL-C,smokingcessation,effectivediabetescontrol,andencouragingphysical\nactivityandhealthyeating.19\n(LevelII,GradeB)\n5.3.2StrokeRiskEstimates\nTheStrokeRiskometerApp,asmartphone-basedapplicationavailableinvariouslanguages\n(includingtheMalaylanguage)allowsforindividualizedstrokeriskcalculation,using20modifiable\nandnon-modifiableriskfactors.Itcontainseducationalvideosforself-managementofriskfactors.20\nTheappcalculatesindividualized5-and10-yearrisksofstrokeandisaneffectivetoolformonitoring\nriskreductionsassociatedwithlifestyleandmedicalinterventions.TheMalayversionhasbeen\nvalidatedforlanguageandcontent(unpublisheddata).21TwointerventionalstudiesusingStroke\nRiskometerasatooltoreducestrokeriskhavebeencompletedamongMalaysianswithhighrisk\n(diabeticsandstrokecarers),withpositiveoutcomes.22,23\nTheuseofStrokeRiskometerandR-FRSCalculatormaybebeneficialinthecommunityandin\nclinicsforindividualizingstrokeriskanditsmanagement.20\n(LevelII,GradeB)\n5.4PreventionandManagementofRiskFactors\n5.4.1LifestyleChanges\nTheUSHealthProfessionalsandNursesstudyshowedthatparticipantswhoachievedallfive\nhealthylifestylechoices(notsmoking,moderateintakeofalcohol,BMI<25kg/m2,dailyexercisefor\n30minutesandahealthydietscoreinthetop40%),hadtheirincidenceofstrokereducedby80%as\ncomparedtothosewhoachievednone.24\nAstudyamong11450Swedishmenwithhighcardiovascularrisk(hypertensive,highcholesterol,\ndiabetes,heartfailureoratrialfibrillation)showedthatadoptingallfivehealthylifestylechoices[(≥5\nservingsoffruitsandvegetablesand<30g/dayofprocessedmeat;notsmoking;≥150minofphysical\nactivity/week;BMI18.5-25kg/m2;lowtomoderatealcoholconsumption(>0to<30g/day)]hada\n72%reductionofstrokeincidenceover9yearsascomparedtothosewhowereadherenttononeor\nonlyonehealthybehaviour.25\nRecommendation:Adoptingahealthylifestyle(dietsrichinfruitsandvegetables,nosmoking,daily\nexerciseof>30minutesor150minutes/week,lowtomoderatealcoholintakeandmaintaininga\nnormalBMIof18.5-25kg/m2)reducesstrokeincidenceinnormalandhigh-riskpopulations.24,25\n(Newrecommendation,LevelI,GradeA)\n5.4.2Hypertension\nHypertensionisthecommonestandmajorriskfactorforbothischaemicandhaemorrhagicstrokesin\nMalaysia,affecting69.9%ofpatientswiththefirsteverstroke.2Theincidenceofstrokeincreasesin\nproportiontobothsystolicanddiastolicbloodpressures.Isolatedsystolichypertensionisan"
    },
    {
        "page_number": 50,
        "text": "50importantriskfactorforstrokeintheelderly(systolicbloodpressure>140mmHganddiastolicblood\npressure<90mmHg).26\nPopulationspecificandindividualizedstrategiesshouldbeconductedtopreventthedevelopmentof\nhypertension.Adoptinghealthylifestylesuchassmokingcessation,DietaryActiontoStop\nHypertension(DASH)diet,increasedphysicalactivityandreducingsaltconsumptionareshownto\nreducetheriskofdevelopinghypertension.27\n(LevelI,GradeA)\n5.4.2.1PrimaryStrokePreventioninSpecificHigh-riskGroupwithHypertension\nTheACCORDBPtrialshowedthatalowertargetsystolicvalueof120mmHgwassuperiortoa\ntargetvalueof140mmHginpreventinganystrokeandnon-fatalstrokeindiabetics,assecondary\nendpoint,butdidnotpreventothercardiovascularevents.28TheSPRINT(SystolicBloodPressure\nInterventionTrial)studyshowedthatintensiveBPloweringregimetoatargetof≤120mmHgin\nhigh-risknon-diabetichypertensivepatientsaged50yearsorolderledtoareductioninall\ncardiovasculareventsandmortalitybutwithanexcessofadverseeventsintheintensivegroup.29\nHowever,therewasnosignificantreductioninstrokeeventinthesepatientscomparedtothe\nnon-intensivegroup.\nLargerandomizedcontrolledtrialsandmeta-analyseshaveconfirmedthatreductioninblood\npressurereducesfirsteverandrecurrentstrokeby40%.30,31\n(LevelI)\nLoweringthesystolicbloodpressureby10mmHgisassociatedwithareductioninriskofstrokeby\naboutathird,irrespectiveofbaselinebloodpressurelevels.31\n(LevelI)\nFordiabeticswithhypertension,loweringsystolicbloodpressuretoatargetof120mmHgorbelow\nwithcarefulmonitoringofadverseeventsledtoasignificantreductioninstrokeincidence.26\nRecommendation:TargetBPfordiabeticsis<130mmHgsystolicand<80mmHgdiastolic,\npreferably<120mmHgiftolerated.\n(Newrecommendation,LevelI,GradeA)\nForhigh-risknon-diabetichypertensivepatients,intensivesystolicBPloweringtobelow120mmHg\nledtoexcessadverseeventswithoutreductioninstrokeincidence.27\n(Newrecommendation,LevelI,GradeB)\nRecommendation:Newlydiagnosedhypertensionintheveryelderly(>80yearsofage)shouldbe\ntreated.32\n(Newrecommendation,LevelI,GradeB)\n5.4.3Smoking\nTheMalaysianNationalStrokeRegistrydatashowedthat51%ofallpatientswiththefirsteverstroke\nweresmokers.Allformsofsmoking,bothactiveandpassive,areamajorriskfactorforstroke.2\nSmokerswhostoppedformorethan5yearshavethesameriskasnon-smokers.33\n(LevelIII)\nRecommendation:Cessationofsmokingisstronglyrecommended.\n(LevelIII,GradeC)"
    },
    {
        "page_number": 51,
        "text": "515.4.3.1SmokingAndNonCommunicableDiseases\nSmokingoftobaccoandtobaccoproducts(cigarette,electroniccigarette/vape,shisha,pipe,cigar\netc.)canleadtovariousnon-communicablediseases(NCDs).Worldwide,morethaneightmillion\npeopledieeveryyearbecauseofthishabit(WHOTobaccoFactSheet,2020).\nHence,thedecisiontointegratesmokingtreatmentwithNCDsisimportanttoreducetheprevalence\nofNCDsandtheircomplications.ThisdecisionwasmadeduringtheWorldHealthOrganization\nFrameworkConventiononTobaccoControl(WHOFCTC)SteeringCommitteeMeetinginDecember\n2019chairedbytheHonourableHealthMinisterofMalaysia.\nThetreatmentforsmokingshouldbeinitiatedbythetreatingdoctorbasedontheassessmentand\ntreatmentoftobaccousedisorderasinTable1.DetailsonthiscanbefoundintheCPGon\nTreatmentofTobaccoUseDisorder2016,availableat:\nhttps://www.moh.gov.my/moh/resources/Penerbitan/CPG/Respiratory/CPG_TobacoDisorder.pdf\nTable5.1:Assessmentandtreatmentoftobaccousedisorder\nASSESSMENTANDTREATMENT\n1.Askanddocumentsmokingstatusforallpatients.\n2.Providebriefadviceonquitsmokingateveryvisittoallsmokers.\n3.AssesslevelofnicotineaddictionusingModifiedFagerströmTestforCigaretteDependence\nQuestionnaire(COMPULSORY)andverifysmokingstatususingcarbonmonoxide(CO)\nbreathanalyser(IFAVAILABLE).\n4.Offerpharmacotherapytoallsmokerswhoareattemptingtoquit,unlesscontraindicated.\n5.Ifselected,usenicotinereplacementtherapy(NRT)foratleasteighttotwelveweeks,\nwhereasvareniclineshouldbeusedforatleasttwelveweeks.\n6.Combinationtherapy(e.g.twoNRTs,anon-NRT,e.g.bupropionwithanNRT)isbetterthan\nmonotherapyinsmokingcessationtreatmentandmaybemostusefulforthosesmokersat\nhighestriskofrelapse.\n7.Usesmokingcessationmedicationswithcautioninspecialpopulations(e.g.childrenand\nadolescents,pregnant,breastfeedingwomen,psychiatricandsubstanceabusedisorder\npatients).\n8.Arrangeaminimumofsixtoeightfacetofacefollow-upsessionsforsmokingcessation\ninterventionsinsixmonthsthroughcounsellingsupportteam(healtheducationofficer,\npharmacistsoranyofficertrainedforquitsmokingservices).\n5.4.4Alcohol\nAlcoholconsumptionhasbeenidentifiedasoneoftheriskfactorsforglobalstrokeburden.33Heavy\nalcoholdrinking,ofmorethan4units/day(1unit=1glasswine=1packofhardliquor),increasesthe\nriskofstroke.\nRecommendation:Avoidheavyalcoholconsumptionorlimitto<1drinkperday.\n(Newrecommendation,LevelII-2,GradeB)\n5.4.5Post-menopausalHormoneReplacementTherapy\nStrokeratesrapidlyriseinwomenoncetheybecomemenopausal.TheNurses’HealthStudy(6-year\nfollow-upof59,337postmenopausalwomen)showedonlyaweakassociationbetweenstrokeand\noestrogenreplacementtherapy.However,theWomen’sHealthInitiativeEstrogenPlusProgestin\nStudy(E+PStudy)showeda31%increaseintheriskofstrokeduetoE+P.34"
    },
    {
        "page_number": 52,
        "text": "52Recommendation:Post-menopausalhormonaltherapymayincreasetheriskofstrokeandisnot\nrecommendedforprimarystrokeprevention.\n(LevelII,GradeB)\n5.4.6Diabetes\nCase-controlstudiesofstrokepatientsandprospectiveepidemiologicalstudieshaveconfirmedan\nindependenteffectofdiabetesonischaemicstroke,withanincreasedrelativeriskindiabetics\nrangingfrom1.8-tonearly6-folds.35\n(LevelII-2)\nRecommendation:Tightcontrolofhypertensionindiabeticsisrecommendedtoreducestroke\nincidence.27\n(LevelI,GradeA)\nAsystematicreviewandmeta-analysisofobservationalcohortandnestedcase-controlcohort\nstudiesshowedthatcomparedtocontrolswithanormalHbA1crange(i.e.<5.7%),patientswith\ndiabetesmellituswithanabnormalHbA1crange(i.e.≥6.5%)hadanincreasedriskoffirst-ever\nstrokewithanaverageHR[]of2.15[95%CI1.76,2.63].Inthosewithapre–diabetesmellitusHbA1c\nrange(i.e.5.7–6.5%)therewasnotincreasedriskoffirst-everstroke(averageHR1.19,95%CI\n0.87,1.62).36\nRecommendation:Moreintensiveglycaemiccontroltargets(HbA1c<6.5%)mayberequiredfor\noptimalischemicstrokeprevention.\n(LevelI,GradeA)\n5.4.7Hyperlipidaemia\nAlthoughtherelationshipbetweenhighcholesterolandincreasedriskofcoronaryheartdiseaseis\nstronger,epidemiologicalstudieshavealsoshownanassociationbetweenraisedserumlipidsand\nriskofischaemicstroke.37,38\nTheMRC/BHF,aRCTinvolving20,536highriskindividualsshowedthatstatintherapysignificantly\nreducedtheincidenceoffatalandnon-fatalstrokesby28%.39Ameta-analysisoftrialsonstatin\ntherapyversuscontrolinindividualswitha5-yearriskofmajorvasculareventslowerthan10%,\nshowedthateach1mmol/LreductioninLDLcholesterollevelsproducedanabsolutereductionin\nmajorvasculareventsofabout11per1000over5years.40\nTheHOPE-3trialstudied12,705patientswithintermediateriskandusedfixed-doseBPlowering\n(CandersartanandHCTZ),cholesterollowering(Rosuvastain)orcombinationtreatmentregime.It\nwasfoundthatalow-doseRosuvastatintherapyandcombinationtreatmentreducedstroke\nincidenceby30%and44%,respectively.41\nAprospectivestudyinvolving7484elderlypopulation(>65years)withnohistoryofvascularevents\nshowedthattheuseofstatinsorfibratesreducedstrokeincidenceby30%.42\nInthehigh-riskgroup(thosewithcardiovasculardisease,occlusivearterialdisease,ordiabetes),\nstatintherapyisrecommendedtoreducetheincidenceofcoronaryeventsandischaemicstrokes,\nevenamongstindividualswithnormalcholesterolconcentrations.39\n(LevelI,GradeA)\nInthehigh-riskgroup,intensivelipidloweringtherapyissuperiorinreducingstrokeascomparedto\nnormaltherapy.39\n(Newrecommendation,LevelI)"
    },
    {
        "page_number": 53,
        "text": "53Lowdosestatinisbeneficialinreducingstrokeriskinpatientswithlowandintermediaterisk.41,42\n(Newrecommendation,LevelII,GradeB)\nLowdosestatinisbeneficialinreducingstrokeriskinelderlypatientswithnovascularevents.42\n(Newrecommendation,LevelII,GradeB)\n5.4.8DietaryFactors\nThePREDIMEDstudyshowedthataMediterraneandietenrichedwitheitheroliveoilormixednuts,\nreducedtheincidenceofstrokeby47%in5yearsascomparedtoalowfatdiet.43Ameta-analysis\ninvolving20prospectivestudiesshowedthatdietrichinfruitsandvegetablesreducedstroke\nincidencewithalinearinverserelationshipbetweenfruitsandvegetablesconsumptionandstroke\nincidence.44\nRecommendation:AMediterraneandietrichinoliveoilandcanolaoil,withlessmeatand\nincreasedvegetablesisbeneficialforstrokeprevention.43\n(Newrecommendation,LevelII,GradeB)\nRecommendation:Adietrichinfruits(citrustype)andvegetables(greenleafy)isbeneficialin\nreducingstroke.44\n(Newrecommendation,LevelII,GradeB)\nRecommendation:DASHdietthatishighinvegetablesandfruitsandlowinsaturatedfatsis\nbeneficialinreducingBP.45\n(Newrecommendation,LevelI,GradeA)\n5.4.9PhysicalActivity\nPhysicalactivityisdefinedasanybodilymovementsinvolvingskeletalmusclesthatresultsinenergy\nexpenditureandmayinvolveoccupationalandleisuretimeactivitiessuchaswalking,commuting\nandhousework.However,meta-analysesofobservationalstudiesonphysicalactivityandstroke\nshowedthatincreasedphysicalactivityinhealthyadultsreducedstrokeincidenceby20-25%46and\nstrokemortalityby17%irrespectiveofgender.47AnalysisfromtheJapaneseDiabetesComplications\nstudyshowedthatincreasedphysicalactivity(30minutesofwalkingdaily)reducedstrokeincidence\nindiabeticsby45%.48\nRecommendation:Increasedphysicalactivityisrecommendedforstrokepreventioninhealthy\nadultsandhigh-riskpatients.46-48\n(Newrecommendation,LevelI,GradeA)\nAsymptomaticCarotidStenosis SeeRevascularizationProcedures\nAtrialfibrillation SeeCardio-embolism&Stroke\n5.4.10MedicalTherapy\n5.4.10.1Aspirin\nTheARRIVEtrialwhichinvolved12500participantswithmoderatecardiovascularriskandlowriskof\nbleeding,showedthatAspirindidnotpreventthefirstoccurrenceofcardiovasculareventsand\nstrokeascomparedtoplacebo.49\nSimilarly,theJapanesePrimaryPreventionProject,arandomizedcontrolledtrialwhichinvolved\nelderlypatients(60-85yearsofage)withhypertension,diabetesandhyperlipidaemiadidnotshow"
    },
    {
        "page_number": 54,
        "text": "54thenetbenefitofAspirininstrokeprevention.TherewereconcernsthatAspirinusemayleadto\nincreasedincidenceofintracranialbleedinginAsianpatients.50\nTheASCENDAspirinstudy,aRCTwhichinvolved15480diabeticpatientsdidnotshowanetbenefit\nofAspirininpreventingstrokeorcardiovascularevents,butwithanincreasedriskofbleeding.51\nRecommendation:DailyAspirinisnotrecommendedforprimarypreventionofstrokeindiabetics,\nmoderateriskindividualsorelderlypatientsinviewofthehighriskofbleedingwhichoutweighsany\nbenefits.49-51\n(Newrecommendation,LevelI,GradeA)\nRecommendationsSummary:\nTable5.2:PrimaryPreventionandManagementofRiskFactors\nFactors RecommendationsLevelof\nEvidenceGrade\nHypertension Self-BPmonitoringisrecommendedforallhypertensive\npatients.\nNewrecommendation\nI A RiskstratificationforhypertensionbasedonCVDrisk,\ntargetorgandamageandcomplicationsare\nrecommendedforoptimizingtherapy.\nNewrecommendation\nLifestylechangesifsystolicBPisbetween\n130-139mmHgand/ordiastolicBPis80-89mmHgwith\nthreetosix-monthlyreview.\nNewrecommendationI A\nTreatmedicallyifsystolicBPis>140mmHgand/or\ndiastolicBPis>90mmHg.I A\nHypertensionshouldbetreatedintheveryelderly\n(age>80years)toreducetheriskofstroke.\nNewrecommendationI B\nDiabetesMellitus Strictbloodpressurecontrolisimportantindiabetics. I A\nMoreintensiveglycaemiccontroltargets(HbA1c\n<6.5%)mayberequiredforoptimalischemicstroke\nprevention.I A\nTargetBPfordiabeticsissystolicBP<130mmHgand\ndiastolicBP<80mmHg,preferably<120mmHgif\ntolerated.\nNewrecommendationI A\nHyperlipidaemia Treatmentofdyslipidaemia/LDL-Cisstratifiedbased\nonrisk.\nI BHigh-riskgroup:loweringLDLto<1.8mmol/lis\nrecommended.\nNewrecommendation\nIntermediateandlowrisk:keepLDL<3.4mmol/l.\nLow-riskgroupmaybenefitfromcholesterol-lowering\ntherapywithastatin.\nNewrecommendation\nNorisk–keepLDL<4.2mmol/L.\nSmoking Cessationofsmoking. III C\nAspirintherapy Aspirintherapyisnotrecommendedforprimary\npreventionofstrokeintheelderly,diabetics,orother\nhigh-riskgroups.\nNewrecommendationI A"
    },
    {
        "page_number": 55,
        "text": "55Post-menopausal\nHormoneReplacement\nTherapyOestrogenbasedHRTisnotrecommendedforprimary\nstrokeprevention. II B\nAlcohol Avoidheavyalcoholconsumptionorlimitto<1drink\nperday.\nNewrecommendationII-2 B\nPhysicalActivity Physicalactivity(occupationalandleisuretime)is\nrecommendedforallgroupsofpatients.\nNewrecommendationI A\nPhysicalactivity>30mins/dayor>150mins/weekas\npartofhealthylifestyleisrecommended\nNewrecommendationI A\nDiet DASHdietisrecommendedtoreduceBP.\nNewrecommendationI A\nMediterraneandiet–(lowglycaemicandhighin\nvegetables)supplementedwithnutsandoliveoilis\nbeneficial.\nNewrecommendationII B\nDiethighinfruitsandleafygreenvegetablesis\nbeneficial.\nNewrecommendationII B\n5.5SecondaryPreventionofStroke\nSecondarypreventionstrategiesareaimedatpreventingrecurrentstroke.Thisshouldbetailored\naccordingtotheindividual’sstrokepathogenesisbasedonneuroimagingandinvestigations(see\nInvestigations).\nTheriskforrecurrentvasculareventsafterstrokeortransientischaemicattackisapproximately5%\nperyearforstroke,3%peryearformyocardialinfarctionand7%peryearforanyoneofstroke,\nmyocardialinfarctionorvasculardeath.52Thisfigureisevenhigherincertainpopulations,especially\ninthosewithhighcerebrovascularatheroscleroticburdenandforpatientswithipsilateralhighgrade\n(70%)extracranialcarotidstenosis.53\n5.5.1Anti-plateletTherapy\nAspirin:ThereissubstantialevidencetosupporttheuseofAspirin.A25%riskreductionofstroke\nwasseeninallpatientswithstrokewhoreceivedAspirin.54Aspiringivenwithin48hourshadshown\ntobebeneficialinreducingrecurrentstrokeanddeaths.54-56Studiescomparingtheeffectsof\ndifferentdosagesofAspirinhadfailedtoshowanydifferencesinstrokerecurrences.57-60\nRecommendation:TherecommendeddoseoforalAspirinpost-strokeis75mgto325mgdaily.\n(LevelI,GradeA)\nAlternativeanti-plateletmedicationscanbeconsideredforpatientswithAspirinallergy,Aspirin\nfailure,AspirinintoleranceorAspirincontraindicationsbasedontheevidencepresentedbelow.\nTiclopidine:PreviousclinicaltrialsdemonstratedthatTiclopidineisslightlysuperiortoAspirin.61,62\nFullbloodcountmonitoringisessentialasneutropeniaisthemostimportantside-effect.61Severe\nneutropeniausuallyoccurswithinthefirst3monthsofuse.Thus,abaselinefullbloodcountshould\nbeperformedevery2-3weeksduringthistimeframe.Ticlopidinecanalsobeusedifthepatienthas\nrecurrentsymptomsdespiteAspirinadministration.\nRecommendation:TherecommendeddoseoforalTiclopidineis250mgtwiceaday.\n(LevelI,GradeA)"
    },
    {
        "page_number": 56,
        "text": "56Clopidogrel:Clopidogrelisanewerthienopyridinederivative.Itisslightlysuperiortothe325mg\ndailydosageofAspirin.63ItmaybemorebeneficialthanAspirininseveralsettings,includingpatients\nwithcontraindicationsorhavingadverseeffectsduetoAspirinandinhighrisksubjectswithmultiple\nriskfactors(i.e.withapreviousstroke,peripheralarterydisease,symptomaticcoronarydiseaseand\ndiabetes)64\nRecommendation:TherecommendeddoseoforalClopidogrelis75mgdaily.\n(LevelI,GradeA)\nTriflusal:TriflusalisaviablealternativetoAspirininsecondarypreventionofischaemicstrokeata\ndosageof600mgdaily.TherearelesshaemorrhagiccomplicationscomparedtoAspirin.Triflusalis\nlicensedinMalaysiaforthesecondarypreventionofischaemicstroke.65\nRecommendation:TherecommendeddoseoforalTriflusalis600mgdaily.\n(LevelI,GradeA)\nCilostazol:Cilostazolisanotheralternativeinthesecondarypreventionofacuteischaemicstrokeat\nadosageof100mgtwicedaily.StudiesfromJapanandChinasupportsthesafetyandefficacy\nofCilostazolforsecondarystrokepreventioninAsianpopulations.However,thereareasyetno\nhigh-qualitydataregardingtheuseofCilostazolforsecondarystrokepreventioninnon-Asianethnic\ngroups.66,67Themostrecentmeta-analysisshowedthatCilostazolappearedtobeeffectivefor\nlong-termsecondarystrokepreventionwithoutincreasingtheriskofhaemorrhage.68Combination\nuseofcilostazolwithaspirinorclopidogrelwasexploredinopen-labeltrialinJapanthatshowed\nadultpatientswithnon-cardioembolicischemicstrokewhohad≥50%stenosisofamajorintracranial\norextracranialartery,ortwoormorevascularriskfactors,hadlowerrecurrentischaemicstroke\ncomparedtomonotherapy(3%vs.7%)withsimilarbleedingrates.69\nRecommendation:TherecommendeddoseoforalCilostazolis100mgtwiceaday.\n(LevelI,GradeA)\nAspirinandClopidogrelcombination:Recentevidencefrom2largetrialsinminorstrokeandhigh\nriskTIApatients(NIHSS<5,ABCD2>2)orhigh-riskTIA,showedthatthosewhoreceiveda\ncombinationofClopidogrelandAspirinhadalowerriskofmajorischaemiceventsfor3weeksto3\nmonths,butahigherriskofmajorhaemorrhageat90daysthanthosewhoreceivedAspirin\nalone.70,71\nRecommendation:Dualantiplatelettherapy(ClopidogrelandAspirin)isrecommendedfor21days\ninpatientswithhighriskTIAorminorischaemicstroke.\n(Newrecommendation,LevelI,GradeA)\nTicagrelor:IntheSOCRATEStrial,TicagrelorwasnotsuperiortoAspirininthepreventionoffatal\nstroke,MIanddeathat90daysinpatientswithminorstrokeorTIA.72However,sub-analysisinthe\nAsianpopulation,showedatrendtowardsreductioninstroke,MIanddeathwithTicagrelor.73Since\ntherewerenosignificantsafetydifferencesinthe2groups,Ticagrelormaybeareasonable\nalternativeinstrokepatientswhohaveacontraindicationtoAspirin.\n(LevelII,GradeB)\nAspirinandTicagrelor:Arecenttrialexaminingtheuseofticagrelorascombinationtherapywith\naspirininpatientswithmild-to-moderateacutenon-cardioembolicischaemicstroke(NIHSSscore≤5)\norTIAwhowerenotundergoingintravenousorendovascularthrombolysis,showedthattheriskof\nthecompositeofstrokeordeathwithin30dayswaslowerwithticagrelor–aspirinthanwithaspirin\nalone,buttheincidenceofdisabilitydidnotdiffersignificantlybetweenthetwogroups.Severe\nbleedingwasmorefrequentwiththeticagrelor-aspirincombinationtherapythanwithaspirinalone.\n74"
    },
    {
        "page_number": 57,
        "text": "57Warfarinisnotindicatedforsecondarystrokepreventionforpatientswithsinusrhythminthe\nabsenceofotherconditionspredisposingtocardioembolicrisk.\n(LevelI,GradeA)\n5.5.2Anti-hypertensiveTreatment\nReductionofbloodpressureaftertheacutephaseofacerebrovasculareventresultsinfurther\nreductionofvascularevents.Thisbenefitwasnotedinbothischaemicandhaemorrhagicstrokein\nhypertensiveandnormotensivesubjects.75Meta-analysesofrandomizedcontrolledtrialsconfirmed\nanapproximate30–40%reductionofstrokeriskwithbloodpressurelowering.76\nInonestudy,thecombinationofanACE-inhibitorandthiazidediureticwasbeneficialinboth\nhypertensiveandnormotensivestrokepatientswheninitiatedtwoweeksaftertheevent.77\nAnotherstudyprovedthesuperiorityofanangiotensinreceptorblocker(ARB),Losartanovera\nbeta-blocker(Atenolol)inaspecificgroupofhigh-riskpatientswithleftventricularhypertrophy,\nincludingsubjectswithpreviousstroke.78\nRecommendation:Inthepost-strokeperiod(2weeksormoreafterstroke),ACE-inhibitorbased\ntherapyhasbeenshowntoreducerecurrentstrokeinnormotensiveandhypertensivepatients.79\n(LevelI,GradeA)\nRecommendation:Otherclassesofanti-hypertensive(ARB-based)therapyappeartobeeffective\ninselectedhigh-riskpopulations.80,81\n(LevelII-1,GradeB)\nThetargetbloodpressureofabsolutelevelsisnotcertain,buttargetsbasedonhypertension\nguidelines(localorinternational)canbefollowedandshouldbeindividualized.82\n(LevelII-1,GradeB)\nThechoiceofantihypertensivedrugtherapy(singleorincombination)shouldalsobeindividualized\nbasedoncurrentevidenceandspecificpatientcharacteristics.83\n(LevelII-1,GradeB)\nCarotidEndarterectomy(CEA) SeeRevascularizationProcedures\n5.5.3LipidLowering\nStatinswereproventoreducevasculareventsamonghighriskpatientsincludingsubjectswith\npreviousstroke.83,84\nRecommendation:Lipidreductionshouldbeconsideredinallpatientswithpreviousischaemic\nstrokes.\n(LevelI,GradeA)\nTheTreatStroketoTargettrialthatinvolved2860patientswithahistoryofischaemicstrokeorTIA\nshowedthatpatientswhoachievedatargetLDLof1.8mmolhadalowercardiovascularandstroke\neventsat3.5yearsthanthosewithatargetLDLof2.5mmol/L.85\nRecommendation:LDLtargetof1.8mmol/Lisrecommended.\n(Newrecommendation,LevelI,GradeA)"
    },
    {
        "page_number": 58,
        "text": "585.6OtherRiskFactors\nThecontrolofriskfactorssuchasbetterglycaemiccontrolindiabetesandsmokingcessationhas\nnotbeenthesubjectofmajorrandomizedsecondarypreventionclinicaltrials.Althoughdiabetesis\nrecognizedasanindependentriskfactorforischaemicstroke,betterdiabetescontrolresultedonlyin\nthereductionofmicrovascularbutnotmacrovascularcomplications.86Inferencescanalsobedrawn\nfrompositiveresultsofprimarypreventiontrials(seeprimarypreventionsection).Nevertheless,\nbettercontroloftheseriskfactorsshouldbeadvocatedforbetteroverallhealthafteranischaemic\nstroke.\nRecommendation:Alldiabeticpatientswithapreviousstrokeshouldmaintainagoodglycaemic\ncontrol.\n(LevelIII,GradeC)\nRecommendation:Allsmokersshouldstopsmoking.\n(LevelIII,GradeC)\nRecommendationsSummary:\nTable5.3:SecondaryPreventionofStroke\nFactors/Treatment RecommendationsLevelof\nEvidenceGrade\nAntiplatelet(Singleagent)\nAspirinTherecommendeddoseofaspirinis75mgto325mgdaily.I A\nAlternatives:\nClopidogrelTherecommendeddoseis75mgdaily. I A\nTiclopidineTherecommendeddoseis250mgtwiceaday. I A\nTriflusalTherecommendeddoseis600mgdaily I A\nCilostazolTherecommendeddoseis100mgtwiceaday. I A\nDoubletherapy CombinationtherapyofClopidogrelandAspirinis\nrecommendedinpatientwithminorischaemicstrokeand\nhigh-riskTIAfor21days.\nNewrecommendationI A\nAntihypertensive\ntreatmentACE-inhibitorbasedtherapyshouldbeusedtoreduce\nrecurrentstrokeinnormotensiveandhypertensive\npatients.I A\nARB-basedtherapymaybenefitselectedhighrisk\npopulations.II-1 B\nLipidlowering Lipidreductionshouldbeconsideredinallpatientswith\npreviousischaemicstrokes.I A\nLDLtarget<1.8mmol/Lisrecommendedinallpatients\nwithpreviousischaemicstroke.\nNewrecommendationI A\nDiabeticcontrol Alldiabeticpatientswithapreviousstrokeshould\nmaintainagoodglycaemiccontrol.III C\nCigarettesmokingAllsmokersshouldstopsmoking. III C"
    },
    {
        "page_number": 59,
        "text": "595.7Cardioembolism\nCardioembolicstrokeaccountsforabout20%ofallischaemicstrokes.87-89Generally,theyare\nsevere,pronetoearlyrecurrence,andmorelikelywhenthereisdocumentedsourceofembolism\nandinvolvementofdifferentcerebrovascularterritoriesormultipleinfarctions.Thepredominant\npathogenicprocessforstrokeassociatedwithcardiacdiseaseisembolismduetoformationof\nintra-atrialandintra-ventricularthrombus.\nAtrialfibrillation(AF)whetherchronicorparoxysmal,isthemostcommoncauseofcardioembolism\nandaccountsfor50%ofallcardiogenicemboli.Otherhigh-riskconditionsarehavingprosthetic\nheartvalves,rheumaticmitralvalvulardisease,acutemyocardialinfarction,andsevereleft\nventriculardysfunction.Non-thromboticembolismmayresultfromatrialmyxomaandendocarditis.\nInvestigationsaredirectedatdemonstratingcardiacsourcesofembolismintheabsenceof\nsignificantatherosclerosisorothervasculardisease.Allpatientswithstroke/TIArequirea12-lead\nelectrocardiogram.A72-hourHoltermonitorisrequiredtodetectparoxysmalAF.Inaddition,all\npatientsunder45yearsofageandthoseinwhombaselineinvestigationsdidnotrevealanapparent\ncauseforstrokewillrequireatransthoracicechocardiogram(TTE).Patientsinwhomthereishigh\nsuspicionofcardioembolismbuthaveanormalTTEmayundergoatrans-oesophageal\nechocardiogram(TOE).ConditionsinwhichthismethodissuperiortoTTEincludethrombiintheleft\natriumandleftatrialappendage,patentforamenovale,atrialseptalaneurysmandaorticarch\natheroma.89,90\nOralanticoagulantmayreducetheriskoffirstandsubsequentstrokeforselectedhigh-riskcardiac\nconditionsbutmustbeweighedagainsttheriskofhaemorrhagiccomplications.87,88,91,92(seetable\n5.4)\nPatientswithlowriskcardiacconditions(suchasmitralvalveprolapse,mitralregurgitation,atrial\nseptalaneurysm,andpatentforamenovale)withoutadditionalriskfactorsmaybeofferedAspirin\n75-325mg/dayforprimarypreventionofstroke.\n(LevelIII)\nIfpatientsareAspirinintolerantthenconsider:Clopidogrel75mgdaily,Ticlopidine250mgbdor\nDipyridamole400mgdaily.87\n(LevelIII,GradeC)\nAnticoagulationisnotindicatedfornon-thromboticcausesofcardiacemboliandmaycause\nsubstantialintracranialhaemorrhageininfectiveendocarditisofnativevalves.87\nAnticoagulationisnotproventoreducerecurrentstrokeinthefirst14daysfollowinganacute\ncardioembolicevent[LevelI]withthepossibleexceptionofprostheticheartvalves,recentMI,\npresenceofintra-cardiacthrombus,AFwithadditionalriskfactorsandpreviousstroke.89(seetable\n5.5)\n(LevelIII)\nFurtherdetailsonstrokeandcardioembolisminChapter13."
    },
    {
        "page_number": 60,
        "text": "60RecommendationsSummary:\nTable5.4:CardiacConditionsPredisposingtoIschaemicstroke\nMajorRisk\nConditionsAdditionalRisk\nFactorsRecommendationsLevelof\nEvidenceGrade\nAtrial\nFibrillationRiskfactorstobe\nassessedby\nCHA2DS2-VAScscore.OACtopreventcardioembolicstrokeis\nrecommendedforallNVAFmalepatients\nwithCHA2DS2-VAScscoreof2ormore\nandfemalepatientswithaCHA2DS2-VASc\nscoreof3ormore.\nNewrecommendationI A\nAspirin75-325mgdailyissufficientfor\npatients<65yearsoldwith‘lone’AFand\nnoadditionalriskfactors.I A\nDirectOralAnticoagulant(DOAC)vs.Warfarin\nDabigatranissuperior(150mgbid)toand\naseffective(110mgbid)ascomparedto\nWarfarin,inpreventingstrokeand\nsystemicembolism.Bleedingratesare\nsimilarwithWarfarinat150mgbidbut\nhavealowerbleedingratesat110mg\nbid.93I A\nRivaroxabanwascomparedwith\nadjusted-dosewarfarinandfoundtobe\nnon-inferiorwithregardstotheprimary\ncompositeendpointofstrokeor\nnon-centralnervoussystemicembolism.94\nNewrecommendationI A\nApixabanwascomparedwith\nadjusted-dosewarfarinandfoundtobe\nsuperiortowarfarininpreventingstrokeor\nsystemicembolism.Apixabanalsocaused\nlessmajorbleedingcomparedwith\nwarfarinandresultedinloweroverall\nmortality.95\nNewrecommendationI A\nEdoxaban*ascomparedtowarfarinwas\nfoundtobenon-inferiorwithregardstothe\nprimaryefficacyendpointandcausedless\nbleeding.96\nNewrecommendation\n*CurrentlynotavailableinMalaysia.I A\nProsthetic\nHeartValves\n(Mechanical)Moderaterisk:\nBileafletortiltingdisk\naorticvalvesinNSRLifelongWarfarin\nII-2 B\nHighrisk:\nBileafletortiltingdisk\naorticvalvesinAF;\nBileafletortiltingdisk\nmitralvalveinAFor\nNSR.LifelongWarfarin(targetINR3.0;range\n2.5-3.5)\nII-3 B\nCaged-balland\ncaged-diskdesigns;\ndocumentedstroke/TIA\ndespiteadequate\ntherapywithWarfarin.LifelongWarfarin\n(targetINR3.0;range2.5-3.5)plusAspirin\n75-150mgdaily II-1 B\nBioprosthetic\nheartvalvesHighrisk:\nAF;leftatrialthrombusIfhigh-riskfactorsarepresent,consider\nWarfarinfor3-12monthsorlonger.III C"
    },
    {
        "page_number": 61,
        "text": "61atsurgery;previous\nstroke/TIAorsystemic\nembolism.Forallotherpatients,give\nWarfarinfor3monthspost-op,then\nAspirin75-150mgdaily.III C\nMitralStenosisHighrisk:\nAF;previousstroke/TIA;\nleftatrialthrombus;left\natrialdiameter>55mm\nonEcho.Ifhighriskfactorspresent,consider\nlong-termWarfarin. II-3 B\nForallotherpatientsstartAspirin\n75-150mgdaily.II-2 B\nMIandLV\ndysfunctionHighrisk:\nAcute/recentMI(<6\nmonths);extensive\ninfarctwithanteriorwall\ninvolvement;previous\nstroke/TIA.\nVeryhighrisk:\nSevereLVdysfunction\n(EF<28%);LV\naneurysm;spontaneous\nechocontrast;LV\nthrombus;dilated\nnon-ischaemic\ncardiomyopathies.IfriskfactorsarepresentwithoutLV\nthrombus:considerWarfarinfor3-6\nmonthsfollowedbyAspirin75-150mg\ndaily.III C\nIfLVthrombusispresent,consider\nWarfarinfor6-12months III C\nFordilatedcardiomyopathiesincluding\nperipartum,considerlifelongWarfarin\nIII C\nRecommendedWarfarindoseINRtarget2.5[range2.0to3.0]unlessstatedotherwise\nTable5.5:AnticoagulationforthePatientwithAcuteCardioembolicStroke\nTreatment RecommendationsLevelof\nEvidenceGrade\nWarfarin Adjusted-dosewarfarinmaybecommencedwithin2-4daysafter\nthepatientisbothneurologicallyandmedicallystable.II-2 C\nHeparin\n(unfractionated)Adjusted-doseunfractionatedheparinmaybestarted\nconcurrentlyforpatientsatveryhighriskofembolism.III C\nAnticoagulationAnticoagulationmaybedelayedfor1-2weeksiftherehasbeen\nsubstantialhaemorrhage.III C\nUrgentroutineanticoagulationwiththegoalofimproving\nneurologicaloutcomesorpreventingearlyrecurrentstrokeisnot\nrecommended.I A\nUrgentanticoagulationisnotrecommendedfortreatmentof\npatientswithmoderate-to-largecerebralinfarctsbecauseofthe\nhighriskofintracranialbleeding.I A\nHAS-BLEDstandsforHypertension,Abnormalrenal/liverfunction,Stroke,Bleedinghistoryor\npredisposition,LabileINR,Elderly(ageover65),andDrugs/alcoholconcomitantly;themaximum\npossiblescoreis9with1pointforeachofthecomponents(withabnormalrenal/liverfunction,for\nexample,apersonsores2ifbotharepresentandsimilarlyfordrugs/alcohol).97,98\"Drugs\"referto\nanymedicationsthatincreasesthebleedingriskduringanticoagulation,suchasAspirin,\nnon-steroidalanti-inflammatorydrugs(NSAIDs),orevensteroidsontopofWarfarin,and\"alcohol\"\nreferstoalcoholabuse.\n(Newrecommendation)"
    },
    {
        "page_number": 62,
        "text": "62Riskofbleedingisasfollowing(seechart):\nHAS-BLEDscorenBleeds,nBleeds/100patients*\n0 7989 1.13\n1 128613 1.02\n2 74414 1.88\n3 1877 3.74\n5.8RevascularisationProcedures\nSurgicalproceduresinstrokemanagementmaybeclassifiedtoproceduresperformedtoprevent\nfirststrokeoccurrence(primarypreventioninasymptomaticpatients)orfollowingastrokeevent\n(secondaryprevention).\n5.8.1PrimaryPrevention\nCarotidendarterectomy(CEA)hasbeencomparedtoconservativemedicaltherapyfor\nasymptomaticpatientswithoutpriorhistoryofTIAorstrokeforwhomimagingofthecarotidarteries\nrevealsadefinitestenosis.Ofthe5publishedrandomizedstudies,only2weresufficientlypowered\ntocomparetheoutcomesbetweensurgeryandmedicaltherapy.Theabsolute5-yearriskreduction\nforpatientswith70-99%carotidarterystenosis(byultrasound)was5.4%intherecentfollow-upof\ntheACSTtrial,whichwasconsistentwiththeACASstudyfromNorthAmerica(5-yearabsoluterisk\nreductionof5.9%).99,100Thistranslatesintoa1%annualstrokeratereduction.Patientswhoare\nasymptomaticandreceivingappropriatemedicaltherapyfaceanannualstrokerateof2%without\nCEA.Surgicalmorbidityandmortalityoftenexceedthisbeneficialriskreduction.IntheACSTand\nACAStrials,surgery-relatedeventswere3.1%and2.3%,respectively.99,100Inanunselectedpatient\ngroupundergoingCEAinacentrewithoutproperauditingofthesurgeonorthecentre’soperative\nrecords,thecomplicationsarelikelytooutweighthebenefitsofCEA.Furthermore,asymptomatic\npatientsshouldnotbeofferedCEAiftheir5-yearprobabilityofdyingfromunrelatedcausesishigh.\nFinally,intheNASCETstudy,nearly45%ofallstrokesoccurringinpatientswithasymptomatic\nstenosismaybeattributabletolacunarinfarctsorcardioembolism.101\nRecommendation:Endarterectomymaybeconsideredinpatientswithhigh-gradeasymptomatic\ncarotidstenosis(70-99%)whenperformedbyasurgeonwithlessthan3%morbidity/mortalityrate.\n(LevelI,GradeA)\nCarefulpatientselection,guidedbycomorbidconditions,lifeexpectancy,andpatientpreference,\nfollowedbyathoroughdiscussionoftherisksandbenefitsoftheprocedureisrequired.Itis\nimportantthatasymptomaticpatientsreceiveappropriatemedicaltreatmentandbefullyevaluated\nforothertreatablecausesofstroke.\n5.8.2SecondaryPrevention\nTwolargerandomizedtrials(NASCETandECST)havecomparedtheoutcomesofpatientswith\nrecentcerebrovascularsymptomstreatedconservativelyorwithcarotidendarterectomy.102,103\nLong-termfollow-upandameta-analysisisavailableforthesetrials.104Standardizingthesame\nmeasurementsanddefinitionsyieldedhighlyconsistentresultsamongthe3trials.Ingeneral,CEAis\nhighlybeneficialforpatientswithcarotidstenosis(70-99%),producinga16%absolute5-yearrisk\nreduction(ARR).Forpatientswith50-69%stenosis,the5-yearARRwas4.6%.Nobenefitwas\nobservedforpatientswithmilderdegreesofstenosis.Subgroupanalysesrevealedthatbenefitsin\nsurgerywasthegreatestinmen,aged75yearsorolder,andthoserandomizedwithin2weeksof\ntheirstrokeevent.Thesestudiesexcludedpatientswithmedicalco-morbidities,previousneck\nirradiationandrecurrentstenosisfollowingpreviousendarterectomy."
    },
    {
        "page_number": 63,
        "text": "63Extracranial-intracranialanastomosisbetweenthesuperficialtemporalandmiddlecerebralarteries\n(EC-ICBypass)hasnotbeenshowntobebeneficialforsecondarystrokepreventionbytheEC/IC\nBypassStudyGroup.\nRecommendation:CEAisindicatedforpatientswithcarotidstenosisof70-99%withoutasevere\nneurologicaldeficitfollowingarecentischaemicevent(lessthan180days)incentreswitha\nperioperativecomplicationrateforallstrokesanddeathsoflessthan6%.\n(LevelI,GradeA)\nRecommendation:EarlyCEAisindicatedforpatientswithcarotidstenosisof70-99%withouta\nsevereneurologicaldeficitwithin2weeksofrecentischaemiceventsincentreswithaperioperative\ncomplicationrateforallstrokesanddeathsoflessthan6%.\n(LevelII-1,GradeB)\nRecommendation:CEAmaybeindicatedforpatientswithcarotidstenosisof50-69%withouta\nsevereneurologicaldeficitwithrecentischaemicevent(lessthan180days)incentreswitha\nperioperativecomplicationrateforallstrokesanddeathsoflessthan6%.\n(LevelIII,GradeC)\nRecommendation:CEAisnotrecommendedforpatientswithcarotidstenosislessthan50%.\n(LevelI,GradeA)\nCEAshouldnotbeperformedincentresnotexhibitinglowcomplicationratessimilartothoseseen\nwithNASCETorECST.\n(LevelI,GradeA)\nRecommendation:Patientsshouldremainonantithrombotictherapybeforeandaftersurgery.\n(LevelII-2,GradeB)\nRecommendation:External/internalcarotidbypassisnotrecommendedforsecondarystroke\nprevention.\n(LevelI,GradeA)\n5.9AngioplastyorStenting\nThisisarapidlyevolvingfieldinstroketreatmentandprevention.Severalrandomizedtrialshave\ncomparedextra-cranialcarotidangioplastyandstenting(CAS)tocarotidendarterectomy\n(CEA).99,101,105,106\nRecommendation:CASrepresentsafeasiblealternativetocarotidendarterectomyforsecondary\nstrokepreventionwhensurgeryisundesirable,technicallydifficult,orinaccessible.107,109\n(LevelII-2)\nInrecentstudies,the4-yearoutcomeindeath,strokeandmyocardialinfarctionwassimilarinCAS\nandCEA.However,theperiproceduralrateofstrokewashigherintheCASgroupwhilethe\nperiproceduralrateofmyocardialinfarctionwashigherintheCEAgroup.Selectionofpatientsfor\neitherCASorCEAmayrequireattentiontoage,withyoungerpatientshavingaslightlybetter\noutcomewithCASandolderpatientshavingabetteroutcomewithCEA.106-112\nThecriterianeededforacentretodoCAS:\nI.highlyqualifiedsurgeonsandinterventionists\nII.surgeonsandinterventioniststhatarecredentialed\nIII.mustusedistalembolicprotectiondevice\nIV.useofdualantiplatelettherapyafterCASforatleast4weeks"
    },
    {
        "page_number": 64,
        "text": "64Recommendation:Distalprotectiondevicesshouldbeusedduringtheprocedureanduseofdual\nantiplateletforatleast4weeksafterCAS.\n(LevelI,GradeA)\nRecommendation:Complexconfigurationoftheaorticarchandinternalcarotidarterytortuosity\nincreasetheriskofcerebralischemiainCAS.113\n(LevelII-2,GradeB)\nIntracranialarterystenting(IAS)isalsotechnicallyfeasiblebuthasnotbeenproventobean\nestablishedtreatmentmodality.Are-stenosisrateofupto30%hasbeenreported.105Clinicaldata\nhasmuchlessevidencewithmorecontroversyascomparedtocarotidangioplasty.105The\nSAMMPRISandVISSITrandomizedtrialsfoundthatpatientswithsymptomaticintracranial\natherosclerosistreatedwithangioplastyandstentinghadworseoutcomesthanthosewhoreceived\nmedicaltherapy114,115.\nTheroleofCASinintra-cranialstenoses,asymptomaticstenosesandacutestrokeisunclearand\nmaynotberecommended.102,103,116However,themostrecentstudy(WEAVETrial)showedthatwith\nexperiencedinterventionalists,andproperpatientselection,theuseofthestentforintracranial\natheroscleroticdiseasedemonstratedalowperiproceduralcomplicationrateandexcellentsafety\nprofile.117\nTherefore,carefulselectionwithextensivemultidisciplinarydiscussionsbycentresexperiencedin\nstrokemanagementisrecommended.Asangioplastywithorwithoutstentingisstillan\ninvestigationalprocedure,itshouldbecarriedoutunderappropriateclinicaltrialprotocols.\nRecommendation:RoleofIASinintra-cranialstenoses,asymptomaticstenosesandacutestrokeis\nunclearandmayberecommended.\n(LevelII-2,GradeC)"
    },
    {
        "page_number": 65,
        "text": "65Table5.6:RevascularisationProcedures\nTreatment RecommendationsLevelof\nEvidenceGrade\nCarotid\nEndarterectomy\n(CEA)PrimaryPrevention\nMaybeconsideredinpatientswithhighgradeasymptomatic\ncarotidstenosis(70-99%)whenperformedbysurgeonswith\nlessthan3%morbidity/mortalityrate.I A\nSecondaryPrevention\nIndicatedformostpatientswithastenosisof70-99%aftera\nrecentischaemiceventincentreswithcomplicationratesof\nlessthan6%.I A\nEarlierintervention(within2weeks)ismorebeneficial. II-1 B\nMaybeindicatedforpatientswithastenosisof50-69%after\narecentischaemiceventincentreswithcomplicationrates\noflessthan6%.III C\nNotrecommendedforpatientswithastenosisoflessthan\n50%.I A\nPatientsshouldremainonantiplatelettherapybeforeand\naftersurgery.II-2 B\nCarotidangioplasty\nandstenting(CAS)CASrepresentsafeasiblealternativetocarotid\nendarterectomyforsecondarystrokepreventionwhen\nsurgeryisundesirable,technicallydifficult,orinaccessible.II-2 B\nDistalprotectiondevicesshouldbeusedduringthe\nprocedure.I A\nUseofdualantiplateletforatleast4weeksafterCAS. I A\nThelong-termsafety(for4years)forCASisasgoodas\nCEA.I A\nComplexconfigurationoftheaorticarchandinternalcarotid\narterytortuosityincreasetheriskofcerebralischemiain\nCASII-2 B\nIntracranial\nangioplasty&stenting\n(IAS)RoleofIASinintra-cranialstenoses,asymptomatic\nstenosesandacutestrokeisunclearandmaybe\nrecommended.II-2 C\nKeyRecommendations:\n1.Strokeisapreventablediseaseandmaybeattributedtomodifiableandnon-modifiablerisk\nfactors.\n2.Modifiableriskfactorsarethefocusofprimarypreventionandcanbeclusteredintothreemain\ngroupsi.e.\na)Lifestyleriskfactors,i.e.,smoking,physicalinactivity,andunhealthyeating\nb)Metabolicriskfactors,i.e.,highsystolicBP,highcholesterol,highfastingbloodglucose,\nloweGFRandhighBMI.\nc)Environmentalfactors,i.e.,airpollutionandleadexposure.\n3.Secondarypreventionofstrokeinvolvesthepreventionofrecurrentstroke,andthismayinvolve\nmedicalinterventionsincludesantiplatelettherapy,anti-hypertensivetreatment,lipid-lowering\nagents,glycaemiccontrol,preventionofcardio-embolismandre-vascularisationproceduresin\nselectedcases."
    },
    {
        "page_number": 66,
        "text": "66INVESTIGATIONS\n6.1InvestigationalObjectives\nInvestigationscarriedoutforstrokepatientsareaimedto:\nI.Confirmthediagnosis\nII.Determinethemechanismofstroke\nIII.Stratifyrisksanddetermineprognosis\nIV.Identifypotentialtreatablelargeobstructivelesionsofthecerebrovascularcirculation\n6.2TypesofInvestigations\n6.2.1HaematologicalInvestigations\nTherequiredhaematologicalinvestigationsaredisplayedinTable6.1.\nTable6.1:HaematologicalInvestigationsRequired\nOnAdmission\nFullbloodcount Excludeanaemia,polycythaemia,thrombocytosis,\nthrombocytopenia,etc.\nRandombloodglucose Excludehypoglycaemiaorhyperglycaemia,new\ndiagnosisofdiabetesmellitus\nUrea&electrolytes Hydrationstatus,excludeselectrolyteimbalances\nClottingprofile* Baseline\nNextDay\nLipidprofile(fasting)\nGlucose(fasting)\nOptionalTests(inselectedpatients)\nVDRL\nAutoimmunescreen ESR,anti-nuclearantibody,rheumatoidfactor,\nanti-doublestrandedDNAantibodies,C3andC4\nlevels,etc.\nThrombophiliascreen&\nlupusanticoagulantSerumfibrinogen,anti-thrombinIII,proteinC,protein\nS,factorV-Leiden,anti-phospholipidantibodies,etc.\nHomocysteine(fasting)\nC-reactiveprotein\n*Ifthrombolysisconsidered\n6.2.2OtherBaselineInvestigations\nOtherbaselineinvestigationsthatarecrucialforthemanagementofstrokearelistedinTable6.2.\nTable6.2:OtherInvestigations\n12leadECG -Mandatory\nAmbulatoryECG -Forsuspectedarrhythmiasorsinoatrialnodedisease6"
    },
    {
        "page_number": 67,
        "text": "676.2.3Imaging\nImportantimaginginvestigationsforsuspectedstrokepatientsareshowninTable6.3.\nTable6.3:ImagingforStrokePatients\nForallsuspectedstroke\nChestx-ray -Mandatory\nCTbrain -Theemergencyneuroimagingscanofchoiceforallpatients\n-Differentiateshaemorrhagefrominfarctionandsomestroke\nmimickers\n-Confirmssiteoflesion,causeoflesionandextentofbrain\naffected\nInselectedpatients\nEchocardiography\n(ECHO)-Forsuspectedcardio-embolism,assesscardiacfunction\nMagneticResonance\nImaging(MRI)-Sensitive\n-Availableinveryselectedsetting,limitedbycost\n-Usefultooltoselectpatientsforrevascularizationwhere\navailable\nCarotidDuplex\nUltrasound-Allowsidentificationofextracranialvesseldisease\n\\TranscranialDoppler\nUltrasound-Identifiesintracranialvesseldiseasewithprognosticand\ntherapeuticimplications\nMRAngiography(MRA)-Non-invasivetooltoassessintra-andextra-cerebralcirculation\n-Objectiveassessmentofvesselstenosis\nCTAngiography\n(Multi-sliceCTscan)\n(CTA)-Non-invasivetooltoassessintra-andextra-cerebralcirculation\n-Involvesintravenouscontrastinjection\nCTorMRPerfusion\n(CTP/MRP)-Non-invasivetool,CTAwithCTP,orMRIwithDWI-MRIwithor\nwithoutMRPisusefulforselectingcandidateforthrombolysis\nandmechanicalthrombectomyintheextendedhours.\nMRVenography -Insuspectedcerebralvenousthrombosis\nContrastAngiogram -Goldstandardassessmentofcerebralvasculature\n-Reservedforpatientsplannedforintervention\nKeyRecommendations:\n1.Investigationscarriedoutinstrokeareaimedtoconfirmthediagnosis,determinethe\nmechanismofstroke,stratifyrisk,andtoidentifypotentialtreatablevascularlesions.\n2.Computedtomography(CT)brainismandatoryandisthepreferredimaginginvestigationin\ntheemergencysettingtodifferentiateshaemorrhage,determinethesite,cause,andextentof\nthelesion.\n3.Advanceimagingmayberequiredinselectedcasesintheemergencysettings,e.g.,ruling\noutstrokemimics,reperfusiontherapyinextendedhoursanddeterminingpotential\nre-vascularisationprocedure.\n4.Selectedbloodinvestigationsandimagingwillberequiredincertainpatientstodeterminethe\naetiologyofstroke."
    },
    {
        "page_number": 68,
        "text": "68EMERGENCYMEDICINESERVICES\nMostpeoplewithacutestroke(95%)havetheirfirstsymptomsoutofhospital.1Basedondatain\nothercountries,approximatelytwo-thirdsofallpatientswhoseekacutecareforstrokearrivetothe\nemergencydepartmentbyambulance.2\nSpecifictherapiesforacutestroke,namelyintravenousthrombolysis,andendovasculartreatment\n(EVT)aretime-criticaltreatments.Thus,theyaremosteffectivewheninitiatedsoonaftertheonsetof\nsymptoms.Propertreatmentanddispositionofstrokepatientsbeginsfromtheout-of-hospital\nenvironment,subsequentlycontinuesintheemergencydepartment(ED),andextendstothe\ninpatientadmission.Therefore,itisessentialforEmergencyMedicineandTraumaService(EMTS)\npersonnel,MedicalEmergencyCoordinationCentre(MECC)orAmbulanceDispatchCentre(ADC)\npersonnel,and/orpre-hospitalcarerespondersandEDpersonnel,torecognisestrokeearlyandas\naccuratelyaspossible.Atthesametime,astrongworkingrelationshiparerequiredbetween\npre-hospitalcarestaffs,EDstaffsandthestroketeamtoimprovetimelyassessmentsandearly\nmanagement.\nEmergencymedicinemanagementframeworkforacutestrokeincludetwodistinctphases:\nI.Pre-hospitalcarephase\nII.Emergencydepartmentclinicalcarephase\n7.1Pre-hospitalManagement\n7.1.1Publiceducation3,4\nRecommendation:Publicorcommunityeducationalprogrammesshouldbedesignedtocreate\nawarenessandknowledgeofstrokewarningsigns.\n(Newrecommendation,LevelII-1,GradeA)\nRecommendation:Theeducationalprogrammesshouldalsoincludethetimelyrecognitionand\nneedtoseekemergencycarebycalling999promptly.\n(Newrecommendation,LevelII-1,GradeA)\n7.1.2Emergencydispatchsystem5,6\nRecommendation:AmbulanceDispatchCentres(ADC)shouldbefamiliarwithcommondescriptors\nusedbypublicforstroke.Wheneverthedescriptorsareused,EmergencyMedicalDispatchers\n(EMD)aretrainedtousethestrokeprotocolstoidentifysuspectedstrokepatients.\n(Newrecommendation,LevelII-1,GradeA)\nRecommendation:ADCshouldhaveaprotocolortoolsthatallowEmergencyMedicalDispatchers\n(EMD)toidentifysuspectedstrokepatients.ExamplesofstrokeassessmenttoolsaretheMDPS\nStrokeDiagnosticToolusedbyMECC,FAST(Face,Arm,Speech,andTime)strokeassessmentor\nCPSS(CincinnatiPrehospitalStrokeScale).\n(Newrecommendation,LevelII-1,GradeA)\nRecommendation:ADCshouldhaveasysteminplacetoallowsuspectedstrokecallstoreceive\npriorityinresponsethatwillfacilitateearlyarrivalofpatientstotheEmergencyDepartment(ED).\n(Newrecommendation,LevelII-1,GradeA)7"
    },
    {
        "page_number": 69,
        "text": "697.1.3Initialon-scenemanagement3-4,7-10\nPHCresponders(amedicallytrainedpersonwhorespondstopre-hospitalcalls,usuallyanAssistant\nMedicalOfficerorStaffNurse)shouldbefamiliarwiththedetectionandmanagementofstroke\npatients. (LevelII-1,GradeA)\nRecommendation:PHCrespondersshouldrapidlyevaluatetheairway,breathingandcirculationin\npatientswithsuspectedacutestroketoidentifylifethreateningsituations,andmanageaccordingly.\n(Newrecommendation,LevelII-1,GradeA)\nThereareseveralvalidatedprehospitalstrokescreeningtoolswhichcanbeutilizedtoidentifystroke\n(pre-hospitaldiagnosticscreeningtools)andtoassessseverityofstroke(pre-hospitalstrokeseverity\nscales)(seeAppendixB).Strokeseverityassessmentmaybeconsideredifpatientdemonstrate\nanysignsofstroke.\nRecommendation:Forstrokeidentification,PHCrespondersshoulduseavalidatedand\nstandardizedassessmenttoolsuchasFASTorBE-FAST(Balance,Eyes,Face,Arm,Speech,Time)\nstrokeassessment.OtheridentificationassessmenttoolsthatcanbeusedincludeCPSS,LAPSS\n(LosAngelesPrehospitalStrokeScreen).11-16\n(Newrecommendation,LevelII-1,GradeA)\nRecommendation:PHCrespondersshouldbetrainedtoidentifyhypoglycaemiaasastroke-mimic\nandapplyappropriatemanagementprotocols.\n(Newrecommendation,LevelI,GradeA)\nRecommendation:PHCrespondersshouldascertainthetimeofonsetofstrokesymptomsfromthe\npatientorwitness(es).\n(Newrecommendation,LevelI,GradeA)\nRecommendation:PHCServiceProvidersshouldensureitsrespondersaremadeawareofthe\nnearesthospitalcapableofprovidingthrombolysisandhospitalcapableofperformingendovascular\nstroketreatment,withintheirservicearea.Awrittenprotocolthatensurestheambulancediversionof\nthepatienttosuchhospitalsshouldbemadeavailableforuse.\n(Newrecommendation,LevelI,GradeA)\nRecommendation:AllstrokepatientsfromPHCwithpositivesignsofstrokewithinthe4.5-hour\ntherapeuticwindowformedicalthrombolytictherapyshouldbetransportedrapidlytoanacutestroke\nreadyhospital.\n(Newrecommendation,LevelII-1,GradeA)\nRecommendation:Titrateddosesofoxygenshouldbedeliveredtostrokepatientswithoxygen\nsaturationlevelsbelow95%.\n(Newrecommendation,LevelII-3,GradeB)\n7.1.4Pre-arrivalcommunication(StrokeAlert)3,4\nRecommendation:PHCRespondersshouldbetrainedtoprovidepre-arrivalnotificationofstroke\npatientstoreceivinghospitals.AmbulanceDispatchCentrescanbeusedasanintermediaryto\nprovidestrokealertcommunicationtohospitals.\n(Newrecommendation,LevelII-1,GradeA)\nRecommendation:MECCandassociatedstrokereadyhospital(s)arerecommendedtohavelocal\nregionalstrokereferralsystem/networkandagreementwiththeEDtofacilitatethetransport\ndecisionfromPHCtoensurethetreatmentwindowof4.5hoursisachieved(Strokesystemofcare).\n(Newrecommendation,LevelI,GradeA)"
    },
    {
        "page_number": 70,
        "text": "707.2EmergencyDepartmentManagement\n7.2.1EDEvaluation\nRecommendation:AllpatientspresentingtoanEDwithsuspectedacutestrokemusthave\nimmediateclinicalevaluationandinvestigationstoestablishthediagnosisandtodeterminethe\neligibilityforintravenousthrombolytictherapyand/orEVT.2,3,17\n(Newrecommendation,LevelI,GradeA)\nRecommendation:TheuseofclinicalscreeningtoolssuchasFASTorBE-FASTtoidentifystroke\nbyEDstaffcanbebeneficial.15-18(addbefast)\n(Newrecommendation,LevelII-2,GradeB)\n7.2.2InitialAssessmentofStrokePatientinED\nRecommendation:EDstaffshouldrapidlyevaluateairway,breathingandcirculationonpatients\nwithsuspectedacutestrokeandmanageaccordingly.1-3\n(Newrecommendation,LevelI,GradeA)\nRecommendation:Allpatientswithsuspectedacutestrokeshouldhavetheirbloodglucose\nconcentrationcheckeduponarrivalattheED.Hypoglycaemiashouldbecorrectedimmediately.2,3\n(Newrecommendation,LevelII-1,GradeA)\nRecommendation:AstandardizedstrokeseverityscalesuchastheNationalInstitutesofHealth\nStrokeScale(NIHSS)shouldbeusedtoassessstrokeseverityintheED.2,3\n(Newrecommendation,LevelII-1,GradeA)\n7.2.3Imaging\nRecommendation:Allpatientswithsuspectedstrokewhoarecandidatesforintravenous\nthrombolysisand/orEVTshouldundergoatleastaCTscanimmediately.Allothersuspectedstroke\npatientsshouldhaveanurgentCT-brain.Inmostcases,anon-contrastCT(NCCT)brainwillprovide\nnecessaryinformationtomakedecisionsaboutacutemanagement.1-3,17\n(Newrecommendation,LevelII-1,GradeA)\nRecommendation:Interpretationofacutestrokeimagingforthrombolysisdecisionsshouldonlybe\nmadebyhealthcareprofessionalswhohavereceivedappropriatetraining.1,19\n(Newrecommendation,LevelIII,GradeC)\n7.2.4OtherConsiderations\nRecommendation:Patientswithacutestrokeshouldonlyreceivesupplementaloxygeniftheir\noxygensaturationisbelow95%.1-4,17\n(Newrecommendation,LevelII-3,GradeB)\nRecommendation:Hypotensionandhypertensioninpatientswithacutestrokeshouldbeidentified\nandmanagedaccordingly.2,3\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Patientswithacutestrokeshouldhavetheirswallowingabilityscreenedasearly\naspossibleafterarrivalatthehospitalandbeforebeinggivenanyoralfood,fluid,ormedication.1,2,17\n(Newrecommendation,LevelII-2,GradeB)"
    },
    {
        "page_number": 71,
        "text": "717.2.5QualityImprovement\nRecommendation:Jointmultidisciplinaryauditstoreviewandmonitorstrokecarequality\nbenchmarks,indicators,evidence-basedpracticesandoutcomesshouldbeperformedperiodically.\nQualityimprovementshouldbeconductedtolookatgapsanddisparitiesinordertoimprovepatient\ncareandoutcome.3\n(Newrecommendation,LevelII-1,GradeA)\nRecommendation:EDpersonnelshouldundergoastandardizedtraininginacutestroke\nmanagement.3,17\n(Newrecommendation,LevelIII,GradeC)\nAppendixClistsanddescribesthetermsrelatedtothischapter.\n.\nRecommendationsSummary:\nTable7.1:EmergencyMedicineServices\nManagement Recommendations Levelof\nEvidenceGrade\nPre-HospitalManagement\nPubliceducationEducationalprogrammes\n-shouldbedesignedtocreateawarenessandknowledgeof\nstrokewarningsigns.\n-shouldincludethetimelyrecognitionandneedtoseek\nemergencycarebycalling999promptly.\nNewrecommendationII-1\nII-1A\nA\nEmergency\ndispatchsystemADC\n-shouldbefamiliarwithcommondescriptorsusedbythe\npublicforstroke.Wheneverthedescriptorsareused,EMD\naretrainedtousethestrokeprotocolstoidentifysuspected\nstrokepatients\n-shouldhaveaprotocolortoolsthatallowEmergency\nMedicalDispatchers(EMD)toidentifysuspectedstroke\npatients.e.g.MDPSStrokeDiagnosticTool,FASTstroke\nassessment.\n-shouldhaveasystemtoprioritiessuspectedstrokecallsto\nfacilitatetheearlyarrivalofpatientstotheED.\nNewrecommendationII-1\nII-1\nII-1A\nA\nA\nInitialon-scene\nmanagementPHCresponders\n-shouldrapidlyevaluateairway,breathingandcirculationto\nidentifylifethreateningsituation,andmanagethem\naccordingly.\n-shoulduseavalidatedandstandardizedstroke\nidentificationassessmenttoolsuchasFASTorBE-FAST\nstrokeassessment\n-shouldbetrainedtoidentifyhypoglycaemiaasa\nstroke-mimicandapplyappropriatemanagementprotocols\n-shouldascertainthetimeofonsetofstrokesymptomsfrom\nthepatientorwitness(es).\nPHCServiceProvidersshouldensureitsrespondersaremade\nawareofthenearesthospitalcapableofprovidingthrombolysisand\nhospitalcapableofperformingendovascularstroketreatment,\nwithintheirservicearea.Awrittenprotocolthatensuresthe\nambulancediversionofthepatienttosuchhospitalsshouldbe\nmadeavailableforuse.II-1\nII-1\nI\nI\nIA\nA\nA\nA\nA"
    },
    {
        "page_number": 72,
        "text": "72AllstrokepatientsfromPHCwithpositivesignsofstrokewithinthe\n4.5-hourtimewindowformedicalthrombolytictherapyshouldbe\ntransportedrapidlytoanacutestrokereadyhospital.\nTitrateddoseofoxygenshouldbedeliveredtostrokepatientswith\nanoxygensaturationlevelofbelow95%.\nNewrecommendationII-1\nII-3A\nB\nPre-arrival\ncommunicationPHCRespondersshouldbetrainedtoprovidepre-arrival\nnotificationofstrokepatientstoreceivinghospitals.\nMECCandassociatedstrokereadyhospital(s)arerecommended\ntohavelocalregionalstrokereferralsystem/networkand\nagreementwiththeEDtofacilitatethetransportdecisionfromPHC\ntoensurethetreatmentwindowof4.5hoursisachieved.\nNewrecommendationII-1\nIA\nA\nEmergencyDepartmentManagement\nEDEvaluationAllpatientspresentingtoanEDwithsuspectedacutestrokemust\nhaveimmediateclinicalevaluationandinvestigationstoestablish\nthediagnosisandtodeterminetheeligibilityforintravenous\nthrombolytictherapyand/orEVT\nTheuseofclinicalscreeningtoolssuchasFASTorBE-FASTto\nidentifystrokebyEDstaffcanbebeneficial\nNewrecommendationI\nII-2A\nB\nInitial\nAssessmentin\nEDEDstaffshouldrapidlyevaluateairway,breathingandcirculationin\npatientswithsuspectedacutestrokeandmanagethemaccordingly\nAllpatientswithsuspectedacutestrokeshouldhavetheirblood\nglucoseconcentrationcheckeduponarrivalattheED\nAstandardizedstrokeseverityscaleshouldbeusedsuchasthe\nNationalInstitutesofHealthStrokeScale(NIHSS)toassessstroke\nseverityintheED\nNewrecommendationI\nII-1\nII-1A\nA\nA\nImaging Allpatientswithsuspectedstrokewhoarecandidatesfor\nintravenousthrombolysisand/orEVTshouldundergoatleastaCT\nscanimmediately.Allothersuspectedstrokepatientsshouldhave\nanurgentCT-brain.\nInterpretationofacutestrokeimagingforthrombolysisdecisions\nshouldonlybemadebyhealthcareprofessionalswhohave\nreceivedappropriatetraining.\nNewrecommendationII-1\nIIIA\nC\nOther\nConsiderationsPatientswithacutestrokeshouldonlyreceivesupplemental\noxygenonlyiftheiroxygensaturationisbelow95%.\nHypotensionandhypertensioninpatientswithacutestrokeshould\nbeidentifiedandmanagedaccordingly.\nPatientswithacutestrokeshouldhavetheirswallowingability\nscreenedasearlyaspossibleafterarrivalatthehospitaland\nbeforebeinggivenanyoralfood,fluid,ormedication\nNewrecommendationII-3\nIII\nII-2B\nC\nB"
    },
    {
        "page_number": 73,
        "text": "73Quality\nImprovementJointmultidisciplinaryaudittoreviewandmonitorstrokecare\nqualitybenchmarks,indicators,evidence-basedpractices,and\noutcomesshouldbeperformedperiodically.\nEDpersonnelshouldundergoastandardizedtraininginacute\nstrokemanagement.\nNewrecommendationII-1\nIIIA\nC\nKeyRecommendations:\n1.Thepublicshouldbeencouragedtocall999iftheysuspectapersonishavingastroke.\n2.Emergencymedicaldispatcherandprehospitalcareprovidershouldbetrainedtorecognizeand\nidentifystrokeandareabletoproviderapidtransportationofsuspectedacutestrokepatientto\nneareststrokereadyhospital.\n3.Assessmentofpatientwithsuspectedacutestrokeinemergencydepartmentshouldbe\nprioritizedinordertoexpeditiouslyestablishstrokediagnosisandtodeterminethebest\nappropriateacutestrokeinterventions.\n4.Auditofacutestrokecareandtrainingofemergencydepartmentpersonnelshouldbeconducted\ntoimprovequalityofcareinacutestrokecases."
    },
    {
        "page_number": 74,
        "text": "74ACUTEGENERALMANAGEMENT\n8.1GeneralManagement\nTheprimaryaimofacutestrokemanagementisforearlyreperfusiontherapywhichwillbecoveredin\nChapter9and10.Thischapterwillcoverthegeneralmanagementofacutestrokethatincludes\nsupportivecareandtreatmentofacutecomplications.Thisisimportanttoimprovethemortalityrates\nandreducethefunctionaldisability.\n8.1.1OxygenandAirwaySupport\nAdequatetissueoxygenationisimperativetopreventhypoxiaandpotentialworseningofthe\nneurologicalinjury.1-5\n(LevelII-3toIII)\nRecommendation:Patientswithacutestrokeshouldonlyreceivesupplementaloxygeniftheir\noxygensaturationisbelow95%andbetitratedtoachieveabove95%.6-9\n(Newrecommendation,LevelII-3,GradeB)\n8.1.2Observation\nRecommendation:Regularobservationismandatorytorecogniseimpairedpulmonaryfunction\n(pulseoxymeter),circulatoryfunction(pulserate,bloodpressure),NIHSSscore,headchart,GCS,\nandcomplicationsfrommasseffect.1\n(LevelIII,GradeC)\n8.1.3Mobilisation\nMostpatientsarefirsttreatedwithbedrest,butmobilisationshouldbeginassoonasthepatient’s\nconditionisjudgedtobestable.10-13\nRecommendation:Mobiliseearlytopreventcomplications.\n(LevelII-3,GradeC)\nAlthoughtwosmallRCTsshowedthatveryearlymobilisation(beginningwithin24hours)was\nfeasibleinanacutesetting,theAVERTtrialshowedthatveryearly,morefrequentandhigherdose\nofmobilisationfocusedonout-of-bedactivitiesinadditiontousualcarewasworseintermsof\noutcomesthanusualcarealone.Veryearlymobilisationreducedtheoddsoffavourableoutcomesat\nthreemonths.14\nRecommendation:High-dose,veryearlymobilisationwithin24hoursofstrokeonsetshouldnotbe\nrecommended.\n(Newrecommendation,Levell)\n8.1.4BloodPressure\nInpatientswithAIS,earlytreatmentofhypertensionisindicatedwhenrequiredbycomorbid\nconditions(e.g.concomitantacutecoronaryevent,acuteheartfailure,aorticdissection,\npost-thrombolysissICH,orpreeclampsia/eclampsia).InpatientswithaBPof≥220/120mmHgwho\nhavenotreceivedIValteplaseorEVTandhavenocomorbidconditionsrequiringacute\nantihypertensivetreatment,thebenefitofinitiatingorreinitiatingtreatmentofhypertensionwithinthe8"
    },
    {
        "page_number": 75,
        "text": "75first48to72hoursisuncertain.ItmightbereasonabletolowerBPby15%duringthefirst24hours\naftertheonsetofstroke.15-20\nRecommendation:LoweringBPinitiallyby15%isprobablysafe.Veryhighbloodpressureshould\nbereducedgradually.\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:DonottreathypertensionifsystolicBPis<220mmHgordiastolicBPis\n<120mmHg.Mildhypertensionisdesirableat160-180/90-100mmHg.\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Proposeddrugs:Labetalol10-20mgbolusesat10minuteintervalsupto\n150-300mgor1mg/mlinfusion,withtherateofinfusionof1-3mg/minororalCaptopril6.25-12.5mg.\nSublingualuseofacalciumantagonist,suchasNifedipine,shouldbeavoidedbecauseoftheriskof\nrapiddeclineinbloodpressure.21\n(LevelII-3,GradeC)\n8.1.5BloodGlucose\nHyperglycaemiafollowingacutestrokeisstronglyassociatedwithsubsequentmortalityandimpaired\nneurologicalrecovery.Thisappliestobothdiabeticsandnon-diabetics.22,23\n(LevelII-3,GradeC)\nTheInternationalDiabetesFederationpublishedacomprehensiveguidelineonmanagingolder\npeoplewithtype2diabeteswhichincludedasectiononmanagementofhyperglycaemiapost-acute\nstroke.24\nAtpresent,theoptimallevelofbloodglucoseafterastrokeisunclear.Asystematicreviewof11\nRCTsconcludedthattheadministrationofintravenousinsulintomaintaintightglucosecontrolwithin\naspecificrange(4.0-7.5mmol/L)inthefirstfewhoursofacuteischaemicstrokedoesnotprovide\nbenefitintermsoffunctionaloutcome,death,orimprovementinfinalneurologicaldeficit,but\nsignificantlyincreasedthenumberofhypoglycaemicepisodes.25\nRecommendation:Afteranacutestroke,treathyperglycaemiatokeepthebloodglucoselevels\nbetween6.0-10.0mmol/Landensurethathypoglycaemiaisavoided.24\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Avoidverytighttargetsofglucosecontrol(4.0-7.5mmol/L)inthefirstfewhours\nofacuteischaemicstroke.\n(Newrecommendation,LevelI,GradeA)\n8.1.6Nutrition\nSustainingnutritionisimportantasmalnutritionafterstrokemightinterferewithrecovery.26Persons\nwithinfarctionsofthebrainstem,multiplestrokes,largehemisphericlesions,ordepressed\nconsciousnessareatthegreatestriskforaspiration.Swallowingimpairmentsareassociatedwithan\nincreasedmortality.\nTheFOODRCT’sshowedthatsupplementeddietwasassociatedwithanabsolutereductioninrisk\nofdeathof0.7%andthatearlytubefeeding(within7daysofadmission)wasassociatedwithan\nabsolutereductioninriskofdeathby5.8%andareductionindeathorpooroutcomesby1.2%.27,28\nRecommendation:Enteralfeedingshouldbestartedwithin7daysofadmission(oralortube\nfeeding).\n(Newrecommendation,LevelI,GradeA)"
    },
    {
        "page_number": 76,
        "text": "76Awaterswallowingtest(refertoAppendixC)shouldbeperformedbeforethepatientisallowedto\neatordrink.Awetvoiceafterswallowing,incompleteoral-labialclosure,orcoughingreflexon\nswallowingindicateshighriskofdevelopingaspiration.Thereisgoodevidencethatamulti-item\ndysphagiascreeningprotocolthatincludesatleastawaterintaketestof10teaspoonsandalingual\nmotortestwasmoreaccuratethanscreeningprotocolswithonlyasingleitem.29\nRecommendation:Performawaterswallowingtest.Insertanasogastrictubeifthepatientfailsthe\nswallowingtest.\n(LevelIII,GradeC)\nAninstrumentalevaluationsuchasavideofluoroscopicswallowingexamination(VFSE)ormodified\nbariumswallowexamination(MBS)canbeperformedlaterifindicated.1,30\n(LevelIII,GradeC)\nIfthepatientfailstheswallowingtest,anasogastrictubeshouldbeinsertedtopreventaspiration.\nPEGtubeissuperiortonasogastrictubefeedingifaprolongedneedfordevicesisanticipated.31\nRecommendation:PEGissuperiortonasogastricfeedingonlyifprolongedenteralfeedingis\nrequired.\n(LevelII-1,GradeB)\n8.1.7Infection\nInfectionisthecommonestcomplicationafteranacutestrokeespeciallypneumoniaandurinarytract\ninfection.32\nTheappearanceoffevershouldpromptasearchforinfectionandappropriateantibiotictherapy\nshouldbeadministeredearly.32Bladdercathetersshouldbeavoidedifpossible.1\nRecommendation:Searchforinfectioniffeverappearsandtreatwithappropriateantibioticsearly.\n(LevelIII,GradeC)\nRoutineuseofprophylacticantibioticshasnotbeenshowntobebeneficial.\n(Newrecommendation,LevelI,GradeA)\n8.1.8Fever\nAmeta-analysissuggestedthatfeveraftertheonsetofstrokewasassociatedwithmarkedincrease\ninmortalityandmorbidity.33\nRecommendation:Antipyreticsshouldbeusedtocontrolelevatedtemperaturesinacutestroke\npatients.33,34\n(LevelII-1,GradeB)\nThebenefitofinducedhypothermiafortreatingpatientswithischaemicstrokeisnotwell\nestablished.35-38\nHypothermiashouldbeofferedonlyinthecontextofon-goingclinicaltrials.\n(Newrecommendation,LevelI,GradeA)"
    },
    {
        "page_number": 77,
        "text": "778.1.9Continence\nTheapplicationofindwellingcathetershouldbetreatedcautiouslyduetotheriskofurinarytract\ninfection.\nRecommendation:Ifbeingused,dailyassessment(withexcellentperineumcare)needstobe\ncarriedoutandshouldberemovedassoonaspossible.39\n(Newrecommendation,LevelI,GradeA)\nRecommendation:Allstrokepatientsshouldbescreenedforurinaryretentionorincontinence,\nfaecalincontinence,andconstipation.Theuseofportableultrasoundmachine(non-invasive)is\nrecommendedforassessingthepost-voidresidualvolume.Abladdertrainingprogramshouldbe\nimplementedinpatientwhohaveurinaryincontinence,includingtheuseofintermittent\ncatheterizationbasedonpost-voidresidualurinevolumeandbowelmanagementproceduresshould\nbetaughttopatients/carersofpatientswithconstipationandfaecalincontinence.39\n(Newrecommendation,LevelIII,GradeC)\n8.1.10RaisedIntracranialPressure\nCerebraloedemaandincreasedintracranialpressurelargelyoccurwithlargecerebralinfarctions.\nRecommendation:Hyperventilationisanemergencymeasurethatactsalmostimmediately;a\nreductionofthePCO2by5to10mmHgcanlowerintracranialpressureby25%to30%.1,40\n(LevelII-2,GradeB)\nDisabilityoutcomesafteracutestrokedidnotdiffersignificantlybetweenpatientsassignedtoa\nlying-flatpositionfor24hoursandpatientsassignedtoasitting-uppositionwiththeheadelevatedto\natleast30degreesfor24hours.41\n(LevelI)\nRecommendation:Mannitol(0.25to0.5g/kg)administeredintravenouslyover20minuteslowers\nintracranialpressureandcanbegivenevery6hours.42Maximumdailydoseis2g/kg.\n(LevelII-2,GradeB)\nRecommendation:Ifhydrocephalusispresent,drainageofcerebrospinalfluidviaan\nintra-ventricularcathetercanrapidlylowerintracranialpressure.1\n(LevelIII,GradeC)\nThepooledresultofRCTsdemonstratedsignificantreductioninmortalitywhendecompressive\ncraniectomywasperformedwithin48hoursofmalignantMCAinfarctioninpatients<60yearsofage,\nwithanabsoluteriskreductioninmortalityof50%(95%CI34–66%)at12months.43\nThereisevidencethatpatientsaged>60yearscanbenefitfromdecompressivecraniectomy.\nHemicraniectomyincreasedsurvivalwithoutseveredisabilityamongpatientsaged61yearsorolder\nwithamalignantmiddle-cerebral-arteryinfarction.Themajorityofsurvivorsrequiredassistancewith\nmostofthebodilyfunctionalneeds.44\nRecommendation:Hemicraniectomyandsurgicaldecompressivetherapywithin48hoursafter\nsymptomonsetisrecommendedtocontrolintracranialpressureandpreventherniationamongthose\npatientswithverylargeinfarctsofthecerebralhemisphere.\n(Newrecommendation,LevelI,GradeA)\nRecommendation:Patients>60yearsofagemaybeconsideredfordecompressivecraniectomyin\nselectedcases.\n(Newrecommendation,LevelI,GradeA)"
    },
    {
        "page_number": 78,
        "text": "78Recommendation:Ventriculostomyandsub-occipitalcraniectomyareeffectiveinrelieving\nhydrocephalusandbrainstemcompressioncausedbylargecerebellarinfarctions.45,46\n(LevelII-2,GradeB)\n8.1.11DeepVeinThrombosis\nVenousthromboembolismisacommon,potentiallyavoidablecauseofdeathandmorbidityin\npatients,includingthosewithstroke.Upto50%ofpatientshavethrombusineitherthecalforthigh\nofthepareticlimb.\nIntermittentpneumaticcompression(IPC)isaneffectivemethodofreducingtheriskofDVTandto\npossiblyimprovesurvivalinavarietyofpatientswhoareimmobileafterstroke.47\nRecommendation:Forimmobilestrokepatientswithoutcontraindications,intermittentpneumatic\ncompression(IPC)inadditiontoroutinecare(aspirinandhydration)isrecommendedoverroutine\ncaretoreducetheriskofdeepveinthrombosis(DVT).\n(Newrecommendation,LevelI,GradeA)\nProphylacticanticoagulants(unfractionatedheparinorLMWH)werenotassociatedwithany\nsignificanteffectonmortalityorfunctionalstatusatthefinalfollow-up.Therewerestatistically\nsignificantreductionsintheincidencesofsymptomaticpulmonaryembolismsandinDVTs,mostof\nwhichwereasymptomatic.Therewerestatisticallysignificantincreasesintheincidencesof\nsymptomaticintracranialhaemorrhageandsymptomaticextracranialhaemorrhages.48\nRecommendation:Thebenefitofprophylactic-dosesubcutaneousheparin(unfractionatedheparin\n[UFH]orLMWH)inimmobilepatientswithAISisnotwellestablished.\n(Newrecommendation,LevelIII,GradeC)\nTheCLOTS1and2trialsshowedthatgraduatedcompressionstockingswereineffectivein\npreventingVTEorimprovingfunctionaloutcomesinstroke.Skinbreaks,ulcers,blisters,andskin\nnecrosisweresignificantlymorecommoninpatientsallocatedtograduatedcompressionstockings\nthaninthosewhoavoidedtheiruse.49,50\nRecommendation:Inischaemicstroke,elasticcompressionstockingsshouldnotbeused.\n(Newrecommendation,LevelI,GradeA)\n8.1.12Seizure\nEarlyseizuresafterstrokearerelativelyuncommon,howeveriftheydooccur,itisassociatedwitha\npooroutcome.Riskfactorsincludesamoreseverestrokeseverityandcorticalinvolvement.\nRecommendation:New-onsetseizuresinadmittedpatientswithacutestrokeshouldbetreated\nusingappropriateshort-actingmedicationsiftheyarenotself-limiting.6,39\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Asingle,self-limitingseizureoccurringattheonset,orwithin24hoursafteran\nischemicstroke(consideredan‘‘immediate’’post-strokeseizure)shouldnotbetreatedwith\nlong-termanticonvulsantmedications.Theuseofprophylacticanti-seizuremedicationsisnot\nrecommended.6,39\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Patientsthathaveanimmediatepost-strokeseizureshouldbemonitoredfor\nrecurrentseizureactivityandshouldbetreatedaspertreatmentrecommendationsforseizuresin\notherneurologicalconditionsandtreatmentshouldbeindividualised.6,39\n(Newrecommendation,LevelIII,GradeC)"
    },
    {
        "page_number": 79,
        "text": "79RecommendationsSummary:\nTable8.1:AcuteGeneralManagement\nFactors RecommendationsLevelof\nEvidenceGrade\nOxygenand\nAirwaysupportPatientswithacutestrokeshouldonlyreceivesupplementaloxygen\niftheiroxygensaturationisbelow95%andbetitratedtoachieve\nabove95%.\nNewrecommendationII-3 B\nObservationRegularobservationismandatorytorecogniseimpairedpulmonary\nfunction(pulseoxymeter),circulatoryfunction(pulserate,blood\npressure),NIHSSscore,headchart,GCS,andcomplicationsfrom\nmasseffect.III C\nMobilisationMobiliseearlytopreventcomplications. II-3 C\nHigh-dose,veryearlymobilisationwithin24hoursofstrokeonset\nshouldnotbeperformedbecauseitcanreducetheoddsofa\nfavourableoutcomeat3months.\nNewrecommendationI -\nBloodPressureLoweringBPinitiallyby15%isprobablysafe.Bloodpressure\nreductionshouldnotbedrastic.\nNewrecommendationIII C\nDonottreathypertensionifsystolicBPis<220mmHgordiastolicBP\nis<120mmHg.Mildhypertensionisdesirableat160-180/90-100\nmmHg.III C\nProposedsubstances:Labetalol10-20mgbolusesat10-minute\nintervalsupto150-300mgor1mg/mlinfusion,rateofinfusionfor\nLabetalolis1-3mg/minororalCaptopril6.25-12.5mg.III C\nBloodGlucoseAfteranacutestroke,treathyperglycaemiatokeeptheblood\nglucoselevelsbetween6.0-10.0mmol/Landensurethat\nhypoglycaemiaisavoided.\nNewrecommendationIII C\nAvoidverytighttargetsofglucosecontrol(4.0-7.5mmol/L)inthe\nfirstfewhoursofacuteischaemicstroke.\nNewrecommendationI A\nNutrition Performawaterswallowingtest. III C\nInsertanasogastrictubeifthepatientfailstheswallowingtest. III C\nPEGissuperiortonasogastricfeedingonlyifprolongedenteral\nfeedingisrequiredII-1 B\nEnteralfeedingshouldbestartedwithin7daysofadmission(oralor\ntubefeeding).\nNewrecommendationI A\nInfection Searchforinfectioniffeverappearsandtreatwithappropriate\nantibioticsearly.III C\nFever Useanti-pyreticstocontrolelevatedtemperatures. II-1 B\nContinenceTheuseapplicationofindwellingcathetershouldbeusedtreated\ncautiouslyduetotheriskofurinarytractinfection.\nNewrecommendationI A\nAllstrokepatientsshouldbeassessedforurinaryretentionor\nincontinence,faecalincontinence,andconstipation.\nNewrecommendationIII C\nRaised\nIntracranial\nPressureHyperventilatetolowertheintracranialpressure. II-2 B\nMannitol(0.25to0.5g/kg)intravenouslyadministeredover20\nminuteslowersintracranialpressureandcanbegivenevery6hours.II-2 B\nIfhydrocephalusispresent,drainageofcerebrospinalfluidviaan\nintraventricularcathetercanrapidlylowertheintracranialpressure.III C\nHemicraniectomyandsurgicaldecompressivetherapywithin48\nhoursaftersymptomonsetisrecommendedtocontroltheI A"
    },
    {
        "page_number": 80,
        "text": "80intracranialpressureandpreventherniationamongthosepatients\nwithverylargeinfarctsofthecerebralhemisphere.\nPatients>60yearsofagemaybeconsideredfordecompressive\ncraniectomyinselectedcases.\nNewrecommendationI A\nVentriculostomyandsub-occipitalcraniectomyareeffectivein\nrelievinghydrocephalusandbrainstemcompressioncausedby\nlargecerebellarinfarctions.II-2 B\nDeepVein\nThrombosis\nProphylaxisForimmobilestrokepatientswithoutcontraindications,intermittent\npneumaticcompression(IPC)inadditiontoroutinecare(aspirinand\nhydration)isrecommendedoverroutinecaretoreducetheriskof\ndeepveinthrombosis(DVT).\nNewrecommendationI A\nThebenefitofprophylactic-dosesubcutaneousheparin\n(unfractionatedheparin[UFH]orLMWH)inimmobilepatientswith\nAISisnotwellestablished.\nNewrecommendationIII C\nInischaemicstroke,elasticcompressionstockingsshouldnotbe\nused.\nNewrecommendationI A\nSeizureNew-onsetseizuresinadmittedpatientswithacutestrokeshouldbe\ntreatedusingappropriateshort-actingmedicationsiftheyarenot\nself-limiting.\nNewrecommendationIII C\nAsingle,self-limitingseizureoccurringattheonset,orwithin24\nhoursafteranischemicstroke(consideredan‘‘immediate’’\npost-strokeseizure)shouldnotbetreatedwithlong-term\nanticonvulsantmedications.Theuseofprophylacticanti-seizure\nmedicationsisnotrecommended.\nNewrecommendationIII C\nPatientsthathaveanimmediatepost-strokeseizureshouldbe\nmonitoredforrecurrentseizureactivityandshouldbetreatedasper\ntreatmentrecommendationsforseizuresinotherneurological\nconditionsandtreatmentshouldbeindividualised.\nNewrecommendationIII C\nKeyRecommendations:\n1.Acutegeneralmanagementinstrokeincludessupportivecareandtreatmentofacute\ncomplicationsinordertoimprovemortalityandfunctionaldisability.\n2.Generalmanagementincludesthemanagementofbloodpressure,glycaemiccontrol,nutritional\nsupport,preventionofinfectionandDVTandalsototreatpotentialsequelae,e.g.raised\nintracranialpressureandseizure."
    },
    {
        "page_number": 81,
        "text": "81REPERFUSIONOFISCHAEMICBRAIN\n9.1 Introduction\nIncerebralinfarcts,restorationofperfusiontotheischaemicbraintissuesisthekeytherapeutic\nstrategy.Theconceptofexistenceofanischaemicpenumbraisfundamentaltothecurrentapproach\ninthetreatmentofischaemicstroke.Althoughthecoreinfarctedtissuesmightnotbesalvageable,\nadjacentdysfunctionaltissuemightbesavedifthecirculationisrestoredandmetabolismis\nnormalized.\nReperfusiontherapyisthesinglemostimportantandbeneficialtreatmentforacuteischaemicstroke.\nItwouldbeconsideredunethicalifnoattemptatreperfusionismade.Reperfusiontherapycanbe\nachievedviaintravenousthrombolysis(IVT)or/andendovascularthrombectomy(EVT).\nIVTisindicatedforpatientswithonsetofsymptomswithin4.5hoursofpresentation,whileEVTfor\nlargevesselocclusion(LVO)couldbeofferedupto24hoursusingadvancedimagingsuchas\nCT/MRperfusionscan.LVOincludetheICAandM1MCAocclusions.ItisreasonabletoincludeEVT\nforACA,PCAandbasilararteryocclusions.1\n(LevelI,GradeA)\nStroketreatmentprotocolandanorganizedstrokepathwayisessentialandshouldbeestablishedto\nachievetherecommendedresponsetimeforIVTandEVT,inordertoimprovetheclinical\noutcomes.1,2Strokeorganizationsshouldincorporatetheemergencydepartment(ED)includingtheir\npre-hospitalcareteam,radiologydepartmentandstroketeam.Themanagementofacuteischaemic\nstrokeatthepre-hospitalcarephaseandemergencydepartmentphasewereexplainedinChapter\n7.\n9.2 RecommendedNIHEmergencyResponseTimeforAIS\nTime(Minutes)\nDoortoMDconsultandinitialworkup≤10min\nDoortoneuroconsult ≤15min\nDoortoCT ≤25min\nDoortoneedle ≤60min\nDoortogroin ≤120min\nStroketeamsmaybecomposedofneurologists/physicians,medicalofficerswith/withoutstroke\nnurses,neuro-interventionalexperts(interventionalneuroradiologistorinterventional\nneurologist/neurosurgeon),rehabilitationphysicians,physiotherapists,occupationaltherapists,\nspeechtherapists,pharmacists,socialworkers,andpsychologists.Thecompositionofthestroke\nteamdependsonwhetherthehospitalisaprimarystrokecentreoracomprehensivestrokecentre.\nRolesofthestroketeamduringtheacutepresentationofischaemicstrokeinclude:\ntoascertainhistoryandfindingsthatarecompatiblewithAIS\nperformNIHSSandmRSscoring\nexcludecontraindications\nreviewneuroimaging\nmakingtreatmentdecisionsandtoadministerIVTand/orEVT\ntocloselymonitorandadmitpatientstothestrokecareunit9"
    },
    {
        "page_number": 82,
        "text": "82Recommendation:Allstrokepatientsshouldbenursed/admittedtoastrokecareunit.3\n(LevelI,GradeA)\nSuspectedAISpatientswithinthereperfusionwindowshouldbesenttostrokereadyhospitalsor\nhospitalswithaCTscan.Therefore,aregionalstrokereferralsystemshouldbedevelopedtoprovide\nswiftreferralandtransportationoftheAISpatienttoadjacentstrokereadyhospitalswhichcouldbe\neitheraprimarystrokecentreoracomprehensivestrokecentre.IVTcanbeinitiatedattheprimary\nstrokecentrepriortothetransfertoacomprehensivestrokecentreforEVT.Hospitalswithinthe\nstrokecaresystemshouldadheretotheprotocoltoprovidethebeststandardofcareavailable.\nInasituationwherearadiologist/stroke-trainedphysicianisnotavailable,telemedicinemaybe\nutilizedtoassistinthemanagementofAISpatient:\nRecommendation:Tele-strokecouldbebeneficialforsiteswithoutinhouseneurologyor\nneuroradiologyservicestohastentheIVTwithAlteplaseeligibilitydecisionmakinganddelivery.1,4-6\n(Newrecommendation,LevelII,GradeB)\nRecommendation:Telephoneconsultationforphysicianisfeasible,safeandmaybeconsideredif\nanin-housestroketeamandtele-strokearenotavailable.7,8\n(Newrecommendation,LevelIII,GradeC)"
    },
    {
        "page_number": 83,
        "text": "83Figure9.1:AcuteIschaemicStrokePathwaySuspectedAISwithinreperfusionwindow\nEDManagement\nFasttrackassessmentbymedicalofficerorphysician\nABCAssessment\nBasichistory,examination,andtests\nActivatestroketeamandradiology\nImaging\nNCCTBrain+/-CTA/MRI+/-PerfusionScanStrokeTeam\nAscertainhistoryandphysicalexaminationNIHSSscaleandmRS\nReviewneuroimagingwith/withoutradiologist\nRuleoutcontraindication\nAdministerIVTand/orEVT\nCloseneurologymonitoringandadmittostrokecareunitPre-ArrivalManagement\nPre-arrivalnotificationtothereceivinghospital\nAmbulancefromnon-strokereadyhospitalPre-HospitalManagement\nHighpriorityambulancedispatch\nPre-hospitalscreeningandassessment(FAST)"
    },
    {
        "page_number": 84,
        "text": "84Figure9.2:RegionalStrokeReferralSystemConceptforAcuteIschaemicStrokeManagementStroke\nReady\nHospitalHospital\nHospital\nHospitalHospital\nStroke\nReady\nHospital\nStroke\nReady\nHospital\nStroke\nReady\nHospitalStroke\nReady\nHospitalComprehensive"
    },
    {
        "page_number": 85,
        "text": "859.3 IntravenousThrombolysis\nForpatientsthatarefoundtobeeligibleforIVT,thebenefitoftherapyistimedependent,and\ntreatmentshouldbeinitiatedasquicklyaspossible.Thus,earlydetectionandactivationofthe\nthrombolysispathwayisparamountandconcertedeffortshouldbemadetodeliverthetreatmentas\nsoonaspossible.\n9.3.1RequirementforThrombolysis(IVT)\nI.Physicianswithexperienceintreatinghyperacutestroke\nII.Neuroimagingavailability;NCCT±CTA;MRI;perfusionscan\nIII.Capabilitytomanagecomplicationsofthrombolysis,particularlyintracranialhaemorrhage,\nandaccesstoneurosurgicalsupport\n9.3.2PatientEligibilityforIVT\nI.Clinicaldiagnosisofacutestrokeatpresentation.\nII.Acutedisablingstrokewithin4.5hoursofpresentationorlastknown/seentobewell.9-15\nIII.Forpatientswhopresentwithawake-upstrokeorstrokeofunknownonsetandarenot\neligibleforEVT,IVTmaybeconsiderediftheMRIshowsstrokewithDWIandFLAIR\nmismatch,andthelesionisnotlargerthan1/3MCAterritory.16\nIV.NCCTorMRIbrainshowsnohaemorrhageorestablishedlargeinfarctcore.\nV.ForpatientswhomeetthecriteriaforEVT,itisreasonabletoproceedwithCTAifindicated\ninpatientswithsuspectedintracranialLVOpriortoobtainingtherenalprofileinpatients\nwithoutahistoryofrenalimpairment.17-22CriteriaforCTAincludeNIHSS>6,presenceof\ncorticalsignsorbrainsteminvolvement.23\nVI.Nocontraindications.\nVII.Useofsono-thrombolysisasadjuvanttherapywithIVTisnotrecommended.24\nVIII.Thrombolysisshallnotbewithheldforaphasicpatientswhocannotgiveconsentand/or\nwithoutanyfamilymembers.\n9.4 ContraindicationsforIntravenousThrombolyticTherapy\n9.4.1AbsoluteContraindication\nI.Pre-treatmentsystolicBPis>185mmHgordiastolicBPis>110mmHg.\nII.Abloodglucose<2.7mmol/l.IVTinpatientswithAISwhopresentswithinitialglucoselevels\n<2.7mmol/l,andthatissubsequentlynormalizedandwhoareotherwiseeligible,maybe\nreasonable.\nIII.CurrentuseoftreatmentdoseofLMWHwithin24hours.\nIV.Useofunfractionatedheparinintheprevious24hoursandaprolongedpartial\nthromboplastintime(aPTT).\nV.IVTcouldbeconsideredwhenappropriatelaboratorytestssuchasaPTT,INR,activated\nclottingtime,thrombintime,ordirectfactorXaactivityassaysarenormalorwhenthe\npatienthasnottakenadoseoftheseanticoagulantsfor>48hoursandtherenalfunctionis\nnormal.\nVI.ForpatientsonDabigatran,reversingitsanticoagulanteffectwithIdarucizumabpriortoIVT\nmaybereasonableforeligiblepatients.25,26\nVII.Prothrombintime(PT)>15seconds,aPTT>40sorINR>1.7\nVIII.Aplateletcount<100,000/microliter"
    },
    {
        "page_number": 86,
        "text": "869.4.2RelativeContraindication\nI.Seriousheadinjuryintheprevious3months\nII.Recentstrokewithin3months\nIII.Recentmyocardialinfarctionwithin8weeks\nIV.Gastrointestinalorurinarybleedingwithinthepreceding21days\nV.Majorsurgerywithinthepreceding14days\nVI.Arterialpunctureatnon-compressiblesitewithinthelast7days\nVII.Priorintracranialhaemorrhageofirremediablecause\nVIII.Seizureattheonsetofstroke.IVTisreasonableinpatientswithaseizureatthetimeof\nonsetofacutestrokeifevidencesuggeststhatresidualimpairmentsaresecondaryto\nstrokeandnotapost-ictalphenomenon\nIX.PremorbidmRS≥4\nX.Peritonealdialysisorhaemodialysis\nXI.Pregnancy(upto10daysofpostpartum)ornursingmotherwithnobleedingtendency\n9.5RegimenforTreatmentofAcuteIschaemicStrokewithIntravenousThrombolysis\n1.Infuse0.9mg/kg(maximumof90mg)over60minuteswith10%ofthedosegivenasa\nbolusdoseover1minute.AlowerdoseofIVAlteplase(0.6mg/kg)wasnotshowntobeof\nequivalenttostandard-doseIVAlteplaseforthereductionofdisabilityat90daysbuthada\nreducedmortalityrate.27\nRecommendation:(Onsetwithin4.5hours)Alteplasedose:0.9mg/kg,max90mg,10%\ngivenasbolusandremainingdoseinfusedover1hour.\n(LevelI,GradeA)\n2.Admitthepatienttoanintensivecareunitorastrokeunitformonitoring.\n3.Performneurologicalassessments*every15minutesduringtheinfusionofAlteplaseand\n1-hourpostIVT,andevery30minutesforthenext4hoursandtheneveryhouruntil24\nhourslapsesfromtheonsetoftreatment.(*GCSandBloodpressure)\n4.Ifthepatientdevelopssevereheadache,acutehypertension,nauseaorvomitingor\nworseningneurologicalsymptomswithanincreaseoftheNIHSSby4andreductionofthe\nGCSby2,discontinuetheinfusionandobtainaCTscanofthebrain.\n5.CloserbloodpressuremonitoringisrequiredifasystolicBPof>180mmHgordiastolicBP\nof>105mmHgisrecorded.Administeranti-hypertensivemedicationstomaintainblood\npressureatorbelowtheselevels.\n6.Delayplacementofnasogastrictubes,indwellingbladdercathetersorintra-arterialpressure\ncatheters.\n7.Avoidantiplateletandanticoagulationdrugsforthefirst24hoursafteradministrationof\nAlteplase.\n8.Recommendation:IVAlteplasemaybeconsideredforacutestrokeonset>4.5upto9\nhoursorinwake-upstrokeorstrokeofuncertainonsetassistedbyCTperfusion,with\nsignificantpenumbracoremismatch.2,3\n(Newrecommendation,LevelII,GradeB)"
    },
    {
        "page_number": 87,
        "text": "879.Recommendation:IVAlteplasemaybeconsideredforacutestrokeofuncertainonsetand\nwake-upstrokeassistedbyMRI(DWI-FLAIRmismatch).1\n(Newrecommendation,LevelII,GradeB)\n10.TenecteplasemightbeconsideredasanalternativetoAlteplasewhenAlteplaseisnot\navailable.28-30\n11.Recommendation:AISpatientswhoarrivewithin4.5hoursofsymptomsonsetandare\neligibleforthrombolytictreatmentcanbeconsideredforintravenousTenecteplasepriorto\nEVT.30(Tenecteplasedoseof0.25mg/kg;maximumdoseof25mg)\n(Newrecommendation,LevelII,GradeB)\n12.Streptokinaseiscontraindicated.\n(LevelI,GradeA)\n9.6 GeneralCare\n9.6.1BPControl\nBloodpressureshouldbekept≤180/105mmHgduringandpostthrombolysis.31-37\n(Newrecommendation,LevelI,GradeA)\nHypotensionandhypovolaemiashouldbecorrectedandavoided.\n(Newrecommendation,LevelI,GradeA)\nPatientotherwiseareeligibleforacutereperfusiontherapyexceptthatifBPis>185/110mmHg\nwith:\nLabetalol10–20mgIVover1–2min,mayrepeatonce;or\nNicardipine5mg/hIV,titrateupby2.5mg/hevery5–15min,maximum15mg/h;when\ndesiredBPreached,adjusttomaintainproperBPlimits;or\nOtheragents(e.g.,Hydralazine,Enalapril,GTN,Nimodipine)mayalsobeconsidered\nGTN5mgpatch\nIVNimodipine\nIfBPisnotmaintained≤185/110mmHg,donotadministerAlteplase\n(Levelll-2,GradeB)\nManagementofBPduringandafterAlteplaseorotheracutereperfusiontherapytomaintainBP\n≤180/105mmHg:\nMonitorBPevery15minfor2hoursfromthestartofAlteplasetherapy,thenevery30min\nfor6hours,andtheneveryhourfor16hours\n(Levelll-2,GradeB)\nIfsystolicBPis>180–230mmHgordiastolicBPis>105–120mmHg:\nIVLabetalol5-10mgbolusfollowedbycontinuousIVinfusion2–8mg/min;or\nIVNicardipine5mg/h,titrateuptodesiredeffectby2.5mg/hevery5–15min,maximum15\nmg/h;or\nIVNitroprusside.IfBPnotcontrolled,considerIVNitroprussideinICUsettingifavailable.IV\nNitroprussideshouldbeadministeredat0.5mcg/kg/minimuminfusion(maximumof\n8mcg/kg/min)\nMaximumdoseofIVLabetalolbolusis300mg\n(Levelll-2,GradeB)"
    },
    {
        "page_number": 88,
        "text": "889.6.2BloodGlucoseControl\nKeepbloodglucoselevelbetween7.8-10.0mmol/L.\nAvoidhypoglycaemia.\n(LevelI,GradeA)\nHyperglycaemiawithinthefirst24hoursofthrombolysisisassociatedwithpooreroutcomesand\nhigherhaemorrhagetransformation.\n(LevelIII,GradeC)\n9.6.3Temperature\nFever(temperature>38°C)shouldbeidentifiedandtreated.\n(LevelI,GradeA)\nHypothermia(temperature<37°C)andhyperthermiaareassociatedwithpooreroutcome.38\n(LevelII,GradeB)\n9.6.4Others\nKeepNBMandputonanIVdriptoensureadequatehydration.Avoidhypotonicsolution.\nNonasogastric(NG)tubeinsertion,catheterization,andinvasiveprocedurefor24hours.\nMinimisephysicalhandlingandmovementtoavoidbruisesandinjury.\nMonitorneurologicalstatusdeteriorationandbleeding.Informifitoccurs.\nNoantiplateletoranticoagulationfortheinitial24hours.\nRepeatCTbrainat24hourspostthrombolysis.\n9.7 ManagementofComplications\n9.7.1Bleeding\n1.StopIVAlteplase\n2.UrgentCTbrainifthereisneurologydeterioration\n3.SendFBC,PT/PTT,GXM,fibrinogen.Repeat2hourlyuntilbleedingiscontrolled.\n4.ControlBP\n5.IVCryoprecipitate6-8bags\n6.IVPlatelets4unitsorCSP1unitifplateletdysfunctionissuspected\n7.ConsultneurosurgicalteamifICH.Frequentneurologychecks.Institutetherapyforelevated\nICPasneeded.\n8.RepeatCryoprecipitate6-8bagsiffibrinogen<200mg/dL\n9.IfPT/PTTprolongeddespitenormalfibrinogen,considerFFP(ifnegative,orderLupus\nanticoagulantandAnticardiolipinantibody)\n10.Referhaematologyteamifcoagulationstillabnormaldespiteperformingalltheabove\nmeasures\n11.Forseverelife-threateningbleeding,considerthefollowingtreatmentafterweighingtherisk\nofrecurrentthromboticstroke:\na)IVTranexamicAcid1gover15minutes,repeatedevery8hoursasnecessary\nb)RecombinantFactorVIIa40-160μg/kgBWasasinglebolusover1-2minutes"
    },
    {
        "page_number": 89,
        "text": "899.7.2Angioedema\n1.StopIVAlteplase\n2.Maintenanceofairway,breathing,andcirculation\n3.IVDiphenhydramine50mg\n4.IVRanitidine50mg\n5.Noimprovement,giveIVMethylprednisolone100mg\n6.Noimprovement,giveS/CEpinephrine0.1%0.3mLorNebuliser0.5mls\n7.CallENT/Anaesthesiateam\n8.Icatibantifavailableandindicated\n9.8 AdministrationofIntravenousThrombolysis\nWerecommendadministeringintravenousthrombolysisinahospitalwithtrainedgeneral\nphysicians,neurologists,geriatriciansoremergencyphysiciansexperiencedinadministrating,\nmonitoringpost-procedure,andmanagingtheassociatedcomplications.\nRecommendationsSummary:\nTable9.1:TreatmentofAcuteIschaemicStrokewithIntravenousThrombolysis\nTreatment RecommendationsLevelof\nEvidenceGrade\nAlteplaseOnsetwithin4.5hours\nDose:0.9mg/kg,max90mg,10%bolusandremainingdoseas\ninfusionover1hour.I A\nOnset>4.5upto9hoursifknownonsetorwake-upstrokeguidedby\nCTperfusion,withpresentsignificantpenumbracoremismatch.\nNewrecommendationII B\nUncertainonsetandwakeupstrokeguidedbyMRI(DWI-FLAIR\nmismatch)\nNewrecommendationII B\nTenecteplaseOnsetwithin4.5hoursandeligibleforthrombolytictreatmentcanbe\nconsideredforintravenousTenecteplasepriortoEVT.\nDose:0.25mg/kg;maximumdoseof25mg\nNewrecommendationII B\nKeyRecommendations:\n1.Intravenousalteplase(0.9mg/kg;maximumdoseof90mg)isrecommendedfordefiniteonset\nstrokeforupto4.5hoursfromtheonsetorthetreatmentwindowcanbeextendedviaCT\nperfusionwithevidenceofpenumbra-coremismatchupto9hoursfromthetimeoflastknownto\nbewell/midpointofsleeporviaMRI(DWI-FLAIRmismatch)toidentifypossiblestrokeonset\nwithin4.5hours.\n2.Intravenoustenecteplase(0.25mg/kg;maximumdoseof25mg)isapossibletreatmentagentin\nacutestrokepresentedwithin4.5hourswithevidenceoflargevesselocclusion."
    },
    {
        "page_number": 90,
        "text": "90ENDOVASCULARTHROMBECTOMY\n10.1AcuteEndovascularThrombectomyTreatment\nAcuteEndovascularThrombectomytreatment(EVT)isconsideredasthestandardofcaresince\n2015followingthepublicationsof5RCTswhichhaveledtoamajorguidelinerevamparoundthe\nworld.1-5EVTisindicatedinacuteischaemicstrokethatpresentswithin6-8hours,andisequally\nbeneficialinselectedpatientsofupto24hoursfromthetimelastseenwell(TLSW)withevidenceof\nlargevesselocclusion(LVO).1-7\nEVTshouldbeofferedatthecomprehensivestrokecentreifthefollowingareavailableandin\ncoordinationwiththeEMS:\nI.Astroketeamconsistingofstrokephysicianandradiologistwithexpertiseinthediagnosisand\nmanagementofstroke.\nII.Astroketeamconsistingofneuro-interventionalexperts(interventionalneuro-radiologistor\ninterventionalneurologist/neurosurgeon).\nIII.AllAISpatientswhoareacandidateforEVTmustatleastundergoNCCTandCTangiography\nfromarchofaorta-vertexwithorwithoutmultiphaseCTAorCTperfusion.MRIwithMRAcanbe\nconsideredinselectedcasesifnecessaryandnotasaroutinemodalitytoavoidanydelays.\n(Newrecommendation,Level1,GradeA)\n10.2IndicationforAcuteEndovascularThrombectomy\nI.BaselinefunctionalstatusmRSof0-2orgenerallyADLindependent.\nII.EVTisindicatedinpatientswhohavereceivedintravenousAlteplase,butdonotwaittoassess\nresponse,andthosewhoarenoteligibleforintravenousAlteplasewithevidenceofLVO.\nIII.PatientswhofulfiltheimagingcriteriaviaassessmentofCTcerebralangiographypriortoEVT\nasfollowing:\na.PatientsshouldhaveaLVOofthemiddlecerebralarteryor/andinternalcarotidarteryor\nproximalM2occlusion.\nb.Forlargearteryocclusionofposteriorcirculation(e.g.,basilarartery),thedecisiontotreat\nshouldbebasedonthepotentialbenefitsandrisksoftreatmentfortheindividualtreatment.8\nc.Forpatientswhoarrivebetween6and24hoursofstrokeonsetorsincethetimelastseen\nwell,multimodalimagingisindicated(CTperfusionsoftwarewhichiscapabletoreproduce\nsimilarobjectiveassessmentsforpenumbraandinfarctcore)andmaybesubjectedtoEVT\nif:10\nNIHSS≥10andinfarctcorevolume0-21mls,age≥80yearsold\nor\nInfarctcorevolume0–31mls,age<80yearsold\nor\nNIHSS≥20infarctcorevolume31-51mls,age<80yearsold\n*(DAWNtrialcriteria)\nOR\nInfarctcorevolumeis<70mls,mismatchratiois≥1.8andmismatch\nvolumeis>15mls\n*(DEFUSE3trialcriteria)"
    },
    {
        "page_number": 91,
        "text": "91Recommendation:EVTisindicatedforAISwithlargevesselocclusion;proximalmiddlecerebral\narterysegment1(M1)/proximalM2occlusion/internalcarotidartery(ICA),andpresentingwithin6\nhoursfromonset.1-5\n(Newrecommendation,LevelI,GradeA)\nRecommendation:EVTisindicatedinselectedpatientswhoarriveafter6hoursandupto24hours\nofstrokeonsetwithevidenceoflargevesselocclusion.5,6\n(Newrecommendation,LevelI,GradeA)\n10.3EarlyRevascularization\nRevascularizationneedstobeorganizedimmediately.ThemajorityoftheEVTstudiesemphasise\ntheimportanceoftheearlytimingofrecanalizationthroughaproperlyorganizedstrokeworkflow,\nwhichwaslackinginthepreviousneutralstudy.Itisveryimportanttounderstandthatthetreatment\nbenefitdeclinesovertime;anddespiterecentevidenceforextendedhoursforreperfusiontherapy\nviaEVT,thereisnoreasontodelayrecanalizationinordertomaximizethepossiblebestoutcome.6,7\nRecommendation:AISpatientswhoarrivewithin4.5hoursofstrokeonsetandareeligibleforrtPA\ntreatmentshouldbeconsideredforthrombolytictreatmentpriortoEVT.1-5\n(Newrecommendation,LevelI,GradeA)\nRecommendation:Forpatientsundergoing“Drip&Ship”(EVTfollowingadministrationofIVT),\nthereshouldbenodelayinproceedingtoEVTtodeterminetheclinicaleffectivenessofAlteplase.1-5\n(Newrecommendation,LevelI,GradeA)\nRecommendation:AISpatientswhoarrivewithin4.5hoursofstrokeonsetandareeligiblefor\nthrombolytictreatmentcanbeconsideredforintravenousTenecteplasepriortoEVT.9\n(Newrecommendation,LevelII,GradeB)\nRecommendation:Transfertohigh-volumecentreshasbeenassociatedwithreducedmortality\nratesafterendovasculartreatmentofacutestroke.Thisislikelytobeachievedwhenhigh-volume\ncentreshaveawell-organizedacutestrokepathway.10\n(Newrecommendation,LevelII,GradeB)\n10.4EndovascularThrombectomyDevices\nAspirationdevicesandStentretrieverareusedwidelyforEVT,andthesedeviceshavebeenused\nalmostexclusivelyinclinicaltrialswithinthepast5years.\n(Newrecommendation,LevelII,GradeB)\n10.5SedationvsGeneralAnaesthesia\nProceduralsedationisgenerallypreferredovergeneralanaesthesiaandintubationinmostpatients\nundergoingEVT.Generalanaesthesiaandintubationishowever,appropriate,ifmedicallyindicated\n(e.g.,forairwaycompromise,respiratorydistress,depressedlevelofconsciousness,severe\nagitation,oranyotherindicationasdeterminedbythetreatingphysician)andinsuchcases,\nexcessiveandprolongedhypotensionandtimedelaysshouldbeavoided.\n(Newrecommendation,LevelII,GradeB)\n10.6EndovascularThrombectomyWorkFlow\nEVTshouldbeofferedatthecomprehensivestrokecentreewhenthefollowingareavailableandin\ncoordinationwiththeEMSasfollowing:"
    },
    {
        "page_number": 92,
        "text": "92Figure10.1:EndovascularThrombectomyWorkFlowPerformplainCTbrainasperprotocol,with/withoutCTangiographyandperfusion\nscanPreparepatientimmediatelyuponarrival\nRenalprofileisnotrequiredforplainCTbrainorCTangiographyBookthenextCTslot\nEnsurethattheEDtransfersthepatientimmediatelyInformtheradiologist/\ninterventionalradiologist/neuroradiologistoncallSuspectedstrokecasesreceivepriorityStaffreceivenotificationfromprimarytriagenurse/medicalassistant\nAssesseligibilityasspecifiedbytheMalaysianClinicalPracticeGuideline.\nAstrokephysician/neurologistshouldconfirmeligibilityandmakethefinaldecision.ReviewCTimagingandconfirmpatienteligibilityforthrombolytictherapy\nNOTELIGIBLE\nIfnoteligible,pleasedocumentreason(s)ELIGIBLE\nAdministerIVrtPAassoonaspossible\nDripandShiporDirect-thrombectomy"
    },
    {
        "page_number": 93,
        "text": "93RecommendationsSummary:\nTable10.1:AcuteEndovascularThrombectomyTreatment\nTreatment RecommendationsLevelof\nEvidenceGrade\nAcuteEndovascular\nThrombectomy\n(EVT)EVTisindicatedforAISwithlargevesselocclusion;proximal\nmiddlecerebralarterysegment1(M1)/proximalM2\nocclusion/internalcarotidartery(ICA),andpresentingwithin6\nhoursfromonset.\nNewrecommendationI A\nEVTisindicatedinselectedpatientswhoarriveafter6hours\nandupto24hoursofstrokeonsetwithevidenceoflargevessel\nocclusion.5,6\nNewrecommendationI A\nEVTbridgingwith\nAlteplase\n(Drip&Ship)AISpatientswhoarrivewithin4.5hoursofstrokeonsetandare\neligibleforrtPAtreatmentshouldbeconsideredfor\nthrombolytictreatmentpriortoEVT.\nNewrecommendationI A\nForpatientsundergoing“Drip&Ship”(EVTfollowing\nadministrationofIVT),thereshouldbenodelayinproceeding\ntoEVTtodeterminetheclinicaleffectivenessofAlteplase.\nNewrecommendationI A\nEVTbridgingwith\nTenecteplaseAISpatientswhoarrivewithin4.5hoursofstrokeonsetandare\neligibleforthrombolytictreatmentcanbeconsideredfor\nintravenousTenecteplasepriortoEVT.\nNewrecommendationII B\nKeyRecommendations:\n1.Hyperacuteendovascularthrombectomyisrecommendedfordefiniteonsetstrokewithevidence\noflargevesselocclusionwhichiswithin6hoursfromtheonsetorthetreatmentwindowcanbe\nextendedviaCT/MRperfusion(penumbra-coremismatch)orMRI(clinical-imagingmismatch)\nwithcurrentevidencesshowedsignificantbenefitupto24hoursfromonset/timelastknownto\nbewell.However,treatmentpathwayshouldnotbedelayed,asthetreatmentoutcomecanbe\ninfluencedbytheimaging-to-recanalizationtime.\n2.Drip&Ship(IVTpriortoEVT)asperChapter9isrecommendedfortheeligiblepatients."
    },
    {
        "page_number": 94,
        "text": "94STROKEUNIT\n11.1StrokeUnit\nAllpatientswithacutestrokeshouldideallyhaveaccesstostrokeunits.Thereisclearevidencethat\nthetreatmentofpatientswithstrokeinstrokeunitssignificantlyreducesdeath,dependency,\ninstitutionalisation,andlengthofhospitalstayascomparedtotreatmentinthegeneralmedical\nward.1-7\nRecommendation:Everyhospitalshouldsetupastrokeunitasitcansignificantlyreducedeaths,\ndependency,institutionalisation,andthelengthofhospitalstay.\n(LevelI,GradeA)\nThisbenefitisindependentofthepatients’age,gender,co-morbidities,andstrokeseverity.1,8\n(LevelI)\nThebenefitsfromtreatmentinastrokeunitarecomparabletotheeffectsachievedwithintravenous\nadministrationofrtPA.9\n(LevelIII)\nAstrokeunitisadedicatedunitinthehospitalthatexclusivelymanagesstrokepatients.Ateamof\nspeciallytrainedstaffprovidecoordinatedmultidisciplinarycarethroughoutthedayfor24hoursto\npatientstreatedinastrokeunit.Thecorespecialitiesofthestroketeamaremedicalpersonnel\n(neurologists,geriatricians,orgeneralphysicianswithinterestinstroke),medicalrehabilitation\nphysicians,pharmacists,nurses,physiotherapists,occupationaltherapists,andspeechtherapists.In\nlargercentres,theteammayconsistofneurosurgeons,socialworkers,anddieticians.The\neffectivenessofastrokeunitisnotnecessarilyrelatedtoacertainmedicalspecialty.Astrokeunit\nrunbygeneralphysicians,geriatricians,neurologists,orspecialistsinrehabilitationmedicinemay\nequallybeeffective.1\n(LevelI)\nIdeally,astrokeunitshouldhave/provide:\nI.Ageographicallydefinedunit\nII.Acoordinatedmulti-disciplinaryteamthatmeetsregularlyfortheexchangeofinformationabout\ninpatientswithstroke\nIII.Information,advice,andsupportforpeoplewithstrokeandtheirfamily/carers\nIV.Managementprotocolsforcommonproblemsbaseduponthebestavailableevidence\nV.Closelinkswiththeprimarycaresetting,communityservicesandpatient’swelfareunit\nVI.Trainingforhealthcareprofessionalsinthespecialtyofstroke\nVII.Theuseofcomprehensivespecializedstrokecare(strokeunits)thatincorporatesrehabilitation\nservicesisrecommended.Ithasbeenshowntoreducemortalityanddisabilities.1\nRecommendation:Theuseofcomprehensivespecializedstrokecare(strokeunits)that\nincorporatesrehabilitationservicesisrecommended.\n(LevelI,GradeA)\nPossiblebenefitsofhavingstrokeunitsincludeearlytreatment,reducedincidenceofinfectionand\nsystemiccomplicationsaswellasearlyandmoreintenserehabilitation.10\n(LevelI)11"
    },
    {
        "page_number": 95,
        "text": "9511.2MultidisciplinaryTeaminStrokeUnit\nThecoremultidisciplinaryteamonastrokeunitshouldconsistofhealthcareprofessionalswith\nstrokeexpertiseincludingphysicians,nurses,occupationaltherapists,physiotherapists,speech\ntherapists,socialworkers,anddietitians.11\n(LevelI,GradeA)\nAdditionalmembersofmultidisciplinaryteammayincludeclinicalpharmacists,dischargeplanneror\ncasemanagers,psychologists,palliativecarespecialists,spiritualcareprovidersandpeersupport\ngroups.\n(LevelII,GradeB)\nRoleofmultidisciplinaryteam:\nI.Shouldassesspatientswithin48hoursandformulatemanagementplan.\nII.Assessmentcomponentsincludedysphagiascreening,moodandcognition,mobility,functional\nassessment,temperature,nutrition,bowelandbladderfunction,skinbreakdownandvenous\nthromboembolismprophylaxis.\nIII.Dischargeplanningandindividualizedassessmentforpost-acuterehabilitationservicesshould\nalsobediscussedassoonasthepatienthasbeenstabilized.\nRecommendation:Astrokeunitshouldbemanagedbyamultidisciplinarystroketeam.\n(LevelI,GradeA)\nStrokeunitswillworkoptimallyifawell-establishedreferralandrehabilitationnetworkisavailable.\nCooperationwithprimarycarephysiciansisessentialfortheprimaryandsecondarypreventionof\nstrokes.\nRegularcommunicationsandcoordinatedcarearekeyaspectsofthestrokeunit.\nStandardizedstrokeordersorintegratedstrokepathwaysimproveadherencetowardsthebest\npracticesforthetreatmentofpatientswithstroke.12,13\nNineKPIareusedasthemeasurementindexfortheeffectivenessofastrokeunitasshownbelow:\nThe9KPI’sRecommendedbytheStrokeCouncilMalaysianSocietyofNeurosciences(MSN)\n2011\n(UsedinMalaysianNationalStrokeRegistry)\n1.ThrombolyticTherapyAdministered\n2.AntithromboticTherapybyEndofHospitalDayTwo\n3.DysphagiaScreening\n4.DeepVeinThrombosis(DVT)Prophylaxis\n5.PatientswithAtrialFibrillationReceivingAnticoagulantTherapy\n6.StrokeEducation\n7.AssessedforRehabilitation.\n8.DischargedonAntiThromboticTherapy\n9.DischargedonCholesterolReducingMedication"
    },
    {
        "page_number": 96,
        "text": "96RecommendationsSummary:\nTable11.1:StrokeUnit\nFactor RecommendationsLevelof\nEvidenceGrade\nStroke\nUnitEveryhospitalshouldsetupastrokeunitasitcansignificantlyreduce\ndeaths,dependency,institutionalisation,andthelengthofhospitalstay.I A\nTheuseofcomprehensivespecializedstrokecare(strokeunits)that\nincorporatesrehabilitationservicesisrecommended.I A\nAstrokeunitshouldbemanagedbyamultidisciplinarystroketeam. I A\nKeyRecommendations:\nTheuseofcomprehensivespecializedstrokecare(strokeunits)thatincorporatesrehabilitation\nservicesareabletoreducemortalityanddisabilitiesamongstrokepatients."
    },
    {
        "page_number": 97,
        "text": "97STROKEINTHEOLDERPERSON\n12.1Introduction\nAnolderpersonisdefinedasthoseaged60yearsandabovebytheMalaysianMinistryofHealth.As\ntheaverageageofgettingastrokeinMalaysiais63years,asignificantnumberofstrokesurvivors\nareintheolderagegroup.\nOlderpersonsareheterogenousinnatureandtheirphysicalandfunctionalstatuscanrangefrom\nveryfittoveryseverelyfrail.Anolderpersonmayalsohavecognitivefunctionrangingfromexcellent\ntoseveredementia.Olderagealoneshouldnotbeanexclusioncriterionforstroketreatmentwithout\nconsideringfunctionalstatusandmedicalco-morbidities.Thisisprovidingthattheolderpersonfulfils\ntheinclusionandexclusioncriteriaforthetreatment.\nFrailtyisdefinedasreducedphysiologicalreservecausingapersontobemoresusceptibletoinsults.\nAusefulscaleindetermininganolderperson’sfitness/frailtylevelistheClinicalFrailtyScale.1Afit\nolderperson’streatmentplancanhavegoalsthatapproximatethoseofayoungerperson.However,\nahallmarkoffrailtyisthatthepersonhasreducedtolerancetomedicaltreatmentandinterventions.\nHence,frailolderpersonsneedtobeassessedcloselyforsideeffectsandadverseeventsfrom\ntreatment.Fewrandomizedcontrolledtrials(RCTs)forstroketreatmentexaminefrailtyasafactor\nassociatedwithoutcomes.Therefore,theclinicianneedstomakeindividualiseddecisionsfor\ntreatmentbasedoneacholderperson’scharacteristics.\nRecommendation:Allolderadultsshouldbescreenedforfrailtyusingavalidatedinstrument\nsuitableforthespecificsettingorcontextwithatailoredmanagementplanthereafter.2\n(Newrecommendation,LevelIII,GradeC)\n12.2Treatmentofacutestroke\n12.2.1StrokeThrombolysis\nTheCochranereviewandmeta-analysisshowsthatolderpatientsbenefitatleastasmuchasthose\nbelowtheageof80years,sothereisnoupperagelimitforstrokethrombolysistreatment,\nparticularlywithinthefirst3hours.3Patientswithmildandseverestrokeandthosewithearlysignsof\ninfarctiononinitialbrainimagingalsobenefitfromtreatment,aslongasearlyradiologicalchanges\nareconsistentwiththestatedtimeofonset.\nRecommendation:Anolderpersonshouldreceiveandcanbenefitfromintravenousthrombolysis.\n(Newrecommendation,LevelI,GradeA)\n12.2.2EndovascularThrombectomy\nAmeta-analysisoffiverandomisedcontrolledtrialswith1287patients,onendovascular\nthrombectomyforanteriorcirculationlargevesselischaemicstrokeversuscontrol,showedthatthere\nwasbenefitacrossallage-groupsinsignificantlyreducingpost-strokedependencyat90days,\nincludinginthoseaged80yearsandabove.4\nRecommendation:Anolderpersoncanbenefitfromendovascularthrombectomyforanterior\ncirculatorylargevesselocclusion.\n(Newrecommendation,LevelI,GradeA)12"
    },
    {
        "page_number": 98,
        "text": "9812.2.3Managementofglucoselevelintheacutephaseofstroke\nTheInternationalDiabetesFederationpublishedacomprehensiveguidelineonmanagingolder\npeoplewithtype2diabeteswhichincludedasectiononmanagementofhyperglycaemiapost-acute\nstroke.5\nAtpresent,theoptimallevelofbloodglucoseafterastrokeisunclear.Asystematicreviewof11\nRCTsconcludedthatadministrationofintravenousinsulintomaintaintightglucosecontrolwithina\nspecificrange(4.0-7.5mmol/L)inthefirstfewhoursofacuteischaemicstrokedoesnotprovide\nbenefitintermsoffunctionaloutcome,death,orimprovementinfinalneurologicaldeficit,but\nsignificantlyincreasedthenumberofhypoglycaemicepisodes.6\nRecommendation:Afteranacutestroke,treathyperglycaemiatokeepthebloodglucoselevels\nbetween6.0-10.0mmol/L(110-180mg/dL)andensurethathypoglycaemiaisavoided.5\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Avoidverytighttargetsofglucosecontrol(4.0-7.5mmol/L)inthefirstfewhours\nofacuteischaemicstroke.\n(Newrecommendation,LevelI,GradeA)\n12.3Managementofriskfactorsforstrokeprevention\n12.3.1Hypertension\nOlderpersonsmaydeveloporthostatichypotension,havefallsandsyncopewhenprescribedwith\nmultipleantihypertensivemedications.HomeBPmonitoringmaysupplementclinicBP\nmeasurementsforamorereflectivepictureoftheoverallBPcontrol.\nOlderpersonswithhighfrailtylevels,advancedcognitiveimpairment,orterminalillness,requires\naccurateprognostication,riskstratificationandsettingoftreatmentgoals.Thesepopulationgroups\narenotrepresentedinlargeRCTsandthereforehavenodemonstratedsafetydataforintensiveBP\nlowering.7\nRecommendation:Olderpersonswhohaveoneormoreofthefollowing:frailty,multiple\ncomorbidities,cognitiveimpairment,requireanindividualisedapproachforbloodpressure\nmanagement.\n(Newrecommendation,LevelI,GradeA)\n12.3.2DiabetesMellitus\nInolderpeople,therapeuticdecisionsonbloodglucosecontrolshouldbebasedoncomprehensive\nassessmentandindividualizedriskstratificationofkeyriskfactors.Hypoglycaemia,hyperglycaemia\nandtheirconsequences,comorbidities,frailty,falls,pain,medicationadherence,andmedicine\nrelatedadverseevents,andlifeexpectancyshouldbeconsideredwhenplanningandmonitoring\ncareforolderpeoplewithdiabetesmellitus.5,8\nRecommendation:Targetsofbloodglucosecontrolinolderpersonswithdiabetesshouldbe\nindividualisedtakingintoaccounttheirfunctionalstatus,medicalcomorbidities,andlikelihoodof\ndevelopingadverseevents.\n(Newrecommendation,LevelIII,GradeC)\n12.3.3Dyslipidaemia\nAmeta-analysisof28RCTswith186,854participantsofwhom14483(8%)wereaged75yearsand\nabove,showedthatstatintherapyproducedsignificantreductionsinmajorvasculareventsincluding"
    },
    {
        "page_number": 99,
        "text": "99stroke,regardlessofage.However,thereislessdirectevidenceofbenefitamongpatientsolderthan\n75yearsforthepurposeofprimarypreventionofvascularevents.Inparticular,inpatientsagedover\n75years,thereductioninstrokerateswasnotfoundtobesignificant.9\nRecommendation:Statinsarerecommendedforstrokepreventioninolderpersonswithlessdirect\nevidenceofbenefitforstrokepreventionandprimarypreventionofvasculareventsinthoseaged\nover75years.\n(Newrecommendation,LevelI,GradeA)\n12.3.4AtrialFibrillation\nOlderpersonswithatrialfibrillationcanbenefitfromanticoagulationforstrokeprevention,eitherwith\nwarfarinoradirectoralanticoagulant(DOAC).DOACswerefoundtohaveabetterefficacy/riskratio\nascomparedtowarfarin.10,11However,thecostofDOACsareconsiderablyhigherthanwarfarin,in\ntermsofthemedicationsthemselves.\nItisimportanttofollowtheindividualDOACsprescriptionguidelinestakingintoconsiderationtheir\nage,bodyweightandcreatinineclearancetodeterminetheappropriatedoseoftheDOAC.Ahigher\npercentageofolderpersonshaveimpairedrenalfunction,lowbodyweightandsarcopenia.\nPrescribingaDOACwithoutfollowingtheprescriptionguidelinesresultsinahighernumberof\nstrokesandadverseevents.12\nFallsanddementiaarenotabsolutecontraindicationtoanticoagulation,thedecisionneedstobe\nmadeonanindividualisedbasis.Fallspreventionmeasuresandcarereducationareimportantin\nthesecircumstances.\nThe2019Beerscriteriarecommendthatrivaroxabananddabigatranareprescribedwithcautionin\nolderpersonsaged75yearsandaboveduetothehigherriskforgastrointestinalbleeding.13\nTheOAC-FORTA(OralAnticoagulant–FitfortheAged)guidelinesrecommendapixabanas\nFORTA-A(highlybeneficial)inolderpersonsandtheotherDOACsandwarfarinasFORTA-B\n(beneficial).11\nRecommendation:Olderpersonswithatrialfibrillationcanbenefitfromoralanticoagulantforstroke\npreventionwithanindividualisedtreatmentplantakingmedicalco-morbidities,functionalstatus,and\nsocialfactorsintoconsideration.\n(Newrecommendation,LevelI,GradeA)\n12.4Medicationmanagementintheolderpersonwithstroke\nOlderpersons,especiallythosewhohadastrokeandseveralstrokeriskfactors,aremorelikelyto\nexperiencepolypharmacy(≥5medications)withhighpillburden,adverseeventsfrommedications,\ndrug-druginteractions,drug-diseaseinteractionsandthehighcostoftreatment.\nWhenprescribingforanolderperson,itisadvisableto\n-simplifythemedicationregime\n-choosewherepossible,medicationsthatrequireonceadayadministration\n-considerrenalandliverfunction,andpresenceofanaemia\n-considerswallowingfunction\n-checkthebodyweight\n-deprescribeorreducedosagesornumberofmedicationsbyprioritisingmedicalconditions,\nreviewingtargetsoftreatmentandsideeffects\n-checkforpotentialdrug-druganddrug-diseaseinteractions"
    },
    {
        "page_number": 100,
        "text": "100Recommendation:Acomprehensivecareplanforafrailolderpersonshouldincludemanagement\nofpolypharmacy.2\n(Newrecommendation,LevelIII,GradeC)\n12.5Deliriumpost-acutestroke\nDeliriumisacommoncomplicationofstroke,affectingatleast1in4acutestrokepatients.14Delirium\ninpost-strokeisassociatedwithhighermortality,increasedlengthofstayandworsefunctional\noutcome.15-17Riskofdevelopingpost-strokedeliriumishigherinpatientswithadvancedage,\npre-strokecognitiveimpairment,atrialfibrillation,previousstroke,leftcorticalstroke,visual\ndisturbances,moreseverestrokeandplatelettowhite-cellcountratio<20.22.14,16-18Amajorityof\ndeliriumweredetectedonthefirstdayofadmissionandtheremainderappearedwithinthenext5\ndays.14,18\nThe4ATisavalidatedtooltoscreenfordeliriuminacutestrokepatients(sensitivity90-100%;\nspecificity65-86%).Itallowsassessmentforall(includingnon-verbal)patients.19\nRecommendation:Allpost-strokepatientsshouldbescreenedfordeliriumthroughout\nhospitalization.14,20\n(Newrecommendation,LevelII-2,GradeB)\nRecommendation:Screeningforpost-strokedeliriumusingthe4ATtoolisrecommended.\n(Newrecommendation,LevelII-2,GradeB)\nRecommendation:Amulti-componentinterventionforpost-strokedeliriumpreventionand\nmanagementshouldbeimplementedtodecreaseincidenceofdeliriumanditsseverityaswellasto\nreducethelengthofstay.21,22\n(Newrecommendation,LevelII-2,GradeB)\n12.6Fallspreventionpost-stroke\nFallsarecommonadverseeventspost-stroke.Theincidenceis7%inthefirstweekbutcanbeas\nhighas73%oneyearaftersufferingastroke.23,24Post-strokefallsmayresultinseriousinjury(such\nasfragilityfracture),fearoffalling,activitieslimitation,increaseddependenceandhighercostof\ncare.25,26Althoughanypatientswithresidualdifficultiesfollowingastrokeareatriskoffalls,patients\nwithmodifiedRankinScale(mRS)scoreof2areatgreaterriskoffalls.27ThisinverseU-shaped\nrelationshipsuggestsinterplaybetweenopportunitiesoffallingandsusceptibilitytofalls.28\nAlthoughinterventionsforpreventingfallsafterstrokearelargelyineffectiveotherthanthose\ninvolvingexercises,peoplewithstrokeshouldbeofferedfallsandfragilityfractureriskassessment\nandmanagementaspartoftheirstrokerehabilitation.29,30\nRecommendation:Allpeoplewithstrokeshouldbeofferedfallsandfragilityfracturerisk\nassessmentandmanagementduringtheirrehabilitationperiod.\n(Newrecommendation,LevelIII,GradeC)\n12.7Dischargeplanningandearlysupporteddischargepoststroke\nTheprocessofrecoveringfromastrokeincludestreatment,spontaneousrecovery,rehabilitation,\nandthereturntocommunityliving.\nAfterreceivingacutecare,rehabilitationwhichistypicallycomplexforolderpersonsisofferedas\nsoonaspossible.Decisionsaboutrehabilitationaremadebythepatients,family,anda\nmultidisciplinaryteam.Somepatientsmaynotneedrehabilitationastheyfullyrecoverorhaveamild\nneurologicaldeficitthatdoesnotinterferewiththeirdailyactivities."
    },
    {
        "page_number": 101,
        "text": "101Averyimportantstageofstrokerecoveryiscalleddischargeplanninganditbeginswiththeperson’s\nreturntocommunitylivingafteracutecareand/orrehabilitation.31Dischargeplanningisanimportant\nandcomplexprocessfollowingacutestrokemanagementtoensureasmoothtransitionfromone\nlevelofcaretoanotherwherethepatient’slevelofcareismatchedtothesiteofcareprovision.The\nobjectiveofdischargeplanningistomaintainthebenefitsofrehabilitationafterthepatienthasbeen\ndischargedfromthehospitaloncetheirgoalsareattained.32\nThebenefitsofdischargeplanningincludereducedlengthofstayandreadmissionrate,and\nimprovedqualityoflife.33\nElementsofdischargeplanningare:\n1.Ensuringthestrokesurvivorhasasafeplacetoliveafterdischarge\n2.Determiningthelevelofcare,assistance,orspecialequipmentthatareneeded\n3.Coordinatingrehabilitationservicesorotherservicesinthehome(suchasvisitsbyaprimary\ncareclinic’sdomiciliarycareteamorahomehealthaide)\n4.Determiningthehealthcareproviderwhowillmonitortheperson’shealthandmedicalneeds\n5.Determiningandtrainingthecaregiverofthepatienttoprovidedailycareandassistance\n6.Helpingthestrokesurvivorexploreemploymentopportunitiesorvolunteeractivitiesand\nmaintainingtheirsocialactivitieswherepossible\nRecommendation:Dischargeplanningforolderpersonswithstrokeshouldoccurattheappropriate\ntimefollowingamultidisciplinaryrecommendationwhereanydecisionsaboutcareismadeinthe\nperson’sbestinterests.\n(Newrecommendation,LevelII-3,GradeB)\nRecommendation:Hospitalin-patientswithstrokewhohavemildtomoderatedisabilityshouldbe\nofferedearlysupporteddischarge,withtreatmentathomebeginningwithin24hoursofdischarge.\n(Newrecommendation,LevelII-3,GradeB)\nRecommendation:Astrokeearlysupporteddischargeteamshouldbeorganisedasasingle\nmulti-disciplinaryteamincluding:\n(Newrecommendation,LevelII-1,GradeA)\n●Doctor\n●Nurse\n●Physiotherapist\n●Occupationaltherapist\n●Speechandlanguagetherapist\n●Clinicalpsychologist\n●Socialworker\nRecommendation:Olderpersonswithstrokeandtheirfamily/carersshouldbeinvolvedindecisions\naboutthedischargeandarepreparedtobeinvolvedintheircare.\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Dischargeplanningshouldincludeequipmentandsupportservicesnecessary\nincludingidentificationofthefollow-uptreatment.\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Evaluationofhomeenvironmentbyanoccupationaltherapistshouldbecarried\nout,bydoingahomevisitorthroughinterviewaboutthehomeenvironment,includingphotographs\norvideostakenwithconsentgivenbythefamilymembers/carers.\n(Newrecommendation,LevelIII,GradeC)"
    },
    {
        "page_number": 102,
        "text": "10212.8End-of-lifecare\nStrokeisoftenthemodeofdeathforolderpersons,eitherasaprimaryincidentorexacerbatedby\notheracuteconditions.Therecognitionthatlifespanislimitedorthatthepatientisdyingshouldbe\nconsideredpositively.Deathshouldberecognizedasaninevitabilityoflife,andhencepalliativecare\nshouldbeconsideredacorecompetencyofthoseaccreditedtodeliverstrokecare.Treatmentatthe\nend-of-lifeforstrokepatientsneedstoprioritizepatientdignityandtheneedtofacilitateagood\ndeath.\nCommonburdensomesymptomsattheendoflifeinstrokeincludeanxiety,agitation,decubitus\nulcers,painandissueswithhydrationandnutrition.34Studiesinvolvingcaregiversofthosewhodied\nofstrokerevealedlimitedpreparationsfortheendoflifewiththeuseofthetermpalliativecare\nequatedto‘lastdaysoflife’.35Thequalityofinterventionstudiesinpalliativecareingeneralislimited,\nwithavailablestudiesconductedmainlyincancerpatients.Availableregistrystudieshavesupported\nimplementationofthepalliativecareprinciplesandencounters.34,36\nRecommendation:Themultidisciplinarystroketeamshouldbetrainedinprinciplesandpracticeof\nend-of-lifecare.\n(Newrecommendation,LevelII-3,GradeC)\nRecommendation:Burdensometreatmentshouldbeavoidedattheend-of-lifecareandthisshould\nincludedecisionstocontinueoralfeedingandhydrationdespitethepotentialriskofaspiration.\n(Newrecommendation,LevelII-3,GradeC)\nRecommendation:Advancedcareplanningshouldbeprovidedforindividualswhoareexpectedto\nhavealimitedlifeexpectancy.\n(Newrecommendation,LevelII-2,GradeB)\nRecommendation:Decisiontowithholdandwithdrawtreatmentshouldtakeintoaccountprior\nexpressedwishesoftheindividualwithstrokewhichoftenneedstobeestablishedfromthe\nnext-of-kinandcloserelations.\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Stroketeamsshouldbepreparedtofacilitatethetransferofcareofthe\nindividualdyingofstroketotheirownhomessupportedbylocalhospicesandpalliativecareservices\nifavailable.\n(Newrecommendation,LevelIII,GradeC)"
    },
    {
        "page_number": 103,
        "text": "103RecommendationsSummary:\nTable12.1:StrokeintheOlderPerson\nManagement RecommendationsLevelof\nEvidenceGrade\nScreeningforFrailtyAllolderadultsshouldbescreenedforfrailtyusinga\nvalidatedinstrumentsuitableforthespecificsettingor\ncontextwithatailoredmanagementplanthereafter.\nNewrecommendationIII C\nStrokeThrombolysisAnolderpersonshouldreceiveandcanbenefitfrom\nintravenousthrombolysis.\nNewrecommendationI A\nEndovascular\nthrombectomyAnolderpersoncanbenefitfromendovascular\nthrombectomyforanteriorcirculatorylargevesselocclusion.\nNewrecommendationI A\nManagementof\nglucoselevelinthe\nacutephaseofstrokeAfteranacutestroke,treathyperglycaemiatokeepthe\nbloodglucoselevelsbetween6.0-10.0mmol/L(110-180\nmg/dL)andensurethathypoglycaemiaisavoided.\nNewrecommendationIII C\nAvoidverytighttargetsofglucosecontrol(4.0-7.5mmol/L)\ninthefirstfewhoursofacuteischaemicstroke.\nNewrecommendationI A\nHypertension Olderpersonswhohaveoneormoreofthefollowing:frailty,\nmultiplecomorbidities,cognitiveimpairment,requirean\nindividualizedapproachforbloodpressuremanagement.\nNewrecommendationI A\nDiabetesMellitus Targetsofbloodglucosecontrolinolderpersonswith\ndiabetesshouldbeindividualizedtakingintoaccounttheir\nfunctionalstatus,medicalcomorbidities,andlikelihoodof\ndevelopingadverseevents.\nNewrecommendationIII C\nDyslipidaemia Statinsarerecommendedforstrokepreventioninolder\npersonswithlessdirectevidenceofbenefitforstroke\npreventionandprimarypreventionofvasculareventsin\nthoseagedover75years.\nNewrecommendationI A\nAtrialFibrillation Olderpersonswithatrialfibrillationcanbenefitfromoral\nanticoagulantforstrokepreventionwithanindividualized\ntreatmentplantakingmedicalco-morbidities,functional\nstatus,andsocialfactorsintoconsideration.\nNewrecommendationI A\nMedication\nmanagementinthe\nolderpersonwith\nstrokeAcomprehensivecareplanforafrailolderpersonshould\nincludethemanagementofpolypharmacy.\nNewrecommendationIII C\nDeliriumpost-acute\nstrokeAllpost-strokepatientsshouldbescreenedfordelirium\nthroughouthospitalization.\nNewrecommendationII-2 B\nScreeningforpost-strokedeliriumusingthe4ATtoolis\nrecommended.\nNewrecommendationII-2 B\nAmulti-componentinterventionforpost-strokedelirium\npreventionandmanagementshouldbeimplementedto\ndecreasethedeliriumincidenceandseverityaswellasto\nreducethelengthofstay.\nNewrecommendationII-2 B"
    },
    {
        "page_number": 104,
        "text": "104Fallsprevention\npost-strokeAllpeoplewithstrokeshouldbeofferedfallsandfragility\nfractureriskassessmentandmanagementduringtheir\nrehabilitationperiod.\nNewrecommendationIII C\nDischargeplanning\nandearlysupported\ndischargepoststrokeDischargeplanningforolderpersonswithstrokeshould\noccurattheappropriatetimefollowingamultidisciplinary\nrecommendationwhereanydecisionsaboutcareismadein\ntheperson’sbestinterests.\nNewrecommendationII-3 B\nHospitalin-patientswithstrokewhohavemildtomoderate\ndisabilityshouldbeofferedearlysupporteddischarge,with\ntreatmentathomebeginningwithin24hoursofdischarge.\nNewrecommendationII-3 B\nAstrokeearlysupporteddischargeteamshouldbe\norganisedasasinglemulti-disciplinaryteamincluding:\n●Doctor\n●Nurse\n●Physiotherapist\n●Occupationaltherapist\n●Speechandlanguagetherapist\n●Clinicalpsychologist\n●Socialworker\nNewrecommendationII-1 A\nOlderpersonswithstrokeandtheirfamily/carersshouldbe\ninvolvedindecisionsaboutthedischargeandareprepared\ntobeinvolvedintheircare.\nNewrecommendationIII C\nDischargeplanningshouldincludeequipmentandsupport\nservicesnecessaryincludingidentificationofthefollow-up\ntreatment.\nNewrecommendationIII C\nEvaluationofhomeenvironmentbyanoccupational\ntherapistshouldbecarriedout,bydoingahomevisitor\nthroughinterviewaboutthehomeenvironment,including\nphotographsorvideostakenwithconsentgivenbythe\nfamilymembers/carers.\nNewrecommendationIII C\nEnd-of-lifecare Themultidisciplinarystroketeamshouldbetrainedin\nprinciplesandpracticeofend-of-lifecare.\nNewrecommendationII-3 C\nBurdensometreatmentshouldbeavoidedattheend-of-life\ncareandthisshouldincludedecisionstocontinueoral\nfeedingandhydrationdespitethepotentialriskof\naspiration.\nNewrecommendationII-3 C\nAdvancedcareplanningshouldbeprovidedforindividuals\nwhoareexpectedtohavealimitedlifeexpectancy.\nNewrecommendationII-2 B\nDecisiontowithholdandwithdrawtreatmentshouldtake\nintoaccountpriorexpressedwishesoftheindividualwith\nstrokewhichoftenneedstobeestablishedfromthe\nnext-of-kinandcloserelations.\nNewrecommendationIII C\nStroketeamsshouldbepreparedtofacilitatethetransferof\ncareoftheindividualdyingofstroketotheirownhomes\nsupportedbylocalhospicesandpalliativecareservicesif\navailable.\nNewrecommendationIII C"
    },
    {
        "page_number": 105,
        "text": "105KeyRecommendations:\n1.Allolderpersonswithacutestrokeshouldbeassessedforfitness/frailtylevelusingavalidated\ninstrumenttofacilitateatailored,individualisedtreatmentplan.\n2.Anolderpersoncanbenefitfromacutetreatmentforstrokeincludingstrokethrombolysisand\nendovascularthrombectomyprovidingtheinclusionandexclusioncriteriaofthetreatmentare\nfollowed.\n3.Anolderpersoncanbenefitfromandshouldreceivetreatmentforstrokepreventionwith\nmanagementofpolypharmacy,individualisedmedicationdosagesandtreatmenttargetsas\ntolerated,forstrokeriskfactors.\n4.Allolderpersonswithstrokeshouldbe:\n-screenedfordeliriumusingavalidatedtool,andreceiveatailoredmulticomponent\ninterventionandmanagementplanfordelirium,whenadmittedwithanacutestroke\n-offeredfallsandfragilityfractureriskassessmentandmanagementduringtheirrehabilitation\nperiod\n-assessedbyamultidisciplinaryteamwithappropriatedischargeplanning\n-abletoreceiveend-of-lifecareandrecommendationswhentheprognosisispooreitherfrom\nthestrokeitself,complications,orotherseriouscomorbidconditions"
    },
    {
        "page_number": 106,
        "text": "10613.1CardioembolicStroke\nCardioembolicstrokeaccountsforabout20%ofallischaemicstrokes.1-3Theyaregenerallysevere,\npronetoearlyrecurrence,morelikelytohappenwhenthereisdocumentedsourceofembolismand\ninvolvedifferentcerebrovascularterritoriesormultipleinfarctions.Thepredominantpathogenic\nprocessforstrokeassociatedwithcardiacdiseaseisembolismduetotheformationofintra-atrial\nandintra-ventricularthrombi.\nAtrialfibrillation(AF)whetherchronicorparoxysmal,isthemostcommoncauseofcardioembolism\nandaccountsfor50%ofallcardiogenicemboli.Otherhigh-riskconditionsareprostheticheartvalves,\nrheumaticmitralvalvulardisease,acutemyocardialinfarction,andsevereleftventriculardysfunction.\nNon-thromboticembolismmayresultfromatrialmyxomaandendocarditis.\nInvestigationsaredirectedatdemonstratingcardiacsourcesofembolismintheabsenceof\nsignificantatherosclerosisorothervasculardisease.Allpatientswithstroke/TIArequirea12-lead\nelectrocardiogram.A72-hourHoltermonitorisrequiredtodetectparoxysmalAF.Inaddition,all\npatientsunder45yearsofageandthoseinwhombaselineinvestigationsdonotrevealanapparent\ncauseforstrokewillrequireatransthoracicechocardiogram(TTE).Patientsinwhomthereishigh\nsuspicionofcardioembolismnotfoundonTTEmayundergoatrans-oesophagealechocardiogram\n(TOE).ConditionsinwhichthismethodissuperiortoTTEincludeidentifyingthrombiintheleftatrium\nandleftatrialappendage,patentforamenovale,atrialseptalaneurysmandaorticarchatheroma.3,4\n13.2StrokePreventioninAtrialFibrillationPatients\nRecommendation:Antiplateletmonotherapyisnotindicatedforstrokepreventioninnon-valvular\natrialfibrillation(NVAF)patients.\n(LevelI,GradeA)\nRecommendation:Oralanticoagulant(OAC)hasbeenproventobesuperiortonotreatmentor\nAspirininpatientswithNVAF.\n(LevelI,GradeA)\nRecommendation:OACtopreventcardioembolicstrokeisrecommendedforallNVAFmale\npatientswithCHA2DS2-VAScscoreof2ormoreandfemalepatientswithaCHA2DS2-VAScscoreof\n3ormore.\n(Newrecommendation,LevelI,GradeA)\nRecommendation:ThechoiceofOACforvalvularAF(moderate-to-severemitralstenosis)and\nmechanicalheartvalvespatientsisaVitaminKAntagonist(Warfarin).\n(LevelI,GradeA)STROKEANDCARDIOEMBOLISM13"
    },
    {
        "page_number": 107,
        "text": "107RecommendationoftreatmentaccordingtoCHA2DS2-VAScScore:\nCHA2DS2-VAScScore\nMale Female\n≥2 OAC ≥3 OAC\n1 ConsiderOAC 2 ConsiderOAC\n0 Notreatment 0-1 Notreatment\n13.3SecondaryStrokePreventioninAtrialFibrillationPatients\nRecommendation:Afteracardioembolicstroke,parenteralanticoagulanttherapy(heparinorlow\nmolecularweightheparin)isnotrecommendedtopreventsecondarystroke.\n(LevelI,GradeA)\nRecommendation:ForthesecondarystrokepreventioninanAFpatient,theinitiationofdirectoral\nanticoagulants(DOACs)isrecommendedasbelowafterexcludinghaemorrhagictransformation:\n(Newrecommendation,LevelII,GradeB)\n1-3-6-12DayRule\nTypeofstrokeNIHSSscoreDaytostartOAC\nTIA 1\nMild <8 3\nModerate 8-15 6\nSevere ≥16 12\nRecommendation:DOACsarepreferredascomparedtoVKAorAspirininAFpatientswitha\npreviousstroke.\n(Newrecommendation,LevelI,GradeA)\nRecommendation:AspirincouldbeconsideredbeforetheinitiationofOACafteranAFpatient\nsuffersfromanischaemicstroke.\n(LevelIII,GradeC)\nRecommendation:TheriskofbleedingishighafterinitiationofcombinationtherapyofOACand\nantiplateletforsecondarystrokeprevention.\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Afterintracranialhaemorrhage,OACcouldbere-initiatedafter4-8weeksina\nNVAFpatientwithhighCHA2DS2-VAScscoreiftheunderlyingcauseandriskfactorsofthebleeding\nhavebeentreated.\n(Newrecommendation,LevelII,GradeB)"
    },
    {
        "page_number": 108,
        "text": "10813.4GeneralMeasuresforDOACsinBleedingandEmergencyIntervention\nMechanicalcompressionifpossible\nIVaccessat2sites\nDeterminetimingoflastDOACdose\nFBC,RP,LFT\nPlasmaexpanders\nConsideractivatedcharcoalifDOACingestionis<2hours\nNotifyon-callhaematologist\nThefollowingchartreferstospecificmeasuresofintervention:\nOAC\nCategoryNameofOACBloodtestsSpecificReversal\nAgentAlternativeTreatment\nOptions\nVitaminK\nantagonistWarfarin INR VitaminK 1.PCC\n2.RecombinantFactor\nVIIa\n3.IVTranexamicAcid\n4.FFP\n5.*Haemodialysis\nonlyforDabigatranDOAC DabigatranaPTT,TTIdarucizumab5gIV(2\ntimesinfusionsof2.5\ngrams)\nRivaroxabanAnti-Factor\nXaAndexanetalfa*\nApixabanAnti-Factor\nXaAndexanetalfa*\n*Notavailableatthetimeofwriting,boxedwarning(FDA)forthromboembolicrisks,ischaemicrisks,\ncardiacarrest,andsuddendeath\nRecommendationsSummary:\nTable13.1:PreventionofStrokeinAtrialFibrillationPatients\nTreatment RecommendationsLevelof\nEvidenceGrade\nStrokePrevention\nAntiplateletmonotherapyAntiplateletmonotherapyisnotindicatedforstroke\npreventioninnon-valvularatrialfibrillation(NVAF)\npatients.I A\nOralanticoagulant(OAC)OAChasbeenproventobesuperiortonotreatmentor\nAspirininpatientswithNVAF.I A\nOACtopreventcardioembolicstrokeisrecommendedfor\nallNVAFmalepatientswithCHA2DS2-VAScscoreof2or\nmoreandfemalepatientswithaCHA2DS2-VAScscoreof\n3ormore.\nNewrecommendationI A\nThechoiceofOACforvalvularAF(moderate-to-severe\nmitralstenosis)andmechanicalheartvalvespatientsis\nVitaminKAntagonist(Warfarin).I A\nSecondaryStrokePrevention\nParenteralanticoagulant\n(heparinorlowmolecular\nweightheparin)Afteracardioembolicstroke,parenteralanticoagulant\ntherapy(heparinorlowmolecularweightheparin)isnot\nrecommendedtopreventsecondarystroke.I A\nDOACs ForsecondarystrokepreventioninanAFpatient,the\ninitiationofDOACsisrecommendedafterexcluding\nhaemorrhagictransformation\nNewrecommendationII B"
    },
    {
        "page_number": 109,
        "text": "109DOACsarepreferredoverVKAandAspirininAF\npatientswithapreviousstroke.\nNewrecommendationI A\nAspirin AspirincouldbeconsideredbeforetheinitiationofOAC\nafteranAFpatientsuffersfromanischaemicstroke.III C\nCombinationtherapyof\nOACandantiplateletTheriskofbleedingishighafterinitiationofcombination\ntherapyofOACandantiplateletforsecondarystroke\nprevention.\nNewrecommendationIII C\nOAC Afterintracranialhaemorrhage,OACcouldbere-initiated\nafter4-8weeksinaNVAFpatientwithhigh\nCHA2DS2-VAScscoreiftheunderlyingcauseandrisk\nfactorsofthebleedinghavebeentreated.\nNewrecommendationII B\nKeyRecommendations:\n1.Cardioembolismisacommoncauseofstroke.Strokepatientmusthavecardiacassessmentto\nlookforcardioemboli.\n2.Itcausesmoreseverestrokeandcarryahighermorbidityandmortalityrates.\n3.Effectivetreatmenttopreventcardioembolismisavailableandshouldbeofferedtopatientat\nrisk.\n4.DOACispreferredoverVKAforNVAF.\n5.PatientonVKAshouldhaveregularINRmonitoringandaimtimeinthetherapeuticrange\n(TTR)>70%.\n6.AntiplateletisnotrecommendedforNVAFforthepreventionofstroke."
    },
    {
        "page_number": 110,
        "text": "110STROKEINSPECIALCIRCUMSTANCES\n14.1StrokeinYoungAdults\nTheincidenceofstrokeinyoungadults(18to45years)isincreasingandtheprevalenceisreported\ntobeapproximately10-15%ofallstrokepatients.1Thecausesandriskfactorsofstrokeinyoung\nadultsisdistinctfromthoseinolderpatients,inwhichcardiacembolismandotheraetiologiesare\nmorecommon,notablynon-atheroscleroticarteriopathiesandhaematologicaldisorders.2,3Therefore,\nthediagnosticevaluationandmanagementstrategyareusuallymorecomprehensiveand\nchallenging.Thischapterwillcovertheaetiologyandriskfactorsinyoungadultswithstroke,in\nadditiontothediagnosisandmanagementofspecificcausesofstrokeinyoungadults.\n14.2YoungStrokeAetiology\nThecausesofischaemicstrokeinyoungadultsarediverseandvarybyage,gender,and\ngeographicregion.4ThecausesmaybeclassifiedaccordingtotheTOASTclassification.\nNon-atheroscleroticarteriopathiessuchasarterialdissectionaswellasprematureatherosclerosis\nduetohypertension,cigarettesmokingandhyperlipidaemiaarecollectivelythemostcommon\ncausesofischaemicstrokeinyoungindividuals.3,5Butoften,thecauseofthestrokeisunknown.6\nCryptogenicstrokeisdefinedasstrokewithoutanyprobablecauseidentifiedafteradequate\ndiagnosticevaluation.7-10Cryptogenicstrokehasbeenreportedinupto40%ofyoungstrokecases.4\nIn2014,theclinicalconstructof“embolicstrokeofundeterminedsource”(ESUS)wasintroducedto\nidentifypatientswithnon-lacunarcryptogenicischaemicstrokesinwhomembolismwasthelikely\nstrokemechanism.About1/6ofstrokepatientsarelabelledasESUSandtheyaregenerallyyounger\npatientswithmilderstrokebutareassociatedwithahigherriskofstrokerecurrence.7,8Todate,there\nisnoevidencetosuggesttheroleofanticoagulantsinthemanagementofESUS.\nTable14.1:AetiologyofYoungStroke\nLargearteryatherosclerosis\nUncommonbeforetheageof40butincidenceincreaseswithage\nClassicvascularriskfactorsarepresent\nManagementissimilarwithstrokeinolderpopulations\nCardiogenicembolism\nCardiactumourscommonlyfoundintheleftatriumandapex(atrialmyxoma,papillary\nfibroelastoma)\nArrhythmia–atrialfibrillation,sicksinussyndrome,etc.\nCardiomyopathy\nInfectionandnon-bacterialthromboticendocarditis\nRheumaticvalvularheartdisease9\nPatentforamenovale(PFO),atrialseptaldefect(ASD),etc.\nSmallvesseldisease\nGenetic:cerebralautosomaldominantarteriopathywithsubcorticalinfarctsand\nleukoencephalopathy(CADASIL)-Notch3mutation11\nSporadic:classicvascularriskfactorsarepresent\nManagementislong-termantiplatelettherapy14"
    },
    {
        "page_number": 111,
        "text": "111Strokeofotherdeterminedcause\nHaematologicalcausesbasedonabnormalbloodcomponents:12\nErythrocytes:polycythaemiavera,sickle-celldisease,paroxysmalnocturnalhaemoglobinuria,\netc.\nLeucocytes:leukaemias,Waldenstrommacroglobulinaemia,multiplemyeloma,\nhypereosinophilicsyndrome,etc.\nPlatelets:essentialthrombocythaemia;thromboticthrombocytopenicpurpura,heparininduced\nthrombocytopaenia,etc.\nCoagulationdisorders:\nProteinCdeficiency\nProteinSdeficiency\nAntithrombindeficiency\nFactorVLeiden\nProthrombinG20210Amutation\nDisseminatedintravascularcoagulation\nAntiphospholipidsyndrome\nHypercoaguablestates–malignancy,pregnancy,oestrogensdehydration\nManagementisanticoagulants\nIllicitdruguse:\nCocaineandamphetaminescausecerebralvasospasm,cardiacarrhythmias,cardiomyopathy,\nacceleratedatherosclerosis,vasculitis,anddirecttoxiceffectsoncerebralvessels\nManagementissupportivetreatment\nArterialdissections:\nSpontaneousorsecondarytotraumaorprimaryarteriopathysuchascysticmedialnecrosis,\nfibromusculardysplasia\nExtracranialcause:carotidarterydissection\nIntracranialcause:vertebralartery,etc.\nManagementisantiplatelettreatment,endovasculartreatment\nVasculitis/inflammatoryarteriopathy:\nVasculitis:primary/secondarytoinfection/drug-related\nPrimary:SLE,polyarteritisnodosa(PAN),Takayasu’sarteritis(affectinglargebloodvessels,\nincludingmajoraorticbranches);granulomatousangiitis,primaryangiitisoftheCNS(PACNS)\naffectingmediumandsmallbloodvessels;Behçetdisease,Churg-Strausssyndrome,\nKohlmeier-Degosdisease13\nComplicationofinfection:TBmeningitis14(mainlyperforatorsandcorticalbranches),syphilis,\npostvaricella,fungal,HIV/AIDS,etc.\nDrugrelated:heroin,LSD,cocaine,amphetamines,ephedrine,phenylpropanolamine\nManagementisimmunosuppressivetreatmentforprimarycauses\nInheritedarteriopathy:11\nFabrydisease:aX-linkedsphingolipidosiscausedbydeficiencyofα-galactosidaseA(α-gal)\nMitochondrialmyopathy,encephalopathy,lacticacidosis,andstrokelikeepisodes(<40years\nold):mostlyduetomitochondrialDNA(mtDNA)A-to-Gtransitionatnucleotide3243ofthe\ntransferRNAofleucine\nOthers:fibromusculardysplasia,dolichoectasia,Susacsyndrome,15CADASIL,retinal"
    },
    {
        "page_number": 112,
        "text": "112vasculopathywithcerebralleukodystrophy(RVCL)duetoTREX1mutation,\nhyperhomocysteinaemiaduetomethylenetetrahydrofolatereductase(MTHFR)gene\npolymorphism,16,17neurofibromatosistype1andhomocystinuria\nMiscellaneous:\nSleepapnoea\nMoyamoyadisease18–progressivestenosisofintracranialarteriesandproximalbranches\n(primaryorsecondarytoothercauses)\nRadiation-inducedarteriopathy-postradiationatheadandneckarea,stenosisofdistalinternal\ncarotidartery\nReversiblecerebralvasoconstrictionsyndrome-precipitatingfactorsincludeshypertension,illicit\ndruguseandmedications\nMigraine–riskiscontroversial,needsfurtherresearch\nHereditaryhaemorrhagictelangiectasia(HHT)-strokecausedbyparadoxicalembolismdueto\npulmonaryarteriovenousmalformations\nStrokeofundeterminedcause\nCryptogenicstroke:\n“Cryptogenic”afterstandardevaluationvs“cryptogenic”afteradditional,specializedevaluation\n“Highlycryptogenic”(i.e.,withnoprobableandnopossiblecausediscovered)vs“ofpossibly\ndeterminedorigin”(i.e.,withnoprobable,butoneormorepossible,causesidentified)\nEmbolicStrokeofUndeterminedSource(ESUS):\nSub-groupofpatientswithcryptogenicischaemicstrokeswithahighpossibilityofanoccult\nembolicsourceofstroke(e.g.undetectedparoxysmalAF,aorticarchplaque,andoccultcancer).\nCriteria:(1)non-lacunarstrokedetectedbyCTorMRI;(2)absenceofextracranialorintracranial\natherosclerosiscausing50%luminalstenosisinarteriessupplyingtheischaemicarea;(3)\nabsenceofamajor-riskcardiacsourceofembolism;and(4)absenceofanyotherspecificcause\nofindexstroke.Lacunarstrokeisdefinedasasubcorticalinfarct1.5cminitslargestdimension\nandinthedistributionofthesmall,penetratingarteries.\nManagementislong-termantiplateletwithnoevidencefororalanticoagulants.OneRCTshowed\ndirectoralanticoagulants(Rivaroxaban)isnotsuperiortoaspirininpreventionofrecurrentstroke\nandassociatedwithhigherriskofbleeding.ProlongedambulatoryECGmonitoringtodetectAF\nismoreimportantasoccultAFoccursinabout25%ofallESUS.\n14.3StrokePatientswithPatentForamenOvale(PFO)\nRecommendation:PFOclosuredeviceshavemoderatebenefittoyoungandmiddle-agedpatients\nwithcryptogenicischaemicstroke.PFOclosuredevicescombinedwithantiplatelettherapyisalso\nrecommended.19\n(Newrecommendation,LevelI,ClassA)\nInpatientswithischaemicstrokeortransientischaemicattack(TIA)andapatentforamenovale\n(PFO)whoarenottreatedwithanticoagulationtreatment,antiplatelettherapyisrecommended.20\n(Newrecommendation,LevelII-1,ClassB)\nRecommendation:AmongischaemicstrokeorTIApatientswhohavebothaPFOandavenous\nsourceofembolism,anticoagulationisindicatedbasedonthecharacteristicsofstroke.20\n(Newrecommendation,LevelI,ClassA)"
    },
    {
        "page_number": 113,
        "text": "113Whenanticoagulanttherapyiscontraindicated,aninferiorvenacavafiltercanbeinserted.20\n(Newrecommendation,LevelIII,ClassC)\nInpatientswithPFOanddeepveinthrombosis(DVT),PFOclosurewithatranscatheterdevicemay\nbeconsidereddependingontheriskofrecurrentDVT.20\n(Newrecommendation,LevelIII,ClassC)\nPFOclosureduringpregnancyisnotrecommended.21Low-doseoralAspirinisthefirstlineof\ntreatment.21IfapregnantpatientwithaknownPFOisatincreasedriskofvenousthrombosis,\nprophylacticlowmolecularweightheparin(LMWH)dosescanbeconsidered.21\nInonestudy,inpatientswhohadarecentcryptogenicstrokeduetoPFOwithanassociatedatrial\nseptalaneurysmorlargeinteratrialshunt,therateofstrokerecurrencewaslowerinpatientswith\ncombinedPFOclosure/antiplatelettherapycomparedtopatientswithantiplatelettherapyalone.22\nHowever,theclosureofPFOwasassociatedwithahigherfrequencyofatrialfibrillation.22\n14.4InvestigationofYoungStroke\nIdentifythecause/predisposingfactor6\nA.Searchfortheclassicalvascularriskfactors\nB.Specialdiagnostictests(seesectiononInvestigations)\nI.ESR,CRPandfastinghomocysteine16\nII.FBC,RP,PT/aPTT,pregnancytest\nIII.Serumandurinetoxicologyscreen\nIV.Auto-antibodyscreen:includingantiphospholipidantibodies,antinuclearantibody,antibody\ntodouble-strandedDNA,rheumatoidfactor,anticardiolipinantibodies,complementlevels,\ncryoglobulinlevel,neutrophilcytoplasmantibody(cANCAandpANCA),Scl-70antibody,\nanti-centromereantibody,anti-Ro(SSA)andanti-La(SSB)cytoplasmicantibodies,serum\nangiotensin-convertingenzyme,anti-proteinase3\nV.Infectiousdiseasepaneltests:varicella-zostervirus,herpessimplexvirus,Epstein-Barr\nvirus,HIV,hepatitisBandCviruses,tuberculosis,syphilis,Lymediseaseandothers\nVI.Genetictests:23forconditionssuchasCADASIL(notch3mutation),RVCL(trex1\nmutation),Hyperhomocysteinaemia(MTHFR677C-Tpleomorphism)andothers\nVII.Plasmaα-galactivityforFabry’sdisease\nVIII.MELAS:Increasedlactateandpyruvatelevelsinserumandcerebrospinalfluid;\nlactate/pyruvateratio,ragged-redfibresstronglypositivesuccinatedehydrogenase\nstaininginmusclebiopsy\nIX.Sleepstudytodetectsleepapnoea\nX.Coagulationscreenifindicated:\ni.Serumfibrinogen\nii.Anti-thrombinIIIlevel\niii.ProteinCandProteinS\niv.FactorV-Leyden\nv.Prothrombingenemutation"
    },
    {
        "page_number": 114,
        "text": "114C.Radiologicalinvestigations-standard(seechapteronInvestigations)andspecialised:\nI.MRI/MRAbrainandintraandextracranialcarotids/CarotidDopplerultrasounds\nII.TransthoracicEchocardiography(todetectatrialmyxomaoranylesionintheheart)\nIII.Trans-esophagealechocardiography(TOE),Lowerextremityultrasound,pelvicCT,orMR\nvenography(inpatientswithPFO)\nIV.Advancedbrainimaging:axialfat-suppressedT1-weightedMRI,high-resolution(3T)\ncontrast-enhancedT1-weightedMRI,PETscan,MRspectroscopy,transcranialDoppler\nultrasoundstudies,percutaneouscerebralangiography.\nD.Others:24-hourHoltermonitoring,prolongedambulatoryECGmonitoring,sleepstudy.\nRecommendations:\nTable14.3:TreatmentofStrokeinCertainCircumstances\nTreatment RecommendationsLevelof\nEvidenceGrade\nAspirin24,25Ifthecauseisnotidentified,Aspirinisusuallygivenwhile\nadditionaltestsareobtainedtoguidethechoicebetween\nlong-termantiplateletoranticoagulanttherapy.III C\nAntiplatelettherapyisrecommendedinpatientswhoarefoundto\nhaveabnormalfindingsoncoagulationtestingafteraninitial\nischaemicstrokeorTIAifanticoagulanttherapyisnot\nadministered.I A\nForpatientswithischaemicstrokeorTIAwhohavean\nanti-phospholipidantibodybutwhodonotfulfilthecriteriafor\nanti-phospholipidantibodysyndrome,antiplatelettherapyis\nrecommendedI B\nForpatientswithischaemicstrokeorTIAwhomeetthecriteriafor\ntheanti-phospholipidantibodysyndromebutinwhom\nanticoagulationisnotyetstarted,antiplatelettherapyisindicatedI A\nDOAC ESUS:\nThereisnoroleofanticoagulantinESUS.\nRivaroxabanwasnotsuperiortoaspirinwithregardtothe\npreventionofrecurrentstrokeafteraninitialembolicstrokeof\nundeterminedsourceandwasassociatedwithahigherriskof\nbleeding.26\nNewrecommendationI ATable14.2:InvestigationofYoungStroke\nInvestigation RecommendationsLevelof\nEvidenceGrade\nHomocysteinaemiaRoutinescreeningforhyperhomocysteinaemiaamongpatients\nwitharecentischaemicstrokeorTIAisnotindicated.III C\nCoagulation\nscreeningTheusefulnessofscreeningforthrombophilicstatesinpatients\nwithischaemicstrokeorTIAisunknown.II-2 C\nAnti-phospholipid\nantibodiesRoutinetestingforanti-phospholipidantibodiesisnot\nrecommendedforpatientswithischaemicstrokeorTIAwho\nhavenoothermanifestationsoftheanti-phospholipidantibody\nsyndromeandwhohaveanalternativeexplanationfortheir\nischaemicevent,suchasatherosclerosis,carotidstenosisorAF.III C\nSleepstudy Asleepstudymightbeconsideredforpatientswithanischaemic\nstrokeorTIA.II-2 B"
    },
    {
        "page_number": 115,
        "text": "115ForpatientswithanischaemicstrokeorTIAandbothaPFOanda\nvenoussourceofembolism,anticoagulationisindicated,\ndependingonthestrokecharacteristics.27\nNewrecommendationI A\nAnticoagulationmightbeconsideredinpatientswhoarefoundto\nhaveabnormalfindingsoncoagulationtestingafteraninitial\nischaemicstrokeorTIA,dependingontheabnormalityandthe\nclinicalcircumstances.\nNewrecommendationII-2 C\nForpatientswithischaemicstrokeorTIAwhomeetthecriteriafor\ntheAPS,anticoagulanttherapymightbeconsidereddependingon\ntheperceptionofriskforrecurrentthromboticeventsandbleeding.\nNewrecommendationII-2 C\nDevice PFOclosuredevicetherapy\nPFOclosuredeviceshavemoderatebenefittoyoungand\nmiddle-agedpatientswithcryptogenicischaemicstroke.PFO\nclosuredevicescombinedwithantiplatelettherapyisalso\nrecommended.19\nNewrecommendationI A\nContinuouspositiveairwaypressure(CPAP)machine\nCPAPtherapymightbeconsideredforpatientswithischaemic\nstrokeorTIAandsleepapnoeagiventheemergingevidencein\nsupportofimprovedoutcomes.28\nNewrecommendationII-2 B\nBlood\ntransfusionForpatientswithsicklecelldiseaseandpriorischaemicstrokeor\nTIA,long-termbloodtransfusionstoreducehaemoglobinSto\n<30%oftotalhaemoglobincompositionarerecommended.29\nNewrecommendationI B\nSupplements Supplementationwithfolate,vitaminB6andvitaminB1\nInadultswitharecentischaemicstrokeorTIAwhoareknownto\nhavemildtomoderatehyperhomocysteinaemia,supplementation\nwithfolate,vitaminB6andvitaminB12safelyreducesthelevelsof\nhomocysteinebuthasnotbeenshowntopreventstroke.\nNewrecommendationIII B"
    },
    {
        "page_number": 116,
        "text": "11614.5CerebralVenousThrombosis\nCVTisatypeofstrokewherethethrombosisoccursinthevenoussideofthebraincirculation,\nleadingtoocclusionofoneormorecerebralveinsandduralvenoussinus.Theageandgender\ndistributionofCVTisdifferentfromthatofischaemicstroke,CVTbeingmorefrequentinyoung\nadultsandwomen.Theincidenceishigherindevelopingcountries.CVTisassociatedwith\nprothromboticconditionseitherduetotransientcausesorpermanentprimarycauses.Inaround13%\nofadultwithCVT,noriskfactorsareidentified.TheEuropeanStrokeOrganizationguideline\naddressesbothdiagnosticandtherapeutictopicsinCVT.10CVTinpregnancyisoutlinedinthe\nchapterofstrokeinpregnancy.\nRecommendations:\nTable14.4:InvestigationofCerebralVenousThrombosis\nInvestigation RecommendationsLevelof\nEvidenceGrade\nCTV/MRV EitherCTorMRvenographycanbeusedasa\nreliablealternativetoDSAforthediagnosisofCVT\ninpatientswithsuspectedCVTII-3 B\nDigitalSubtractionAngiography\n(DSA)DSAasadiagnosticmodalityisindicatedincasesof\nsuspectedCVTwhenthediagnosisofCVTdoubtful\nwithnon-invasiveimagingalone.30II-1 C\nD-Dimer MeasurementofD-dimerbeforeneuroimagingis\nrecommendedinpatientswithsuspectedCVT,\nexceptinthosewithisolatedheadacheorprolonged\ndurationofsymptoms(highfalsenegativerates)II-2 B\nThrombophiliascreening Thrombophiliascreeningmaybeperformedin\npatientswithhighpre-testprobabilityofhaving\nseverethrombophilia(i.e.apersonaland/orfamily\nhistoryofvenousthrombosis,youngageatCVT,\nCVTwithoutatransientorapermanentriskfactor)\ntopreventrecurrentvenousthromboticevents.\nHowever,routinethrombophiliascreeningisnot\nrecommendedtoreducedeaths,improvefunctional\noutcome,orpreventrecurrentvenousthrombosisin\npatientswithCVT.II-3 B\nOccultmalignancyscreeningRoutinescreeningforoccultmalignancyinpatients\nwithCVTisnotrecommendedtoimproveoutcomesII-3 B\nTable14.5:TreatmentofCentralVenousThrombosis\nTreatment RecommendationsLevelof\nEvidenceGrade\nAcuteanticoagulant\ntreatmentTreatmentofadultpatientswithacuteCVTwithheparinin\ntherapeuticdosageisrecommended,includinginthosewith\nintracerebralhaemorrhageatbaseline.I B\nTypeofheparinTreatmentofpatientswithacuteCVTwithLMWHinsteadof\nUFHisrecommended(unlessfastreversalofthe\nanticoagulanteffectisrequired,orthepatienthas\ncontraindicationstoLMWH).I B\nThrombolysisin\nacuteCVTThrombolysisinacuteCVTpatientswithapre-treatmentlow\nriskofpooroutcomeisnotrecommended.III C\nEndovascular\ntherapyor\nThrombectomyEndovasculartherapyorThrombectomymaybeconsideredin\npatientswithclinicaldeteriorationdespiteanticoagulation,or\nwithsevereneurologicaldeficitsorincoma.30II-2 C"
    },
    {
        "page_number": 117,
        "text": "117Warfarin Usingoralanticoagulants(vitaminKantagonists)foravariable\nperiod(3-12months)afterCVTisrecommendedtoprevent\nrecurrentCVTandothervenousthromboembolicevents.\nPatientswithrecurrentvenousthrombosisorwithan\nassociatedprothromboticconditionwithahighthromboticrisk\nmayneedpermanentanticoagulation.Wesuggestfollowing\nspecificrecommendationsforthepreventionofrecurrent\nvenousthromboemboliceventsinsuchconditions.III C\nDOACs TreatmentofCVTwithDOACsisnotrecommendedespecially\nduringtheacutephase.III C\nTherapeuticLPTherapeuticLPisnotrecommended.However,itmaybe\nconsideredinpatientswithcerebralvenousthrombosisand\nsignsofintracranialhypertension,becauseofapotential\nbeneficialeffectonvisuallossand/orheadache,wheneverits\nsafetyprofileisacceptable.III C\nAcetazolamideAcetazolamideisnotrecommendedinpatientswithacuteCVT\ntopreventdeathsortoimprovethefunctionaloutcomes.\nHowever,inisolatedintracranialhypertensionsecondaryto\nCVT,causingsevereheadachesoristhreateningthevision,\nAcetazolamidemaybeconsideredifitssafetyprofileis\nacceptableIII C\nSteroids SteroidsinpatientswithacuteCVTwithoutanyco-existing\ninflammatorydiseasesarenotrecommendedtoprevent\ndeathsortoimprovethefunctionaloutcomesIII C\nShunt Routineshunting(withoutothersurgicaltreatment)inpatients\nwithacuteCVTandimpendingbrainherniationdueto\nparenchymallesionsisnotrecommendedtopreventdeathII-3 C\nDecompressive\nsurgeryDecompressivesurgeryforpatientswithacuteCVTand\nparenchymallesion(s)withimpendingherniationis\nrecommendedtopreventdeath.II-1 B\nAntiepilepticdrugs\n(AEDs)AntiepilepticdrugsinpatientswithacuteCVTwith\nsupratentoriallesionsandseizuresarerecommendedto\npreventearlyrecurrentseizures.II-3 C\nKeyRecommendations:\n5.Youngonsetstrokerequiresmorecomprehensiveinvestigationtodeterminethestroke\naetiology.\n6.Diagnosisofcryptogenicstrokeandembolicstrokeofunderterminedsource(ESUS)ismade\nafterstandardevaluationtoruleoutpossiblecauseofstroke.\n7.FurtherspecializedinvestigationsneededinthecryptogenicorESUSstrokeforexample\nprolongedHoltermonitoringtolookforatrialfibrillationortolookforevidenceofpatentforamen\novale(PFO).\n8.Cerebralvenousthrombosisisoneofthemajorcauseofvenousinfarctandwouldrequire\ninvestigationstodeterminethecauseofthrombosis.Treatmentmainlydirectedat\nanticoagulationwithadjunctivetherapytopreventassociatedcomplications."
    },
    {
        "page_number": 118,
        "text": "118MANAGEMENTOFSTROKEINPREGNANCY\n15.1BurdenandAetiology\nTheincidenceofpregnancy-associatedstrokeis10.2per100 000deliveries.1Theincidencerateof\nstrokeinpregnancyishigherintheperipartumandpostpartumperiod,especiallyinthefirstsixto\ntwelveweeksafterdelivery.2-5InaJapanesestudy,mostpregnancy-associatedstrokeswere\nhaemorrhagicstrokes(73.5%),lessthanaquarter(24.5%)wereischaemicstrokesandrarely,there\nweremixedstrokes(2%).6\nInapreviousstudy,75.7%ofthepatientswithischaemicstrokewerearterialinfarctsand24.3%\nwerevenousinfarctions.6Maincausesofischaemicstrokeinpregnancywerecongenitalheart\ndiseases,valvularheartdiseases,atrialfibrillation(AF)andinheritablecoagulationabnormalities.1\nMostcommonaetiologiesofcerebralhaemorrhagewereaneurysm(19.8%),arteriovenous\nmalformation(17.1%),pregnancy-inducedhypertension(11.7%)andHELLPsyndrome.1\n15.2Investigations\nMagneticresonanceimaging(MRI)ofthebrain(withoutgadoliniumcontrast)istheradiological\nmodalityofchoiceforinvestigatingstrokesinpregnancy.5MRIofthebrainintheantenatalperiodis\nnotassociatedwithincreasedadverseeventstothefoetus.7-9However,MRIofthebrainshouldbe\nusedcarefully.8MRIofthebrainshouldonlybeusedwhenthetestcananswerthepatient’sclinical\nquestionandprovidesmedicalbenefitstothepregnantpatient.8However,antenatalexposureto\ngadoliniumcontrastwasreportedtoincreasetheriskofstillbirth,neonataldeath,rheumatological,\ninflammatoryandinfiltrativeskinconditionsinonestudy.9\n15.3Management\nBloodpressureshouldbereducedtolessthan160/110mmHg.10Incasesofpreeclampsiaorsevere\nhypertensionwithneurologicalsymptoms,theaimistoachieveanurgentandsustainedreductionof\nbloodpressuretolessthan160/110mmHgtoreducetheriskofmaternalstroke.10Inacute\nhaemorrhagicstrokeinpregnancy,bloodpressurecanbecontrolledwithMethyldopa,Labetaloland\nlongactingNifedipine.10Thegoalistocorrectthebloodpressureto<160/110mmHg,followedby\ntitrationoftheanti-hypertensivemedicationstoreducethebloodpressureconsistentlyto<140/90\nmmHg.10Thecoagulopathiesshouldalsobecorrected.10\nRecommendation:Inischaemicarterialstrokes,Aspirinupto150 mgdailyiswelltoleratedduring\npregnancy.5Pregnantpatientswithawell-definedlowriskconditionsmaybegivenUFHorLMWHin\nthefirsttrimester,followedbyalowdoseofaspirininthesecondandthirdtrimesters.11\n(LevelII,GradeB)\nRecommendation:Inpregnantpatientswithawell-definedlowriskconditions,noantiplateletother\nthanAspirincanbeprescribed.11\n(LevelIII,GradeC)\nRecommendation:Inpregnantwomenwithawell-definedhigh-riskcondition,VitaminK\nantagonistsneedtobeavoidedbetweenthe6thand12thweeksofpregnancyandalsonearthe\nterm.11\nDuringthisperiod,UFHorLMWHcanbeused.11\n(LevelII,GradeB)15"
    },
    {
        "page_number": 119,
        "text": "119Recommendation:Inaddition,thepregnantpatientswithawell-definedhigh-riskconditionon\nDOACsshouldbegivenUFHorLMWHbetweenthe6thand12thweeksofpregnancy.11\n(Newrecommendation,LevelIII,GradeC)\nRecommendation:Atotherweeksofgestation,Warfarincanbegiven.11\n(LevelIII,GradeC)\nRecommendation:Whenthelabourprocessispharmacologicallyinduced,Aspirincanbe\ncontinued.11\n(LevelIII,GradeC)\nRecommendation:UFHandLMWHneedtobestopped24hoursbeforetheinductionoflabour.11\n(LevelIII,GradeC)\nRecommendation:UFHandLMWHshouldberestartedwithin24hoursofdeliveryifthereareno\ncontraindications.11\n(LevelIII,GradeC)\nRecommendation:VitaminKantagonists(withoutaloadingdose)mayberestartedafter24hours\nofdeliveryiftherearenocontraindications.11\n(LevelIII,GradeC)\nPatientswithcerebralvenousthrombosis(CVT)canbeadministeredwitheitherunfractionated\nheparin(UFH)orlowmolecularweightheparin(LMWH)tillatleastsixweekspostpartum.12The\nmanagementofthepatientswithdissectionofthecarotidandvertebralarteriesincludesmonitoring\nonlyorusinglow-doseAspirin.12LMWHcanbeconsideredinsomecasesinwhichdissectionisin\nthehighestthromboticriskperiod(peri-partumtosixweekspost-partum).12\nThereislackofevidenceregardingthesafetyofstatinsinpregnancy.12Statinsshouldbestopped\nduringpreconceptionandthroughoutpregnancy.12Ingeneral,strokemanagementdecisionsare\nbasedonsymptomseverity,maternalmedicalconditions,andwishesofthepatientandherfamily.10\nRehabilitationshouldbestartedearly.10Rehabilitationisbasedonamultidisciplinaryteam\ndiscussionsanddecisions.10"
    },
    {
        "page_number": 120,
        "text": "120RecommendationsSummary:\nTable15.1:ManagementofStrokeinPregnancy\nManagement RecommendationsLevelof\nEvidenceGrade\nDuring\npregnancyInAIS,Aspirinupto150 mgdailyiswelltoleratedduring\npregnancy.\nPregnantpatientswithawell-definedlowriskconditionsmaybe\ngivenUFHorLMWHinthefirsttrimester,followedbyalowdose\naspirininthesecondandthirdtrimesters.III C\nInpregnantpatientswithawell-definedlowriskconditions,no\nantiplateletotherthanAspirincanbeprescribed.III C\nInpregnantwomenwithawell-definedhigh-riskcondition,Vitamin\nKantagonistsneedtobeavoidedbetweenthe6thand12thweeks\nofpregnancyandalsoneartoterm.\nDuringthisperiod,UFHorLMWHcanbeused.II B\nInaddition,thepregnantpatientswithawell-definedhigh-risk\nconditionondirectoralanticoagulants(DOACs)shouldbegiven\nUFHorLMWHbetweenthe6thand12thweeksofpregnancy.\nNewrecommendationIII C\nAtotherweeksofgestation,Warfarincanbegiven. III C\nLabour\ninductionWhenthelabourprocessispharmacologicallyinduced,Aspirin\ncanbecontinued.III C\nUFHandLMWHneedtobestopped24hoursbeforetheinduction\noflabour.III C\nUFHandLMWHshouldberestartedwithin24hoursofdeliveryif\ntherearenocontraindications.III C\nVitaminKantagonists(withoutaloadingdose)mayberestarted\nafter24hoursofdeliveryiftherearenocontraindications.III C\nKeyRecommendations:\n1.MRIofthebrain(withoutgadoliniumcontrast)istheradiologicalmodalityofchoicefor\ninvestigatingstrokesinpregnancy.\n2.Aspirinistheonlychoiceofantiplateletforpregnantpatientswithawell-definedlowrisk\ncondition."
    },
    {
        "page_number": 121,
        "text": "121STROKETHERAPIESWITHLIMITEDEVIDENCE\nAvarietyofmedicinesandtreatmentmodalitieshavebeenusedforstroke.Althoughyettobe\nproveneffective,theymaybeconsideredfortreatmentinacutestroke(Table16.1).\nTable16.1:StrokeTherapyModalities\nTherapy Description\nNeuroAid Themedicinedidnotdemonstrateanystatisticallysignificantbenefitafter3\nmonthsalthoughsomesmallstudiesshowedthatitcouldbeeffectivein\nimprovingfunctionalindependenceandmotorrecovery,andissafefor\npatientswithaprimarilynon-acutestablestroke.1-3\nCiticoline Citicolineiswidelyusedafterstrokebutisnotprovenstatisticallytobe\nbeneficialinthetreatmentofacutestroke.4,5\nCerebrolysin Cerebrolysinisalsonotproveninthemanagementofacutestroke.6-8\nEdaravone Meta-analysisofEdavaroneshowedsomebenefitsinimprovingneurological\nimpairmentinacuteischaemicstrokeandintracerebralhaemorrhagebutwas\nnotproventoreducedeathandlong-termdisabilityinbothtypesofstroke.9\nGingko Therewaslimitedevidenceontosupporttheuseofgingkobilobaintermsof\nimprovingqualityoflifeandotherstrokeevents.Assuch,morestudiesare\nneededbeforeitcanberecommendedforroutineuseinimproving\nneurologicalandcognitivefunctioninpatientswithacuteischaemicstroke.10\nVitaminB BasedontheVitatopstrial,VitaminBsupplementsdidnothelpinsecondary\nstrokepreventionbutshowedsomebenefitifthepatienthadconcomitant\nhyperhomocysteinaemia.11,12\nFolicAcid Folicacidsupplementationdidnotdemonstrateamajoreffectinpreventing\nstroke.However,potentialmildbenefitsinprimarystrokeprevention,\nespeciallywhenfolateiscombinedwithBvitaminsandinmalepatients,\nrequiresfurtherinvestigation.13\nSelective\nSerotonin\nReuptake\nInhibitorsFluoxetine20mggivendailyfor6monthsafteracutestrokedoesnotseemto\nimprovethefunctionaloutcomes.Astudyshowedthateventhoughthe\ntreatmentreducedtheoccurrenceofdepression,itincreasedthefrequencyof\nbonefractures.Therefore,recentevidencedoesnotsupporttheroutineuse\noffluoxetineeitherforthepreventionofpost-strokedepressionorto\npromoterecoveryoffunction.14\nAcupuncture Acupuncture,frommultipletrials,didnotshowanysignificantbenefitand\nefficacyintermsoffunctionalrecoveryafterstroke.15-17Arecent\nmeta-analysisconcludedthattheapparentreductionindependencyand\nimprovementinneurologicalrecoveryassociatedwiththeuseofacupuncture\ninacutestrokeareconfoundedbytheuseofopencontrols.Howeverthe\nadverseeventsassociatedwithacupunctureweregenerallyreportedtobe\nminorandusuallydidnotresultinstoppingtreatment.18\nTranscranial\nMagnetic\nStimulation(TMS)TMShasshownsomepromisingresultsinimprovingthemotorrecoveryafter\nstroke.However,itmayneedmoreevidencebeforeitcanbeusedasadaily\nrehabilitationtoolforrstroke.19-22\nTocovid\n(Tocotrienol)Tocovid(tocotrienol)hasonlybeenproveninanimalstudiestobeeffectiveas\nneuroprotectivetreatmentinstroke,butnotinhumanstudies.23-25However,\nonestudyshowedthattocotrienolmayattenuatetheprogressionofwhite\nmatterlesion26.\nSelenium Seleniumlevelshavebeenshowntobeonthelowersideduringanacute\nstroke.However,thereisstillnoevidenceofbenefitfromSelenium16"
    },
    {
        "page_number": 122,
        "text": "122supplementationinacutestrokealthoughafewanimalstudieshaveshown\nsomebenefits.27-29\nPiracetam Piracetamplayedalimitedroleintherehabilitationoftheoveralllanguage\nimpairmentandonlyshowedbenefitasregardstothewrittenlanguageability\nbasedonameta-analysis.Itseffectontheoveralllinguisticlevelandwritten\nlanguagetendstoemergewithinashortperiodanddeclinesthereafter.\nPiracetamalsodidnotsignificantlyimproveneurologicorfunctionaloutcome\ninacutestrokepatients.30,31\nKeyRecommendations:\n1.Thereareavarietyofstrokemedicationsandtreatmentmodalities,buttheevidenceisvery\nlimited."
    },
    {
        "page_number": 123,
        "text": "123QUALITYASSURANCE\nStrokeCareQualityMeasurestoMonitorforHospitalsprovidingThrombolysisand/orThrombectomy\nServicesinMalaysia1-11\nStrokeCareQualityMinimal\nmeasures\n1PercentageofIschemicStroke(IS)patientsreceivingIVThrombolytictherapy\n(IVrt-PA),<35minutesofCTBraininitiation(CTBraininitiationtoneedletime)>65%\n2PercentageofallsuspectedstrokepatientswhounderwentCTorMRIBrain\nimagingwithin24hoursofpresentingthemselvestotheemergency\ndepartment.>90%\n3Percentageofnewlyconfirmedstrokepatientswhounderwentbedside\nscreeningfordysphagia>90%\n4PercentageofIschemicStrokepatientsdischargedwithantiplatelets(ifthere\nwerenocontraindications)>80%\n5PercentageofAF-relatedstrokepatientsgivenanticoagulantsbeforedischarge\norplannedforeventualanticoagulation(iftherewerenocontraindications)>80%\n6.Percentageofadmittedpost-strokepatientsweredischargedwithproper\ndischargeplan:\n-Cardiovascularriskfactorsaddressed\n-Rehabilitationteamreferral\n-Strokeeducation\n-Smokingcessationeducation>90%17"
    },
    {
        "page_number": 124,
        "text": "124AppendixA.MeSHtermsorfreetexttermsusedforliteraturesearch\n(Reference:Rationale,ObjectivesAndProcessOfGuidelineDevelopment)APPENDICES\nChapter RelatedTopics SearchTermsUsed\n- StrokeStroke\nBraininfarct*\nBrainischemia\nBrainisch?emi*\nCerebralinfarct*\nCerebrovascularaccident*\nCVA\nCerebrovascularinfarct*\nAcuteischemi*stroke\nCarotidarterythrombosis\nAnteriorcerebralarteryinfarction\nMiddlecerebralarteryinfarction\nPosteriorcerebralarteryinfarction\nAnteriorcirculationocclusion\n- AND\nOREpidemiology,DefinitionandClassificationofStrokeEpidemiology\nPrevalence\nDefinition\nDescription\nClassification\nCategorization\nORCausesandPathophysiologyCauses\nAetiology\nPathophysiology\nMechanism\nORDiagnosisandInitialAssessmentDiagnosis\nDifferentialdiagnosis\nSign\nSymptoms\nClinicalfeatures\nClinicalpresentation\ninitialassessment\nORPrognosisPrognosis\nSurvival\nMortality\nDisability\nRecurrent\nProgress\nORPreventionofStrokePrevention\nPrimaryprevention\nSecondaryprevention\nPredisposingfactor\nRiskfactor\nModifiableriskfactor\nNonmodifiableriskfactor\nRiskstratification\nRiskestimate\nManagementofriskfactor"
    },
    {
        "page_number": 125,
        "text": "125Revascularisation\nCarotidendarterectomy\nCEA\nCarotidangioplasty\nStenting\nIntracranialangioplasty\nORInvestigationsInvestigations\nImaging\nAssessment\nOREmergencyMedicineServicesEmergencymedicineservices\nEMS\nPre-hospitalmanagement\nPrearrival\nEmergencydepartment\nInitialmanagement/evaluation/assessment\nORAcuteManagementAcutemanagement\nGeneralmanagement\nORReperfusionofIschaemicBrainReperfusion\nIntravenousthrombolysis\nIVT\nAlteplase\nTenecteplase\nOREndovascularThrombectomyEndovascularthrombectomy\nThrombectomy\nPercutaneousthrombectomy\nEndovascularprocedures\nMechanicalthrombectomy\nNeuro-thrombectomy\nEmbolectomy\nCerebralrevascularization\nEndovascularembolectomy\nIntraarterialembolectomy\nIntra-arterialthrombectomy\nBalloonangioplasty\nStent\nMechanicalthrombolysis\nEndovasculartherapy\nEndovasculartreatment\nORStrokeUnitStrokeunit\nStroketeam\nORStrokeintheOlderPersonOlderperson\nElderly\nAgeabove60\nORStrokeandCardioembolismCardioembolism\nAtrialfibrillation\nORStrokeinSpecialCircumstancesYoungadult\nCryptogenic\nEmbolicstrokeofundeterminedsource\nESUS\nPatentforamenovale\nPFO\nCerebralvenousthrombosis\nORManagementofStrokeinPregnancyPregnancy\nDuringpregnancy\nLabourinduction\nORStrokeTherapieswithLimitedEvidenceStroketherapy\nLimitedevidence\nTreatmentmodalities"
    },
    {
        "page_number": 126,
        "text": "126AppendixB.PrehospitalStrokeScreeningTool\n(ReferenceChapter:Chapter7)\nAcuteStrokePre-HospitalDiagnosticScreeningTools\nAssessmentTools Items/Scoring\nFaceArmSpeechTest(FAST)1.Facialpalsy,\n2.Armweakness,\n3.Speechdisturbance.\nAbnormalitydemonstratedononeormoreitemsisindicativeof\nsuspectedstroke\nBalance,Eye,FaceArmSpeech\nTest(BEFAST)1.Balance\n2.Eyesighchanges\n3.Facialweakness\n4.ArmWeakness\n5.SpeechDifficulties\nAbnormalitydemonstratedononeormoreitemsisindicativeof\nsuspectedstroke\nCincinnatiPrehospitalStroke\nScale1.Presence/absenceoffacialpals\n2.Unilateralarmweakness\n3.Speechimpairment.\nAbnormalitydemonstratedononeormoreitemsisindicativeof\nsuspectedstroke\nLosAngelesPrehospitalStroke\nScreen(LAPSS)1.Age>45\n2.Historyofseizuresabsent\n3.Symptomduration<24hr\n4.Atbaseline,patientisnotwheelchairboundorbedridden\n5.Bloodsugarbetween60and400mg/dL\n6.Obviousasymmetry(rightversusleft)\n7.Facialsmile/grimace\n8.Grip\n9.Armstrength\nIf1–5areyeswithasymmetryonexamthenLAPScriteriaare\nmetindicatingsuspectedstroke\n*note:ThereareseveralotherPre-HospitalDiagnosticScreeningToolsavailableforuseas\nscreeningtools."
    },
    {
        "page_number": 127,
        "text": "127Pre-HospitalStrokeSeverityScale\nAssessmentTools Items/Scoring\nFieldAssessment\nStrokeTriagefor\nEmergency\nDestination\n(FAST-ED)6-items\n1.Facialpalsy(0-1)\n2.Armweakness(0-2)\n3.Speechchanges(0-2)\n4.Eyedeviation(0-2)\n5.Denial/neglect(0-2)\n6.Time(documentationfordecisionmaking)notscored\nTotalpossiblescore:9\nLargevesselocclusion(LVO)ispossibleifscore4ormore\nTheLosAngeles\nMotorScale(LAMS)3items\n1.Facialdroop(absent=0,present=1)\n2.Armdrift(absent=0,driftsdown=1,fallsrapidly=2)\n3.Gripstrength(normal=0,weak=1,nogrip=2)\nTotalpossiblescore5\nLVOispossibleifscore4ormore\nCincinnatiPrehospital\nStrokeSeverityScale3items\n1.Conjugategazedeviation(≥1onNIHSSitemforgaze)(0-2)\n2.Incorrectlyanswerstoatleast1of2LOCquestions(ageorcurrent\nmonth)anddoesnotfollowatleast1of2commands(closeeyes,\nopenandclosehand).(0-1)\n3.Cannotholdarm(left,rightorboth)upfor10seconds.(0-1)\nTotalpossiblescore4\nLVOispossibleifscore1ormore\nVision,Aphasia,and\nNeglect(VAN)Patientsareaskedtoraisebotharmsupandholdthemupfor10s.Ifthe\npatientdemonstratesanylevelofdrift,weaknessorparalysis,the\nassessmentcontinues.Otherwise,patientisVANnegativeandscreen\nends.\nItems\n1.Visualdisturbances:fieldcut,doublevision,new-onsetblindness\n(present/absent)\n2.Aphasia:Expressive,receptive,mixed(present/absent)\n3.Neglect:Forcedgaze,unabletofeelbothsidesatsametimeor\ndoesnotrecognizearm,ignoringoneside(present/absent)\nScoring:None\nIfweaknesspresent+≥1positivefinding=VANpositive(LVOispossible)\n*note:ThereareseveralotherPre-HospitalStrokeSeverityScalesavailableforuseasscreening\ntools.TheabovelistarejustfewexamplesofPre-HospitalStrokeSeverityScales."
    },
    {
        "page_number": 128,
        "text": "128AppendixC.Operationaldefinition-TermsandDescriptions\n(ReferenceChapter:Chapter7)\nTerms Descriptions\nBypass Ambulancesaredirectedtootherfacilitiesbybypassingthe\noriginaldestination.Itistoensurethestrokepatientissenttothe\nneareststrokecentreratherthanafacilitythatisnotcapableof\nthrombolysingthestrokepatient.\nCalltaker AtrainedpersoninMECCwhoreceivescallsfromthepublic\nthrough999andmanagesthecall.\nDispatchpriorityLevelofpriorityassignedtoeachcaseaccordingtotheclinical\nurgency.Thereare4levelsofpriority:Priority1,priority2,priority\n3andpriority4.Priority1isthehighestprioritylevelinthedispatch\nsystem.\nDispatching\nsystemAcomputerizedsysteminMECCmannedbythecalltakerto\nmanageallincoming999callsfromthepublicanddispatchesthe\nappropriateresponseteamtothescene.\nPHCresponderAmedicallytrainedperson(usuallyanAssistantMedicalOfficer/\nStaffNurse)whorespondstopre-hospitalcalls.\nPre-arrivalalertProvidingnotificationofanincomingcasepriortothepatient’s\narrival."
    },
    {
        "page_number": 129,
        "text": "129AppendixD.TypesofSwallowingTest\n(ReferenceChapter:Chapter8)"
    },
    {
        "page_number": 130,
        "text": "130Chapter1:Epidemiology,DefinitionandClassificationofStroke\n1.FeiginVL,KrishnamurthiRV,ParmarP,NorrvingB,MensahGA,BennettDA,etal.Updateontheglobal\nburdenofischemicandhaemorrhagicstrokein1990-2013:TheGBD2013Study.Neuroepidemiology\n2015;45(3):161–76.\n2.AzizZA,LeeYY,NgahBA,SidekNN,LooiI,HanipMR,etal.AcuteStrokeRegistryMalaysia,2010-2014:\nResultsfromtheNationalNeurologyRegistry.JStrokeCerebrovascDis2015;24(12):2701-9.\n3.HwongWY,AzizZA,SidekNN,BotsML,SelvarajahS,KappelleLJ,SivasampuS,VaartjesI.\nPrescriptionofsecondarypreventivedrugsafterischemicstroke:resultsfromtheMalaysianNational\nStrokeRegistry.BMCNeurol2017;17(1):203.\n4.VenketasubramanianN,YoonBW,PandianJ,NavarroJC.StrokeepidemiologyinSouth,Eastand\nSouth-EastAsia:Areview.JStroke2017;19(3):286-94.\n5.AzizZA,LeeYY,SidekNN,NgahBA,LooiI,HanipMR,BasriHB.Genderdisparitiesandthrombolysis\nuseamongpatientwithfirst-everischemicstrokeinMalaysia.NeurolRes2016;38(5):406-13.\n6.SaccoRL,KasnerSE,BroderickJP,CaplanLR,ConnorsJJ,CulebrasA,ElkindMS,GeorgeMG,\nHamdanAD,HigashidaRT,HohBL.Anupdateddefinitionofstrokeforthe21stcentury:astatementfor\nhealthcareprofessionalsfromtheAmericanHeartAssociation/AmericanStrokeAssociation.Stroke.2013\nJul;44(7):2064-89.\n7.AllenLM,HassoAN,HandwerkerJ,FaridH.Sequence-specificMRimagingfindingsthatareusefulin\ndatingischemicstroke.Radiographics.2012Sep-Oct;32(5):1285-97;discussion1297-9.\n8.EastonJD,SaverJL,AlbersGW,AlbertsMJ,ChaturvediS,FeldmannE,HatsukamiTS,HigashidaRT,\nJohnstonSC,KidwellCS,LutsepHL.Definitionandevaluationoftransientischemicattack:ascientific\nstatementforhealthcareprofessionalsfromtheAmericanHeartAssociation/AmericanStrokeAssociation\nStrokeCouncil;CouncilonCardiovascularSurgeryandAnesthesia;CouncilonCardiovascularRadiology\nandIntervention;CouncilonCardiovascularNursing;andtheInterdisciplinaryCouncilonPeripheral\nVascularDisease:theAmericanAcademyofNeurologyaffirmsthevalueofthisstatementasan\neducationaltoolforneurologists.Stroke.2009Jun1;40(6):2276-93.\n9.BamfordJ,SandercockP,DennisM,BurnJ,WarlowC.Classification,andnaturalhistoryofclinically\nidentifiablesubtypesofcerebralinfarction.Lancet.1991;337:1521–1526\n10.AdamsHPJr,BendixenBH,KappelleLJ,etal.Classificationofsubtypeofacuteischemicstroke.\nDefinitionsforuseinamulticentreclinicaltrial.TOAST.TrialofOrg10172inAcuteStroke\nTreatment.Stroke.1993;24(1):35-41.doi:10.1161/01.str.24.1.35\n11.AyH,BennerT,ArsavaEM,etal.Acomputerizedalgorithmforetiologicclassificationofischemicstroke:\ntheCausativeClassificationofStrokeSystem.Stroke.2007;38(11):2979-2984.\ndoi:10.1161/STROKEAHA.107.490896\n12.AmarencoP,BogousslavskyJ,CaplanLR,DonnanGA,WolfME,HennericiMG.TheASCOD\nphenotypingofischemicstroke(UpdatedASCOPhenotyping).Cerebrovasculardiseases.2013;36(1):\n1-5.\n13.GaoS,WangD.Chineseischemicstrokesubclassification.Frontiersinneurology.2011Feb15;2:6.REFERENCES"
    },
    {
        "page_number": 131,
        "text": "131Chapter2:CausesandPathophysiology\n1.AdamsHP,DavisPH,LeiraEC,ChangKC,BendixenBH,ClarkeWR,etal.BaselineNIHStrokeScale\nscorestronglypredictsoutcomeafterstroke:AreportoftheTrialofOrg10172inAcuteStrokeTreatment\n(TOAST).Neurology1999;53(1):126-31.\n2.NenciGG.Unifyingconceptofarterialvasculardisease.EurHeartJ1999;1(SupplementA):A27-A30.\n3.DeSilvaDA,WoonFP,LeeMP,ChenCPLH,ChangHM,WongMC.SouthAsianpatientswithischemic\nstroke:intracraniallargearteriesarethepredominantsiteofdisease.Stroke2007;38(9):2592-4.\n4.FisherCM.Lacunes:small,deepcerebralinfarcts.Neurology1965;15(8):774–84.\n5.Cardiogenicbrainembolism:ThesecondreportoftheCerebralEmbolismTaskForce.ArchNeurol1989;\n46(7):727-43.\n6.HankeyGJ.Potentialnewriskfactorsforischemicstroke:whatistheirpotential?Stroke2006;37(8):\n2181-8.\n7.GrysiewiczRA,ThomasK,PandeyDK.Epidemiologyofischemicandhemorrhagicstroke:incidence,\nprevalence,mortality,andriskfactors.NeurolClin2008;26(4):871-95.\n8.O'DonnellMJ,ChinSL,RangarajanS,XavierD,LiuL,ZhangH,etal.Globalandregionaleffectsof\npotentiallymodifiableriskfactorsassociatedwithacutestrokein32countries(INTERSTROKE):a\ncase-controlstudy.Lancet2016;388(10046):761-75.\n9.CaplanLR.Basicpathology,anatomy,andpathophysiologyofstroke.In:Caplan’sstroke:aclinical\napproach.Boston:Butterworth-Heinemann,2000:19.\n10.SannaT,DiennerHC,PassmanRS,DiLazaroV,BernsteinRA,MorelloCA,etal.Cryptogenicstrokeand\nunderlyingatrialfibrillation.NEnglJMed2014;370(26):2478-86.\n11.HartRG,DienerHC,CouttsSB,EastonJD,GrangerCB,O’DonnellMJ,etal.Embolicstrokesof\nundeterminedsource:thecaseforanewclinicalconstruct.LancetNeurol2014;13(4):429-38.\nChapter3:DiagnosisandInitialAssessment\n1.HankeyGJ.Stroke.Lancet2017;389(10069):641–54.\n2.HankeyGJ,BlackerDJ.Isitastroke?BMJ2015;350:h56.\n3.EdlowJA,SelimMH.Atypicalpresentationsofacutecerebrovascularsyndromes.LancetNeurol2011;\n10(6):550–60.\n4.FernandesPM,WhiteleyWN,HartSR,Al-ShahiSalmanR.(2013).Strokes:mimicsandchameleons.\nPractNeurol2013;13(1):21–8.\n5.LibmanRB,WirkowskiE,AlvirJ,RaoTH.Conditionsthatmimicstrokeintheemergencydepartment.\nImplicationsforacutestroketrials.ArchNeurol1995;52(11):1119-22.\n6.AyisSA,CokerB,RuddAG,DennisMS,WolfeCDA.Predictingindependentsurvivalafterstroke:a\nEuropeanstudyforthedevelopmentandvalidationofstandardisedstrokescalesandpredictionmodelsof\noutcome.JNeurolNeurosurgPsychiatry2012;84(3):288–96.\n7.GibsonLM,WhiteleyW.Thedifferentialdiagnosisofsuspectedstroke:asystematicreview.JRColl\nPhysiciansEdinb2013;43(2):114-8.\nChapter4:Prognosis\n1.CaplanLR.Intracerebralhaemorrhage.Lancet1992;339(8794):656-8."
    },
    {
        "page_number": 132,
        "text": "1322.LabovitzDL,SaccoRL.Intracerebralhaemorrhage:update.CurrOpinNeurol2001;14(1):103-8.\n3.QureshiAI,TuhrimS,BroderickJP,BatjerHH,HondoH,HanleyDF.Spontaneuousintracerebral\nhaemorrhage.NEngJMed2001;344(19):1450-60.\n4.KiyoharaY,KuboM,KatoI,TanizakiY,TanakaK,OkuboK,etal.Ten-yearprognosisofstrokeandrisk\nfactorsfordeathinaJapanesecommunity:TheHisayamastudy.Stroke2003;34(10):2343-7.\n5.PaolucciS,AntonucciG,GrassoMG,BragoniM,CoiroP,DeAngelisD,etal.Functionaloutcomeof\nischaemicandhaemorrhagicstrokepatientsafterinpatientrehabilitation:amatchedcomparison.Stroke\n2003;34(12):2851-65.\n6.WongKS.Riskfactorsforearlydeathinacuteischaemicstrokeandintracererbalhemorrhage:A\nprospectivehospitalbasedstudyinAsia.AsianAcuteStrokeAdvisoryPanel.Stroke1999;30(11):\n2326-30.\n7.Kolominisky-RabasPL,WeberM,GefellerO,NeundoerferB,HeuschmannPU.Epidemiologyof\nischaemicstrokesubtypesaccordingtoTOASTcriteria;incidence,recurrenceandlong-termsurvivalin\nischaemicstrokesubtypes,apopulation-basedstudy.Stroke2001;32(12):2735-40.\n8.Immonen-RaihaP,MahonenM,TuomilehtoJ,SalomaaV,KaarsaloE,NarvaEV,etal.Trendsincase\nfatalityofstrokeinFinlandduring1983-92.Stroke1997;28(12):2493-9.\n9.Peltonen,M,Stegmayr,B,Asplund,K.Timetrendsinlong-termafterstroke:TheNorthernSweden\nMultinationalMonitoringofTrendsandDeterminantsinCardiovasculardisease(MONICA)study,1985-94.\nStroke1998;29(7):1358-65.\n10.StrokeUnitTrialists’Collaboration.Acollaborativesystemicreviewoftherandomizedtrialsoforganized\ninpatient(strokeunit)careafterfirststroke.BMJ1997;314(7088):1151-59.\n11.IndredavikB,BakkeF,SolbergR,RoksethR,HaaheimLL,HolmeI.Benefitofastrokeunit:arandomised\ncontrolledtrial.Stroke1991;22(8):1026-31.\n12.LanghorneP,WilliamsBO,GilchristW,HowieK.Dostrokeunitssavelives?Lancet1993;342(8868):\n395-8.\n13.JogrensenHS,NakayamaH,RaaschouHO,LarsenK,HubbeP,OlsenTS.Theeffectofastrokeunit:\nreductionsinmortality,dischargeratetonursinghome,lengthofhospitalstay,andcost.A\ncommunity-basedstudy.Stroke1995;26(7):1178-82.\n14.IndredavikB,SlordahlSA,BakkeF,RoksethR,HaheimLL.Strokeunittreatment.Long-termeffects.\nStroke1997;28(10):1861-6.\n15.IndredavikB,BakkeF,SlordahlSA,RoksethR,HaheimLL.Strokeunittreatment.10-yearfollow-up.\nStroke1999;30(8):1524-7.\n16.DennisM,BurnJP,SandercockPAG,BamfordJM,WadeDT,WarlowCP.Long-termsurvivalafter\nfirst-everstroke:theOxfordshireCommunityStrokeProject.Stroke1993;24(6);796-800.\n17.HankeyGJ,JamrozikK,BroadhurstRJ,FroresS,BurvillPW,AndersonCS,etal.Five-yearsurvivalafter\nfirst-everstrokeandrelatedprognosticfactorsinthePerthCommunitystrokeStudy.Stroke2000;31(9):\n2080-6.\n18.TerentA.Cerebrovascularmortality10yearsafterstroke:apopulation-basedstudy.Stroke2004;35(7):\ne343-5.\n19.Luengo-FernandezR,PaulNLM,GrayAM,PendleburyST,BullLM,WelchSJV.Populationbasedstudy\nofdisabilityandinstitutionalizationaftertransientischemicattackandstroke:10-yearresultsoftheOxford\nVascularStudy.Stroke2013;44(10):2854–61."
    },
    {
        "page_number": 133,
        "text": "13320.AyisSA,CokerB,RuddAG,DennisMS,WolfeCDA.Predictingindependentsurvivalafterstroke:a\nEuropeanstudyforthedevelopmentandvalidationofstandardisedstrokescalesandpredictionmodelsof\noutcome.JNeurolNeurosurgPsychiatry2012;84(3):288–96.\n21.BasriH,AliRA.Predictorsofin-hospitalmortalityafteranacuteischaemicstroke.NeurolJSoutheast\nAsia2003;8:5-8.\n22.HartCL,HoleDJ,SmithGD.Riskfactorsand20yearsstrokemortalityinmenandwomeninthe\nRenfrew/PaisleystudyinScotland.Stroke1999;30(10):1999-2007.\n23.HankeyGJ,JamrozikK,BroadhurstRJ,ForbesS,BurvillPW,AndersonCS,Stewart-WynneEG.\nLong-termriskofrecurrentstrokeinthePerthCommunityStrokeStudy.Stroke1998;29(12):2491-2500.\n24.BurnJ,DennisM,BambordJ,SandercockP,WaseD,WarlowC.Long-termriskofrecurrentstrokeafter\nafirst-everstroke.TheOxfordshireCommunityStrokeProject.Stroke1994;25(2):333-7.\n25.MohanKM,WolfeCDA,RuddAG,HeuschmannPU,Kolominsky-RabasPL,Grieve,AP.Riskand\ncumulativeriskofstrokerecurrence:asystematicreviewandmeta-analyses.Stroke2011;42(5):\n1489-94.\n26.HardieK,HankeyGJ,JamrozikK,BroadhurstRJ,AndersonC.Ten-yearriskoffirstrecurrentstrokeand\ndisabilityafterfirst-everstrokeinthePerthCommunityStrokeStudy.Stroke2004;35(3):731-5.\n27.HankeyGJ.Stroke.Lancet2017;389(10069):641–54.\n28.KwakkelG,KollenB,TwiskJ.Impactoftimeonimprovementofoutcomeafterstroke.Stroke2006;37(9):\n2348-53.\n29.DimyanMA,CohenLG.Neuroplasticityinthecontextofmotorrehabilitationafterstroke.NatRevNeurol\n2011;7(2):76-85.\nChapter5:PreventionofStroke\n1.FeiginVL,NorrvingB,MensahGA.Globalburdenofstroke.CircRes2017;120:439-448.\n2.AzizZA,LeeYL,NgahBA,SidekNN,LooiI,HanipMR,HamidonBB.AcuteStrokeRegistryMalaysia,\n2010-2014:ResultsfromtheNationalNeurologyRegistry.JStrokeCerebrovascDis2015;24:2701-2709.\n3.AzizZA.AnnualReportofTheMalaysianStrokeRegistry2009-2016.Availablefrom:\nhttps://www.neuro.org.my/wp-content/uploads/2019/03/Stroke-registry-report-2009-2016.pdf\n4.O’DonnellMJ,ChinS,RangarajanS,etal.Globalandregionaleffectsofpotentiallymodifiableriskfactors\nassociatedwithacutestrokein32countries(INTERSTROKE):acase-controlstudy.Lancet2016:388:\n761-775.\n5.FeiginVL,RothGA,NaghaviN,ParmarP,KrishnamurthiR,ChughS,etal.Globalburdenofstrokeand\nriskfactorsin188countries,during1990–2013:asystematicanalysisfortheGlobalBurdenofDisease\nStudy2013.LancetNeurol2016;15:913-924.\n6.NationalHealthMorbiditySurvey2011ReportVolumeII(Non-CommunicableDisease).Availablefrom:\nhttp://iku.moh.gov.my/images/IKU/Document/REPORT/NHMS2011-VolumeII.pdf\n7.NationalHealthMorbiditySurvey2015ReportVolumeII)(NoncommunicableDiseases).Availablefrom:\nhttp://iku.moh.gov.my/images/IKU/Document/REPORT/nhmsreport2015vol2.pdf\n8.BrownRD,WhisnantJP,SicksJD,etal.Strokeincidence,prevalence,andsurvival:seculartrendsin\nRochester,Minnesota,through1989.Stroke1996;27:373-380.\n9.WolfPA,D’AgostinoRB,O’NealMA,etal.Seculartrendsinstrokeincidenceandmortality:the\nFraminghamStudy.Stroke1992;23:1551-1555."
    },
    {
        "page_number": 134,
        "text": "13410.SaccoRL,Boden-AlbalaB,GanR,etal.Strokeincidenceamongwhite,blackandHispanicresidentsof\nanurbancommunity:thenorthernManhattanStrokeStudy.AmJEpidemiol1998;147:259-268.\n11.KittnerSJ,SternBJ,FeeserBR,etal.Pregnancyandtheriskofstroke.NEnglJMed1996;335:768-774.\n12.QureshiAI,GilesWH,CroftJB,etal.Numberofpregnanciesandriskforstrokeandstrokesubtypes.\nArchNeurol1997;54:203-206.\n13.MoscaL,MansonJE,SutherlandSE,etal.Cardiovasculardiseaseinwomen:astatementforhealthcare\nprofessionalsfromtheAmericanHeartAssociationWritingGroup.Circulation1997;96:2468-2482.\n14.WelinL,SvardsuddK,WilhelmsenL,etal.Analysisofriskfactorsforstrokeinacohortofmenbornin\n1913.NEnglJMed1987;317:521-526.\n15.KielyDK,WolfPA,CupplesLA,etal.Familialaggregationofstroke:theFraminghamStudy.Stroke1993;\n24:1366-1371.\n16.WolfPA,D'AgostinoRB,BelangerAJ,KannelWB.Probabilityofstroke:Ariskprofilefromthe\nFraminghamstudy.Stroke1991;22:312–318.\n17.Hippisley-CoxJ,CouplandC,VinogradovaY.PredictingcardiovascularriskinEnglandandWales:\nprospectivederivationandvalidationofQRISK2.BMJ2008;336:1475–1482.\n18.FlueckigerP,LongstrethW,HerringtonD,YeboahJ.RevisedFraminghamStrokeRiskScore,\nnon-traditionalriskmarkers,andincidentstrokeinamultiethniccohort.Stroke2018;49:363–369.\n19.Primary&SecondaryPreventionofCardiovascularDisease2017.NationalHeartAssociationofMalaysia.\nAvailablefrom:https://www.malaysianheart.org/files/597736485dd17.pdf\n20.ParmarP,KrishnamurthiR,IkramMA,HofmanA,MirzaSS,VarakinY,etal.TheStroke\nRiskometerTMApp:validationofadatacollectiontoolandstrokeriskpredictor.IntJStroke2015;\n10:231-244.\n21.WanAsyrafWZ,NorlinahMI.ValidationstudyofMalayversionofStrokeRiskometeramongMalaysian\nPopulation(unpublisheddata).\n22.TeeMK,WanAsyrafWZ,ShahSA,RizalAM,FeiginVL,NorlinahMI.EfficacyandfeasibilityoftheStroke\nRiskometer™Proappinimprovinglifestylefactorsandreducingstrokeriskindiabeticpatients.(Masters\ninInternalMedicineDissertation2019,UKM–unpublisheddata)\n23.RadhiyahH,MohdFairuzA,AbdulAzizAF,MdMonotoEM,SinghA,NorlinahMI,WanAsyrafWZ.\nInfluenceofStrokeRiskometerApplication(SRA©)onlifestylechanges:Apilotrandomisedcontrolled\ntrialamongMalaysiancaregivers.(MastersinFamilyMedicineDissertation2019,UKM-unpublished\ndata)\n24.ChiuveSE,RexrodeKM,SpiegelmanD,LogroscinoG,MansonJE,RimmEB.Primarypreventionof\nstrokebyhealthylifestyle.Circulation2008:118:947-954\n25.LarssonSC,AkessonA,WolkA.Primarypreventionofstrokebyahealthylifestyleinahigh-riskgroup.\nNeurology2015;84:2224-2228.\n26.TheSeventhReportoftheJointNationalCommitteeonPrevention,Detection,EvaluationandTreatment\nofHighBloodPressure:TheJNC7Report.JAMA2003;289(19):2560-2571.\n27.Whelton PK, Carey RM, Aronow WS, et al.\nACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNAGuidelineforthePrevention,Detection,\nEvaluation,andManagementofHighBloodPressureinAdults:AReportoftheAmericanCollegeof\nCardiology/AmericanHeartAssociationTaskForceonClinicalPracticeGuidelines.Hypertension2018;\n71:e13-e115"
    },
    {
        "page_number": 135,
        "text": "13528.TheACCORDstudygroup.Effectsofintensiveblood-pressurecontrolintype2diabetesmellitus.NEngJ\nMedicine2010;362:1575-1585\n29.TheSPRINTResearchGroup.Arandomizedtrialofintensiveversusstandardblood-pressurecontrol.N\nEngJMedicine2015;373:2103-2116\n30.BrownRD,WhisnantJP,SicksJD,etal.Strokeincidence,prevalence,andsurvival:seculartrendsin\nRochester,Minnesota,through1989.Stroke1996;27:373-380.\n31.BulpittC,FletcherA,BeckettN,CoopeJ,Gil-ExtremeraB,ForetteF,NachevC,PotterJ,SeverP,\nStaessenJ,SwiftC,TuomilehtoJ.HypertensionintheVeryElderlyTrial(HYVET):protocolforthemain\ntrial.DrugsAging2001;18(3):151-64.\n32.BeckettNS,PetersR,FletcherAE,StaessenJA,LiuL,DumitrascuD,etal.Treatmentofhypertensionin\npatients80yearsofageorolder.NEngJMedicine2008;358:1887-1898.\n33.FeiginVL,KrishnamurthiR,ParmarP,NorrvingB,MensahGA,BennettDA,etal.Ischemicand\nHemorrhagicStrokein1990-2013:TheGBD2013Study.Neuroepidemiology2015;45:161-176.\n34.RossouwJE,AndersonGL,PrenticeRL,etal.Risksandbenefitsofestrogenplusprogestininhealthy\npostmenopausalwomen:principalresultsFromtheWomen'sHealthInitiativerandomizedcontrolledtrial.\nJAMA2002;288(3):321-33.\n35.BrownSA,MorrisettJ,BoerwinkleE,etal.Therelationoflipoprotein[a]concentrationsand\napolipoprotein[a]phenotypeswithasymptomaticatherosclerosisinsubjectsoftheAtherosclerosisRiskin\nCommunities(ARIC)Study.ArteriosclerThromb1993;13:1558–66.\n36.MitsiosJP,EkinciEI,MitsiosGP,ChurilovL,ThijsV.RelationshipBetweenGlycatedHemoglobinand\nStrokeRisk:ASystematicReviewandMeta-Analysis.JAmHeartAssoc.2018May17;7(11):e007858.\n37.StamlerJ,VaccaroO,NeatonJD,WentworthD.Diabetes,otherriskfactors,and12-yrcardiovascular\nmortalityformenscreenedintheMultipleRiskFactorInterventionTrial.DiabetesCare\n1993;16(2):434-444.\n38.ScandinavianSimvastatinSurvivalStudyGroup.Randomisedtrialofcholesterolloweringin4444patients\nwithcoronaryheartdisease:theScandinavianSimvastatinSurvivalStudy(4S).Lancet1994;\n344(8934):1383-1389.\n39.HeartProtectionStudyCollaborativeGroup.MRC/BHFHeartProtectionStudyofcholesterollowering\nwithsimvastatinin20,536high-riskindividuals:arandomisedplacebo-controlledtrial.Lancet2002;\n360:7-22.\n40.CholesterolTreatmentTrialists’(CTT)Collaborators.TheeffectsofloweringLDLcholesterolwithstatin\ntherapyinpeopleatlowriskofvasculardisease:meta-analysisofindividualdatafrom27randomised\ntrials.Lancet2012;380:581–590.\n41.YusufS,BoschJ,DagenaisG,ZhuJ,XavierD,LiuL,etal.Cholesterolloweringinintermediate-risk\npersonswithoutcardiovasculardisease.NEngJMedicine2016;374:2021-2031.\n42.AnnickA,TobiasK,MarionB,etal.Primarypreventionwithlipidloweringdrugsandlongtermriskof\nvasculareventsinolderpeople:populationbasedcohortstudy.BMJ2015;350:h2335.\n43.EstruchR,RosE,Salas-SalvadóJ,etal.Primarypreventionofcardiovasculardiseasewitha\nMediterraneandiet.NEngJMedicine2013;368:1279-1290.\n44.HuD,HuangJ,WangY,ZhangD,QuY.Fruitsandvegetablesconsumptionandriskofstroke.A\nmeta-analysisofprospectivecohortstudies.Stroke2014;45:1613–1619.\n45.AppelLJ,MooreTJ,ObarzanekE,etal.Aclinicaltrialoftheeffectsofdietarypatternsonbloodpressure.\nDASHCollaborativeResearchGroup.NEnglJMed1997;336:1117-1124."
    },
    {
        "page_number": 136,
        "text": "13646.LeeCD,FolsomAR,BlairSN.Physicalactivityandstrokerisk:ameta-analysis.Stroke2003;\n34:2475–2481.\n47.DiepL,KwagyanJ,Kurantsin-MillsJ,WeirR,Jayam-TrouthA.Associationofphysicalactivityleveland\nstrokeoutcomesinmenandwomen:ameta-analysis.JWomensHealth(Larchmt)2010;19:1815–1822.\n48.SoneH,TanakaS,IimuroS,etal.Long-termlifestyleinterventionlowerstheincidenceofstrokein\nJapanesepatientswithtype2diabetes:anationwidemulti-centrerandomisedcontrolledtrial(theJapan\nDiabetesComplicationsStudy).Diabetologia2010;53:419-428.\n49.GazianoM,BrotonsC,CoppolecchiaR,etal.Useofaspirintoreduceriskofinitialvasculareventsin\npatientsatmoderateriskofcardiovasculardisease(ARRIVE):arandomised,double-blind,\nplacebo-controlledtrial.Lancet2018;392:1036-1046\n50.UchiyamaS,IshizukaN,ShimadaK,etal.Aspirinforstrokepreventioninelderlypatientswithvascular\nriskfactors.Stroke2016;47:1605-1611.\n51.TheASCENDStudyCollaborativeGroup.EffectsofAspirinforprimarypreventioninpersonswith\ndiabetesmellitus.NEnglJMed2018;379:1529-1539.\n52.WarlowCP,DennisMS,VanGijn,etal.Preventingrecurrentstrokeandotherseriousvascularevents.In:\nStroke:apracticalguidetomanagement.Oxford:BlackwellScience2001;653-672.\n53.HuanLi,WongKS.LongtermmortalityandrecurrentstrokeriskamongChinesestrokepatientswith\npredominantlyintracranialatherosclerosis.Stroke2003;34:2361-2366.\n54.AntithromboticTrialists’Collaboration.Collaborativemeta-analysisofrandomizedclinicaltrialsof\nanti-platelettherapyforpreventionofdeath,myocardialinfarctionandstrokeinhighriskpatients.BMJ\n2002;324:71-86.\n55.InternationalStrokeTrialCollaborativeGroup.TheInternationalStrokeTrial(IST):arandomisedtrialof\nAspirin,subcutaneousheparin,both,orneitheramong19435patientswithacuteischaemicstroke.\nLancet1997;349:1569-81.\n56.CAST(ChineseAcuteStrokeTrial)CollaborativeGroup.Randomisedplacebo-controlledtrialofearly\naspirinusein20,000patientswithacuteischaemicstroke.Lancet1997;349:1641-1649.\n57.ChenZM,SandercockP,PanHC,etal.IndicationsforearlyAspirinuseinacuteischemicstroke:A\ncombinedanalysisof40000randomizedpatientsfromtheChineseacutestroketrialandtheinternational\nstroketrial.Stroke2000;31:1240-1249.\n58.DutchTIATrialStudyGroup:AcomparisonoftwodosesofAspirin(30mgvs283mgaday)inpatients\nafteratransientischemicattackoraminorischemicstroke.NEnglJMed1991;325:1261-1266.\n59.AlgraA,vanGijn.Aspirinatanydoseabove30mgoffersonlymodestprotectionaftercerebralischaemia.\nJNeurolNeurosurgPsychiatry1996;60:197-199.\n60.FarrellB,GoodwinJ,RichardsS,WarlowC.TheUnitedKingdomtransientischaemicattack(UK-TIA)\nAspirintrial:finalresults.JNeurolNeurosurgPsychiatry1991;54:1044-1054.\n61.GentM,BlakelyJA,EastonJD,etal.TheCanadianAmericanTiclopidineStudy(CATS)in\nthromboembolicstroke.Lancet1989;1215-1220.\n62.GoyanJE.The“trials”ofalongtermclinicaltrial:TheticlopidineaspirinstrokestudyandtheCanadian\nAmericanTiclopidineStudy.ControlClinTrials1989;10(Suppl4):S236-S244.\n63.CAPRIEsteeringcommittee.Arandomized,blindedtrialofClopidogrelversusAspirininpatientsatriskof\nischaemicevents(CAPRIE).Lancet1996;348:1329-1339."
    },
    {
        "page_number": 137,
        "text": "13764.RinglebPA,BhattDL,HirschAT,TopolEJ,HackeW.BenefitofClopidogreloverAspirinisamplifiedin\npatientswithahistoryofischemicevents.Stroke2004;35(2):528-532.\n65.GuidelinesforManagementofIschaemicStrokeandTransientIschaemicAttack2009.Websiteaccessed;\nhttp://www.eso-stroke.org.18thJanuary2011.\n66.ShinoharaY,KatayamaY,UchiyamaS,etal.Cilostazolforpreventionofsecondarystroke(CSPS2):an\naspirincontrolled,doubleblind,randomizednon–inferioritytrial.LancetNeurology2010;9:959-968.\n67.HuangY,ChengY,WuJ,LiY,XuE,HongZ,LiZ,ZhangW,DingM,GaoX,FanD.Cilostazolasan\nalternativetoaspirinafterischaemicstroke:arandomised,double-blind,pilotstudy.TheLancet\nNeurology.2008Jun1;7(6):494-9.\n68.McHutchisonC,BlairGW,AppletonJP,ChappellFM,DoubalF,BathPM,WardlawJM.Cilostazolfor\nSecondaryPreventionofStrokeandCognitiveDecline:SystematicReviewandMeta-Analysis.Stroke.\n2020Aug;51(8):2374-85\n69.ToyodaK,UchiyamaS,YamaguchiT,EastonJD,KimuraK,HoshinoH,SakaiN,OkadaY,TanakaK,\nOrigasaH,NaritomiH.Dualantiplatelettherapyusingcilostazolforsecondarypreventioninpatientswith\nhigh-riskischaemicstrokeinJapan:amulticentre,open-label,randomisedcontrolledtrial.TheLancet\nNeurology.2019Jun1;18(6):539-48.\n70.WangY,WangY,ZhaoX,LiuL,WangD,WangC,CHANCEInvestigators.Clopidogrelwithaspirinin\nacuteminorstrokeortransientischemicattack.NEnglJMed2013;369:11–19.\n71.JohnstonSC,EastonJD,FarrantM,POINTInvestigators.ClopidogrelandAspirininacuteIschemic\nstrokeandhigh-riskTIA.NEnglJMed2018;379:215-225.\n72.JohnstonSC,AmarencoP,AlbersGW,SOCRATESSteeringCommitteeandInvestigators.Ticagrelor\nversusAspirininacutestrokeortransientischemicattack.NEnglJMed2016;375:35-43.\n73.WangY,MinematsuK,WongKS,SOCRATESSteeringCommitteeandInvestigators.Ticagrelorinacute\nstrokeortransientischemicattackinAsianpatients:FromtheSOCRATEStrial(AcuteStrokeorTransient\nIschemicAttackTreatedwithAspirinorTicagrelorandPatientOutcomes).Stroke2017;48(1):167-173.\n74.JohnstonSC,AmarencoP,DenisonH,EvansSR,HimmelmannA,JamesS,KnutssonM,LadenvallP,\nMolinaCA,WangY.TicagrelorandAspirinorAspirinAloneinAcuteIschemicStrokeorTIA.New\nEnglandJournalofMedicine.2020Jul16;383(3):207-17.\n75.GueyffierF,BoisselJP,BoutitieF,etal.Effectofantihypertensivetreatmentinpatientshavingalready\nsufferedfromstroke.Gatheringtheevidence.TheINDANAProjectCollaborators.Stroke1997;\n28:2557-2562.\n76.LawesCCM,BennettDa,FeiginVL,RodgersA.bloodpressureandstroke:anoverviewofpublished\nreviews.Stroke2004;35:776785.\n77.PROGRESSCollaborativeGroup.RandomizedtrialofaPerindropril-basedbloodpressurelowering\nregimentamong6105individualswithpreviousstrokeortransientischaemicattack.Lancet2001;\n358:1033-1041.\n78.LindholmLH,IbsenH,DahlofB,etal.Cardiovascularmorbidityandmortalityinpatientswithdiabetesin\ntheLosartanInterventionforendpointreductioninhypertensionstudy(LIFE):arandomizedtrialagainst\nAtenolol.Lancet2002;359:1004-1010.\n79.HeartOutcomesPreventionEvaluationstudyinvestigators.Effectsofanangiotensin-converting–enzyme\ninhibitor,Ramipril,oncardiovasculareventsinhigh-riskpatients.NEnglJMed2000;342:145-153.\n80.JikeiHeartStudyGroup.ValsartaninaJapanesepopulationwithhypertensionandothercardiovascular\ndisease:arandomised,open-label,blindedendpointmorbidity-mortalitystudy.Lancet2007;\n369:1431-1439."
    },
    {
        "page_number": 138,
        "text": "13881.TheONTARGETInvestigators.Telmisartan,Ramipril,orbothinpatientsathighriskforvascularevents.\nNEnglJMed2008;358:1547-1559.\n82.AmericanHeartAssociationGuidelinesonPreventionofStrokeinpatientswithIschaemicstrokeorTIA.\nStroke2006;37:577-617.\n83.Cholesterol,diastolicbloodpressureandstroke:13,000strokesin450,000peoplein45prospective\ncohorts.ProspectiveStudiesCollaboration.Lancet1995;346:1647-1653.\n84.HeartProtectionStudyCollaborativeGroup.MRC/BHFHeartProtectionStudyofcholesterollowering\nwithsimvastatinin20536high-riskindividuals:arandomizedplacebo-controlledtrial.Lancet2002;\n360:7-22.\n85.AmarencoP,KimJS,LabreucheJ,TreatStroketoTargetInvestigators.AcomparisonoftwoLDL\ncholesteroltargetsafterischemicstroke.NEnglJMed2020;382:9-19.\n86.UKProspectiveDiabetesStudy(UKPDS)GroupIntensiveblood-glucosecontrolwithSulphonylureasor\nInsulincomparedwithconventionaltreatmentandriskcomplicationsinpatientswithtype2diabetes\n(UKPDS33).Lancet1998;352:837-853.\n87.6thACCPConsensusConferenceonAntithromboticTherapy(co-chairs:JDalen,JHirsch,GGuyatt)\nCHEST119/1(Suppl.)Jan2001.\n88.ABCofantithrombotictherapy(edsGYLip,ABlann)BMJPublishing(London)2003.\n89.Guidelinesfortheearlymanagementofpatientswithischemicstroke.Ascientificstatementfromthe\nstrokecounciloftheAmericanStrokeAssociation.(AdamsHP,chair).Stroke2003;34:1056-1083.\n90.McNamaraRL,LimaAC,WheltonPK,PoreNR.Echo-cardiographicidentificationofcardiovascular\nsourcesofembolitoguideclinicalmanagementofstroke:Acost-effectivenessanalysis.AnnInternMed\n1997;127:775-787.\n91.LipGYH.Thromboprophylaxisforatrialfibrillation.Lancet1999;353:4-6.\n92.BonowRO,CarobelloD,deLeonAC,etal.ACC/AHAguidelinesforthemanagementofpatientswith\nvalvularheartdisease.JAmCollCardiol1998;32:1486-1488.\n93.ConnollySJ,EzekowitzMD,YusufS,EikelboomJ,OldgrenJ,ParekhA,PogueJ,ReillyPA,ThemelesE,\nVarroneJ,WangS.Dabigatranversuswarfarininpatientswithatrialfibrillation.NewEnglandJournalof\nMedicine.2009Sep17;361(12):1139-51.\n94.PatelMR,MahaffeyKW,GargJ,etal.Rivaroxabanversuswarfarininnonvalvularatrialfibrillation.NEngl\nJMed.2011;365(10):883-891.\n95.GrangerCB,AlexanderJH,McMurrayJJ,LopesRD,HylekEM,HannaM,Al-KhalidiHR,AnsellJ,AtarD,\nAvezumA,BahitMC.Apixabanversuswarfarininpatientswithatrialfibrillation.NewEnglandJournalof\nMedicine.2011Sep15;365(11):981-92.\n96.GiuglianoRP,RuffCT,BraunwaldE,MurphySA,WiviottSD,HalperinJL,WaldoAL,EzekowitzMD,\nWeitzJI,ŠpinarJ,RuzylloW.Edoxabanversuswarfarininpatientswithatrialfibrillation.NewEngland\nJournalofMedicine.2013Nov28;369(22):2093-104.\n97.LipGYH,FrisonL,HalperinJL,etal.Comparativevalidationofanovelriskscoreforpredictingbleeding\nriskinanticoagulatedpatientswithatrialfibrillation.JAmCollCardiol2011;57:173-180.\n98.PistersR,LaneDA,NieuwelaatR,etal.Anovel,user-friendlyscore(HAS-BLED)toassessone-yearrisk\nofmajorbleedinginatrialfibrillationpatients:TheEuroHeartSurvey.Chest2010;138:1093-1100.\n99.AdamsHP,StrokeCounciloftheAmericanHeartAssociation/AmericanStrokeAssociation.Guidelines\nfortheearlymanagementofpatientswithischemicstroke.Stroke2003;34:1056-1083."
    },
    {
        "page_number": 139,
        "text": "139100.RothwellPM,EliasziwM,GutnikovSA,etal.Endarterectomyforsymptomaticcarotidstenosisinrelation\ntoclinicalsubgroupsandtimingofsurgery.Lancet2004;363:915-924.\n101.NorthAmericanSymptomaticCarotidEndarterectomyTrialists’CollaborativeGroup.Thefinalresultsof\ntheNASCETtrial.NEngJMed1998;339:1415-1425.\n102.NorthAmericanSymptomaticCarotidEndarterectomyTrialCollaborators(NASCET).Beneficialeffectof\ncarotidendarterectomyinsymptomaticpatientswithhighgradecarotidstenosis.NEnglJMed1991;325:\n445-453.\n103.EuropeanCarotidSurgeryTrialists`CollaborativeGroup.MRCEuropeanCarotidSurgeryTrial:Interim\nresultsforsymptomaticpatientswithsevere(70-99%)orwithmild(0-29%)carotidstenosis.Lancet1991;\n337:1235-1243.\n104.BarnettHJ,TaylorDW,EliasziwM,etal.Benefitofcarotidendarterectomyinpatientswithsymptomatic\nmoderateorseverestenosis.NEnglJMed1998;339:1415-1425.\n105.ACSTCollaborativeGroup.Preventionofdisablingandfatalstrokesbysuccessfulcarotidendarterectomy\ninpatientswithoutrecentneurologicalsymptoms:randomizedcontrolledtrial.Lancet2004;\n363:1491-1501.\n106.RothwellPM,EliasziwM,GutnikovSA,etal.Analysisofpooleddatafromtherandomizedcontrolledtrials\nofendarterectomyforsymptomaticcarotidstenosis.Lancet2003;361:107-115.\n107.TheEuropeanCarotidSurgeryTriallists(ECST)CollaborativeGroup.Riskofstrokeinthedistributionof\nanasymptomaticcarotidartery.Lancet1995;345:209-212.\n108.BakerWH,ACASInvestigators.Effectofcontralateralocclusiononlong-termefficacyofendarterectomy\nintheAsymptomaticCarotidAtherosclerosisStudy(ACAS).Stroke2000;31:2330-2334.\n109.EC/ICBypassStudyGroup.Failureofextracranial-intracranialarterialbypasstoreducetheriskof\nischemicstroke.Resultsofaninternationalrandomizedtrial.NEngJMed1985;313:1191-2000.\n110.CRESTinvestigators.Stentingversusendarterectomyfortreatmentofcarotid-arterystenosis.NEngJ\nMed2010;363:11-23.\n111.RinglebPA,AllenbergJ,BruckmannH,etal.30DayresultsfromtheSPACEtrialofstent-protected\nangioplastyversuscarotidendarterectomyinsymptomaticpatients:arandomisednon-inferioritytrial.\nLancet2006;368:1239-1247.\n112.EderleJ,DobsonJ,FeatherstoneRL,etal.Carotidarterystentingcomparedwithendarterectomyin\npatientswithsymptomaticcarotidstenosis(InternationalCarotidStentingStudy):aninterimanalysisofa\nrandomisedcontrolledtrial.Lancet2010;375:985-97.\n113.MüllerMD,AhlhelmFJ,vonHesslingA,DoigD,NederkoornPJ,MacdonaldS,LyrerPA,vanderLugtA,\nHendrikseJ,StippichC,vanderWorpHB,RichardsT,BrownMM,EngelterST,BonatiLH.Vascular\nAnatomyPredictstheRiskofCerebralIschemiainPatientsRandomizedtoCarotidStentingVersus\nEndarterectomy.Stroke.2017May;48(5):1285-1292.\n114.ChimowitzMI,LynnMJ,DerdeynCP,TuranTN,FiorellaD,LaneBF,JanisLS,LutsepHL,BarnwellSL,\nWatersMF,HohBL.Stentingversusaggressivemedicaltherapyforintracranialarterialstenosis.New\nEnglandJournalofMedicine.2011Sep15;365(11):993-1003.\n115.ZaidatOO,FitzsimmonsBF,WoodwardBK,WangZ,Killer-OberpfalzerM,WakhlooA,GuptaR,Kirshner\nH,MegerianJT,LeskoJ,PitzerP.Effectofaballoon-expandableintracranialstentvsmedicaltherapyon\nriskofstrokeinpatientswithsymptomaticintracranialstenosis:theVISSITrandomizedclinicaltrial.Jama.\n2015Mar24;313(12):1240-8.\n116.EuropeanStrokeInitiativeRecommendationsforStrokeManagement–Update2003.CerebrovascDis\n2003;16:311-337."
    },
    {
        "page_number": 140,
        "text": "140117.AlexanderMJ,ZaunerA,ChaloupkaJC,BaxterB,CallisonRC,GuptaR,SongSS,YuW,WEAVETrial\nInvestigators.WEAVEtrial:finalresultsin152on-labelpatients.Stroke.2019Apr;50(4):889-94.\nChapter7:EmergencyMedicineServices\n1.PartyIS.Nationalclinicalguidelineforstroke.London:RoyalCollegeofPhysicians2016.\n2.BoulangerJM,LindsayMP,GubitzG,SmithEE,StottsG,FoleyN,etal.Canadianstrokebestpractice\nrecommendationsforacutestrokemanagement:pre-hospital,emergencydepartmentandacuteinpatient\nstrokecare,6thedition,update2018.IntJStroke2018;13(9):949-84.\n3.PowersWJ,RabinsteinAA,AckersonT,AdeoyeOM,BambakidisNC,BeckerK,etal.2018guidelinesfor\ntheearlymanagementofpatientswithacuteischemicstroke:aguidelineforhealthcareprofessionals\nfromtheAmericanHeartAssociation/AmericanStrokeAssociation.Stroke2018;49(3):e46-99.\n4.KobayashiA,CzlonkowskaA,FordGA,FonsecaAC,LuijckxGJ,KorvJ,etal.EuropeanAcademyof\nNeurologyandEuropeanStrokeOrganizationconsensusstatementandpracticalguidancefor\npre-hospitalmanagementofstroke.EurJNeurol2018;25(3):425-33.\n5.BohmK,KurlandL.Theaccuracyofmedicaldispatch-asystematicreview.ScandJTraumaResusc\nEmergMed2018;26(1):94.\n6.BerglundA,SvenssonL,SjostrandC,vonArbinM,vonEulerM,WahlgrenN,etal.Higherpre-hospital\nprioritylevelofstrokeimprovesthrombolysisfrequencyandtimetostrokeunit:theHyperAcuteSTroke\nAlarm(HASTA)study.Stroke2012;43(10):2666-70.\n7.AdamsHPJr,delZoppoG,AlbertsMJ,BhattDL,BrassL,FurlanA,etal.Guidelinesfortheearly\nmanagementofadultswithischemicstroke:aguidelinefromtheAmericanHeartAssociation/American\nStrokeAssociationStrokeCouncil,ClinicalCardiologyCouncil,CardiovascularRadiologyand\nInterventionCouncil,andtheAtheroscleroticPeripheralVascularDiseaseandQualityofCareOutcomes\ninResearchInterdisciplinaryWorkingGroups:theAmericanAcademyofNeurologyaffirmsthevalueof\nthisguidelineasaneducationaltoolforneurologists.Stroke2007;38(5):1655-711.\n8.AbarbanellNR.Ispre-hospitalbloodglucosemeasurementnecessaryinsuspectedcerebrovascular\naccidentpatients?AmJEmergMed2005;23(7):823-7.\n9.GloberNK,SporerKA,GulumaKZ,SerraJP,BargerJA,BrownJF,etal.Acutestroke:current\nevidence-basedrecommendationsforpre-hospitalcare.WestJEmergMed2016;17(2):104-28.\n10.ClawsonJJ,ScottG,GardettI,YoungquistS,TaillacP,FivazC,etal.Predictiveabilityofanemergency\nmedicaldispatchstrokediagnostictoolinidentifyinghospital-confirmedstrokes.JStrokeCerebrovascDis\n2016;25(8):2031-42.\n11.Rudd,M.,Buck,D.,Ford,G.A.andPrice,C.I.,2016.Asystematicreviewofstrokerecognition\ninstrumentsinhospitalandprehospitalsettings.EmergencyMedicineJournal;33(11):pp.818-822.\n12.Antipova,D.,Eadie,L.,Macaden,A.andWilson,P.,2019.Diagnosticaccuracyofclinicaltoolsfor\nassessmentofacutestroke:asystematicreview.BMCemergencymedicine;19(1),:p.49.\n13.Zhelev,Z.,Walker,G.,Henschke,N.,Fridhandler,J.andYip,S.,2019.Prehospitalstrokescalesas\nscreeningtoolsforearlyidentificationofstrokeandtransientischemicattack.CochraneDatabaseof\nSystematicReviews,(4).\n14.Pickham,D.,Valdez,A.,Demeestere,J.,Lemmens,R.,Diaz,L.,Hopper,S.,delaCuesta,K.,Rackover,\nF.,Miller,K.andLansberg,M.G.,2019.PrognosticvalueofBEFASTvs.FASTtoidentifystrokeina\nprehospitalsetting.PrehospitalEmergencyCare;23(2):pp.195-200.\n15.AroorS,SinghR,GoldsteinLB.BE-FAST(Balance,Eyes,Face,Arm,Speech,Time)Reducingthe\nProportionofStrokesMissedUsingtheFASTMnemonic.Stroke.2017Feb;48(2):479-81."
    },
    {
        "page_number": 141,
        "text": "14116.ElAmmarF,ArdeltA,DelBruttoVJ,LogginiA,BulwaZ,MartinezRC,McKoyCJ,BrorsonJ,MansourA,\nGoldenbergFD.BE-FAST:ASensitiveScreeningTooltoIdentifyIn-HospitalAcuteIschemicStroke.\nJournalofStrokeandCerebrovascularDiseases.2020Apr17:104821.\n17.StrokeFoundation.Clinicalguidelinesforstrokemanagement2017.\n18.WhiteleyWN,WardlawJM,DennisMS,SandercockPA.Clinicalscoresfortheidentificationofstrokeand\ntransientischaemicattackintheemergencydepartment:across-sectionalstudy.JNeurolNeurosurg\nPsychiatry2011;82(9):1006-10.\n19.SpokoynyI,RamanR,ErnstromK,DemaerschalkBM,LydenPD,HemmenTM,etal.Pooledassessment\nofcomputedtomographyinterpretationbyvascularneurologistsintheSTRokEDOCtelestrokenetwork.J\nStrokeCerebrovascDis2014;23(3):511-5.\nChapter8:AcuteGeneralManagement\n1.AdamsHP,AdamsRJ,BrottT,ZoppoGJ,FurlanA,GoldsteinLB,etal.Guidelinesfortheearly\nmanagementofpatientswithischaemicstroke:ascientificstatementfromthestrokecouncilofthe\nAmericanStrokeAssociation.Stroke2003;34(4):1056-83.\n2.KriegerD,HackeW.Theintensivecareofthestrokepatient.In:BarnettHJM,etal,eds.Stroke:\nPathophysiology,DiagnosisandManagement.3rdEd.NewYork:ChurchillLivingstone1998.\n3.GrottaJ,PasteurW,KhwajaG,HamelT,FisherM,RamirezA.Electiveintubationforneurologic\ndeteriorationafterstroke.Neurology1995;45(4):640–4.\n4.AdamsHPJr.Managementofpatientswithacuteischaemicstroke.Drugs1997;54(Supplement3):\n60–9.\n5.TreibJ,GrauerMT,WoessnerR,MorgenthalerM.Treatmentofstrokeonanintensivestrokeunit:anovel\nconcept.IntensiveCareMed2000;26(11):1598–611.\n6.PowersWJ,RabinsteinAA,AckersonT,AdeoyeOM,BambakidisNC,BeckerK,etal.2018Guidelines\nfortheearlymanagementofpatientswithacuteischemicstroke:aguidelineforhealthcareprofessionals\nfromtheAmericanHeartAssociation/AmericanStrokeAssociation.Stroke2018;49(3):e46–e110.\n7.RuddAG,BowenA,YoungG,JamesMA.NationalClinicalGuidelinesforStroke:5thEdition2016.Clin\nMed(Lond)2017.\n8.RonningOM,GuldvogB.Shouldstrokevictimsroutinelyreceivesupplementaloxygen?A\nquasi-randomizedcontrolledtrial.Stroke1999;30(10):2033–7.\n9.RoffeC,AliK,WarusevitaneA,SillsS,PountainS,AllenM,etal.TheSOSpilotstudy:aRCTofroutine\noxygensupplementationearlyafteracutestroke--effectonrecoveryofneurologicalfunctionatoneweek.\nPlosOne2011;6(5):e19113.\n10.LanghorneP.Measurestoimproverecoveryintheacutephaseofstroke.CerebrovascDis1999;\n9(Supplement5):2–5.\n11.HamidonBB,RaymondAA.Riskfactorsandcomplicationsofacuteischaemicstrokepatientsat\nHUKM.MedJMalaysia2003;58(4):307-13.\n12.LinnSL,GranatMH,LeesKR.Preventionofshouldersubluxationafterstrokewithelectrical\nstimulation.Stroke1999;30(5):963–8.\n13.TutuarimaJA,vanderMeulenJH,deHaanRJ,vanStratenA,LimburgM.Riskfactorsforfallsof\nhospitalizedstrokepatients.Stroke1997;28(2):297–301.\n14.AVERTTrialCollaborationGroup.Efficacyandsafetyofveryearlymobilisationwithin24hofstroke\nonset(AVERT):arandomisedcontrolledtrial.Lancet2015;386(9988):46–55."
    },
    {
        "page_number": 142,
        "text": "14215.HornJ,deHaanRJ,VermeulenM,LimburgM.VeryEarlyNimodipineUseinStroke(VENUS):a\nrandomized,double-blind,placebo-controlledtrial.Stroke2001;32(2):461–5.\n16.SchraderJ,LudersS,KulschewskiA,BergerJ,ZidekW,etal.,AcuteCandesartanCilexetilTherapy\ninStrokeSurvivorsStudyGroup.TheACCESSStudy:evaluationofAcuteCandesartanCilexetil\nTherapyinStrokeSurvivors.Stroke2003;34(7):1699–703.\n17.PotterJF,RobinsonTG,FordGA,MistriA,JamesM,ChernovaJ,etal.ControllingHypertensionand\nHypotensionImmediatelyPost-Stroke(CHHIPS):arandomised,placebo-controlled,double-blindpilottrial.\nLancetNeurol2009;8(1):48–56.\n18.RobinsonTG,PotterJF,FordGA,BulpittCJ,ChernovaJetal.,COSSACSInvestigators.Effectsof\nantihypertensivetreatmentafteracutestrokeintheContinueorStopPost-StrokeAntihypertensives\nCollaborativeStudy(COSSACS):aprospective,randomised,open,blinded-endpointtrial.LancetNeurol\n2010;9(8):767–75.\n19.HeJ,ZhangY,XuT,ZhaoQ,WangD,ChenCS,etal.,CATISInvestigators.Effectsofimmediateblood\npressurereductionondeathandmajordisabilityinpatientswithacuteischemicstroke:theCATIS\nrandomizedclinicaltrial.JAMA2014;311(5):479–89.\n20.EnosTrialInvestigators,BathPM,WoodhouseL,ScuttP,KrishnanK,WardlawJM,etal.Efficacyofnitric\noxide,withorwithoutcontinuingantihypertensivetreatment,formanagementofhighbloodpressurein\nacutestroke(ENOS):apartial-factorialrandomisedcontrolledtrial.Lancet2015;385(9968):617–28.\n21.GrossmanE,MesserliFH,GrodzickiT,KoweyP.Shouldamoratoriumbeplacedonsublingualnifedipine\ncapsulesgivenforhypertensiveemergenciesandpseudoemergencies?JAMA1996;276(16):1328–31.\n22.HamidonBB,RaymondAA.Theimpactofdiabetesmellitusonin-hospitalstrokemortality.JPostgrad\nMed2003;49(4):306-8.\n23.ScottJF,RobinsonGM,FrenchJM,O’ConnelJE,AlbertiKG,GrayCS.Glucosepotassiuminsulin\ninfusionsinthetreatmentofacutestrokepatientswithmildtomoderatehyperglycaemia:theGlucose\nInsulininStrokeTrial(GIST).Stroke1999;30(4):793-9.\n24.DunningT,SinclairA,ColagiuriS.NewIDFGuidelineformanagingtype2diabetesinolderpeople.\nDiabetesResClinPract.2014;103(3):538-40.\n25.BellolioMF,GilmoreRM,GantiL.Insulinforglycaemiccontrolinacuteischaemicstroke.Cochrane\nDatabaseSystRev.2014(1):Cd005346.\n26.RobbinsJ.Theevolutionofswallowingneuroanatomyandphysiologyinhumans:apractical\nperspective.AnnNeurol1999;46(3):279–280.\n27.DennisM,LewisS,CranswickG,ForbesJ,FOODTrialCollaboration.FOOD:amulticentrerandomised\ntrialevaluatingfeedingpoliciesinpatientsadmittedtohospitalwitharecentstroke.HealthTechnol\nAssess2006;10(2):iii–iv,ix-x,1-120.\n28.DennisMS,LewisSC,WarlowC,FOODTrialCollaboration.Effectoftimingandmethodofenteraltube\nfeedingfordysphagicstrokepatients(FOOD):amulticentrerandomisedcontrolledtrial.Lancet2005,\n365(9461):764-72.\n29.MartinoR,MakiE,DiamantN.IdentificationofdysphagiausingtheTorontoBedsideSwallowing\nScreeningTest(TOR-BSST):are10teaspoonsofwaternecessary?IntJspeechLangPathol2014;16(3):\n193-8.\n30.AddingtonWR,StephensRE,GillilandK,RodriguezM.Assessingthelaryngealcoughreflexandtherisk\nofdevelopingpneumoniaafterstroke.ArchPhysMedRehabil1999;80(2):150–4."
    },
    {
        "page_number": 143,
        "text": "14331.WijdicksEF,McMahonMM.Percutaneousendoscopicgastronomyafteracutestroke:complicationsand\noutcome.CerebrovascDis1999;9(2):109-11.\n32.HamidonBB,RaymondAA,NorlinahMI,JefferelliSB.Thepredictorsofearlyinfectionafteranacute\nischaemicstroke.SingaporeMedJ2003;44(2):73-6.\n33.HajatC,HajatS,SharmaP.Effectsofpost-strokepyrexiaonstrokeoutcome:ameta-analysisofstudies\ninstrokepatients.Stroke2000;31(2):410–4.\n34.WangY,LimLL,LeviC,HellerRF,FisherJ.Influenceofadmissionbodytemperatureonstrokemortality.\nStroke2000;31(2):404–9.\n35.LydenP,HemmenT,GrottaJ,RappK,ErnstromK,RzesiewiczT,etal.ResultsoftheICTuS2Trial\n(IntravascularCoolingintheTreatmentofStroke2).Stroke2016;47(12):2888–95.\n36.GeurtsM,PeterssonJ,BrizziM,Olsson-HauS,LuijckxGJ,AlgraA,etal.COOLIST(CoolingforIschemic\nStrokeTrial):amulti-centre,open,randomized,phaseII,clinicaltrial.Stroke2017;48(1):219–21.\n37.PiironenK,TiainenM,MustanojaS,KaukonenKM,MeretojaA,TatlisumakT,etal.Mildhypothermia\nafterintravenousthrombolysisinpatientswithacutestroke:arandomizedcontrolledtrial.Stroke2014;\n45(2):486–91.\n38.HemmenTM,RamanR,GulumaKZ,MeyerBC,GomesJA,Cruz-FloresS,etal.,fortheICTuS-L\nInvestigators.IntravenousThrombolysisPlusHypothermiaforAcuteTreatmentofIschemicStroke\n(ICTuS-L):finalresults.Stroke2010;41(10):2265–70.\n39.BoulangerJM,LindsayMP,GubitzG,SmithEE,StottsG,FoleyN,BhogalS,BoyleK,BraunL,Goddard\nT,HeranMK.Canadianstrokebestpracticerecommendationsforacutestrokemanagement:prehospital,\nemergencydepartment,andacuteinpatientstrokecare,update2018.InternationalJournalofStroke.\n2018Dec;13(9):949-84.\n40.GujjarAR,DeibertE,MannoEM,DuffS,DiringerMN.Mechanicalventilationforischemicstrokeand\nintracerebralhemorrhage:indications,timing,andoutcome.Neurology1998;51(2):447–51.\n41.AndersonCS,ArimaH,LavadosP,BillotL,ResM,HackettMl,etal.Cluster-randomized,crossovertrial\nofHeadPositioninginAcuteStroke(HeadPoSTTrial).NEnglJMed2017;376:2437-47.\n42.MannoEM,AdamsRE,DerdeynCP,PowersWJ,DiringerMN.Theeffectsofmannitoloncerebral\noedemaafterlargehemisphericcerebralinfarct.Neurology1999;52(3):583–87.\n43.VahediK,HofmeijerJ,JuettlerE,VicautE,GeorgeB,AlgraA,etal.,DECIMAL,DESTINY,andHAMLET\nInvestigators.Earlydecompressivesurgeryinmalignantinfarctionofthemiddlecerebralartery:apooled\nanalysisofthreerandomisedcontrolledtrials.LancetNeurol2007;6(3):215–22.\n44.JuttlerE,UnterbergA,WoitzikJ,BoselJ,AmiriH,SakowitzOW,etal.Hemicraniectomyinolderpatients\nwithextensivemiddle-cerebral-arterystroke.NEnglJMed2014;370(12):1091-100.\n45.HornigCR,RustDS,BusseO,JaussM,LaunA.Space-occupyingcerebellarinfarction:clinicalcourse\nandprognosis.Stroke1994;25(2):372–4.\n46.ChoDY,ChenTC,LeeHC.Ultra-earlydecompressivecraniectomyformalignantmiddlecerebralartery\ninfarction.SurgNeurol2003;60(3):227–32.\n47.CLOTS(ClotsinLegsOrsTockingsafterStroke)TrialsCollaboration,DennisM,SandercockP,ReidJ,\nGrahamC,ForbesJ,etal.Effectivenessofintermittentpneumaticcompressioninreductionofriskof\ndeepveinthrombosisinpatientswhohavehadastroke(CLOTS3):amulticentrerandomisedcontrolled\ntrial.Lancet2013;382(9891):516-24."
    },
    {
        "page_number": 144,
        "text": "14448.DennisM,CasoV,KappelleLJ,PavlovicA,SandercockP.EuropeanStrokeOrganisation(ESO)\nguidelinesforprophylaxisforvenousthromboembolisminimmobilepatientswithacuteischaemicstroke.\nEurStrokeJ2016;1(1):6–19.\n49.TheCLOTSTrialsCollaboration,DennisM,SandercockPA,ReidJ,GrahamC,MurrayG,etal.\nEffectivenessofthigh-lengthgraduatedcompressionstockingstoreducetheriskofdeepveinthrombosis\nafterstroke(CLOTStrial1):amulticentre,randomisedcontrolledtrial.Lancet2009;373(9679):1958-65.\n50.TheCLOTS(ClotsinLegsOrsTockingsafterStroke)TrialCollaboration.Thigh-Lengthversus\nbelow-kneestockingsfordeepvenousthrombosisprophylaxisafterstroke:arandomizedtrial.AnnIntern\nMed2010;153(9):553–62.\nChapter9:ReperfusionofIschemicBrain\n1.PowersWJ,RabinsteinAA,AckersonT,AdeoyeOM,BambakidisNC,BeckerK,BillerJ,etal.2018\nguidelinesfortheearlymanagementofpatientswithacuteischemicstroke-aguidelineforhealthcare\nprofessionalsfromtheAmericanHeartAssociation/AmericanStrokeAssociation.Stroke2018;49(3):\ne46-e110.\n2.SchregelK,BehmeD,TsogkasI,KnauthM,MaierI,KarchA,etal.Effectsofworkflowoptimizationin\nendovascularlytreatedstrokepatients–apre-posteffectivenessstudy.PlosOne2016;11(12):\ne0169192.\n3.StrokeUnitTrialists'Collaboration.Organisedinpatient(strokeunit)careforstroke.CochraneDatabase\nSystRev2013;9:CD000197.\n4.PuetzV,BodechtelU,GerberJC,DzialowskiI,KunzA,WolzM,etal.ReliabilityofbrainCTevaluationby\nstrokeneurologistsintelemedicine.Neurology2013;80(4):332–8.\n5.MitchellJR,SharmaP,ModiJ,SimpsonM,ThomasM,HillMD,etal.Asmartphoneclient-server\nteleradiologysystemforprimarydiagnosisofacutestroke.JMedInternetRes2011;13(2):e31.\n6.KepplingerJ,BarlinnK,DeckertS,ScheibeM,BodechtelU,SchmittJ.Safetyandefficacyof\nthrombolysisintelestroke:asystematicreviewandmeta-analysis.Neurology2016;87(13):1344–351.\n7.FongWC,IsmailM,LoJW,LiJT,WongAH,NgYW,etal.Telephoneandteleradiologyguided\nthrombolysiscanachievesimilaroutcomeasthrombolysisbyneurologiston-site.JStrokeCerebrovasc\nDis2015;24(6):1223-8.\n8.RuddM,RodgersH,CurlessR,SudlowM,HuntleyS,MadhavaB,etal.Remotespecialistassessment\nforintravenousthrombolysisofacuteischemicstrokebytelephone.EmergMedJ2012;29(9):704-8.\n9.WardlawJM,MurrayV,BergeE,delZoppoGJ.Thrombolysisforacuteischaemicstroke.Cochrane\nDatabaseSystRev2014;7:CD000213.\n10.HackeW,DonnanG,FieschiC,KasteM,vonKummerR,BroderickJP,etal.Associationofoutcomewith\nearlystroketreatment:pooledanalysisofATLANTIS,ECASSandNINDSrt-PAstroketrials.Lancet2004;\n363(9411):768–74.\n11.WardlawJM,MurrayV,BergeE,delZoppoG,SandercockP,LindleyRL,etal.Recombinanttissue\nplasminogenactivatorforacuteischemicstroke:anupdatedsystematicreviewandmeta-analysis.Lancet\n2012;379(9834):2364–72.\n12.WahlgrenN,AhmedN,DavalosA,FordGA,GrondM,HackeW,etal.Thrombolysiswithalteplasefor\nacuteischaemicstrokeintheSafeImplementationofThrombolysisinStroke-MonitoringStudy\n(SITS-MOST):anobservationalstudy.Lancet2007;369(9558):275–82.\n13.IST-3CollaborativeGroup,SandercockP,WardlawJM,LindleyRI,DennisM,CohenG,etal.The\nbenefitsandharmsofintravenousthrombolysiswithrecombinanttissueplasminogenactivatorwithin6h"
    },
    {
        "page_number": 145,
        "text": "145ofacuteischaemicstroke(theThirdInternationalStrokeTrial[IST-3]):arandomisedcontrolledtrial.\nLancet2012;379(9834):2352–63.\n14.LeesKR,EmbersonJ,BlackwellL,BluhmkiE,DavisSM,DonnanGA,etal.Effectsofalteplaseforacute\nstrokeonthedistributionoffunctionaloutcomes:apooledanalysisof9trials.Stroke2016;47(9):2373–9.\n15.HackeW,KasteM,BluhmkiE,BrozmanM,DavalosA,GuidettiD,etal.Thrombolysiswithalteplase3to\n4.5hoursafteracuteischemicstroke.NEnglJMed2008;359(13):1317–29.\n16.ThomallaG,SimonsenCZ,BoutitieF,AndersenG,BerthezeneY,ChengB,etal.MRI-guided\nthrombolysisforstrokewithunknowntimeofonset.NEnglJMed2018;379(7):611-22.\n17.EhrlichME,TurnerHL,CurrieLJ,WintermarkM,WorrallBB,SoutherlandAM.Safetyofcomputed\ntomographicangiographyintheevaluationofpatientswithacutestroke:asingle-centreexperience.\nStroke2016;47(8):2045–50.\n18.AulickyP,MikulikR,GoldemundD,ReifM,DufekM,KubelkaT.SafetyofperformingCTangiographyin\nstrokepatientstreatedwithintravenousthrombolysis.JNeurolNeurosurgPsychiatry2010;81(7):783–7.\n19.LimaFO,LevMH,LevyRA,SilvaGS,EbrilM,deCamargoEC,etal.Functionalcontrast-enhancedCT\nforevaluationofacuteischemicstrokedoesnotincreasetheriskofcontrast-inducednephropathy.AJNR\nAmJNeuroradiol2010;31(5):817–21.\n20.HopyanJJ,GladstoneDJ,MalliaG,SchiffJ,FoxAJ,SymonsSP,etal.RenalsafetyofCTangiography\nandperfusionimagingintheemergencyevaluationofacutestroke.AJNRAmJNeuroradiol2008;29(10):\n1826–30.\n21.KrolAL,DzialowskiI,RoyJ,PuetzV,SubramaniamS,CouttsSB,etal.Incidenceofradio-contrast\nnephropathyinpatientsundergoingacutestrokecomputedtomographyangiography.Stroke2007;38(8):\n2364–6.\n22.JosephsonSA,DillonWP,SmithWS.IncidenceofcontrastnephropathyfromcerebralCTangiography\nandCTperfusionimaging.Neurology2005;64(10):1805–6.\n23.SmithEE,KentDM,BulsaraKR,LeungLY,LichtmanJH,ReevesMJ,etal.Accuracyofprediction\ninstrumentsfordiagnosinglargevesselocclusioninindividualswithsuspectedstroke:asystematicreview\nforthe2018guidelinesfortheearlymanagementofpatientswithacuteischemicstroke:aguidelinefor\nhealthcareprofessionalsfromtheAmericanHeartAssociation/AmericanStrokeAssociation.Stroke\n2018;49(3):e111-e122.\n24.NacuA,KvistadCE,NaessH,OygardenH,LogalloN,AssmusJ,etal.NOR-SASS(Norwegian\nSonothrombolysisinAcuteStrokeStudy):randomizedcontrolledcontrast-enhancedsonothrombolysisin\nanunselectedacuteischemicstrokepopulation.Stroke2017;48(2):335–41.\n25.PikijaS,SztrihaLK,MutzenbachJS,GolaszewskiSM,SellnerJ.IdarucizumabinDabigatran-treated\npatientswithacuteischemicstrokereceivingalteplase:asystematicreviewoftheavailableevidence.\nCNSDrugs2017;31(9):747-57.\n26.DienerHC,BernsteinR,ButcherK,CampbellB,CloudG,DavalosA,etal.Thrombolysisand\nthrombectomyinpatientstreatedwithDabigatranwithacuteischemicstroke:expertopinion.IntJStroke\n2017;12(1):9–12.\n27.AndersonCS,RobinsonT,LindleyRI,ArimaH,LavadosPM,LeeTH,etal.Low-doseversus\nstandard-doseintravenousalteplaseinacuteischemicstroke.NEnglJMed2016;374(24):2313–23.\n28.HuangX,CheripelliBK,LloydSM,KalladkaD,MoretonFC,SiddiquiA,etal.Alteplaseversus\nTenecteplaseforthrombolysisafterischemicstroke(ATTEST):aphase2,randomized,open-label,\nblindedendpointstudy.LancetNeurol2015;14(4):368–76.\n29.LogalloN,NovotnyV,AssmusJ,KvistadCE,AlteheldL,RonningOM,etal.Tenecteplaseversus"
    },
    {
        "page_number": 146,
        "text": "146alteplaseformanagementofacuteischaemicstroke(NOR-TEST):aphase3,randomised,open-label,\nblindedendpointtrial.LancetNeurol2017;16(10):781–8.\n30.CampbellBCV,MitchellPJ,ChurilovL,YassiN,KleinigTJ,DowlingRJ,etal.Tenecteplaseversus\nAlteplasebeforethrombectomyforischemicstroke.NEnglJMed2018;378(17):1573-82.\n31.ButcherK,ChristensenS,ParsonsM,DeSilvaDA,EbingerM,LeviC,etal.Post-thrombolysisblood\npressureelevationisassociatedwithhaemorrhagictransformation.Stroke2010;41(1):72–7.\n32.PeriniF,DeBoniA,MarconM,BolganI,PellizzariM,DionisioLD.Systolicbloodpressurecontributesto\nintracerebralhaemorrhageafterthrombolysisforischemicstroke.JNeurolSci2010;297(1-2):52–4.\n33.ToniD,AhmedN,AnziniA,LorenzanoS,BrozmanM,KasteM,etal.Intravenousthrombolysisinyoung\nstrokepatients:resultsfromtheSITS-ISTR.Neurology2012;78(12):880–7.\n34.MazyaM,EgidoJA,FordGA,LeesKR,MikulikR,ToniD,etal.Predictingtheriskofsymptomatic\nintracerebralhemorrhageinischemicstroketreatedwithintravenousalteplase:SafeImplementationof\nTreatmentsinStroke(SITS)symptomaticintracerebralhemorrhageriskscore.Stroke2012;43(6):1524-\n31.\n35.WuW,HuoX,ZhaoX,LiaoX,WangC,PanY,etal.Relationshipbetweenbloodpressureandoutcomes\ninacuteischemicstrokepatientsadministeredlyticmedicationintheTIMS-ChinaStudy.PlosOne2016;\n11(2):e0144260.\n36.EndoK,KarioK,KogaM,NakagawaraJ,ShiokawaY,YamagamiH,etal.Impactofearlybloodpressure\nvariabilityonstrokeoutcomesafterthrombolysis:theSAMURAIrt-PARegistry.Stroke2013;44(3):\n816–8.\n37.WaltimoT,HaapaniemiE,SurakkaIL,MelkasS,SairanenT,SiboltG,etal.Post-thrombolyticblood\npressureandsymptomaticintracerebralhemorrhage.EurJNeurol2016;23(12):1757–62.\n38.SaxenaM,YoungP,PilcherD,BaileyM,HarrisonD,BellomoR,etal.Earlytemperatureandmortalityin\ncriticallyillpatientswithacuteneurologicaldiseases:traumaandstrokedifferfrominfection.Intensive\nCareMed2015;41(5):823–32.\nChapter10:AcuteManagement–EndovascularThrombectomy\n1.BerkhemerOA,FransenPS,BeumerD,vandenBergLA,LingsmaHF,YooAJ,etal.Arandomizedtrial\nofintra-arterialtreatmentforacuteischemicstroke.NEnglJMed2015;372(1):11-20.\n2.CampbellBCV,MitchellPJ,KleinigTJ,DeweyHM,ChurilovL,YassiN,etal.Endovasculartherapyfor\nischemicstrokewithperfusion-imagingselection.NEnglJMed2015;372(11):1009-18.\n3.GoyalM,DemchukAM,MenonBK,EesaM,RempelJL,ThorntonJ,etal.Randomizedassessmentof\nrapidendovasculartreatmentofischemicstroke.NEnglJMed2015;372(11):1019-30.\n4.JovinTG,ChamorroA,CoboE,MiquelMA,MolinaCA,RoviraA,etal.Thrombectomywithin8hoursafter\nsymptomonsetinischemicstroke.NEnglJMed2015;372(24):2296-306.\n5.SaverJL,GoyalM,BonafeA,DienerHC,LevyEI,PereiraVM,etal.Stent-retrieverthrombectomyafter\nintravenoust-PAvs.t-PAaloneinstroke.NEnglJMed2015;372(24):2285-95.\n6.AlbersGW,MarksMP,KempS,ChristensenS,TsaiJP,SantiagoOrtega-Gutierrez,etal.Thrombectomy\nforstrokeat6to16hourswithselectionbyperfusionimaging.NEnglJMed2018;378(8):708-18.\n7.NogueiraRG,JadhavAP,HaussenDC,BonafeA,BudzikRF,BhuvaP,etal.Thrombectomy6to24\nhoursafterstrokewithamismatchbetweendeficitandinfarct.NEnglJMed2018;378(1):11-21."
    },
    {
        "page_number": 147,
        "text": "1478.BoulangerJM,LindsayMP.Canadianstrokebestpracticerecommendationsforacutestroke\nmanagement:Pre-hospital,emergencydepartmentandacuteinpatientstrokecare,6thEdition,Update\n2018.2018;1747493018786616.\n9.RinaldoL,BrinjikjiW,RabinsteinAA.Transfertohigh-volumecentresassociatedwithreducedmortality\nafterendovasculartreatmentofacutestroke.Stroke2017;48(5):1316-21.\nChapter11:StrokeUnit\n1.StrokeUnitTrialists’Collaboration.Acollaborativesystemicreviewoftherandomizedtrialsoforganized\ninpatient(strokeunit)careafterfirststroke.BMJ1997;314(7088):1151-59.\n2.IndredavikB,BakkeF,SolbergR,RoksethR,HaaheimLL,HolmeI.Benefitofastrokeunit.A\nrandomisedcontrolledtrial.Stroke1997;22(8):1026-31.\n3.LanghorneP,WilliamsBO,GilchristW,HowieK.Dostrokeunitssavelives?Lancet1993;342(8868):\n395-8.\n4.JogrensenHS,NakayamaH,RaaschouHO,LarsenK,HubbeP,OlsenTS.Theeffectofastrokeunit:\nreductionsinmortality,dischargeratetonursinghome,lengthofhospitalstay,andcost.A\ncommunity-basedstudy.Stroke1995;26(7):1178-82.\n5.IndredavikB,SlordahlSA,BakkeF,RoksethR,HaheimLL.Strokeunittreatment.Long-termeffects.\nStroke1997;28(10):1861-6.\n6.IndredavikB,BakkeF,SlordahlSA,RoksethR,HaheimLL.Strokeunittreatment.10-yearfollow-up.\nStroke1999;30(8):1524-7.\n7.KalraL,EvansA,PerezI,KnappM,DonaldsonN,SwiftCG.Alternativestrategiesforstrokecare:a\nprospectiverandomizedcontrolledtrial.Lancet2000;356(9233):894-9.\n8.JogensenHS,KammersgaardLP,HouthJ,NakayamaH,RaaschouHO,LarsenK,etal.Whobenefits\nfromtreatmentandrehabilitationinastrokeUnit?Acommunity-basedstudy.Stroke2000;31(2):434-9.\n9.GilliganAK,ThriftAG,SturmJW,DeweyHM,MacdonellRA,DonnanGA.Strokeunits,tissue\nplasminogenactivator,aspirinandneuroprotection:whichstrokeinterventioncouldprovidethegreatest\ncommunitybenefit?CerebrovascDis2005;20(4):239–44.\n10.EvanA,PerezI,HarrafF,MelbournA,SteadmanJ,DonaldsonN,etal.Candifferencesinmanagement\nprocessesexplaindifferentoutcomesbetweenstrokeunitandstroke-teamcare?Lancet2001;358(9293):\n1586-92.\n11.BoulangerJM,LindsayMP,GubitzG,SmithEE,StottsG,FoleyN,BhogalS,BoyleK,BraunL,Goddard\nT,HeranMK.Canadianstrokebestpracticerecommendationsforacutestrokemanagement:prehospital,\nemergencydepartment,andacuteinpatientstrokecare,update2018.InternationalJournalofStroke.\n2018Dec;13(9):949-84.\n12.CaliforniaAcuteStrokePilotRegistryInvestigators.Theimpactofstandardizedstrokeorderson\nadherencetobestpractices.Neurology2005;65(3):360–5.\n13.KwanJ,SandercockP.In-hospitalcarepathwaysforstroke.CochraneDatabaseSystRev2002;\n(2):CD002924.\nChapter12:StrokeintheOlderPerson\n1.RockwoodK,SongX,MacKnightC,BergmanH,HoganDB,McDowellI,etal.Aglobalclinicalmeasure\noffitnessandfrailtyinelderlypeople.Cmaj.2005;173(5):489-95."
    },
    {
        "page_number": 148,
        "text": "1482.DentE,MorleyJE,Cruz-JentoftAJ,WoodhouseL,Rodríguez-MañasL,FriedLP,etal.PhysicalFrailty:\nICFSRInternationalClinicalPracticeGuidelinesforIdentificationandManagement.JNutrHealthAging.\n2019;23(9):771-87.\n3.WardlawJM,MurrayV,BergeE,delZoppoGJ.Thrombolysisforacuteischaemicstroke.Cochrane\nDatabaseSystRev.2014;2014(7):Cd000213.\n4.GoyalM,MenonBK,vanZwamWH,DippelDW,MitchellPJ,DemchukAM,etal.Endovascular\nthrombectomyafterlarge-vesselischaemicstroke:ameta-analysisofindividualpatientdatafromfive\nrandomisedtrials.Lancet.2016;387(10029):1723-31.\n5.DunningT,SinclairA,ColagiuriS.NewIDFGuidelineformanagingtype2diabetesinolderpeople.\nDiabetesResClinPract.2014;103(3):538-40.\n6.BellolioMF,GilmoreRM,GantiL.Insulinforglycaemiccontrolinacuteischaemicstroke.Cochrane\nDatabaseSystRev.2014(1):Cd005346.\n7.WeissJ,FreemanM,LowA,FuR,KerfootA,PaynterR,etal.BenefitsandHarmsofIntensiveBlood\nPressureTreatmentinAdultsAged60YearsorOlder:ASystematicReviewandMeta-analysis.Ann\nInternMed.2017;166(6):419-29.\n8.MorleyJE,SinclairA.Individualisingtreatmentforolderpeoplewithdiabetes.Lancet.2013;\n382(9890):378-80.\n9.Efficacyandsafetyofstatintherapyinolderpeople:ameta-analysisofindividualparticipantdatafrom28\nrandomisedcontrolledtrials.Lancet.2019;393(10170):407-15.\n10.BaiY,GuoSD,DengH,ShantsilaA,FauchierL,MaCS,etal.Effectivenessandsafetyoforal\nanticoagulantsinolderpatientswithatrialfibrillation:asystematicreviewandmeta-regressionanalysis.\nAgeAgeing.2018;47(1):9-17.\n11.WehlingM,CollinsR,GilVM,HanonO,HardtR,HoffmeisterM,etal.AppropriatenessofOral\nAnticoagulantsfortheLong-TermTreatmentofAtrialFibrillationinOlderPeople:Resultsofan\nEvidence-BasedReviewandInternationalConsensusValidationProcess(OAC-FORTA2016).Drugs\nAging.2017;34(7):499-507.\n12.DillingerJG,AleilB,CheggourS,BenhamouY,BéjotY,MarechauxS,etal.Dosingissueswith\nnon-vitaminKantagonistoralanticoagulantsforthetreatmentofnon-valvularatrialfibrillation:Whywe\nshouldnotunderdoseourpatients.ArchCardiovascDis.2018;111(2):85-94.\n13.AmericanGeriatricsSociety2019UpdatedAGSBeersCriteria®forPotentiallyInappropriateMedication\nUseinOlderAdults.JAmGeriatrSoc.2019;67(4):674-94.\n14.ShawRC,WalkerG,ElliottE,QuinnTJ.OccurrenceRateofDeliriuminAcuteStrokeSettings:\nSystematicReviewandMeta-Analysis.Stroke.2019;50(11):3028-36.\n15.ShiQ,PresuttiR,SelchenD,SaposnikG.Deliriuminacutestroke:asystematicreviewandmeta-analysis.\nStroke.2012;43(3):645-9.\n16.QuJ,ChenY,LuoG,ZhongH,XiaoW,YinH.DeliriumintheAcutePhaseofIschemicStroke:Incidence,\nRiskFactors,andEffectsonFunctionalOutcome.JStrokeCerebrovascDis.2018;27(10):2641-7.\n17.KotfisK,Bott-OlejnikM,SzylińskaA,ListewnikM,RotterI.Characteristics,RiskFactorsAndOutcomeOf\nEarly-OnsetDeliriumInElderlyPatientsWithFirstEverAcuteIschemicStroke-AProspective\nObservationalCohortStudy.ClinIntervAging.2019;14:1771-82.\n18.PasinskaP,KowalskaK,KlimiecE,WilkA,Szyper-MaciejowskaA,DziedzicT,etal.PoststrokeDelirium\nClinicalMotorSubtypes:ThePRospectiveObservationalPOLIshStudy(PROPOLIS).JNeuropsychiatry\nClinNeurosci.2019;31(2):104-11.\n19.MansuttiI,SaianiL,PaleseA.Detectingdeliriuminpatientswithacutestroke:asystematicreviewoftest\naccuracy.BMCNeurol.2019;19(1):310.\n20.YoungJ,MurthyL,WestbyM,AkunneA,O'MahonyR.Diagnosis,prevention,andmanagementof\ndelirium:summaryofNICEguidance.Bmj.2010;341:c3704."
    },
    {
        "page_number": 149,
        "text": "14921.SongJ,LeeM,JungD.TheEffectsofDeliriumPreventionGuidelinesonElderlyStrokePatients.Clin\nNursRes.2018;27(8):967-83.\n22.BrownEG,JosephsonSA,AndersonN,ReidM,LeeM,DouglasVC.Evaluationofamulticomponent\npathwaytoaddressinpatientdeliriumonaneurosciencesward.BMCHealthServRes.2018;18(1):106.\n23.IndredavikB,RohwederG,NaalsundE,LydersenS.Medicalcomplicationsinacomprehensivestroke\nunitandanearlysupporteddischargeservice.Stroke.2008;39(2):414-20.\n24.SackleyC,BrittleN,PatelS,EllinsJ,ScottM,WrightC,etal.Theprevalenceofjointcontractures,\npressuresores,painfulshoulder,otherpain,falls,anddepressionintheyearafteraseverelydisabling\nstroke.Stroke.2008;39(12):3329-34.\n25.SchmidAA,RittmanM.Consequencesofpoststrokefalls:activitylimitation,increaseddependence,and\nthedevelopmentoffearoffalling.AmJOccupTher.2009;63(3):310-6.\n26.WalshME,SorensenJ,GalvinR,WilliamsDJ,HarbisonJA,MurphyS,etal.Firstyearpost-stroke\nhealthcarecostsandfall-statusamongthosedischargedtothecommunity.EurStrokeJ.2018;\n3(3):254-62.\n27.AshburnA,HyndmanD,PickeringR,YardleyL,HarrisS.Predictingpeoplewithstrokeatriskoffalls.Age\nAgeing.2008;37(3):270-6.\n28.WeiWE,DeSilvaDA,ChangHM,YaoJ,MatcharDB,YoungSHY,etal.Post-strokepatientswith\nmoderatefunctionhavethegreatestriskoffalls:aNationalCohortStudy.BMCGeriatr.2019;19(1):373.\n29.DenissenS,StaringW,KunkelD,PickeringRM,LennonS,GeurtsAC,etal.Interventionsforpreventing\nfallsinpeopleafterstroke.CochraneDatabaseSystRev.2019;10(10):Cd008728.\n30.RoyalCollegeofPhysicians(UK)IntercollegiateStrokeWorkingParty.NationalClinicalGuidelinefor\nStroke.FifthEdition2016.\n31.LanghorneP,BaylanS.Earlysupporteddischargeservicesforpeoplewithacutestroke.Cochrane\nDatabaseSystRev.2017;7(7):Cd000443.\n32.RodgersH,PriceC.Strokeunitcare,inpatientrehabilitationandearlysupporteddischarge.ClinMed\n(Lond).2017;17(2):173-7.\n33.ArchieRR,BorenSA.Opportunitiesforinformaticstoimprovedischargeplanning:asystematicreviewof\ntheliterature.AMIAAnnuSympProc.2009;2009:16-20.\n34.ErikssonH,MilbergA,HjelmK,FriedrichsenM.EndofLifeCareforPatientsDyingofStroke:A\nComparativeRegistryStudyofStrokeandCancer.PLoSOne.2016;11(2):e0147694.\n35.KendallM,CoweyE,MeadG,BarberM,McAlpineC,StottDJ,etal.Outcomes,experiencesand\npalliativecareinmajorstroke:amulticentre,mixed-method,longitudinalstudy.Cmaj.2018;\n190(9):E238-e46.\n36.SinghT,PetersSR,TirschwellDL,CreutzfeldtCJ.PalliativeCareforHospitalizedPatientsWithStroke:\nResultsFromthe2010to2012NationalInpatientSample.Stroke.2017;48(9):2534-40.\nChapter13:StrokeandCardioembolism\n1.DalenJ,HirschJ,GuyattG.Thesixth(2000)ACCPguidelinesforantithrombotictherapyforprevention\nandtreatmentofthrombosis.AmericanCollegeofChestPhysicians.Chest2001;119(1Suppl):1s-2s.\n2.ABCofantithrombotictherapy(Eds.LipGY,BlannA).BMJPublishing(London)2003.\n3.AdamsHP,AdamsRJ,BrottT,delZoppoGJ,FurlanA,GoldsteinLB,etal.Guidelinesfortheearly\nmanagementofpatientswithischemicstroke.Ascientificstatementfromthestrokecouncilofthe\nAmericanStrokeAssociation.Stroke2003;34(4):1056-83."
    },
    {
        "page_number": 150,
        "text": "1504.McNamaraRL,LimaAC,WheltonPK,PoreNR.Echocardiographicidentificationofcardiovascular\nsourcesofembolitoguideclinicalmanagementofstroke:Acost-effectivenessanalysis.AnnInternMed\n1997;127(9):775-87.\nChapter14:StrokeinSpecialCircumstances\n1.FeiginVL,RothGA,NaghaviM,ParmarP,KrishnamurthiR,ChughS,etal.Globalburdenofstrokeand\nriskfactorsin188countries,during1990–2013:asystematicanalysisfortheGlobalBurdenofDisease\nStudy2013.LancetNeurol2016;15(9):913-24.\n2.JacobsBS,Boden-AlbalaB,LinIF,SaccoRL.StrokeintheyounginthenorthernManhattanstrokestudy.\nStroke2002;33(12):2789–93.\n3.GeorgeMG,TongX,KuklinaEV,LabartheDR.Trendsinstrokehospitalizationsandassociatedrisk\nfactorsamongchildrenandyoungadults,1995-2008.AnnNeurol2011;70(5):713–21.\n4.EkkerMS,BootEM,SinghalAB,TanKS,DebetteS,TuladharAM,etal.Epidemiology,aetiology,and\nmanagementofischaemicstrokeinyoungadults.LancetNeurol2018;17(9):790–801.\n5.LiF,YangLi,YangR,XuW,ChenF,LiN,etal.IschemicstrokeinyoungadultsofNorthernChina:\ncharacteristicsandriskfactorsforrecurrence.EurNeurol2017;77(3–4):115–22.\n6.SinghalAB,BillerJ,ElkindMS,FullertonHJ,JauchEC,KittnerSJ,etal.Recognitionandmanagementof\nstrokeinyoungadultsandadolescents.Neurology2013;81(12):1089–97.\n7.HartRG,DienerHC,CouttsSB,EastonJD,GrangerCB,O’DonnellMJ,etal.Embolicstrokesof\nundeterminedsource:thecaseforanewclinicalconstruct.LancetNeurol2014;13(4):429–38.\n8.StornelloM,CappellaniR,MicieliG,SaccoS,SpolveriS,SterziR,etal.Cryptogenicstroke.Italian\nJournalofMedicine2016;10(3):185–94.\n9.HartRG,CataneseL,PereraKS,NtaiosG,ConnollySJ.Embolicstrokeofundeterminedsource:a\nsystematicreviewandclinicalupdate.Stroke2017;48(4):867–72.\n10.FerroJM,BousserMG,CanhaoP,CoutinhoJM,CrassardI,DentaliF,etal.Europeanstroke\norganizationguidelineforthediagnosisandtreatmentofcerebralvenousthrombosis–endorsedbythe\nEuropeanAcademyofNeurology.EuropeanStrokeJournal2017;2(3):195–221.\n11.TestaiFD,GorelickPB.Inheritedmetabolicdisordersandstrokepart2:homocystinuria,organicacidurias,\nandureacycledisorders.ArchNeurol2010;67(2):148–53.\n12.ArboixA,JimenezC,MassonsJ,ParraO,BessesC.Hematologicaldisorders:acommonlyunrecognized\ncauseofacutestroke.ExpertRevHematol2016;9(9):891–901.\n13.AmatoC,FerriR,EliaM,CosentinoF,SchepisC,SiragusaM,etal.Nervoussysteminvolvementin\nDegosdisease.AJNRAmJNeuroradiol2005;26(3):646–9.\n14.TaiMLS,ViswanathanS,RahmatK,NorHM,KadirKAA,GohKJ,etal.Cerebralinfarctionpatternin\ntuberculousmeningitis.SciRep2016;6:38802.\n15.Vishnevskia-DaiV,ChapmanJ,SheinfeldR,SharonT,Huna-BaronR,ManorRS,etal.Susacsyndrome:\nclinicalcharacteristics,clinicalclassification,andlong-termprognosis.Medicine2016;95(43):e5223.\n16.LehotskyJ,TothovaB,KovalskaM,DobrotaD,BenovaA,KalenskaD,etal.Roleofhomocysteineinthe\nischemicstrokeanddevelopmentofischemictolerance.FrontiersNeurosci2016;10:538.\n17.BarbaraVoetschMP,andJLMP.Homocysteine,MTHFR677C→Tpolymorphismandischemicstroke\nrisk.NEJMJournalWatch[Internet].JournalWatch2002.\n18.ScottRM,SmithER.Moyamoyadiseaseandmoyamoyasyndrome.NEnglJMed2009;\n360(12):1226–37."
    },
    {
        "page_number": 151,
        "text": "15119.SaverJL,MattleHP,ThalerD.Patentforamenovaleclosureversusmedicaltherapyforcryptogenic\nischemicstroke:atopicalreview.Stroke.2018Jun;49(6):1541-8.\n20.KernanWN,OvbiageleB,BlackHR,BravataDM,ChimowitzMI,EzekowitzMD,etal.Guidelinesforthe\npreventionofstrokeinpatientswithstrokeandtransientischemicattack:aguidelineforhealthcare\nprofessionalsfromtheAmericanHeartAssociation/AmericanStrokeAssociation.Stroke2014;\n45(7):2160–236.\n21.SwartzRH,LadhaniNNN,FoleyN,NerenbergK,BalS,BarrettJ,etal.Canadianstrokebestpractice\nconsensusstatement:Secondarystrokepreventionduringpregnancy.IntJStroke2018;13(4):406-19.\n22.MasJL,DerumeauxG,GuillonB,MassardierE,HosseiniH,MechtouffL,etal.Patentforamenovale\nclosureoranticoagulationvs.antiplateletsafterstroke.NEnglJMed2017;377(11):1011-21.\n23.TerniE,GianniniN,BrondiM,MontanoV,BonuccelliU,MancusoM.Geneticsofischaemicstrokein\nyoungadults.BBAClinical2014;3:96–106.\n24.KernanWN,OvbiageleB,BlackHR,BravataDM,ChimowitzMI,EzekowitzMD,etal.Guidelinesforthe\npreventionofstrokeinpatientswithstrokeandtransientischemicattack:aguidelineforhealthcare\nprofessionalsfromtheAmericanHeartAssociation/AmericanStrokeAssociation.Stroke2014;\n45(7):2160-236.\n25.JauchEC,SaverJL,AdamsHP,BrunoA,ConnorsJJB,DemaerschalkBM,etal.Guidelinesfortheearly\nmanagementofpatientswithacuteischemicstroke:aguidelineforhealthcareprofessionalsfromthe\nAmericanHeartAssociation/AmericanStrokeAssociation.Stroke2013;44(3):870-947.\n26.HartRG,SharmaM,MundlH,KasnerSE,BangdiwalaSI,BerkowitzSD,etal.Rivaroxabanforstroke\npreventionafterembolicstrokeofundeterminedsource.NEnglJMed2018;378(23):2191–2201.\n27.TurcG,CalvetD,GuerinP,SroussiM,ChatellierG,MasJL,etal.Closure,anticoagulationorantiplatelet\ntherapyforcryptogenicstrokewithpatentforamenovale:systematicreviewofrandomizedtrials,\nsequentialmeta-analysisandnewinsightsfromtheCLOSEstudy.JAmHeartAssoc2018;7(12):1-12.\n28.BrillAK,HorvathT,SeilerA,CamiloM,HaynesAG,OttSR,etal.CPAPastreatmentofsleepapneaafter\nstroke.Neurology2018;90(14):e1222-e1230.\n29.EstcourtLJ,FortinPM,HopewellS,TrivellaM,WangWC.Bloodtransfusionforpreventingprimaryand\nsecondarystrokeinpeoplewithsicklecelldisease.CochraneDatabaseSystRev2017;1:CD003146.\n30.LeeS-K,MokinM,HettsSW,etal.Currentendovascularstrategiesforcerebralvenousthrombosis:\nreportoftheSNISStandardsandGuidelinesCommitteeJNeuroInterventSurg2018;10:803–810.\nChapter15:ManagementofStrokeinPregnancy\n1.LeffertLR,ClancyCR,BatemanBT,BryantAS,KuklinaEV.Hypertensivedisordersand\npregnancy-relatedstroke:frequency,trends,riskfactors,andoutcomes.ObstetGynecol2015;\n125(1):124-31.\n2.SwartzRH,CayleyML,FoleyN,LadhaniNNN,LeffertL,BushnellC,etal.Theincidenceof\npregnancy-relatedstroke:asystematicreviewandmeta-analysis.IntJStroke2017;12(7):687-97.\n3.BanL,SpriggN,AbdulSultanA,Nelson-PiercyC,BathPM,LudvigssonJF,etal.Incidenceoffirststroke\ninpregnantandnon-pregnantwomenofchildbearingage:apopulation-basedcohortstudyfromEngland.\nJAmHeartAssoc2017;6(4):e004601.\n4.KamelH,NaviBB,SriramN,HovsepianDA,DevereuxRB,ElkindMS.Riskofathromboticeventafterthe\n6-weekpostpartumperiod.NEnglJMed2014;370(14):1307-15.\n5.vanAlebeekME,deHeusR,TuladharAM,deLeeuwFE.Pregnancyandischemicstroke:apractical\nguidetomanagement.CurrOpinNeurol2018;31(1):44-51."
    },
    {
        "page_number": 152,
        "text": "1526.YoshidaK,TakahashiJC,TakenobuY,SuzukiN,OgawaA,MiyamotoS.Strokesassociatedwith\npregnancyandpuerperium:anationwidestudybytheJapanStrokeSociety.Stroke2017;48(2):276-82.\n7.StrizekB,JaniJC,MucyoE,DeKeyzerF,PauwelsI,ZianeS,etal.SafetyofMRimagingat1.5Tin\nfetuses:aretrospectivecase-controlstudyofbirthweightsandtheeffectsofacousticnoise.Radiology\n2015;275(2):530-7.\n8.CommitteeonObstetricPractice.CommitteeOpinionNo.723:Guidelinesfordiagnosticimagingduring\npregnancyandlactation.ObstetGynecol2017;130(4):e210-6.\n9.RayJG,VermeulenMJ,BharathaA,MontaneraWJ,ParkAL.AssociationbetweenMRIexposureduring\npregnancyandfetalandchildhoodoutcomes.JAMA2016;316(9):952-61.\n10.LadhaniNNN,SwartzRH,FoleyN,NerenbergK,SmithEE,GubitzG,etal.Canadianstrokebestpractice\nconsensusstatement:acutestrokemanagementduringpregnancy.IntJStroke2018;13(7):743-58.\n11.CasoV,FalorniA,BushnellCD,AcciarresiM,RemohíJ,SpriggN,etal.Pregnancy,hormonaltreatments\nforinfertility,contraception,andmenopauseinwomenafterischemicstroke:aconsensusdocument.\nStroke2017;48(2):501-6.\n12.SwartzRH,LadhaniNNN,FoleyN,NerenbergK,BalS,BarrettJ,etal.Canadianstrokebestpractice\nconsensusstatement:Secondarystrokepreventionduringpregnancy.IntJStroke2018;13(4):406-19.\nChapter16:StrokeTherapieswithLimitedEvidence\n1.VenketasubramanianN,YoungSH,TaySS,UmapathiT,LaoAY,GanHH,etal.ChineseMedicineNeuroAiD\nEfficacyonStrokeRecovery–ExtensionStudy(CHIMES-E):amulti-centrestudyoflong-termefficacy.Cerebrovasc\nDis2015;39(5-6):309-18.\n2.Gonzalez-FraileE,Martin-CarrascoM,BallesterosJ.EfficacyofMLC601onfunctionalrecoveryafterstroke:A\nsystematicreviewandmeta-analysisofrandomizedcontrolledtrials.BrainInj2016;30(3):267-70.\n3.SiddiquiFJ,VenketasubramanianN,ChanES,ChenC,etal.EfficacyandsafetyofMLC601\n(NeuroAiD®),atraditionalchinesemedicine,inpoststrokerecovery:asystematicreview.Cerebrovasc\nDis2013;35(Suppl1):8-17.\n4.SecadesJJ,Alvarez-SabinJ,CastilloJ,Diez-TejedorE,Martinez-VilaE,RiosJ,etal.Citicolineforacute\nischemicstroke:asystematicreviewandformalmeta-analysisofrandomized,double-blind,and\nplacebo-controlledtrials.JStrokeCerebrovascDis2016;25(8):1984-96.\n5.DavalosA,Alvarez-SabinJ,CastilloJ,Diez-TejedorE,FerroJ,Martinez-VilaE,etal.Citicolineinthe\ntreatmentofacuteischaemicstroke:aninternational,randomised,multicentre,placebo-controlledstudy\n(ICTUStrial).Lancet2012;380(9839):349-57.\n6.ZhangD,DongY,LiY,ChenJ,WangJ,HouL.EfficacyandsafetyofCerebrolysinforacuteischemic\nstroke:ameta-analysisofrandomizedcontrolledtrials.BiomedResearchInt2017;2017:4191670.\n7.ZiganshinaLE,AbakumovaT,VernayL.Cerebrolysinforacuteischemicstroke.CochraneDatabaseSyst\nRev2016;12:CD007026.\n8.GuekhtA,HeissbD,GusevcE,VesterdJ,DopplereE,MuresanufD.Cerebrolysinandrecoveryafter\nstroke(CARS2):arandomized,placebo-controlled,double-blind,multicentreclinicalstudy.Jofthe\nNeurologicalSciences2015;357(Suppl1):e103.\n9.YangJ,CuiX,LiJ,ZhangC,ZhangJ,LiuM.Edaravoneforacutestroke:Meta-analysesofdatafrom\nrandomizedcontrolledtrials.DevNeurorehabil2015;18(5):330-5.\n10.ChongPZ,NgHY,TaiJT,LeeSW.EfficacyandSafetyofGinkgobilobainPatientswithAcuteIschemic\nStroke:ASystematicReviewandMeta-Analysis.TheAmericanJournalofChineseMedicine.2020Apr\n30;48(03):513-34."
    },
    {
        "page_number": 153,
        "text": "15311.TooleJF,MalinowMR,ChamblessLE,SpenceJD,PettigrewLC,HowardVJ,etal.Lowering\nhomocysteineinpatientswithischemicstroketopreventrecurrentstroke,myocardialinfarction,anddeath:\ntheVitaminInterventionforStrokePrevention(VISP)randomizedcontrolledtrial.JAMA2004;291(5):\n565–75.\n12.VITATOPSTrialStudyGroup.Bvitaminsinpatientswithrecenttransientischaemicattackorstrokeinthe\nvitaminstopreventstroke(VITATOPS)trial:arandomised,double-blind,parallel,placebo-controlledtrial.\nLancetNeurol2010;9(9):855–65.\n13.LeeM,HongKS,ChangSC,SaverJL.Efficacyofhomocysteine-loweringtherapywithfolicacidinstroke\nprevention:ameta-analysis.Stroke.2010Jun1;41(6):1205-12.\n14.DennisM,MeadG,ForbesJ,GrahamC,HackettM,HankeyGJ,HouseA,LewisS,LundströmE,\nSandercockP,InnesK.Effectsoffluoxetineonfunctionaloutcomesafteracutestroke(FOCUS):a\npragmatic,double-blind,randomised,controlledtrial.TheLancet.2019Jan19;393(10168):265-74.\n15.ParkJB,WhiteAR,JamesMA,HemsleyAG,JohnsonP,ChambersJ,etal.Acupunctureforsub-acute\nstrokerehabilitation.ArchInternMed2005;165:2026-31.\n16.KongJC,LeeMS,ShinBC,SongYS,ErnstE.Acupunctureforfunctionalrecoveryafterstroke:a\nsystematicreviewofsham-controlledrandomizedclinicaltrials.CMAJ2010;182(16):1723-29.\n17.HopwoodV,LewithG,PrescottP,CampbellMJ.Evaluatingtheefficacyofacupunctureindefined\naspectsofstrokerecovery:arandomised,placebocontrolledsingleblindstudy.JNeurol2008;\n255(6):858-66.\n18.XuM,LiD,ZhangS.Acupunctureforacutestroke.CochraneDatabaseofSystematicReviews.2018(3).\n19.SmithMC,StinearCM.Transcranialmagneticstimulation(TMS)instroke:Readyforclinicalpractice?J\nClinNeurosci2016;31:10-4.\n20.DionisioA,DuarteIC,PatricioM,Castelo-BrancoM.Theuseofrepetitivetranscranialmagnetic\nstimulationforstrokerehabilitation:asystemicreview.JStrokeCerebrovascDis2018;27(1):1-31.\n21.ChangWH,KimYH,BangOY,KimST,ParkYH,LeePK.Long-termeffectsofrTMSonmotorrecoveryin\npatientsaftersubacutestroke.JRehabilMed2010;42(8):758-64.\n22.KimYH,YouSH,KoMH,ParkJW,LeeKH,JangSH,etal.Repetitivetranscranialmagnetic\nstimulation-inducecorticomotorexcitabilityandassociatedmotorskillacquisitioninchronicstroke.Stroke\n2006;37(6):1471-76.\n23.JiaoY,ShangJ,OhtaY,YanH,LiuX,LiX,etal.NeuroprotectiveeffectsofTocovidpre-treatmentina\nmousestrokemodel.JStrokeCerebrovascDis2018;27(8):2166-74.\n24.QureshiAA,KarpenCW,QureshiN,PapasianCJ,MorrisonDC,FoltsJD.Tocotrienols-inducedinhibition\nofplateletthrombusformationandplateletaggregationinstenosedcaninecoronaryarteries.Lipids\nHealthDis2011;10:58.\n25.MishimaK,TanakaT,PuF,EgashiraN,IwasakiK,HidakaR,etal.VitaminEisoformsalpha-tocotrienol\nandgamma-tocopherolpreventcerebralinfarctioninmice.NeurosciLett2003;337(1):56-60.\n26.GopalanY,ShuaibIL,MagossoE,AnsariMA,AbuBakarMR,WongJW,KhanNA,LiongWC,Sundram\nK,NgBH,KaruthanC.ClinicalinvestigationoftheprotectiveeffectsofpalmvitaminEtocotrienolson\nbrainwhitematter.Stroke.2014May;45(5):1422-8\n27.AngelovaEA,AtanassovaPA,ChalakovaNT,DimitrovBD.Associationsbetweenserumseleniumand\ntotalplasmahomocysteineduringtheacutephaseofischaemicstroke.EurNeurol2008;60(6):298-303."
    },
    {
        "page_number": 154,
        "text": "15428.ZimmermannC,WinnefeldK,StreckS,RoskosM,HaberlRL.Antioxidantstatusinacutestrokepatients\nandpatientsatstrokerisk.EurNeurol2004;51(3):157-61.\n29.ShrivastavaS.CombinedeffectofHEDTAandseleniumagainstaluminuminducedoxidativestressinrat\nbrain.JTraceElemMedBiol2012;26(2-3):210-4.\n30.ZhangJ,WenRL,ChenZ,LuoB.Piracetamforaphasiainpost-strokepatients:asystematicreviewand\nmeta-analysisofrandomizedcontrolledtrials.CNSDrugs2016;30(7):575-87.\n31.DeynPPD,ReuckJD,DeberdtW,VlietinckR,OrgogozoJ.Treatmentofacuteischemicstrokewith\npiracetam.MembersofthePiracetaminAcuteStrokeStudy(PASS)Group.Stroke1997;\n28(12):2347–52.\nChapter17:QualityAssurance\n1.TechnicalspecificationforKeyPerformanceIndicators(KPI)forNeurologyClinicalService;Medical\nProgram2019,MinistryofHealthMalaysia.\n2.GuidelinesfortheEarlyManagementofPatientsWithAcuteIschemicStroke:2019Updatetothe2018\nGuidelinesfortheEarlyManagementofAcuteIschemicStrokeAGuidelineforHealthcareProfessionals\nFromtheAmericanHeartAssociation/AmericanStrokeAssociation.\n3.DuncanPW,ZorowitzR,BatesB,ChoiJY,GlasbergJJ,GrahamGD,KatzRC,LambertyK,Reker\nD.ManagementofAdultStrokeRehabilitationCare:aclinicalpracticeguideline.\nStroke.2005;36:e100–e143.\n4.LakshminarayanK,TsaiAW,TongX,etal.Utilityofdysphagiascreeningresultsinpredictingpoststroke\npneumonia.Stroke2010;41:2849–2854.\n5.DingD,LuCZ,FuJH,etal.Associationofantiplatelettherapywithlowerriskofdeathandrecurrent\ncerebrovasculareventsafterischemicstrokeresultsfromtheChinaIschemicStrokeRegistryStudy.Circ\nJ2009;73:2342–2347.\n6.SandercockPAG,CounsellC,TsengMC,etal.Oralantiplatelettherapyforacuteischemicstroke\n(Review).CochraneDatabaseSystRev2014;3:CD000029\n7.RothwellPM,AlgraA,ChenZ,etal.Effectsofaspirinonriskandseverityofearlyrecurrentstrokeafter\ntransientischemicattackandischemicstroke:time-courseanalysisofrandomised\ntrials.Lancet2016;388:365–375.\n8.SandercockPAG,CounsellC,KaneEJ.Anticoagulantsforacuteischemicstroke.CochraneDatabase\nSystRev2015;3:CD000024.\n9.AndersenKK,OlsenTS.Reducedpoststrokemortalityinpatientswithstrokeandatrialfibrillationtreated\nwithanticoagulants:resultsfromaDanishquality-controlregistryof22179patientswithischemic\nstroke.Stroke2007;38:259–263\n10.ÅsbergS,HenrikssonKM,FarahmandB,etal.Ischemicstrokeandsecondarypreventioninclinical\npractice:Acohortstudyof14529patientsintheSwedishStrokeRegister.Stroke2010;41:1338–1342.\n11.DowlatshahiD,DemchukAM,FangJ,etal.Associationofstatinsandstatindiscontinuationwithpoor\noutcomeandsurvivalafterintracerebralhemorrhage.Stroke2012;43:1518–1523."
    },
    {
        "page_number": 155,
        "text": "155ACKNOWLEDGEMENT\nThemembersofCPGDevelopmentGroupwouldliketoexpresstheirgratitudeandappreciationto\nthefollowingpersonsfortheircontributions:\nHealthTechnologyAssessmentSection,MinistryofHealth,Malaysiafortheirvaluableguidance\nBoehringerIngelheimSdnBhdforfinancialsupportforeditorialassistance\nAllthosewhohavecontributeddirectlyorindirectlytothedevelopmentoftheCPG\nDISCLOSURESTATEMENT\nTheDevelopmentGroupmembershavecompletedthedisclosureforms.Noneofthemholdshares\ninpharmaceuticalfirmsoractasconsultantstosuchfirms.\n(DetailsareavailableuponrequestfromtheCPGsecretariat)\nSOURCEOFFUNDING\nThedevelopmentoftheCPGwassupportedviaunrestrictededucationalgrantfromMalaysiaStroke\nCouncilandBoehringerIngelheimSdnBhd.Viewsandinterestsofthefundingbodyhavenot\ninfluencedthefinalrecommendations."
    },
    {
        "page_number": 156,
        "text": "156\nMalaysianSocietyofNeurosciences\nNeurologyLaboratory,6thFloor,SouthTower\nUniversityofMalayaMedicalCentre\n50603KualaLumpur\nMalaysia"
    }
]